,Sentence,ESG BERT Topic 1,ESG BERT Topic 2,ESG BERT Topic 3,Mapped Criteria Topic 1,Mapped Criteria Topic 2,Mapped Criteria Topic 3
Line 1,"FY 2019 Sustainability Report 2I believe that healthcare is the most consequential industry in the  world.
","('Business_Model_Resilience', 0.3257538676261902)","('Systemic_Risk_Management', 0.23081114888191223)","('Supply_Chain_Management', 0.2063949853181839)","('NON-ESG', 0.3257538676261902)","('NON-ESG', 0.23081114888191223)","('NON-ESG', 0.2063949853181839)"
Line 2,"Our work provides an opportunity to make a life-changing  difference for our customers, their patients, and the communities   we serve and in which we live and work.
","('Human_Rights_And_Community_Relations', 0.3770920932292938)","('Employee_Engagement_Inclusion_And_Diversity', 0.17360754311084747)","('Access_And_Affordability', 0.08082456141710281)","('NON-ESG', 0.3770920932292938)","('NON-ESG', 0.17360754311084747)","('NON-ESG', 0.08082456141710281)"
Line 3,"Our Purpose— advancing the  world of health ™—is as impactful as it is inspiring; it reminds us that we  all play a part in changing the world for the better, every single day.
","('Human_Rights_And_Community_Relations', 0.2937503755092621)","('Access_And_Affordability', 0.17421700060367584)","('Business_Model_Resilience', 0.09355106949806213)","('NON-ESG', 0.2937503755092621)","('NON-ESG', 0.17421700060367584)","('NON-ESG', 0.09355106949806213)"
Line 4,"With the global reach of BD comes a great deal of responsibility.
","('Human_Rights_And_Community_Relations', 0.45028945803642273)","('Access_And_Affordability', 0.15047886967658997)","('Employee_Engagement_Inclusion_And_Diversity', 0.03980280086398125)","('NON-ESG', 0.45028945803642273)","('NON-ESG', 0.15047886967658997)","('NON-ESG', 0.03980280086398125)"
Line 5,"Five  years ago, we initiated a broader and more integrated approach to  sustainability, and I am pleased with not only how far we have come,  but how that approach has enabled us to respond to the significant  social issues that have reverberated across the globe in recent months.
","('Human_Rights_And_Community_Relations', 0.9186094999313354)","('Business_Model_Resilience', 0.009457639418542385)","('Physical_Impacts_Of_Climate_Change', 0.006505154073238373)","(['Community Relations'], 0.9186094999313354)","('NON-ESG', 0.009457639418542385)","('NON-ESG', 0.006505154073238373)"
Line 6,"Our associates have rallied around our Purpose, developing innovative  diagnostic solutions for COVID-19 in record time, increasing the  availability of products used in sample collection and the treatment of  critically ill patients, and working with countries around the world to  enable the delivery of a potential COVID-19 vaccine.
","('Access_And_Affordability', 0.3349391222000122)","('Customer_Welfare', 0.13180001080036163)","('Product_Quality_And_Safety', 0.09265567362308502)","('NON-ESG', 0.3349391222000122)","('NON-ESG', 0.13180001080036163)","('NON-ESG', 0.09265567362308502)"
Line 7,"And we have  come together to have important, frank discussions about race and  equality, celebrating our differences while challenging each other to  make further progress in advancing our own culture of inclusion while  addressing the systemic inequities faced by people of color.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9716392755508423)","('Human_Rights_And_Community_Relations', 0.003333629807457328)","('Employee_Health_And_Safety', 0.0022531000431627035)","(['Human Capital Development'], 0.9716392755508423)","('NON-ESG', 0.003333629807457328)","('NON-ESG', 0.0022531000431627035)"
Line 8,"We remain focused on supporting priority health needs that are  aligned with the U.N. Sustainable Development Goals (SDG) and  shared value creation—meaning how we address unmet societal  needs through business models and initiatives that also contribute to  the commercial success of BD.
","('Business_Model_Resilience', 0.38232141733169556)","('Human_Rights_And_Community_Relations', 0.2318340539932251)","('Supply_Chain_Management', 0.04729140177369118)","('NON-ESG', 0.38232141733169556)","('NON-ESG', 0.2318340539932251)","('NON-ESG', 0.04729140177369118)"
Line 9,"I am pleased to share with you the  progress we are making toward our 2020 sustainability goals.
","('Business_Model_Resilience', 0.5615549087524414)","('Product_Design_And_Lifecycle_Management', 0.056673888117074966)","('Physical_Impacts_Of_Climate_Change', 0.04899246618151665)","(['Codes of Business Conduct'], 0.5615549087524414)","('NON-ESG', 0.056673888117074966)","('NON-ESG', 0.04899246618151665)"
Line 10,"These  goals provide the framework for how we manage, and make an impact  on, the most relevant social and environmental issues for our company.
","('Human_Rights_And_Community_Relations', 0.9344555139541626)","('Business_Model_Resilience', 0.006238448433578014)","('Physical_Impacts_Of_Climate_Change', 0.005264818202704191)","(['Community Relations'], 0.9344555139541626)","('NON-ESG', 0.006238448433578014)","('NON-ESG', 0.005264818202704191)"
Line 11,"Innovation In recent years, we’ve assembled a leading portfolio of solutions to  better serve the entire healthcare continuum—from discovery to  diagnosis, to the process of care, to the treatment of disease.
","('Access_And_Affordability', 0.3000275492668152)","('Employee_Health_And_Safety', 0.12261440604925156)","('Customer_Welfare', 0.0993897095322609)","('NON-ESG', 0.3000275492668152)","('NON-ESG', 0.12261440604925156)","('NON-ESG', 0.0993897095322609)"
Line 12,"Our evolution has been driven by the successful acquisition and  integration of CareFusion and C.
","('Access_And_Affordability', 0.2800866961479187)","('Customer_Welfare', 0.1593349725008011)","('Systemic_Risk_Management', 0.05907706543803215)","('NON-ESG', 0.2800866961479187)","('NON-ESG', 0.1593349725008011)","('NON-ESG', 0.05907706543803215)"
Line 13,"R.
","('Management_Of_Legal_And_Regulatory_Framework', 0.16864672303199768)","('Human_Rights_And_Community_Relations', 0.08567094802856445)","('Ecological_Impacts', 0.06714435666799545)","('NON-ESG', 0.16864672303199768)","('NON-ESG', 0.08567094802856445)","('NON-ESG', 0.06714435666799545)"
Line 14,"Bard, and we are leveraging our  broad new capabilities to accelerate innovation, seeking new and  better solutions that address our customers’ unmet needs, improve  patient outcomes, reduce the cost of care and expand access.
","('Access_And_Affordability', 0.7643858194351196)","('Customer_Welfare', 0.034719984978437424)","('Energy_Management', 0.020121414214372635)","(['Health Outcome Contribution'], 0.7643858194351196)","('NON-ESG', 0.034719984978437424)","('NON-ESG', 0.020121414214372635)"
Line 15,"Our Purpose and innovating to solve major health problems are  mutually reinforcing goals.
","('Employee_Health_And_Safety', 0.7548848986625671)","('Access_And_Affordability', 0.046755366027355194)","('Product_Quality_And_Safety', 0.027471117675304413)","(['Operational Eco-Efficiency'], 0.7548848986625671)","('NON-ESG', 0.046755366027355194)","('NON-ESG', 0.027471117675304413)"
Line 16,"When we innovate to increase access to  quality healthcare, it benefits people and societies throughout the  world and drives our business performance.
","('Access_And_Affordability', 0.8894975185394287)","('Human_Rights_And_Community_Relations', 0.010687149129807949)","('Critical_Incident_Risk_Management', 0.01054481603205204)","(['Health Outcome Contribution'], 0.8894975185394287)","('NON-ESG', 0.010687149129807949)","('NON-ESG', 0.01054481603205204)"
Line 17,"We call this “innovating on  Purpose,” and it’s an approach that led to 25 major product launches  in FY 2019, including the Purewick ™ Female External Catheter and  WavelinQ ™ 4F Arteriovenous Fistula Creation Device in our BD  Interventional segment; the BD HealthSight ™ Data Manager 1.1 Suite  of Technologies in our BD Medical segment; and the BD Cor ™ and   BD FACSDuet ™ Systems in our BD Life Sciences segment.
","('Product_Design_And_Lifecycle_Management', 0.2591594457626343)","('Customer_Welfare', 0.16123604774475098)","('Access_And_Affordability', 0.1478695571422577)","('NON-ESG', 0.2591594457626343)","('NON-ESG', 0.16123604774475098)","('NON-ESG', 0.1478695571422577)"
Line 18,"While we have even more major launches planned for FY 2020,   we are also working to tackle some of the largest challenges in  healthcare—including rapidly mustering our resources to respond  to the global COVID-19 pandemic by developing multiple products  for the rapid diagnosis of the virus.
","('Physical_Impacts_Of_Climate_Change', 0.1998109519481659)","('Critical_Incident_Risk_Management', 0.1485300064086914)","('Data_Security', 0.09932295978069305)","('NON-ESG', 0.1998109519481659)","('NON-ESG', 0.1485300064086914)","('NON-ESG', 0.09932295978069305)"
Line 19,"Access We partner and collaborate with public and nonprofit organizations  around the world to address priority health needs.
","('Access_And_Affordability', 0.7877887487411499)","('Employee_Health_And_Safety', 0.05162957310676575)","('Critical_Incident_Risk_Management', 0.020258789882063866)","(['Health Outcome Contribution'], 0.7877887487411499)","('NON-ESG', 0.05162957310676575)","('NON-ESG', 0.020258789882063866)"
Line 20,"This year, we were recognized by Fortune  magazine on its annual list of  companies who “Change the World.” We earned this honor for our  work, helping to combat the threat of antimicrobial resistance through  programs that raise awareness and mobilize and activate the  healthcare industry, as well as leaders and communities around the  world, to take action to extend the useful life of medications.
","('Selling_Practices_And_Product_Labeling', 0.18811002373695374)","('Customer_Welfare', 0.17025724053382874)","('Access_And_Affordability', 0.07442668080329895)","('NON-ESG', 0.18811002373695374)","('NON-ESG', 0.17025724053382874)","('NON-ESG', 0.07442668080329895)"
Line 21,"This is the third time BD has made this prestigious list since its  inception—something only 17 companies can claim.Efficiency As climate change increasingly becomes one of the most disruptive  forces around the world, we have identified opportunities to make  environmental improvements across our value chain and build resilience  in our global operations.
","('Physical_Impacts_Of_Climate_Change', 0.9095402359962463)","('Business_Model_Resilience', 0.037435341626405716)","('Supply_Chain_Management', 0.007291036657989025)","(['Climate Change'], 0.9095402359962463)","('NON-ESG', 0.037435341626405716)","('NON-ESG', 0.007291036657989025)"
Line 22,"This year, we have integrated environmental  performance data for Bard into our reporting, and while this has  impacted progress against some of our targets, I’m confident that  integration efforts will drive continued improvements.
","('Business_Model_Resilience', 0.2763941287994385)","('Physical_Impacts_Of_Climate_Change', 0.11808564513921738)","('Human_Rights_And_Community_Relations', 0.09695370495319366)","('NON-ESG', 0.2763941287994385)","('NON-ESG', 0.11808564513921738)","('NON-ESG', 0.09695370495319366)"
Line 23,"Since setting our  2020 sustainability targets, we’ve continued to reduce our Scope 1 and 2  greenhouse gas emissions and water consumption.
","('GHG_Emissions', 0.9665932059288025)","('Management_Of_Legal_And_Regulatory_Framework', 0.003499566577374935)","('Ecological_Impacts', 0.003229915862902999)","(['Climate Change'], 0.9665932059288025)","('NON-ESG', 0.003499566577374935)","('NON-ESG', 0.003229915862902999)"
Line 24,"We remain  committed to renewable energy, such as installations of on-site solar  power generation across our sites—most recently, at our global  headquarters in Franklin Lakes, NJ.
","('Energy_Management', 0.9788606762886047)","('Management_Of_Legal_And_Regulatory_Framework', 0.002326174173504114)","('Product_Design_And_Lifecycle_Management', 0.001997915329411626)","(['Operational Eco-Efficiency'], 0.9788606762886047)","('NON-ESG', 0.002326174173504114)","('NON-ESG', 0.001997915329411626)"
Line 25,"Recognizing the increased interest from our stakeholders about our  climate change management program, we are also publishing  disclosures in line with the recommendations of the Task Force on  Climate-related Financial Disclosures (TCFD).
","('Physical_Impacts_Of_Climate_Change', 0.9503247737884521)","('Business_Model_Resilience', 0.008535399101674557)","('GHG_Emissions', 0.007335239090025425)","(['Climate Change'], 0.9503247737884521)","('NON-ESG', 0.008535399101674557)","('NON-ESG', 0.007335239090025425)"
Line 26,"BD is one of over 1,000  organizations that supports the recommendations of the TCFD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8651160597801208)","('GHG_Emissions', 0.020674580708146095)","('Human_Rights_And_Community_Relations', 0.013812370598316193)","(['Corporate Governance'], 0.8651160597801208)","('NON-ESG', 0.020674580708146095)","('NON-ESG', 0.013812370598316193)"
Line 27,"Empowerment By building and engaging diverse teams and leveraging the unique  ideas, backgrounds and experiences of our associates, we can deliver  better outcomes for our global marketplace.
","('Employee_Engagement_Inclusion_And_Diversity', 0.966036856174469)","('Human_Rights_And_Community_Relations', 0.004005401860922575)","('Employee_Health_And_Safety', 0.0026416247710585594)","(['Human Capital Development'], 0.966036856174469)","('NON-ESG', 0.004005401860922575)","('NON-ESG', 0.0026416247710585594)"
Line 28,"This focus on inclusion and  diversity has long been a cultural priority at BD, and it is embedded in  The BD Way, the set of values, leadership commitments and mindset  that guides our behavior and actions.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9731011986732483)","('Employee_Health_And_Safety', 0.0024744211696088314)","('Human_Rights_And_Community_Relations', 0.002298607723787427)","(['Human Capital Development'], 0.9731011986732483)","('NON-ESG', 0.0024744211696088314)","('NON-ESG', 0.002298607723787427)"
Line 29,"As executive sponsor of WIN (Women’s Initiative Network), the  company’s largest associate resource group (ARG), I’ve seen firsthand   the impact we can have when we create a culture of individual  belonging and empowerment.
","('Human_Rights_And_Community_Relations', 0.5779163837432861)","('Employee_Engagement_Inclusion_And_Diversity', 0.24773477017879486)","('Access_And_Affordability', 0.029261145740747452)","(['Community Relations'], 0.5779163837432861)","('NON-ESG', 0.24773477017879486)","('NON-ESG', 0.029261145740747452)"
Line 30,"Members of our ARGs have been  instrumental in creating opportunities for our more than 65,000   global associates to network, navigate their careers and find—or  be—a mentor.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8845027089118958)","('Business_Model_Resilience', 0.012018163688480854)","('Employee_Health_And_Safety', 0.010821743868291378)","(['Human Capital Development'], 0.8845027089118958)","('NON-ESG', 0.012018163688480854)","('NON-ESG', 0.010821743868291378)"
Line 31,"Long-term impact While we’re proud of our accomplishments in FY 2019, we will never be  satisfied with maintaining the status quo.
","('Business_Model_Resilience', 0.16680575907230377)","('Human_Rights_And_Community_Relations', 0.1556731015443802)","('Employee_Engagement_Inclusion_And_Diversity', 0.13317424058914185)","('NON-ESG', 0.16680575907230377)","('NON-ESG', 0.1556731015443802)","('NON-ESG', 0.13317424058914185)"
Line 32,"Just as we continuously seek  new innovations to help more patients live better lives, we strive to be  the best employer, the best environmental steward and the best  corporate citizen we can possibly be.
","('Access_And_Affordability', 0.7477352023124695)","('Employee_Health_And_Safety', 0.027364198118448257)","('Product_Design_And_Lifecycle_Management', 0.024782877415418625)","(['Health Outcome Contribution'], 0.7477352023124695)","('NON-ESG', 0.027364198118448257)","('NON-ESG', 0.024782877415418625)"
Line 33,"We are in the process of taking our  sustainability work to the next level, developing our 2030 impact goals  that reflect the new company that BD has become.
","('Business_Model_Resilience', 0.5805591344833374)","('Product_Design_And_Lifecycle_Management', 0.07807975262403488)","('Supply_Chain_Management', 0.05846627801656723)","(['Codes of Business Conduct'], 0.5805591344833374)","('NON-ESG', 0.07807975262403488)","('NON-ESG', 0.05846627801656723)"
Line 34,"I’m excited to share  the new strategy later in 2020, along with bold commitments that will  continue our focus on shared value creation.
","('Business_Model_Resilience', 0.7540397047996521)","('Supply_Chain_Management', 0.03359619900584221)","('Product_Design_And_Lifecycle_Management', 0.02397420071065426)","(['Codes of Business Conduct'], 0.7540397047996521)","('NON-ESG', 0.03359619900584221)","('NON-ESG', 0.02397420071065426)"
Line 35,"Our role in creating a better, healthier world has never been more clear  than it is today, and our associates take tremendous pride in helping the  caregivers, researchers and other healthcare professionals who serve  patients all around the world.
","('Access_And_Affordability', 0.7219627499580383)","('Human_Rights_And_Community_Relations', 0.03570141643285751)","('Employee_Health_And_Safety', 0.03257663547992706)","(['Health Outcome Contribution'], 0.7219627499580383)","('NON-ESG', 0.03570141643285751)","('NON-ESG', 0.03257663547992706)"
Line 36,"We look forward to working with you—our  stakeholders—as we continue advancing the world of health ™.
","('Access_And_Affordability', 0.28142786026000977)","('Employee_Health_And_Safety', 0.2239740788936615)","('Human_Rights_And_Community_Relations', 0.08424469083547592)","('NON-ESG', 0.28142786026000977)","('NON-ESG', 0.2239740788936615)","('NON-ESG', 0.08424469083547592)"
Line 37,"Sincerely,   Tom Polen CEO and PresidentTo our stakeholders3This report provides an update on our global environmental,  social and governance (ESG) performance against our 2020  goals, during Fiscal Year 2019 (October 1, 2018 to September  30, 2019) for Becton, Dickinson and Company (also known as  “BD”) and our subsidiaries, unless otherwise stated.
","('Human_Rights_And_Community_Relations', 0.43690621852874756)","('Business_Model_Resilience', 0.18454399704933167)","('Management_Of_Legal_And_Regulatory_Framework', 0.07309994846582413)","('NON-ESG', 0.43690621852874756)","('NON-ESG', 0.18454399704933167)","('NON-ESG', 0.07309994846582413)"
Line 38,"We report annually on our sustainability performance, and  published our last report, which highlighted progress made in  Fiscal Year 2018, in June 2019.
","('Business_Model_Resilience', 0.453891783952713)","('Systemic_Risk_Management', 0.10015418380498886)","('Physical_Impacts_Of_Climate_Change', 0.09081986546516418)","('NON-ESG', 0.453891783952713)","('NON-ESG', 0.10015418380498886)","('NON-ESG', 0.09081986546516418)"
Line 39,"In December 2017, BD acquired C.R. Bard (“Bard”), a leading  multinational developer, manufacturer and marketer of  innovative, life-enhancing medical technologies in the fields of  vascular, urological, oncological and surgical specialty products.
","('Product_Design_And_Lifecycle_Management', 0.6413642764091492)","('Customer_Welfare', 0.09232738614082336)","('Product_Quality_And_Safety', 0.05098901316523552)","(['Product Stewardship'], 0.6413642764091492)","('NON-ESG', 0.09232738614082336)","('NON-ESG', 0.05098901316523552)"
Line 40,"Bard data is integrated into all data provided throughout this  report, unless noted.
","('Customer_Privacy', 0.6653510332107544)","('Data_Security', 0.09242874383926392)","('Business_Model_Resilience', 0.024497246369719505)","(['Privacy Protection'], 0.6653510332107544)","('NON-ESG', 0.09242874383926392)","('NON-ESG', 0.024497246369719505)"
Line 41,"This report contains standard disclosures from the Global  Reporting Initiative ™ (GRI) Sustainability Reporting Guidelines.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48797231912612915)","('Business_Model_Resilience', 0.08427170664072037)","('Systemic_Risk_Management', 0.05016849935054779)","('NON-ESG', 0.48797231912612915)","('NON-ESG', 0.08427170664072037)","('NON-ESG', 0.05016849935054779)"
Line 42,"While this report is not intended to meet the requirements   of the GRI Sustainability Reporting Guidelines, reference  numbers for standard disclosures have been included where   full or partial information has been provided.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5489634275436401)","('Business_Model_Resilience', 0.0694955587387085)","('Product_Quality_And_Safety', 0.03635326400399208)","(['Corporate Governance'], 0.5489634275436401)","('NON-ESG', 0.0694955587387085)","('NON-ESG', 0.03635326400399208)"
Line 43,"This report contains standard disclosures from the Sustainability  Accounting Standards Board (SASB) Medical Equipment and  Supplies Sustainability Accounting Standard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.22350434958934784)","('Systemic_Risk_Management', 0.14497216045856476)","('Product_Quality_And_Safety', 0.11115451157093048)","('NON-ESG', 0.22350434958934784)","('NON-ESG', 0.14497216045856476)","('NON-ESG', 0.11115451157093048)"
Line 44,"While this report is  not intended to meet all the requirements of the SASB standard,  reference numbers for disclosures have been included where full  or partial information has been provided.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4207904040813446)","('Product_Quality_And_Safety', 0.07577693462371826)","('Selling_Practices_And_Product_Labeling', 0.06568791717290878)","('NON-ESG', 0.4207904040813446)","('NON-ESG', 0.07577693462371826)","('NON-ESG', 0.06568791717290878)"
Line 45,"Data in this report has not been externally assured.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3102823793888092)","('Customer_Privacy', 0.19210472702980042)","('Data_Security', 0.06999839097261429)","('NON-ESG', 0.3102823793888092)","('NON-ESG', 0.19210472702980042)","('NON-ESG', 0.06999839097261429)"
Line 46,"Reporting and performance data include information on our  owned and operated facilities.
","('Customer_Privacy', 0.13299979269504547)","('Supply_Chain_Management', 0.12429361045360565)","('Management_Of_Legal_And_Regulatory_Framework', 0.11729998141527176)","('NON-ESG', 0.13299979269504547)","('NON-ESG', 0.12429361045360565)","('NON-ESG', 0.11729998141527176)"
Line 47,"We have processes in place to  ensure that reporting on key sustainability performance  indicators is as accurate and robust as possible, and we  continually work to improve them.
","('Business_Model_Resilience', 0.25674042105674744)","('Systemic_Risk_Management', 0.17791107296943665)","('Management_Of_Legal_And_Regulatory_Framework', 0.11644133925437927)","('NON-ESG', 0.25674042105674744)","('NON-ESG', 0.17791107296943665)","('NON-ESG', 0.11644133925437927)"
Line 48,"We seek feedback from stakeholders each year, which informs  our selection of content for sustainability reporting.
","('Business_Model_Resilience', 0.23847784101963043)","('Management_Of_Legal_And_Regulatory_Framework', 0.135081946849823)","('Product_Design_And_Lifecycle_Management', 0.07911022007465363)","('NON-ESG', 0.23847784101963043)","('NON-ESG', 0.135081946849823)","('NON-ESG', 0.07911022007465363)"
Line 49,"For contact  information, see the final page of this report.
","('Customer_Privacy', 0.6141272783279419)","('Business_Model_Resilience', 0.07191815972328186)","('Selling_Practices_And_Product_Labeling', 0.031185753643512726)","(['Privacy Protection'], 0.6141272783279419)","('NON-ESG', 0.07191815972328186)","('NON-ESG', 0.031185753643512726)"
Line 50,"Our previous sustainability report is available on our website .
","('Business_Model_Resilience', 0.16897065937519073)","('Supply_Chain_Management', 0.15555469691753387)","('Product_Design_And_Lifecycle_Management', 0.15208183228969574)","('NON-ESG', 0.16897065937519073)","('NON-ESG', 0.15555469691753387)","('NON-ESG', 0.15208183228969574)"
Line 51,"About this report GRI disclosures: 102-1, 102-10, 102-50, 102-51, 102-52, 102-53, 102-54, 102-564BD is one of the largest global medical technology companies in  the world and is advancing the world of health ™ by improving  medical discovery, diagnostics and the delivery of care.
","('Product_Design_And_Lifecycle_Management', 0.2038004994392395)","('Customer_Welfare', 0.19039307534694672)","('Access_And_Affordability', 0.11118321120738983)","('NON-ESG', 0.2038004994392395)","('NON-ESG', 0.19039307534694672)","('NON-ESG', 0.11118321120738983)"
Line 52,"The  company supports the heroes on the front lines of healthcare by  developing innovative technology, services and solutions that  help advance both clinical therapy for patients and clinical  process for healthcare providers.
","('Access_And_Affordability', 0.4405955672264099)","('Customer_Welfare', 0.11319583654403687)","('Product_Design_And_Lifecycle_Management', 0.056462906301021576)","('NON-ESG', 0.4405955672264099)","('NON-ESG', 0.11319583654403687)","('NON-ESG', 0.056462906301021576)"
Line 53,"BD and its 65,000 employees  have a passion and commitment to help enhance the safety and  efficiency of clinicians’ care delivery process, enable laboratory  scientists to accurately detect disease and advance researchers’  capabilities to develop the next generation of diagnostics and  therapeutics.
","('Employee_Health_And_Safety', 0.406095951795578)","('Product_Quality_And_Safety', 0.30784258246421814)","('Customer_Welfare', 0.047227077186107635)","('NON-ESG', 0.406095951795578)","('NON-ESG', 0.30784258246421814)","('NON-ESG', 0.047227077186107635)"
Line 54,"BD has a presence in virtually every country and  partners with organizations around the world to address some of the most challenging global health issues.
","('Employee_Health_And_Safety', 0.4369007647037506)","('Access_And_Affordability', 0.13454896211624146)","('Critical_Incident_Risk_Management', 0.07138382643461227)","('NON-ESG', 0.4369007647037506)","('NON-ESG', 0.13454896211624146)","('NON-ESG', 0.07138382643461227)"
Line 55,"By working in close  collaboration with customers, BD can help enhance outcomes,  lower costs, increase efficiencies, improve safety and expand  access to healthcare.
","('Product_Quality_And_Safety', 0.44293850660324097)","('Employee_Health_And_Safety', 0.3776084780693054)","('Access_And_Affordability', 0.03203575313091278)","('NON-ESG', 0.44293850660324097)","('NON-ESG', 0.3776084780693054)","('NON-ESG', 0.03203575313091278)"
Line 56,"For more information on BD, please visit our website .
","('Access_And_Affordability', 0.20369628071784973)","('Management_Of_Legal_And_Regulatory_Framework', 0.11545752733945847)","('Systemic_Risk_Management', 0.07298832386732101)","('NON-ESG', 0.20369628071784973)","('NON-ESG', 0.11545752733945847)","('NON-ESG', 0.07298832386732101)"
Line 57,"BD is headquartered in Franklin Lakes NJ and serves over  190 countries.
","('Employee_Engagement_Inclusion_And_Diversity', 0.15003833174705505)","('Business_Model_Resilience', 0.09689553827047348)","('Access_And_Affordability', 0.08465993404388428)","('NON-ESG', 0.15003833174705505)","('NON-ESG', 0.09689553827047348)","('NON-ESG', 0.08465993404388428)"
Line 58,"Further details about BD (including location of operations and  direct economic impact generated and distributed) can be found  in our 2019 10-K filing .
","('Systemic_Risk_Management', 0.3262608051300049)","('Business_Model_Resilience', 0.1571853905916214)","('Management_Of_Legal_And_Regulatory_Framework', 0.0690097063779831)","('NON-ESG', 0.3262608051300049)","('NON-ESG', 0.1571853905916214)","('NON-ESG', 0.0690097063779831)"
Line 59,"BD corporate headquarters, Franklin Lakes, NJ.About BD GRI disclosures: 102-1, 102-2, 102-3, 102-4, 102-5, 102-6, 102-7, 201-About our businesses The BD Medical segment  focuses on providing innovative solutions to  reduce the spread of infection, enhance  diabetes treatment, advance drug delivery,  improve surgical procedures and provide  effective and safe medication management.
","('Employee_Health_And_Safety', 0.39649051427841187)","('Product_Quality_And_Safety', 0.12888668477535248)","('Access_And_Affordability', 0.07191592454910278)","('NON-ESG', 0.39649051427841187)","('NON-ESG', 0.12888668477535248)","('NON-ESG', 0.07191592454910278)"
Line 60,"Customers served include hospitals and  clinics; physicians; governmental and public  health agencies; healthcare workers; retail  pharmacies; pharmaceutical and biotech  companies; and consumers.
","('Customer_Welfare', 0.25109702348709106)","('Access_And_Affordability', 0.16375558078289032)","('Competitive_Behavior', 0.07030601054430008)","('NON-ESG', 0.25109702348709106)","('NON-ESG', 0.16375558078289032)","('NON-ESG', 0.07030601054430008)"
Line 61,"The BD Life Sciences  segment  delivers innovative solutions  from discovery to diagnosis, continually  advancing science and clinical outcomes  across infectious disease and cancer.
","('Access_And_Affordability', 0.3330203890800476)","('Customer_Welfare', 0.15457266569137573)","('Product_Quality_And_Safety', 0.06643572449684143)","('NON-ESG', 0.3330203890800476)","('NON-ESG', 0.15457266569137573)","('NON-ESG', 0.06643572449684143)"
Line 62,"Offerings include preanalytical solutions   for sample management; immunology  research solutions, including flow cytometry  and multiomics tools; microbiology and  molecular diagnostics; lab automation   and informatics solutions; and differentiated  reagents and assays.
","('Customer_Welfare', 0.25023889541625977)","('GHG_Emissions', 0.0732572078704834)","('Access_And_Affordability', 0.06647907197475433)","('NON-ESG', 0.25023889541625977)","('NON-ESG', 0.0732572078704834)","('NON-ESG', 0.06647907197475433)"
Line 63,"Customers served  include research institutions, industrial   and reference laboratories; blood banks;  hospitals and clinics; alternate site  healthcare; public health agencies;  academic and government institutions; and  pharmaceutical and biotech companies.
","('Access_And_Affordability', 0.37870675325393677)","('Customer_Welfare', 0.13693803548812866)","('Management_Of_Legal_And_Regulatory_Framework', 0.06029853969812393)","('NON-ESG', 0.37870675325393677)","('NON-ESG', 0.13693803548812866)","('NON-ESG', 0.06029853969812393)"
Line 64,"The BD Interventional  segment  focuses on developing  innovative surgical, endovascular,   urological and critical care interventions   that not only meet clinical needs but also  deliver value to health systems and improve  patients’ lives.
","('Access_And_Affordability', 0.6548548936843872)","('Employee_Health_And_Safety', 0.05993196740746498)","('Critical_Incident_Risk_Management', 0.042570870369672775)","(['Health Outcome Contribution'], 0.6548548936843872)","('NON-ESG', 0.05993196740746498)","('NON-ESG', 0.042570870369672775)"
Line 65,"Customers served include  hospitals and clinics; physicians; ambulatory  surgery centers; nurses; and consumers.
","('Customer_Welfare', 0.23850753903388977)","('Access_And_Affordability', 0.12865591049194336)","('Selling_Practices_And_Product_Labeling', 0.0718412697315216)","('NON-ESG', 0.23850753903388977)","('NON-ESG', 0.12865591049194336)","('NON-ESG', 0.0718412697315216)"
Line 66,"Phasix™ ST Mesh Arctic Sun™  Temperature  Management  SystemSample products: BD Alaris™ Infusion SystemBD Hypak™  Glass  Prefillable  Syringes Sample products: BD Vacutainer® Blood  Collection TubesBD FACSLyric™ Flow Cytometry System BD Kiestra™ Lab  Automation SolutionsBD MAX™ Open  System Reagent SuiteSample products:BD MaxZero™  Needle-Free  Connector BD Nano™   4mm Pen Needle Lutonix™ 035 Drug Coated  Balloon PTA Catheter LifeStent™  Vascular   Stent System GRI disclosures: 102-2, 102-6Company structure BD is structured to serve customers by providing unique solutions.
","('Customer_Welfare', 0.18873588740825653)","('Access_And_Affordability', 0.16166871786117554)","('Employee_Health_And_Safety', 0.07826244086027145)","('NON-ESG', 0.18873588740825653)","('NON-ESG', 0.16166871786117554)","('NON-ESG', 0.07826244086027145)"
Line 67,"Phasix™ ST Mesh Arctic Sun™  Temperature  Management  SystemSample products: BD Alaris™ Infusion SystemBD Hypak™  Glass  Prefillable  Syringes Sample products: BD Vacutainer® Blood  Collection TubesBD FACSLyric™ Flow Cytometry System BD Kiestra™ Lab  Automation SolutionsBD MAX™ Open  System Reagent SuiteSample products:BD MaxZero™  Needle-Free  Connector BD Nano™   4mm Pen Needle Lutonix™ 035 Drug Coated  Balloon PTA Catheter LifeStent™  Vascular   Stent System GRI disclosures: 102-2, 102-6Company structure BD is structured to serve customers by providing unique solutions.
","('Customer_Welfare', 0.20248545706272125)","('Business_Model_Resilience', 0.1650579869747162)","('Product_Design_And_Lifecycle_Management', 0.15691521763801575)","('NON-ESG', 0.20248545706272125)","('NON-ESG', 0.1650579869747162)","('NON-ESG', 0.15691521763801575)"
Line 68,"The data below represents the company structure for FY 2019.
","('Systemic_Risk_Management', 0.4401964545249939)","('Business_Model_Resilience', 0.2084333598613739)","('Supply_Chain_Management', 0.06258131563663483)","('NON-ESG', 0.4401964545249939)","('NON-ESG', 0.2084333598613739)","('NON-ESG', 0.06258131563663483)"
Line 69,"Revenue by geography (millions of dollars) United States  (including  Puerto Rico) $9,Other (including Latin America, Canada and EMA [which includes   the Commonwealth of Independent States, Middle East and Africa])  $1,476 Europe $3,Greater Asia (including Japan  and Asia Pacific) $2,$3.9$2.6$1.1$1.$1.$1.$1.$1.1$1.4$1.Medication Delivery Solutions    Urology and Critical CarePeripheral  InterventionSurgeryMedication Management  Solutions   Diabetes CarePharmaceutical  SystemsPreanalytical  Systems Diagnostic  Systems Biosciences $17.Total BD revenueRevenue by segment (billions of dollars) Values in this exhibit reflect  rounded numbers in  billions and include Bard.$4.BD Life   Sciences $3.BD  Interventional$9.BD  Medical GRI disclosures: 102-6, 102-77Value chain profile BD has more than 700 core suppliers that provide key materials,  including plastics, glass, metals, textiles, electronic and mechanical  sub-assemblies, and various paper, agricultural, biological, chemical  and petrochemical products.BD manufactures and sells over 80,000 products worldwide.
","('Customer_Welfare', 0.26820841431617737)","('Access_And_Affordability', 0.20214010775089264)","('Competitive_Behavior', 0.05845063179731369)","('NON-ESG', 0.26820841431617737)","('NON-ESG', 0.20214010775089264)","('NON-ESG', 0.05845063179731369)"
Line 70,"Revenue by geography (millions of dollars) United States  (including  Puerto Rico) $9,Other (including Latin America, Canada and EMA [which includes   the Commonwealth of Independent States, Middle East and Africa])  $1,476 Europe $3,Greater Asia (including Japan  and Asia Pacific) $2,$3.9$2.6$1.1$1.$1.$1.$1.$1.1$1.4$1.Medication Delivery Solutions    Urology and Critical CarePeripheral  InterventionSurgeryMedication Management  Solutions   Diabetes CarePharmaceutical  SystemsPreanalytical  Systems Diagnostic  Systems Biosciences $17.Total BD revenueRevenue by segment (billions of dollars) Values in this exhibit reflect  rounded numbers in  billions and include Bard.$4.BD Life   Sciences $3.BD  Interventional$9.BD  Medical GRI disclosures: 102-6, 102-77Value chain profile BD has more than 700 core suppliers that provide key materials,  including plastics, glass, metals, textiles, electronic and mechanical  sub-assemblies, and various paper, agricultural, biological, chemical  and petrochemical products.BD manufactures and sells over 80,000 products worldwide.
","('Supply_Chain_Management', 0.7567209601402283)","('Product_Design_And_Lifecycle_Management', 0.08388607949018478)","('Customer_Welfare', 0.02480742707848549)","(['Supply Chain Management'], 0.7567209601402283)","('NON-ESG', 0.08388607949018478)","('NON-ESG', 0.02480742707848549)"
Line 71,"Revenue by geography (millions of dollars) United States  (including  Puerto Rico) $9,Other (including Latin America, Canada and EMA [which includes   the Commonwealth of Independent States, Middle East and Africa])  $1,476 Europe $3,Greater Asia (including Japan  and Asia Pacific) $2,$3.9$2.6$1.1$1.$1.$1.$1.$1.1$1.4$1.Medication Delivery Solutions    Urology and Critical CarePeripheral  InterventionSurgeryMedication Management  Solutions   Diabetes CarePharmaceutical  SystemsPreanalytical  Systems Diagnostic  Systems Biosciences $17.Total BD revenueRevenue by segment (billions of dollars) Values in this exhibit reflect  rounded numbers in  billions and include Bard.$4.BD Life   Sciences $3.BD  Interventional$9.BD  Medical GRI disclosures: 102-6, 102-77Value chain profile BD has more than 700 core suppliers that provide key materials,  including plastics, glass, metals, textiles, electronic and mechanical  sub-assemblies, and various paper, agricultural, biological, chemical  and petrochemical products.BD manufactures and sells over 80,000 products worldwide.
","('Product_Design_And_Lifecycle_Management', 0.9231030941009521)","('Product_Quality_And_Safety', 0.013956423848867416)","('Customer_Welfare', 0.012077096849679947)","(['Product Stewardship'], 0.9231030941009521)","('NON-ESG', 0.013956423848867416)","('NON-ESG', 0.012077096849679947)"
Line 72,"We market our products in the United States and  internationally through independent distribution channels  and directly to end users with company associates or  independent sales representatives.
","('Product_Design_And_Lifecycle_Management', 0.6751487255096436)","('Selling_Practices_And_Product_Labeling', 0.11828705668449402)","('Customer_Welfare', 0.06270736455917358)","(['Product Stewardship'], 0.6751487255096436)","('NON-ESG', 0.11828705668449402)","('NON-ESG', 0.06270736455917358)"
Line 73,"GRI disclosure: 102-6Customers served BD Medical BD Life Sciences BD Interventional Hospitals • • • Clinics • • • Laboratories • Physicians' office practices • • • Consumers and retail pharmacies • Government agencies * • • • Academic and government institutions • • • Public health agencies • • Nonprofit public health agencies • Blood banks • Pharmaceutical companies† • • Biotechnology companies • • Healthcare workers • Ambulatory surgical centers •8The Antibribery and Anticorruption Program helps keep  associates pointed in the right direction.
","('Access_And_Affordability', 0.2734243869781494)","('Customer_Welfare', 0.16132643818855286)","('Competitive_Behavior', 0.09674776345491409)","('NON-ESG', 0.2734243869781494)","('NON-ESG', 0.16132643818855286)","('NON-ESG', 0.09674776345491409)"
Line 74,"GRI disclosure: 102-6Customers served BD Medical BD Life Sciences BD Interventional Hospitals • • • Clinics • • • Laboratories • Physicians' office practices • • • Consumers and retail pharmacies • Government agencies * • • • Academic and government institutions • • • Public health agencies • • Nonprofit public health agencies • Blood banks • Pharmaceutical companies† • • Biotechnology companies • • Healthcare workers • Ambulatory surgical centers •8The Antibribery and Anticorruption Program helps keep  associates pointed in the right direction.
","('Ecological_Impacts', 0.5529837608337402)","('Competitive_Behavior', 0.07038141787052155)","('GHG_Emissions', 0.05498741939663887)","(['Natural Capital'], 0.5529837608337402)","('NON-ESG', 0.07038141787052155)","('NON-ESG', 0.05498741939663887)"
Line 75,"In support of the  program, the Ethics and Compliance function provides resources  to regional and local country management to enhance their  anticorruption and compliance business practices.
","('Business_Ethics', 0.9524847269058228)","('Management_Of_Legal_And_Regulatory_Framework', 0.012808650732040405)","('Product_Quality_And_Safety', 0.0036964432802051306)","(['Business Ethics'], 0.9524847269058228)","('NON-ESG', 0.012808650732040405)","('NON-ESG', 0.0036964432802051306)"
Line 76,"This includes  incorporating compliance requirements into existing business  practices and advising local management on anticorruption  compliance-related issues.
","('Management_Of_Legal_And_Regulatory_Framework', 0.44042232632637024)","('Business_Ethics', 0.4353184401988983)","('Product_Quality_And_Safety', 0.014342552050948143)","('NON-ESG', 0.44042232632637024)","('NON-ESG', 0.4353184401988983)","('NON-ESG', 0.014342552050948143)"
Line 77,"A key focus for BD is driving compliance in our distributor  networks across the globe, resulting in stronger business  relationships while upholding our reputation.
","('Business_Ethics', 0.4322746694087982)","('Management_Of_Legal_And_Regulatory_Framework', 0.2996656596660614)","('Systemic_Risk_Management', 0.061000850051641464)","('NON-ESG', 0.4322746694087982)","('NON-ESG', 0.2996656596660614)","('NON-ESG', 0.061000850051641464)"
Line 78,"The Antibribery and Anticorruption Program is advanced by  fostering collaboration with business leaders to deliver  consistent and clear policies and approval processes—along  with enhanced third-party due diligence procedures—to help  provide assurance that BD is “winning business the right way.”BD is committed to training all associates via both in-person,  scenario-based sessions and learning management system  courses that leverage policy materials, such as the Global  Standards for Interactions with Healthcare Professionals,  Healthcare Organizations and Government Officials.
","('Management_Of_Legal_And_Regulatory_Framework', 0.934537947177887)","('Business_Ethics', 0.01593620330095291)","('Human_Rights_And_Community_Relations', 0.0062318481504917145)","(['Corporate Governance'], 0.934537947177887)","('NON-ESG', 0.01593620330095291)","('NON-ESG', 0.0062318481504917145)"
Line 79,"The Antibribery and Anticorruption Program is advanced by  fostering collaboration with business leaders to deliver  consistent and clear policies and approval processes—along  with enhanced third-party due diligence procedures—to help  provide assurance that BD is “winning business the right way.”BD is committed to training all associates via both in-person,  scenario-based sessions and learning management system  courses that leverage policy materials, such as the Global  Standards for Interactions with Healthcare Professionals,  Healthcare Organizations and Government Officials.
","('Access_And_Affordability', 0.6301009654998779)","('Management_Of_Legal_And_Regulatory_Framework', 0.08182830363512039)","('Product_Quality_And_Safety', 0.05142761021852493)","(['Health Outcome Contribution'], 0.6301009654998779)","('NON-ESG', 0.08182830363512039)","('NON-ESG', 0.05142761021852493)"
Line 80,"Joint training with distributors is a core component of the  Antibribery and Anticorruption Program.
","('Product_Quality_And_Safety', 0.22503861784934998)","('Access_And_Affordability', 0.1754850298166275)","('Management_Of_Legal_And_Regulatory_Framework', 0.08049095422029495)","('NON-ESG', 0.22503861784934998)","('NON-ESG', 0.1754850298166275)","('NON-ESG', 0.08049095422029495)"
Line 81,"These sessions  combine required anticorruption training with information  about our overall strategy, progress updates for each business  segment and new products.
","('Product_Design_And_Lifecycle_Management', 0.8990153670310974)","('Business_Model_Resilience', 0.018689582124352455)","('Product_Quality_And_Safety', 0.012592935934662819)","(['Product Stewardship'], 0.8990153670310974)","('NON-ESG', 0.018689582124352455)","('NON-ESG', 0.012592935934662819)"
Line 82,"We are committed to a strong ethics and compliance culture.
","('Business_Ethics', 0.9594777226448059)","('Customer_Privacy', 0.003684713738039136)","('Product_Quality_And_Safety', 0.003138007130473852)","(['Business Ethics'], 0.9594777226448059)","('NON-ESG', 0.003684713738039136)","('NON-ESG', 0.003138007130473852)"
Line 83,"We do not tolerate actions or behaviors that are inconsistent  with our values or violate the BD Code of Conduct or applicable  laws and regulations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7307474613189697)","('Business_Ethics', 0.1763094812631607)","('Competitive_Behavior', 0.011155868880450726)","(['Corporate Governance'], 0.7307474613189697)","('NON-ESG', 0.1763094812631607)","('NON-ESG', 0.011155868880450726)"
Line 84,"All BD associates are responsible for  reinforcing our ethics and compliance culture and sustaining our  reputation as a company dedicated to quality and integrity.
","('Business_Ethics', 0.9678337574005127)","('Product_Quality_And_Safety', 0.0024933088570833206)","('Customer_Privacy', 0.0024566466454416513)","(['Business Ethics'], 0.9678337574005127)","('NON-ESG', 0.0024933088570833206)","('NON-ESG', 0.0024566466454416513)"
Line 85,"We  encourage and expect everyone at BD to speak up by asking  questions, raising concerns, seeking guidance and reporting  actual or suspected violations of laws, our Code of Conduct, our  policies or our high ethical standards.
","('Business_Ethics', 0.9603245854377747)","('Management_Of_Legal_And_Regulatory_Framework', 0.006024516653269529)","('Product_Quality_And_Safety', 0.005023536738008261)","(['Business Ethics'], 0.9603245854377747)","('NON-ESG', 0.006024516653269529)","('NON-ESG', 0.005023536738008261)"
Line 86,"This requirement extends  to all associates, vendors and other third parties working  on our behalf.The following BD Values further strengthen our culture of ethics  and compliance and guide how we hold ourselves accountable  to our shareholders and stakeholders.
","('Business_Ethics', 0.9709649682044983)","('Management_Of_Legal_And_Regulatory_Framework', 0.0028930213302373886)","('Competitive_Behavior', 0.002388887805864215)","(['Business Ethics'], 0.9709649682044983)","('NON-ESG', 0.0028930213302373886)","('NON-ESG', 0.002388887805864215)"
Line 87,"• We do what is right.
","('Human_Rights_And_Community_Relations', 0.23524053394794464)","('Business_Ethics', 0.08716137707233429)","('Management_Of_Legal_And_Regulatory_Framework', 0.06498222798109055)","('NON-ESG', 0.23524053394794464)","('NON-ESG', 0.08716137707233429)","('NON-ESG', 0.06498222798109055)"
Line 88,"• We thrive on innovation and demand quality.
","('Product_Design_And_Lifecycle_Management', 0.31479111313819885)","('Competitive_Behavior', 0.26795312762260437)","('Business_Model_Resilience', 0.10546170175075531)","('NON-ESG', 0.31479111313819885)","('NON-ESG', 0.26795312762260437)","('NON-ESG', 0.10546170175075531)"
Line 89,"• We are all accountable.
","('Business_Ethics', 0.6002901196479797)","('Management_Of_Legal_And_Regulatory_Framework', 0.14142952859401703)","('Competitive_Behavior', 0.049626246094703674)","(['Business Ethics'], 0.6002901196479797)","('NON-ESG', 0.14142952859401703)","('NON-ESG', 0.049626246094703674)"
Line 90,"• We learn and improve every day.
","('Access_And_Affordability', 0.26872801780700684)","('Employee_Engagement_Inclusion_And_Diversity', 0.23067523539066315)","('Human_Rights_And_Community_Relations', 0.07375331223011017)","('NON-ESG', 0.26872801780700684)","('NON-ESG', 0.23067523539066315)","('NON-ESG', 0.07375331223011017)"
Line 91,"• We help each other be great.
","('Human_Rights_And_Community_Relations', 0.3716264069080353)","('Access_And_Affordability', 0.09838979691267014)","('Management_Of_Legal_And_Regulatory_Framework', 0.09008834511041641)","('NON-ESG', 0.3716264069080353)","('NON-ESG', 0.09838979691267014)","('NON-ESG', 0.09008834511041641)"
Line 92,"These values are cascaded through all levels of the organization.
","('Business_Model_Resilience', 0.18405240774154663)","('Business_Ethics', 0.14286383986473083)","('Competitive_Behavior', 0.10703873634338379)","('NON-ESG', 0.18405240774154663)","('NON-ESG', 0.14286383986473083)","('NON-ESG', 0.10703873634338379)"
Line 93,"Read more about our commitment to ethics and compliance on   our website .
","('Business_Ethics', 0.9631218314170837)","('Management_Of_Legal_And_Regulatory_Framework', 0.00419103167951107)","('Competitive_Behavior', 0.0033199368044734)","(['Business Ethics'], 0.9631218314170837)","('NON-ESG', 0.00419103167951107)","('NON-ESG', 0.0033199368044734)"
Line 94,"The BD Code of Conduct sets the foundation for how we  behave at BD.
","('Business_Ethics', 0.8619783520698547)","('Management_Of_Legal_And_Regulatory_Framework', 0.06656736880540848)","('Product_Quality_And_Safety', 0.008186524733901024)","(['Business Ethics'], 0.8619783520698547)","('NON-ESG', 0.06656736880540848)","('NON-ESG', 0.008186524733901024)"
Line 95,"The value “We do what is right” is the cornerstone  of our code.
","('Management_Of_Legal_And_Regulatory_Framework', 0.1839570701122284)","('Human_Rights_And_Community_Relations', 0.15188461542129517)","('Business_Ethics', 0.13748124241828918)","('NON-ESG', 0.1839570701122284)","('NON-ESG', 0.15188461542129517)","('NON-ESG', 0.13748124241828918)"
Line 96,"To do what is right, we follow the laws, rules and  company policies that apply to us.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9474550485610962)","('Business_Ethics', 0.007067467551678419)","('Human_Rights_And_Community_Relations', 0.006100552622228861)","(['Corporate Governance'], 0.9474550485610962)","('NON-ESG', 0.007067467551678419)","('NON-ESG', 0.006100552622228861)"
Line 97,"We also follow the highest  ethical standards, even when there’s no specific law or policy.
","('Business_Ethics', 0.9082727432250977)","('Competitive_Behavior', 0.015695063397288322)","('Management_Of_Legal_And_Regulatory_Framework', 0.013574366457760334)","(['Business Ethics'], 0.9082727432250977)","('NON-ESG', 0.015695063397288322)","('NON-ESG', 0.013574366457760334)"
Line 98,"Our code provides guidance and resources to help us follow  through on these ethical standards and protect our reputation.Everyone at BD—from directors to officers and associates—must  follow our code.
","('Business_Ethics', 0.9336637258529663)","('Director_Removal', 0.008102918975055218)","('Management_Of_Legal_And_Regulatory_Framework', 0.007775790523737669)","(['Business Ethics'], 0.9336637258529663)","('NON-ESG', 0.008102918975055218)","('NON-ESG', 0.007775790523737669)"
Line 99,"It applies equally to everyone, no matter their  position or level.
","('Director_Removal', 0.17216430604457855)","('Employee_Engagement_Inclusion_And_Diversity', 0.16385036706924438)","('Labor_Practices', 0.14055508375167847)","('NON-ESG', 0.17216430604457855)","('NON-ESG', 0.16385036706924438)","('NON-ESG', 0.14055508375167847)"
Line 100,"This is a condition of employment at BD.
","('Labor_Practices', 0.9177292585372925)","('Employee_Engagement_Inclusion_And_Diversity', 0.02031286619603634)","('Employee_Health_And_Safety', 0.005260281264781952)","(['Labor Practice Indicators'], 0.9177292585372925)","('NON-ESG', 0.02031286619603634)","('NON-ESG', 0.005260281264781952)"
Line 101,"Our  code is available in English and 20 other languages.
","('Employee_Engagement_Inclusion_And_Diversity', 0.20076853036880493)","('Access_And_Affordability', 0.12598523497581482)","('Management_Of_Legal_And_Regulatory_Framework', 0.10344691574573517)","('NON-ESG', 0.20076853036880493)","('NON-ESG', 0.12598523497581482)","('NON-ESG', 0.10344691574573517)"
Line 102,"All  associates are required to complete training on our code  annually, and the code is easily accessible to all associates on  our company intranet pages.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4088619351387024)","('Business_Ethics', 0.12998373806476593)","('Customer_Privacy', 0.07797784358263016)","('NON-ESG', 0.4088619351387024)","('NON-ESG', 0.12998373806476593)","('NON-ESG', 0.07797784358263016)"
Line 103,"Our Code of Conduct is available on our website  and through  our Ethics and Compliance mobile app for BD associates.How we do business Ethics and compliance Code of Conduct Antibribery and anticorruptionGRI disclosure: 102-GRI disclosure: 102-GRI disclosure: 102-169At BD, we are committed to operating in a way that respects the  human rights of all associates, as well as the people in our  supply chains, the communities in which we operate and those  who are impacted by our products.
","('Business_Ethics', 0.9320303797721863)","('Human_Rights_And_Community_Relations', 0.010034557431936264)","('Management_Of_Legal_And_Regulatory_Framework', 0.006280108820647001)","(['Business Ethics'], 0.9320303797721863)","('NON-ESG', 0.010034557431936264)","('NON-ESG', 0.006280108820647001)"
Line 104,"Rather than doing the minimum required, BD is focused on  doing what is right .
","('Management_Of_Legal_And_Regulatory_Framework', 0.26052576303482056)","('Human_Rights_And_Community_Relations', 0.15896187722682953)","('Business_Ethics', 0.13491782546043396)","('NON-ESG', 0.26052576303482056)","('NON-ESG', 0.15896187722682953)","('NON-ESG', 0.13491782546043396)"
Line 105,"This value, along with the rest of our values,  guide our efforts on having a positive social impact across our  businesses and operations.
","('Human_Rights_And_Community_Relations', 0.9554004669189453)","('Access_And_Affordability', 0.0034248316660523415)","('Business_Model_Resilience', 0.0030652922578155994)","(['Community Relations'], 0.9554004669189453)","('NON-ESG', 0.0034248316660523415)","('NON-ESG', 0.0030652922578155994)"
Line 106,"Our commitment to human rights is guided by the principles  outlined in the UN Declaration of Human Rights, and extends  beyond BD processes and practices to those in our  supply chains.
","('Supply_Chain_Management', 0.9212615489959717)","('Labor_Practices', 0.008844456635415554)","('Human_Rights_And_Community_Relations', 0.007463687565177679)","(['Supply Chain Management'], 0.9212615489959717)","('NON-ESG', 0.008844456635415554)","('NON-ESG', 0.007463687565177679)"
Line 107,"We believe that all people should be treated with dignity and  respect, and we are committed to conducting our business in a  manner consistent with this principle.
","('Human_Rights_And_Community_Relations', 0.7882683873176575)","('Business_Ethics', 0.036270562559366226)","('Employee_Health_And_Safety', 0.023271098732948303)","(['Community Relations'], 0.7882683873176575)","('NON-ESG', 0.036270562559366226)","('NON-ESG', 0.023271098732948303)"
Line 108,"We comply with applicable employment and human rights laws  and regulations wherever we have operations; we expect our  suppliers to do the same.In all of our operations: • We provide a safe and healthy workplace for our associates.
","('Employee_Health_And_Safety', 0.5257472395896912)","('Human_Rights_And_Community_Relations', 0.11628420650959015)","('Labor_Practices', 0.10571835935115814)","(['Operational Eco-Efficiency'], 0.5257472395896912)","('NON-ESG', 0.11628420650959015)","('NON-ESG', 0.10571835935115814)"
Line 109,"• We do not use child labor.
","('Labor_Practices', 0.9705916047096252)","('Waste_And_Hazardous_Materials_Management', 0.002800801768898964)","('Director_Removal', 0.0024876969400793314)","(['Labor Practice Indicators'], 0.9705916047096252)","('NON-ESG', 0.002800801768898964)","('NON-ESG', 0.0024876969400793314)"
Line 110,"• We do not use forced, prison, indentured, bonded or  involuntary labor.
","('Labor_Practices', 0.9747187495231628)","('Director_Removal', 0.0024250245187431574)","('Waste_And_Hazardous_Materials_Management', 0.00191391259431839)","(['Labor Practice Indicators'], 0.9747187495231628)","('NON-ESG', 0.0024250245187431574)","('NON-ESG', 0.00191391259431839)"
Line 111,"• We prohibit discrimination in our hiring and  employment practices.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9130445718765259)","('Labor_Practices', 0.03415606915950775)","('Employee_Health_And_Safety', 0.005434224847704172)","(['Human Capital Development'], 0.9130445718765259)","('NON-ESG', 0.03415606915950775)","('NON-ESG', 0.005434224847704172)"
Line 112,"• We prohibit physical abuse and harassment of associates, as  well as the threat of either.
","('Employee_Health_And_Safety', 0.34439295530319214)","('Business_Ethics', 0.2603631317615509)","('Labor_Practices', 0.10454301536083221)","('NON-ESG', 0.34439295530319214)","('NON-ESG', 0.2603631317615509)","('NON-ESG', 0.10454301536083221)"
Line 113,"• We support the freedom of association and the rights of  workers and employers to bargain collectively.Our associates are expected to report any actual or suspected  violations of laws, the BD Code of Conduct, our policies or our  high ethical standards.
","('Labor_Practices', 0.9520971179008484)","('Business_Ethics', 0.009631561115384102)","('Director_Removal', 0.004418730270117521)","(['Labor Practice Indicators'], 0.9520971179008484)","('NON-ESG', 0.009631561115384102)","('NON-ESG', 0.004418730270117521)"
Line 114,"Associates can report these in a number  of ways, including via the BD Ethics Helpline, which is available  anywhere in the world 24 hours a day, 7 days a week.
","('Access_And_Affordability', 0.34546366333961487)","('Product_Quality_And_Safety', 0.07856437563896179)","('Business_Ethics', 0.07587067782878876)","('NON-ESG', 0.34546366333961487)","('NON-ESG', 0.07856437563896179)","('NON-ESG', 0.07587067782878876)"
Line 115,"Alternatively, associates may use our independently operated,  web-based reporting tool, where BD associates worldwide can  make a report in their native language from any computer or  mobile device with internet access.
","('Data_Security', 0.17633786797523499)","('Management_Of_Legal_And_Regulatory_Framework', 0.1641431599855423)","('Customer_Privacy', 0.09350864589214325)","('NON-ESG', 0.17633786797523499)","('NON-ESG', 0.1641431599855423)","('NON-ESG', 0.09350864589214325)"
Line 116,"The helpline provides  translation services as needed, and reports can be made  anonymously where permitted by law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21026960015296936)","('Access_And_Affordability', 0.18510259687900543)","('Customer_Privacy', 0.16180634498596191)","('NON-ESG', 0.21026960015296936)","('NON-ESG', 0.18510259687900543)","('NON-ESG', 0.16180634498596191)"
Line 117,"Associates can also  report violations to their supervisor, management, Human  Resources, the Law Group or directly to Ethics & Compliance.
","('Business_Ethics', 0.9592912793159485)","('Management_Of_Legal_And_Regulatory_Framework', 0.005251999944448471)","('Product_Quality_And_Safety', 0.003714409191161394)","(['Business Ethics'], 0.9592912793159485)","('NON-ESG', 0.005251999944448471)","('NON-ESG', 0.003714409191161394)"
Line 118,"Regardless of the outcome, associates are never penalized for  bringing such matters to the company’s attention in good faith.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5974921584129333)","('Business_Ethics', 0.261696994304657)","('Competitive_Behavior', 0.03531905263662338)","(['Corporate Governance'], 0.5974921584129333)","('NON-ESG', 0.261696994304657)","('NON-ESG', 0.03531905263662338)"
Line 119,"BD does not tolerate any form of retaliation.Local toll-free numbers for the helpline are included in our   Code of Conduct, and the web-based reporting tool can be  accessed from any computer or mobile device with internet  access from our website  or directly via our Ethics and  Compliance mobile app for BD associates.
","('Business_Ethics', 0.7802241444587708)","('Management_Of_Legal_And_Regulatory_Framework', 0.1314861923456192)","('Product_Quality_And_Safety', 0.009528541006147861)","(['Business Ethics'], 0.7802241444587708)","('NON-ESG', 0.1314861923456192)","('NON-ESG', 0.009528541006147861)"
Line 120,"In FY 2019, the Ethics Office received more than 800 contacts  from associates worldwide seeking guidance or reporting  concerns.
","('Business_Ethics', 0.9434796571731567)","('Management_Of_Legal_And_Regulatory_Framework', 0.013630801811814308)","('Director_Removal', 0.005334522575139999)","(['Business Ethics'], 0.9434796571731567)","('NON-ESG', 0.013630801811814308)","('NON-ESG', 0.005334522575139999)"
Line 121,"BD takes all reports of violations of laws, BD policies  and our high ethical standards seriously.
","('Business_Ethics', 0.9618366360664368)","('Management_Of_Legal_And_Regulatory_Framework', 0.005656360182911158)","('Product_Quality_And_Safety', 0.0048604803159832954)","(['Business Ethics'], 0.9618366360664368)","('NON-ESG', 0.005656360182911158)","('NON-ESG', 0.0048604803159832954)"
Line 122,"We promptly, fairly and  thoroughly investigate all reports.
","('Critical_Incident_Risk_Management', 0.2703165113925934)","('Business_Ethics', 0.11689437925815582)","('Customer_Privacy', 0.08751736581325531)","('NON-ESG', 0.2703165113925934)","('NON-ESG', 0.11689437925815582)","('NON-ESG', 0.08751736581325531)"
Line 123,"Depending on the findings,  we may take corrective action, such as discipline up to and  including termination of employment or providing  nondisciplinary-based training and process improvements in  areas where a gap has been identified.
","('Labor_Practices', 0.4534251391887665)","('Employee_Engagement_Inclusion_And_Diversity', 0.22442255914211273)","('Employee_Health_And_Safety', 0.0958208441734314)","('NON-ESG', 0.4534251391887665)","('NON-ESG', 0.22442255914211273)","('NON-ESG', 0.0958208441734314)"
Line 124,"GRI disclosure: 102-We comply with all applicable laws and regulations that govern  the interactions between medical technology companies and  healthcare professionals, healthcare organizations and  government officials in the many countries in which we do  business.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9651918411254883)","('Business_Ethics', 0.003894125111401081)","('Product_Quality_And_Safety', 0.0025153595488518476)","(['Corporate Governance'], 0.9651918411254883)","('NON-ESG', 0.003894125111401081)","('NON-ESG', 0.0025153595488518476)"
Line 125,"To help ensure compliance, BD has adopted various  industry codes, including the Advanced Medical Technology  Association (AdvaMed) Code of Ethics in the United States and  MedTech Europe Code of Ethics.
","('Business_Ethics', 0.961340606212616)","('Management_Of_Legal_And_Regulatory_Framework', 0.006567089818418026)","('Systemic_Risk_Management', 0.0030411703046411276)","(['Business Ethics'], 0.961340606212616)","('NON-ESG', 0.006567089818418026)","('NON-ESG', 0.0030411703046411276)"
Line 126,"BD associates receive  information and training about these codes in a number of  ways, including periodic communications, and online and in-person trainings at conferences and meetings.
","('Management_Of_Legal_And_Regulatory_Framework', 0.19349786639213562)","('Product_Quality_And_Safety', 0.17731310427188873)","('Employee_Engagement_Inclusion_And_Diversity', 0.1222713366150856)","('NON-ESG', 0.19349786639213562)","('NON-ESG', 0.17731310427188873)","('NON-ESG', 0.1222713366150856)"
Line 127,"Associates can  access detailed information on our expectations through our  intranet and our Ethics and Compliance mobile app.
","('Business_Ethics', 0.9568812847137451)","('Management_Of_Legal_And_Regulatory_Framework', 0.009285627864301205)","('Product_Quality_And_Safety', 0.0038337919395416975)","(['Business Ethics'], 0.9568812847137451)","('NON-ESG', 0.009285627864301205)","('NON-ESG', 0.0038337919395416975)"
Line 128,"Key  provisions of applicable industry codes are also incorporated  into various global policies, including the Global Standards for  Interactions with Healthcare Professionals, Healthcare  Organizations and Government Officials.
","('Management_Of_Legal_And_Regulatory_Framework', 0.751238226890564)","('Business_Ethics', 0.09127715975046158)","('Product_Quality_And_Safety', 0.040503520518541336)","(['Corporate Governance'], 0.751238226890564)","('NON-ESG', 0.09127715975046158)","('NON-ESG', 0.040503520518541336)"
Line 129,"GRI disclosure: 102-16   SASB disclosure: HC-MS-510a.2Reporting ethics concerns Interactions with healthcare professionals Human rights10Our goal is to provide an executive compensation program that  best serves the long-term interests of our shareholders.
","('Business_Ethics', 0.965286135673523)","('Management_Of_Legal_And_Regulatory_Framework', 0.004138266667723656)","('Competitive_Behavior', 0.0030087889172136784)","(['Business Ethics'], 0.965286135673523)","('NON-ESG', 0.004138266667723656)","('NON-ESG', 0.0030087889172136784)"
Line 130,"We  believe that attracting and retaining superior talent and  rewarding performance is key to delivering long-term shareholder returns, and that a competitive compensation  program is critical to that end.
","('Competitive_Behavior', 0.8856255412101746)","('Business_Model_Resilience', 0.019632278010249138)","('Employee_Engagement_Inclusion_And_Diversity', 0.015421230345964432)","(['Business Ethics'], 0.8856255412101746)","('NON-ESG', 0.019632278010249138)","('NON-ESG', 0.015421230345964432)"
Line 131,"For further details of executive  compensation, see our  proxy statements .• Policies   – BD Code of Conduct , which reinforces our commitment      to human rights and details how to report suspected      violations anywhere in our supply chain   – BD Expectations for Suppliers , our code of conduct      designed for our thousands of suppliers • Practices geared towards ensuring modern slavery and  human trafficking do not exist in our workforce and those of  our suppliers.
","('Labor_Practices', 0.37942180037498474)","('Supply_Chain_Management', 0.1819765865802765)","('Employee_Health_And_Safety', 0.12461069971323013)","('NON-ESG', 0.37942180037498474)","('NON-ESG', 0.1819765865802765)","('NON-ESG', 0.12461069971323013)"
Line 132,"– We do not charge any of our associates recruitment fees,      and do not work with recruitment agencies that engage in      this practice.
","('Employee_Engagement_Inclusion_And_Diversity', 0.757716953754425)","('Labor_Practices', 0.06552497297525406)","('Competitive_Behavior', 0.02873568795621395)","(['Human Capital Development'], 0.757716953754425)","('NON-ESG', 0.06552497297525406)","('NON-ESG', 0.02873568795621395)"
Line 133,"– We do not withhold identity documents, immigration      documents, or any other personal documentation of      our associates.
","('Customer_Privacy', 0.9350587129592896)","('Labor_Practices', 0.006679673213511705)","('Employee_Engagement_Inclusion_And_Diversity', 0.005545914638787508)","(['Privacy Protection'], 0.9350587129592896)","('NON-ESG', 0.006679673213511705)","('NON-ESG', 0.005545914638787508)"
Line 134,"– We encourage our associates to report, without fear of      retaliation, any matters related to human trafficking,      modern slavery or any other human rights violations.• Due diligence, including initial assessments of suppliers  against 12 risk factors including ESG risk • Risk management efforts to ensure compliance against  related policies throughout our operations   – For example, our Global Operations and Human Resources      teams work to ensure compliance with our policies      prohibiting forced labor, human trafficking and modern      slavery across all of our operations, including      manufacturing operations.
","('Human_Rights_And_Community_Relations', 0.7024831175804138)","('Business_Ethics', 0.09615571796894073)","('Employee_Health_And_Safety', 0.03230034187436104)","(['Community Relations'], 0.7024831175804138)","('NON-ESG', 0.09615571796894073)","('NON-ESG', 0.03230034187436104)"
Line 135,"– We encourage our associates to report, without fear of      retaliation, any matters related to human trafficking,      modern slavery or any other human rights violations.• Due diligence, including initial assessments of suppliers  against 12 risk factors including ESG risk • Risk management efforts to ensure compliance against  related policies throughout our operations   – For example, our Global Operations and Human Resources      teams work to ensure compliance with our policies      prohibiting forced labor, human trafficking and modern      slavery across all of our operations, including      manufacturing operations.
","('Labor_Practices', 0.8114003539085388)","('Employee_Health_And_Safety', 0.04418933764100075)","('Business_Ethics', 0.030146466568112373)","(['Labor Practice Indicators'], 0.8114003539085388)","('NON-ESG', 0.04418933764100075)","('NON-ESG', 0.030146466568112373)"
Line 136,"• Training and capacity building, both internally and for  key suppliers BD strives to continuously improve its programs to ensure  compliance with applicable laws and high ethical standards to  meet the expectations of our customers, shareholders,  associates, communities and other stakeholders.
","('Business_Ethics', 0.22516389191150665)","('Management_Of_Legal_And_Regulatory_Framework', 0.19863514602184296)","('Product_Quality_And_Safety', 0.18374261260032654)","('NON-ESG', 0.22516389191150665)","('NON-ESG', 0.19863514602184296)","('NON-ESG', 0.18374261260032654)"
Line 137,"Our Corporate Governance Principles outline how we hold  ourselves accountable to shareholders and stakeholders.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5729523301124573)","('Business_Ethics', 0.14361624419689178)","('Director_Removal', 0.05039451643824577)","(['Corporate Governance'], 0.5729523301124573)","('NON-ESG', 0.14361624419689178)","('NON-ESG', 0.05039451643824577)"
Line 138,"These principles address the operation of our Board and its  committees; strategic and succession planning; director  qualifications, independence, compensation and equity ownership; and the ability of shareholders and others to  communicate directly with Board members.
","('Director_Removal', 0.7614567875862122)","('Management_Of_Legal_And_Regulatory_Framework', 0.033863604068756104)","('Employee_Engagement_Inclusion_And_Diversity', 0.023663967847824097)","(['Anti-Crime Policy & Measures'], 0.7614567875862122)","('NON-ESG', 0.033863604068756104)","('NON-ESG', 0.023663967847824097)"
Line 139,"Further details can be found on the Corporate   Governance website .
","('Management_Of_Legal_And_Regulatory_Framework', 0.6690994501113892)","('Business_Ethics', 0.07235395163297653)","('Competitive_Behavior', 0.05843741446733475)","(['Corporate Governance'], 0.6690994501113892)","('NON-ESG', 0.07235395163297653)","('NON-ESG', 0.05843741446733475)"
Line 140,"BD is governed by a Board of Directors consisting of 12  members, 11 of whom are independent.
","('Director_Removal', 0.7398785948753357)","('Management_Of_Legal_And_Regulatory_Framework', 0.03171154484152794)","('Business_Ethics', 0.024278130382299423)","(['Anti-Crime Policy & Measures'], 0.7398785948753357)","('NON-ESG', 0.03171154484152794)","('NON-ESG', 0.024278130382299423)"
Line 141,"Our Board  members  have a variety of backgrounds, which reflects our continuing  efforts to achieve a diversity of viewpoints, experiences and  knowledge, as well as ethnicities and genders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9734119176864624)","('Human_Rights_And_Community_Relations', 0.0017346463864669204)","('Customer_Privacy', 0.001684514107182622)","(['Human Capital Development'], 0.9734119176864624)","('NON-ESG', 0.0017346463864669204)","('NON-ESG', 0.001684514107182622)"
Line 142,"Our Board is  comprised of four female directors and eight male directors, one  of whom is African American.There are five operating Board  committees (listed below) and  an executive committee that meets only as needed: • Audit • Compensation and Management Development • Corporate Governance and Nominating • Quality and Regulatory • Science, Marketing, Innovation and Technology A charter for each committee outlines its mission, the  qualifications required for membership and its members’ duties.
","('Director_Removal', 0.6167209148406982)","('Employee_Engagement_Inclusion_And_Diversity', 0.103615902364254)","('Management_Of_Legal_And_Regulatory_Framework', 0.04121280089020729)","(['Anti-Crime Policy & Measures'], 0.6167209148406982)","('NON-ESG', 0.103615902364254)","('NON-ESG', 0.04121280089020729)"
Line 143,"See more about our Board of Directors on the Corporate  Governance website .
","('Director_Removal', 0.6804164052009583)","('Management_Of_Legal_And_Regulatory_Framework', 0.061613306403160095)","('Business_Model_Resilience', 0.02942848764359951)","(['Anti-Crime Policy & Measures'], 0.6804164052009583)","('NON-ESG', 0.061613306403160095)","('NON-ESG', 0.02942848764359951)"
Line 144,"Executive compensationBoard compositionCorporate governance Corporate Governance Principles GRI disclosures: 102-18, 102-22, 102-23, 102-24, 102-25, 102-28, 102-Leadership recognition FORTUNE’s  America’s Most Innovative Leaders List   (Vince Forlenza ranked #41) AdvaMed—Lifetime Achievement Award for BD Board  Member, Catherine BurzikBD has programs in place to monitor and advance human rights  efforts throughout the company.
","('Human_Rights_And_Community_Relations', 0.9330275654792786)","('Access_And_Affordability', 0.007124160882085562)","('Business_Ethics', 0.00604459410533309)","(['Community Relations'], 0.9330275654792786)","('NON-ESG', 0.007124160882085562)","('NON-ESG', 0.00604459410533309)"
Line 145,"These include:11Strong, long-term relationships with policymakers help   us better understand unmet public health needs around   the world.
","('Access_And_Affordability', 0.39312365651130676)","('Critical_Incident_Risk_Management', 0.1529478281736374)","('Employee_Health_And_Safety', 0.06580410152673721)","('NON-ESG', 0.39312365651130676)","('NON-ESG', 0.1529478281736374)","('NON-ESG', 0.06580410152673721)"
Line 146,"BD engages in public policy advocacy through ongoing,  constructive and transparent interactions with government  officials and stakeholder groups.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9026817679405212)","('Human_Rights_And_Community_Relations', 0.029153093695640564)","('Access_And_Affordability', 0.008710997179150581)","(['Corporate Governance'], 0.9026817679405212)","('NON-ESG', 0.029153093695640564)","('NON-ESG', 0.008710997179150581)"
Line 147,"All advocacy activities are  directed toward furthering the company’s Purpose of advancing  the world of health ™, without regard to the personal political  affiliations or views of any individual BD associates at any level  across the organization.
","('Employee_Engagement_Inclusion_And_Diversity', 0.23022302985191345)","('Management_Of_Legal_And_Regulatory_Framework', 0.12620025873184204)","('Competitive_Behavior', 0.11860328167676926)","('NON-ESG', 0.23022302985191345)","('NON-ESG', 0.12620025873184204)","('NON-ESG', 0.11860328167676926)"
Line 148,"We employ public policy professionals who work closely with our country and business leaders to make  constructive contributions to policy discussions relevant to the  company and to the communities in which we operate.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8204604387283325)","('Human_Rights_And_Community_Relations', 0.0737004280090332)","('Physical_Impacts_Of_Climate_Change', 0.011296343989670277)","(['Corporate Governance'], 0.8204604387283325)","('NON-ESG', 0.0737004280090332)","('NON-ESG', 0.011296343989670277)"
Line 149,"We  leverage our diverse expertise, global reach and collaborations  with healthcare professionals, patients and others to advance  sound public policy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.26876989006996155)","('Employee_Engagement_Inclusion_And_Diversity', 0.18240876495838165)","('Access_And_Affordability', 0.08935270458459854)","('NON-ESG', 0.26876989006996155)","('NON-ESG', 0.18240876495838165)","('NON-ESG', 0.08935270458459854)"
Line 150,"Our participation in the political process, including lobbying and  the BD Political Action Committee “PAC”, is governed by the  Board of Directors and the Executive Leadership team.Participation in the political process In areas where BD has deep experience, the company develops  public policy positions that guide our advocacy efforts  worldwide.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7960666418075562)","('Human_Rights_And_Community_Relations', 0.04202662408351898)","('Director_Removal', 0.021586120128631592)","(['Corporate Governance'], 0.7960666418075562)","('NON-ESG', 0.04202662408351898)","('NON-ESG', 0.021586120128631592)"
Line 151,"We currently have a range of global public policy  positions available online .
","('Management_Of_Legal_And_Regulatory_Framework', 0.8934966921806335)","('Human_Rights_And_Community_Relations', 0.013917071744799614)","('Competitive_Behavior', 0.009334568865597248)","(['Corporate Governance'], 0.8934966921806335)","('NON-ESG', 0.013917071744799614)","('NON-ESG', 0.009334568865597248)"
Line 152,"We also engage in policy dialogues to advance regulatory and  reimbursement frameworks that ensure the safety and efficacy of medical technologies while enabling timely patient access to  them.
","('Product_Quality_And_Safety', 0.863268256187439)","('Employee_Health_And_Safety', 0.018854234367609024)","('Selling_Practices_And_Product_Labeling', 0.016076181083917618)","(['Product Quality & Recall Management'], 0.863268256187439)","('NON-ESG', 0.018854234367609024)","('NON-ESG', 0.016076181083917618)"
Line 153,"We promote sensible tax policies that enhance  competitiveness and innovation, support policies and programs  that advance biomedical research and seek to expand access to  care for all people.Public policy advocacyThe Center for Political Accountability (CPA)  recognized BD  with a first-place rating of 100% on their 2019 corporate political  disclosure and accountability index.
","('Management_Of_Legal_And_Regulatory_Framework', 0.927709698677063)","('Competitive_Behavior', 0.024052415043115616)","('Business_Ethics', 0.005555621813982725)","(['Corporate Governance'], 0.927709698677063)","('NON-ESG', 0.024052415043115616)","('NON-ESG', 0.005555621813982725)"
Line 154,"The ranking benchmarks  Fortune 500 companies and is produced by CPA in conjunction  with the Zicklin Center for Business Ethics Research at the Wharton School at the University of Pennsylvania.
","('Business_Ethics', 0.6705375909805298)","('Systemic_Risk_Management', 0.1359570175409317)","('Competitive_Behavior', 0.07247965037822723)","(['Business Ethics'], 0.6705375909805298)","('NON-ESG', 0.1359570175409317)","('NON-ESG', 0.07247965037822723)"
Line 155,"This is the  third year in a row that BD has received a perfect score for the  transparency with which we conduct our political engagement,  and it is a designation that investors watch.Engaging in a transparent manner 12* Data represents calendar years (including Bard data) †Trade associations: AdvaMed, Healthcare Institute of New Jersey, California Life Sciences Association, North Carolina Biosciences Organization ‡Issue-based coalitions: Diagnostic Test Working Group, Medical Device Competitiveness Coalition, Physicians Fee Schedule Pathology Payment Coalition, United for Medical Research$809,623  Public policy consultants$690,BD associates$102,Issue-based coalitions† $196,Trade associations‡ $1,798,2302018*Role of political contributions The company prohibits the use of corporate funds and assets to  support U.S. federal or state candidates, political parties, ballot  measures or referendum campaigns.
","('Business_Ethics', 0.6481402516365051)","('Competitive_Behavior', 0.20539434254169464)","('Systemic_Risk_Management', 0.03441477194428444)","(['Business Ethics'], 0.6481402516365051)","('NON-ESG', 0.20539434254169464)","('NON-ESG', 0.03441477194428444)"
Line 156,"This is the  third year in a row that BD has received a perfect score for the  transparency with which we conduct our political engagement,  and it is a designation that investors watch.Engaging in a transparent manner 12* Data represents calendar years (including Bard data) †Trade associations: AdvaMed, Healthcare Institute of New Jersey, California Life Sciences Association, North Carolina Biosciences Organization ‡Issue-based coalitions: Diagnostic Test Working Group, Medical Device Competitiveness Coalition, Physicians Fee Schedule Pathology Payment Coalition, United for Medical Research$809,623  Public policy consultants$690,BD associates$102,Issue-based coalitions† $196,Trade associations‡ $1,798,2302018*Role of political contributions The company prohibits the use of corporate funds and assets to  support U.S. federal or state candidates, political parties, ballot  measures or referendum campaigns.
","('Management_Of_Legal_And_Regulatory_Framework', 0.906611979007721)","('Competitive_Behavior', 0.015422348864376545)","('Business_Ethics', 0.012436875142157078)","(['Corporate Governance'], 0.906611979007721)","('NON-ESG', 0.015422348864376545)","('NON-ESG', 0.012436875142157078)"
Line 157,"Exceptions to this policy  require approval by the CEO, the general counsel and a  designated member of the Board of Directors Corporate Nominating and Governance Committee.
","('Director_Removal', 0.6434741020202637)","('Management_Of_Legal_And_Regulatory_Framework', 0.16185332834720612)","('Business_Ethics', 0.021495409309864044)","(['Anti-Crime Policy & Measures'], 0.6434741020202637)","('NON-ESG', 0.16185332834720612)","('NON-ESG', 0.021495409309864044)"
Line 158,"To date, no  exceptions have been sought or approved.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7158582806587219)","('Competitive_Behavior', 0.07855161279439926)","('GHG_Emissions', 0.020365891978144646)","(['Corporate Governance'], 0.7158582806587219)","('NON-ESG', 0.07855161279439926)","('NON-ESG', 0.020365891978144646)"
Line 159,"Certain conditions must also be met for any political  contributions outside of the United States.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8132700324058533)","('Director_Removal', 0.02935843914747238)","('Labor_Practices', 0.021626610308885574)","(['Corporate Governance'], 0.8132700324058533)","('NON-ESG', 0.02935843914747238)","('NON-ESG', 0.021626610308885574)"
Line 160,"$848,008  Public policy consultants$592,BD associates$112,Issue-based coalitions† $193,Trade associations‡ $1,746,1252019* For calendar year 2019, the company spent approximately $1.7  million on salaries and expenses associated with lobbying in the  United States, which was roughly the same as the company’s  2018 expenditure.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8568288683891296)","('Labor_Practices', 0.02301044948399067)","('Director_Removal', 0.022902250289916992)","(['Corporate Governance'], 0.8568288683891296)","('NON-ESG', 0.02301044948399067)","('NON-ESG', 0.022902250289916992)"
Line 161,"We file quarterly reports regarding our federal  lobbying activities with the Office of the Clerk of the House of  Representatives and the Secretary of the Senate.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7678780555725098)","('Competitive_Behavior', 0.04298340529203415)","('Director_Removal', 0.020363427698612213)","(['Corporate Governance'], 0.7678780555725098)","('NON-ESG', 0.04298340529203415)","('NON-ESG', 0.020363427698612213)"
Line 162,"The BD PAC contributed a total of $101,000 to candidates in 2019, an  increase of approximately $16,000 over the prior year.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5470260977745056)","('Competitive_Behavior', 0.06092219054698944)","('Director_Removal', 0.05479131266474724)","(['Corporate Governance'], 0.5470260977745056)","('NON-ESG', 0.06092219054698944)","('NON-ESG', 0.05479131266474724)"
Line 163,"All contributions made by the BD PAC are also publicly reported.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8094926476478577)","('Director_Removal', 0.021455014124512672)","('Business_Ethics', 0.01932338997721672)","(['Corporate Governance'], 0.8094926476478577)","('NON-ESG', 0.021455014124512672)","('NON-ESG', 0.01932338997721672)"
Line 164,"For details on U.S. lobby expenditures by year, visit our website .As permitted under U.S. law, the company operates a political  action committee.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8317071199417114)","('Energy_Management', 0.022674938663840294)","('Competitive_Behavior', 0.020974650979042053)","(['Corporate Governance'], 0.8317071199417114)","('NON-ESG', 0.022674938663840294)","('NON-ESG', 0.020974650979042053)"
Line 165,"The BD PAC is a mechanism to enable  eligible U.S. associates to voluntarily support candidates for  elected office who share our perspectives and approaches to  public policy issues.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8155152201652527)","('Competitive_Behavior', 0.025213731452822685)","('Human_Rights_And_Community_Relations', 0.024875199422240257)","(['Corporate Governance'], 0.8155152201652527)","('NON-ESG', 0.025213731452822685)","('NON-ESG', 0.024875199422240257)"
Line 166,"BD has not authorized the establishment of  any PACs operating on the state or local level.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9352332949638367)","('Human_Rights_And_Community_Relations', 0.0078052617609500885)","('Director_Removal', 0.005823524668812752)","(['Corporate Governance'], 0.9352332949638367)","('NON-ESG', 0.0078052617609500885)","('NON-ESG', 0.005823524668812752)"
Line 167,"Contributions to the BD PAC are entirely voluntary and are governed by the   BD PAC Bylaws.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9040431976318359)","('Business_Ethics', 0.01332793664187193)","('Director_Removal', 0.012550760991871357)","(['Corporate Governance'], 0.9040431976318359)","('NON-ESG', 0.01332793664187193)","('NON-ESG', 0.012550760991871357)"
Line 168,"BD provides administrative support to the PAC,  as permitted under federal law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9277307391166687)","('Business_Ethics', 0.02050384320318699)","('Competitive_Behavior', 0.007028114981949329)","(['Corporate Governance'], 0.9277307391166687)","('NON-ESG', 0.02050384320318699)","('NON-ESG', 0.007028114981949329)"
Line 169,"For annual reporting of itemized PAC contributions and any  other corporate contributions, visit our website .Political Action Committee: BD PAC U.S. lobbying expenditures GRI disclosure: 415-113Ensuring product safety At BD, we create value for our patients and customers through predictable delivery of differentiated, high-value products and solutions.
","('Product_Quality_And_Safety', 0.5028199553489685)","('Product_Design_And_Lifecycle_Management', 0.27132681012153625)","('Selling_Practices_And_Product_Labeling', 0.05479293316602707)","(['Product Quality & Recall Management'], 0.5028199553489685)","('NON-ESG', 0.27132681012153625)","('NON-ESG', 0.05479293316602707)"
Line 170,"We work relentlessly to develop solutions that advance healthcare and improve worker and patient safety.
","('Employee_Health_And_Safety', 0.9811697602272034)","('Critical_Incident_Risk_Management', 0.002583865774795413)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015237251063808799)","(['Operational Eco-Efficiency'], 0.9811697602272034)","('NON-ESG', 0.002583865774795413)","('NON-ESG', 0.0015237251063808799)"
Line 171,"Product safety is at the heart of how we design, manufacture and deliver products.
","('Product_Quality_And_Safety', 0.8017686605453491)","('Product_Design_And_Lifecycle_Management', 0.08389435708522797)","('Selling_Practices_And_Product_Labeling', 0.017426280304789543)","(['Product Quality & Recall Management'], 0.8017686605453491)","('NON-ESG', 0.08389435708522797)","('NON-ESG', 0.017426280304789543)"
Line 172,"This section details some of that work.
","('Management_Of_Legal_And_Regulatory_Framework', 0.14635568857192993)","('Ecological_Impacts', 0.10354364663362503)","('Business_Model_Resilience', 0.08300095051527023)","('NON-ESG', 0.14635568857192993)","('NON-ESG', 0.10354364663362503)","('NON-ESG', 0.08300095051527023)"
Line 173,"In addition to designing quality into our products, it is essential  to implement best-in-class supplier quality programs.
","('Product_Design_And_Lifecycle_Management', 0.9355831742286682)","('Product_Quality_And_Safety', 0.01269439235329628)","('Supply_Chain_Management', 0.010156269185245037)","(['Product Stewardship'], 0.9355831742286682)","('NON-ESG', 0.01269439235329628)","('NON-ESG', 0.010156269185245037)"
Line 174,"The Global  Procurement function partners with the Quality function to  ensure that we clearly define the impact suppliers of materials  and services can have on BD products and put the appropriate  controls in place when selecting, approving and maintaining  our suppliers.
","('Product_Design_And_Lifecycle_Management', 0.9283327460289001)","('Supply_Chain_Management', 0.01648949459195137)","('Product_Quality_And_Safety', 0.00835074856877327)","(['Product Stewardship'], 0.9283327460289001)","('NON-ESG', 0.01648949459195137)","('NON-ESG', 0.00835074856877327)"
Line 175,"Our supplier management program oversees the quality and  safety practices of all our suppliers.
","('Supply_Chain_Management', 0.5712883472442627)","('Employee_Health_And_Safety', 0.09734675288200378)","('Product_Quality_And_Safety', 0.08798834681510925)","(['Supply Chain Management'], 0.5712883472442627)","('NON-ESG', 0.09734675288200378)","('NON-ESG', 0.08798834681510925)"
Line 176,"Our program focuses  on four areas: • Performance management  comprises the procedures that  govern how BD identifies, classifies and assesses the  qualifications of our suppliers, and manages our relationship  with each of them.• Supplier continuous improvement programs  employ our  operational excellence methodologies (Lean and Six Sigma),  with specific vendors to define, plan and execute projects that  bring significant improvements in performance, savings and  overall value to BD.
","('Supply_Chain_Management', 0.9495901465415955)","('Labor_Practices', 0.004323913715779781)","('Systemic_Risk_Management', 0.003928754478693008)","(['Supply Chain Management'], 0.9495901465415955)","('NON-ESG', 0.004323913715779781)","('NON-ESG', 0.003928754478693008)"
Line 177,"• Supplier engagement  is central to our ability to identify and  partner with suppliers capable of bringing innovation and new  technology to the market.
","('Supply_Chain_Management', 0.9350934028625488)","('Product_Design_And_Lifecycle_Management', 0.009749376215040684)","('Business_Model_Resilience', 0.0041002859361469746)","(['Supply Chain Management'], 0.9350934028625488)","('NON-ESG', 0.009749376215040684)","('NON-ESG', 0.0041002859361469746)"
Line 178,"• Supply base risk management  quantifies and mitigates  risks posed to our supply chains, such as business  discontinuity, financial liquidity, price fluctuations  and pandemics.Product quality and safety As BD continues to introduce innovative technologies, our robust quality and regulatory management ensures we deliver to the  highest standards to the millions of people who use our products each day.
","('Product_Design_And_Lifecycle_Management', 0.504089891910553)","('Product_Quality_And_Safety', 0.35163185000419617)","('Selling_Practices_And_Product_Labeling', 0.020085301250219345)","(['Product Stewardship'], 0.504089891910553)","('NON-ESG', 0.35163185000419617)","('NON-ESG', 0.020085301250219345)"
Line 179,"Our Quality Policy guides us to consistently provide  superior products and services worldwide, achieved through customer focus, continuous improvement and maintaining an effective  quality system.
","('Product_Design_And_Lifecycle_Management', 0.9137154817581177)","('Product_Quality_And_Safety', 0.029973622411489487)","('Customer_Welfare', 0.007849348708987236)","(['Product Stewardship'], 0.9137154817581177)","('NON-ESG', 0.029973622411489487)","('NON-ESG', 0.007849348708987236)"
Line 180,"From our suppliers, we expect superior levels of service, quality, cost effectiveness and innovation.
","('Supply_Chain_Management', 0.5757796764373779)","('Product_Design_And_Lifecycle_Management', 0.25639936327934265)","('Business_Model_Resilience', 0.022631026804447174)","(['Supply Chain Management'], 0.5757796764373779)","('NON-ESG', 0.25639936327934265)","('NON-ESG', 0.022631026804447174)"
Line 181,"Finally, compliance  with existing and emerging regulations is the foundation of what we do.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9680442810058594)","('Competitive_Behavior', 0.0023256205022335052)","('Director_Removal', 0.002037640893831849)","(['Corporate Governance'], 0.9680442810058594)","('NON-ESG', 0.0023256205022335052)","('NON-ESG', 0.002037640893831849)"
Line 182,"Quality management plays a key role in our success by “making  quality certain."" We are driven by our vision of an organization  where transactions are correct the first time, where efficient and  effective processes drive our competitiveness and where all  associates can successfully demonstrate the intent and spirit of  the Quality Policy.
","('Competitive_Behavior', 0.35450997948646545)","('Business_Model_Resilience', 0.2663196623325348)","('Systemic_Risk_Management', 0.07741998881101608)","('NON-ESG', 0.35450997948646545)","('NON-ESG', 0.2663196623325348)","('NON-ESG', 0.07741998881101608)"
Line 183,"Our quality systems help ensure compliance with applicable  global regulations and establish standards for product design,  manufacturing and distribution.
","('Product_Quality_And_Safety', 0.7625312209129333)","('Product_Design_And_Lifecycle_Management', 0.07301977276802063)","('Management_Of_Legal_And_Regulatory_Framework', 0.028069455176591873)","(['Product Quality & Recall Management'], 0.7625312209129333)","('NON-ESG', 0.07301977276802063)","('NON-ESG', 0.028069455176591873)"
Line 184,"Prior to marketing or selling  most of our products, we must secure approval or clearance   from the FDA and counterpart regulatory agencies outside of  the United States.
","('Selling_Practices_And_Product_Labeling', 0.46442335844039917)","('Management_Of_Legal_And_Regulatory_Framework', 0.15380384027957916)","('Product_Quality_And_Safety', 0.10046819597482681)","('NON-ESG', 0.46442335844039917)","('NON-ESG', 0.15380384027957916)","('NON-ESG', 0.10046819597482681)"
Line 185,"Once BD introduces a product into the market,  the FDA and counterpart regulatory agencies outside of the  United States periodically review our quality systems and  product performance.
","('Product_Quality_And_Safety', 0.5445327162742615)","('Selling_Practices_And_Product_Labeling', 0.13641691207885742)","('Product_Design_And_Lifecycle_Management', 0.08049968630075455)","(['Product Quality & Recall Management'], 0.5445327162742615)","('NON-ESG', 0.13641691207885742)","('NON-ESG', 0.08049968630075455)"
Line 186,"We regularly analyze our quality processes  and specifications to ensure efficiency and effectiveness.
","('Product_Design_And_Lifecycle_Management', 0.5707857608795166)","('Supply_Chain_Management', 0.06633484363555908)","('Product_Quality_And_Safety', 0.06253515183925629)","(['Product Stewardship'], 0.5707857608795166)","('NON-ESG', 0.06633484363555908)","('NON-ESG', 0.06253515183925629)"
Line 187,"When an associate joins BD, they complete training on the  quality and regulatory requirements for the medical device  industry as part of their orientation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.951331615447998)","('Product_Quality_And_Safety', 0.006806735880672932)","('Business_Ethics', 0.004888295661658049)","(['Corporate Governance'], 0.951331615447998)","('NON-ESG', 0.006806735880672932)","('NON-ESG', 0.004888295661658049)"
Line 188,"All associates receive   the required training to perform their roles and responsibilities  effectively.
","('Human_Rights_And_Community_Relations', 0.2858516275882721)","('Management_Of_Legal_And_Regulatory_Framework', 0.1785620003938675)","('Employee_Engagement_Inclusion_And_Diversity', 0.11758743226528168)","('NON-ESG', 0.2858516275882721)","('NON-ESG', 0.1785620003938675)","('NON-ESG', 0.11758743226528168)"
Line 189,"Quality management and training All BD manufacturing locations operate under a certified quality  system.
","('Product_Quality_And_Safety', 0.5041624903678894)","('Business_Ethics', 0.0733058899641037)","('Product_Design_And_Lifecycle_Management', 0.06036800518631935)","(['Product Quality & Recall Management'], 0.5041624903678894)","('NON-ESG', 0.0733058899641037)","('NON-ESG', 0.06036800518631935)"
Line 190,"For the vast majority (100 sites), this is ISO 13485:2016  Medical Device Quality System.
","('Product_Quality_And_Safety', 0.634752094745636)","('Business_Ethics', 0.061271559447050095)","('Employee_Health_And_Safety', 0.03223191201686859)","(['Product Quality & Recall Management'], 0.634752094745636)","('NON-ESG', 0.061271559447050095)","('NON-ESG', 0.03223191201686859)"
Line 191,"We have a few sites which  operate under a more general ISO 9001:2015 system as they  manufacture products for research use only.
","('Product_Design_And_Lifecycle_Management', 0.9539567232131958)","('Product_Quality_And_Safety', 0.01077516283839941)","('Customer_Welfare', 0.003987451083958149)","(['Product Stewardship'], 0.9539567232131958)","('NON-ESG', 0.01077516283839941)","('NON-ESG', 0.003987451083958149)"
Line 192,"All sites with an   ISO 13485 or 9001 quality system undergo an annual  surveillance audit to assure conformance of the QMS to the  standards.
","('Product_Quality_And_Safety', 0.4161035716533661)","('Management_Of_Legal_And_Regulatory_Framework', 0.2469705492258072)","('Business_Ethics', 0.0544743612408638)","('NON-ESG', 0.4161035716533661)","('NON-ESG', 0.2469705492258072)","('NON-ESG', 0.0544743612408638)"
Line 193,"Additionally, BD has 23 sites which have a Medical Device Single Audit Program (MDSAP) ISO 13485:2016  certification.
","('Product_Quality_And_Safety', 0.43279600143432617)","('Management_Of_Legal_And_Regulatory_Framework', 0.12266338616609573)","('Access_And_Affordability', 0.10802744328975677)","('NON-ESG', 0.43279600143432617)","('NON-ESG', 0.12266338616609573)","('NON-ESG', 0.10802744328975677)"
Line 194,"The certification program includes regulations for  five countries and these audits are shared with the competent  authorities in these countries.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8435177206993103)","('Product_Quality_And_Safety', 0.042354606091976166)","('Business_Ethics', 0.01792037859559059)","(['Corporate Governance'], 0.8435177206993103)","('NON-ESG', 0.042354606091976166)","('NON-ESG', 0.01792037859559059)"
Line 195,"The MDSAP participating  countries are Australia, Brazil, Canada, Japan and the United  States.
","('Management_Of_Legal_And_Regulatory_Framework', 0.39001256227493286)","('Competitive_Behavior', 0.13049359619617462)","('GHG_Emissions', 0.06462765485048294)","('NON-ESG', 0.39001256227493286)","('NON-ESG', 0.13049359619617462)","('NON-ESG', 0.06462765485048294)"
Line 196,"MSDAP audits are conducted by third-party notified  bodies which are themselves certified by the five member  countries as auditing organizations for the program.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8712862133979797)","('Business_Ethics', 0.038827452808618546)","('Systemic_Risk_Management', 0.0113566555082798)","(['Corporate Governance'], 0.8712862133979797)","('NON-ESG', 0.038827452808618546)","('NON-ESG', 0.0113566555082798)"
Line 197,"Quality management systems Supplier managements and audits14The Regulatory Affairs, Quality Assurance and Quality  Compliance teams at BD work together on product-related  regulatory processes, from product concept to obsolescence.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6259875893592834)","('Product_Quality_And_Safety', 0.14452894032001495)","('Business_Ethics', 0.059250637888908386)","(['Corporate Governance'], 0.6259875893592834)","('NON-ESG', 0.14452894032001495)","('NON-ESG', 0.059250637888908386)"
Line 198,"The Global Regulatory Affairs Monitoring Initiative (GRAMI), a  system that links our worldwide regulatory associates, is set up to  allow the global regulatory team members to monitor changes  in regulations, requirements and regulatory agency policies that  could affect BD operations and products.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9695601463317871)","('Business_Ethics', 0.003105823416262865)","('Competitive_Behavior', 0.00280448398552835)","(['Corporate Governance'], 0.9695601463317871)","('NON-ESG', 0.003105823416262865)","('NON-ESG', 0.00280448398552835)"
Line 199,"The GRAMI team is comprised of BD regulatory professionals  with expertise in worldwide regulatory policy areas, including compliance, product registrations, labeling standards and other  areas of pre- and postapproval regulatory requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3881235122680664)","('Selling_Practices_And_Product_Labeling', 0.1984362006187439)","('Product_Quality_And_Safety', 0.19134089350700378)","('NON-ESG', 0.3881235122680664)","('NON-ESG', 0.1984362006187439)","('NON-ESG', 0.19134089350700378)"
Line 200,"When changes are identified, they are communicated to  individuals in relevant business units, functions and  manufacturing sites who are part of the GRAMI notifications  system.
","('Business_Model_Resilience', 0.15263397991657257)","('Management_Of_Legal_And_Regulatory_Framework', 0.11982554197311401)","('Data_Security', 0.11276179552078247)","('NON-ESG', 0.15263397991657257)","('NON-ESG', 0.11982554197311401)","('NON-ESG', 0.11276179552078247)"
Line 201,"In addition, BD regulatory leaders in various regions  engage in meaningful dialogue with their regulators and trade  associations to seek better understanding, alignment and  improvements in regulatory requirements and processes that  affect BD as well as the regulated medical technology industry.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9695349335670471)","('Competitive_Behavior', 0.00432217912748456)","('Business_Ethics', 0.0030733735766261816)","(['Corporate Governance'], 0.9695349335670471)","('NON-ESG', 0.00432217912748456)","('NON-ESG', 0.0030733735766261816)"
Line 202,"BD has policies and procedures to ensure the advertising and  promotion of our products complies with applicable laws and regulations.
","('Selling_Practices_And_Product_Labeling', 0.6272311806678772)","('Management_Of_Legal_And_Regulatory_Framework', 0.10108920186758041)","('Product_Quality_And_Safety', 0.04661690816283226)","(['Marketing Practices'], 0.6272311806678772)","('NON-ESG', 0.10108920186758041)","('NON-ESG', 0.04661690816283226)"
Line 203,"Expectations around the promotion of our products  are laid out in our Code of Conduct.
","('Product_Design_And_Lifecycle_Management', 0.7937966585159302)","('Selling_Practices_And_Product_Labeling', 0.07689695805311203)","('Product_Quality_And_Safety', 0.038256317377090454)","(['Product Stewardship'], 0.7937966585159302)","('NON-ESG', 0.07689695805311203)","('NON-ESG', 0.038256317377090454)"
Line 204,"SASB disclosure: HC-MS-270a.2Regulatory compliance Product marketingPerformance management processes include conducting quality  systems assessments (QSAs) for key suppliers according to a  risk-classification process, determined by both a fixed frequency  and the quality history of the supplier’s site.
","('Supply_Chain_Management', 0.8050665259361267)","('Product_Design_And_Lifecycle_Management', 0.07814623415470123)","('Product_Quality_And_Safety', 0.014997330494225025)","(['Supply Chain Management'], 0.8050665259361267)","('NON-ESG', 0.07814623415470123)","('NON-ESG', 0.014997330494225025)"
Line 205,"QSAs ensure that the  facilities’ manufacturing materials or components we procure  have effective quality systems in place to ensure the final  product will consistently comply with our specifications and  adhere to all regulatory requirements.
","('Product_Design_And_Lifecycle_Management', 0.8361470699310303)","('Product_Quality_And_Safety', 0.08116530627012253)","('Selling_Practices_And_Product_Labeling', 0.013523890636861324)","(['Product Stewardship'], 0.8361470699310303)","('NON-ESG', 0.08116530627012253)","('NON-ESG', 0.013523890636861324)"
Line 206,"BD participates in the  MDSAP, an international coalition to jointly leverage regulatory  resources to manage an efficient, effective and sustainable  single audit program focused on the oversight of medical device  manufacturers.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9701715707778931)","('Business_Ethics', 0.0028402903117239475)","('Product_Quality_And_Safety', 0.0023071321193128824)","(['Corporate Governance'], 0.9701715707778931)","('NON-ESG', 0.0028402903117239475)","('NON-ESG', 0.0023071321193128824)"
Line 207,"Participation in this program will allow for the  conduct of a single regulatory audit of a medical device manufacturer’s quality management system that satisfies   the requirements of multiple regulatory jurisdictions.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9148784875869751)","('Business_Ethics', 0.022577228024601936)","('Product_Quality_And_Safety', 0.008504637517035007)","(['Corporate Governance'], 0.9148784875869751)","('NON-ESG', 0.022577228024601936)","('NON-ESG', 0.008504637517035007)"
Line 208,"Auditing Organizations (e.g., BSI, NSAI) execute audits.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4432102143764496)","('Business_Ethics', 0.34882524609565735)","('Systemic_Risk_Management', 0.04122733324766159)","('NON-ESG', 0.4432102143764496)","('NON-ESG', 0.34882524609565735)","('NON-ESG', 0.04122733324766159)"
Line 209,"The FDA is transitioning from the Quality System Regulation  (QSR) to ISO 13485 to better align with MDSAP.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8188403844833374)","('Product_Quality_And_Safety', 0.032796021550893784)","('Competitive_Behavior', 0.03114117868244648)","(['Corporate Governance'], 0.8188403844833374)","('NON-ESG', 0.032796021550893784)","('NON-ESG', 0.03114117868244648)"
Line 210,"As of August 31,  2018, 2,711 MDSAP certificates have been issued to the industry.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7464740872383118)","('Product_Quality_And_Safety', 0.046786997467279434)","('Director_Removal', 0.021525327116250992)","(['Corporate Governance'], 0.7464740872383118)","('NON-ESG', 0.046786997467279434)","('NON-ESG', 0.021525327116250992)"
Line 211,"Currently there are 5 participating countries which include  Australia, the United States, Brazil, Canada and Japan as well as  2 observers, WHO and the European Union.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6903061866760254)","('Human_Rights_And_Community_Relations', 0.044172052294015884)","('Competitive_Behavior', 0.03976352885365486)","(['Corporate Governance'], 0.6903061866760254)","('NON-ESG', 0.044172052294015884)","('NON-ESG', 0.03976352885365486)"
Line 212,"Other countries can  voluntarily accept the MDSAP audit reports from the  manufacturer but do not have access to the MDSAP Regulatory  Portal.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9677550196647644)","('Business_Ethics', 0.0037163454107940197)","('Director_Removal', 0.0024831707123667)","(['Corporate Governance'], 0.9677550196647644)","('NON-ESG', 0.0037163454107940197)","('NON-ESG', 0.0024831707123667)"
Line 213,"Learn more about our Procurement Strategy .A key part of our product development program is the selection  of the right materials that ensure patient safety, device  functional performance and continuity of the device to the  healthcare market.
","('Product_Design_And_Lifecycle_Management', 0.7039660215377808)","('Product_Quality_And_Safety', 0.1839011013507843)","('Selling_Practices_And_Product_Labeling', 0.014940178953111172)","(['Product Stewardship'], 0.7039660215377808)","('NON-ESG', 0.1839011013507843)","('NON-ESG', 0.014940178953111172)"
Line 214,"There are five criteria that are considered  when selecting materials for any of our devices: •  What is critical to the function of the product?
","('Product_Design_And_Lifecycle_Management', 0.9412612915039062)","('Energy_Management', 0.006848787423223257)","('Supply_Chain_Management', 0.0068045370280742645)","(['Product Stewardship'], 0.9412612915039062)","('NON-ESG', 0.006848787423223257)","('NON-ESG', 0.0068045370280742645)"
Line 215,"•  What is critical to the manufacturability of the product?
","('Product_Design_And_Lifecycle_Management', 0.9556736350059509)","('Product_Quality_And_Safety', 0.004345973953604698)","('Customer_Welfare', 0.0038555390201509)","(['Product Stewardship'], 0.9556736350059509)","('NON-ESG', 0.004345973953604698)","('NON-ESG', 0.0038555390201509)"
Line 216,"•  What is crucial to the quality of the product?
","('Product_Design_And_Lifecycle_Management', 0.9424113631248474)","('Product_Quality_And_Safety', 0.01104319840669632)","('Selling_Practices_And_Product_Labeling', 0.00521051324903965)","(['Product Stewardship'], 0.9424113631248474)","('NON-ESG', 0.01104319840669632)","('NON-ESG', 0.00521051324903965)"
Line 217,"•  What is critical to compliance with regulation?
","('Management_Of_Legal_And_Regulatory_Framework', 0.9684648513793945)","('Energy_Management', 0.0026373371947556734)","('GHG_Emissions', 0.002467636950314045)","(['Corporate Governance'], 0.9684648513793945)","('NON-ESG', 0.0026373371947556734)","('NON-ESG', 0.002467636950314045)"
Line 218,"•  What is critical to business requirements?
","('Supply_Chain_Management', 0.3139423131942749)","('Business_Model_Resilience', 0.22450518608093262)","('Product_Design_And_Lifecycle_Management', 0.09235890954732895)","('NON-ESG', 0.3139423131942749)","('NON-ESG', 0.22450518608093262)","('NON-ESG', 0.09235890954732895)"
Line 219,"Once required material properties have been established, potential  materials can be identified for feasibility studies.
","('Product_Design_And_Lifecycle_Management', 0.42779412865638733)","('Waste_And_Hazardous_Materials_Management', 0.1619405746459961)","('Supply_Chain_Management', 0.10250585526227951)","('NON-ESG', 0.42779412865638733)","('NON-ESG', 0.1619405746459961)","('NON-ESG', 0.10250585526227951)"
Line 220,"These studies include selection regarding characteristics that include chemical,  toxicological, physical and mechanical properties.
","('Product_Quality_And_Safety', 0.5466740131378174)","('Selling_Practices_And_Product_Labeling', 0.11533203721046448)","('Product_Design_And_Lifecycle_Management', 0.06803146749734879)","(['Product Quality & Recall Management'], 0.5466740131378174)","('NON-ESG', 0.11533203721046448)","('NON-ESG', 0.06803146749734879)"
Line 221,"All materials are  rigorously evaluated for safety and suitability for their intended  clinical application.
","('Product_Quality_And_Safety', 0.8670331239700317)","('Customer_Welfare', 0.018427684903144836)","('Selling_Practices_And_Product_Labeling', 0.014117629267275333)","(['Product Quality & Recall Management'], 0.8670331239700317)","('NON-ESG', 0.018427684903144836)","('NON-ESG', 0.014117629267275333)"
Line 222,"Such evaluations include qualification against  national and international standards for biological safety   (e.g., ISO 10993 and U.S. FDA guidance on same [2016]) and  comply with U.S. and international regulations for biological  (patient) safety.
","('Product_Quality_And_Safety', 0.9135677218437195)","('Selling_Practices_And_Product_Labeling', 0.008120055310428143)","('Product_Design_And_Lifecycle_Management', 0.007397633045911789)","(['Product Quality & Recall Management'], 0.9135677218437195)","('NON-ESG', 0.008120055310428143)","('NON-ESG', 0.007397633045911789)"
Line 223,"Materials are also subject to re-evaluation under  conditions as defined in these standards and regulations, for  example, upon any change in source or specification.
","('Product_Design_And_Lifecycle_Management', 0.3811485767364502)","('Supply_Chain_Management', 0.13104787468910217)","('Management_Of_Legal_And_Regulatory_Framework', 0.06849218904972076)","('NON-ESG', 0.3811485767364502)","('NON-ESG', 0.13104787468910217)","('NON-ESG', 0.06849218904972076)"
Line 224,"All materials  are subject to BD established controls with respect to formulation  continuity and ongoing quality conformance.Selecting materials For each of the critical areas, various questions will be asked in order to generate a list  of required material properties.
","('Product_Design_And_Lifecycle_Management', 0.4534205198287964)","('Supply_Chain_Management', 0.18210016191005707)","('Waste_And_Hazardous_Materials_Management', 0.08252595365047455)","('NON-ESG', 0.4534205198287964)","('NON-ESG', 0.18210016191005707)","('NON-ESG', 0.08252595365047455)"
Line 225,"For example: Critical to function:    Who is the end user?
","('Data_Security', 0.27548161149024963)","('Competitive_Behavior', 0.15114125609397888)","('Customer_Privacy', 0.08946950733661652)","('NON-ESG', 0.27548161149024963)","('NON-ESG', 0.15114125609397888)","('NON-ESG', 0.08946950733661652)"
Line 226,"What critical material properties will enable function?
","('Supply_Chain_Management', 0.3035142123699188)","('Waste_And_Hazardous_Materials_Management', 0.23849694430828094)","('Product_Design_And_Lifecycle_Management', 0.1440502554178238)","('NON-ESG', 0.3035142123699188)","('NON-ESG', 0.23849694430828094)","('NON-ESG', 0.1440502554178238)"
Line 227,"Critical to manufacturability:    What manufacturing processes will be used?
","('Product_Design_And_Lifecycle_Management', 0.9022252559661865)","('Energy_Management', 0.01802729442715645)","('Supply_Chain_Management', 0.013259828090667725)","(['Product Stewardship'], 0.9022252559661865)","('NON-ESG', 0.01802729442715645)","('NON-ESG', 0.013259828090667725)"
Line 228,"What sterilization method is necessary to  ensure sterility?
","('Employee_Health_And_Safety', 0.4150806963443756)","('Access_And_Affordability', 0.16710424423217773)","('Product_Quality_And_Safety', 0.15117226541042328)","('NON-ESG', 0.4150806963443756)","('NON-ESG', 0.16710424423217773)","('NON-ESG', 0.15117226541042328)"
Line 229,"Critical to quality:    What properties need to be monitored/measured to ensure the product performs consistently?
","('Product_Design_And_Lifecycle_Management', 0.8319932818412781)","('Product_Quality_And_Safety', 0.07448294013738632)","('Customer_Welfare', 0.014574771746993065)","(['Product Stewardship'], 0.8319932818412781)","('NON-ESG', 0.07448294013738632)","('NON-ESG', 0.014574771746993065)"
Line 230,"Critical to compliance :   What regulatory requirements must the product comply with?
","('Management_Of_Legal_And_Regulatory_Framework', 0.940643310546875)","('Business_Ethics', 0.009151234291493893)","('Product_Quality_And_Safety', 0.008671361953020096)","(['Corporate Governance'], 0.940643310546875)","('NON-ESG', 0.009151234291493893)","('NON-ESG', 0.008671361953020096)"
Line 231,"Critical to business requirements:    Are there constraints on cost or supplier?
","('Supply_Chain_Management', 0.9388482570648193)","('Water_And_Wastewater_Management', 0.005466347094625235)","('Labor_Practices', 0.004917678888887167)","(['Supply Chain Management'], 0.9388482570648193)","('NON-ESG', 0.005466347094625235)","('NON-ESG', 0.004917678888887167)"
Line 232,"What options are available for second sources?BD is committed to ensuring patient safety via robust  postmarket surveillance of our products.
","('Product_Quality_And_Safety', 0.8117549419403076)","('Product_Design_And_Lifecycle_Management', 0.057614341378211975)","('Selling_Practices_And_Product_Labeling', 0.029378829523921013)","(['Product Quality & Recall Management'], 0.8117549419403076)","('NON-ESG', 0.057614341378211975)","('NON-ESG', 0.029378829523921013)"
Line 233,"Central to this is a  comprehensive product complaint management program, where  every complaint is evaluated for potential safety issues and  determination of need to report as a vigilance event to the FDA  and other global competent authorities.
","('Product_Quality_And_Safety', 0.9118662476539612)","('Selling_Practices_And_Product_Labeling', 0.011901747435331345)","('Employee_Health_And_Safety', 0.009657208807766438)","(['Product Quality & Recall Management'], 0.9118662476539612)","('NON-ESG', 0.011901747435331345)","('NON-ESG', 0.009657208807766438)"
Line 234,"BD business units  conduct routine complaint trending evaluations as part of  corrective and preventive action programs to address corrections  needed for complaint issues where any trend is detected.
","('Business_Ethics', 0.6045673489570618)","('Management_Of_Legal_And_Regulatory_Framework', 0.12147361785173416)","('Critical_Incident_Risk_Management', 0.05786590278148651)","(['Business Ethics'], 0.6045673489570618)","('NON-ESG', 0.12147361785173416)","('NON-ESG', 0.05786590278148651)"
Line 235,"In addition, as part of the BD Global Medical Safety and  Governance organization, a medical safety review board and  medical affairs safety council routinely reviews complaints and  adverse event data specifically looking for potential safety  signals.
","('Product_Quality_And_Safety', 0.6458781361579895)","('Employee_Health_And_Safety', 0.2367347776889801)","('Access_And_Affordability', 0.011640078388154507)","(['Product Quality & Recall Management'], 0.6458781361579895)","('NON-ESG', 0.2367347776889801)","('NON-ESG', 0.011640078388154507)"
Line 236,"The results of these reviews are shared with the BD  business unit VP of Medical Affairs when applicable, as well as  part of a monthly Quality and Regulatory leadership meeting.We have escalation policies where potential safety-related issues  are investigated with the objective of determining the need for  field actions.
","('Employee_Health_And_Safety', 0.5416708588600159)","('Product_Quality_And_Safety', 0.33014464378356934)","('Access_And_Affordability', 0.013077630661427975)","(['Operational Eco-Efficiency'], 0.5416708588600159)","('NON-ESG', 0.33014464378356934)","('NON-ESG', 0.013077630661427975)"
Line 237,"BD has a corporate-level policy for internal  communications and escalation regarding any allegation of a  patient death related to a BD product.
","('Employee_Health_And_Safety', 0.8221655488014221)","('Product_Quality_And_Safety', 0.03469865769147873)","('Access_And_Affordability', 0.01671179011464119)","(['Operational Eco-Efficiency'], 0.8221655488014221)","('NON-ESG', 0.03469865769147873)","('NON-ESG', 0.01671179011464119)"
Line 238,"This policy requires  reporting to the chief medical officer, the chief quality officer,  the chief regulatory officer and the chief regulatory counsel.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9377418160438538)","('Director_Removal', 0.008271277882158756)","('Systemic_Risk_Management', 0.005363691598176956)","(['Corporate Governance'], 0.9377418160438538)","('NON-ESG', 0.008271277882158756)","('NON-ESG', 0.005363691598176956)"
Line 239,"The  process assures each and every potential patient death is  investigated in a prompt and thorough manner.
","('Employee_Health_And_Safety', 0.8802658915519714)","('Critical_Incident_Risk_Management', 0.028044741600751877)","('Access_And_Affordability', 0.011617747135460377)","(['Operational Eco-Efficiency'], 0.8802658915519714)","('NON-ESG', 0.028044741600751877)","('NON-ESG', 0.011617747135460377)"
Line 240,"The escalation  process is in addition to routine evaluation of all complaints and  global vigilance reporting requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6549197435379028)","('Business_Ethics', 0.1450703740119934)","('Critical_Incident_Risk_Management', 0.029932910576462746)","(['Corporate Governance'], 0.6549197435379028)","('NON-ESG', 0.1450703740119934)","('NON-ESG', 0.029932910576462746)"
Line 241,"Details of FDA actions, including recalls and number of fatalities  related to products as reported in the FDA Manufacturer and  User Facility Device Experience (MAUDE) can be found on the  FDA website .
","('Product_Quality_And_Safety', 0.6397956013679504)","('Selling_Practices_And_Product_Labeling', 0.10292136669158936)","('Product_Design_And_Lifecycle_Management', 0.02974570356309414)","(['Product Quality & Recall Management'], 0.6397956013679504)","('NON-ESG', 0.10292136669158936)","('NON-ESG', 0.02974570356309414)"
Line 242,"SASB disclosures: HC-MS-250a.1; HC-MS-250a.3   GRI disclosure: 416-2Postmarket surveillance16Our Materials of Concern (MOC) list guides the way we address  the reduction of MOC across our portfolio.
","('Supply_Chain_Management', 0.33022540807724)","('Product_Design_And_Lifecycle_Management', 0.09540729224681854)","('Systemic_Risk_Management', 0.08815374225378036)","('NON-ESG', 0.33022540807724)","('NON-ESG', 0.09540729224681854)","('NON-ESG', 0.08815374225378036)"
Line 243,"The list contains both  regulated and nonregulated substances that we consider to be  of concern and is updated twice a year.
","('Selling_Practices_And_Product_Labeling', 0.28835368156433105)","('Product_Quality_And_Safety', 0.13652881979942322)","('Customer_Welfare', 0.10858749598264694)","('NON-ESG', 0.28835368156433105)","('NON-ESG', 0.13652881979942322)","('NON-ESG', 0.10858749598264694)"
Line 244,"It includes substances  the company has put special emphasis on—for example, PVC  and phthalates—and those that BD has chosen to avoid and/or  reduce from its products and packaging.
","('Product_Design_And_Lifecycle_Management', 0.41559430956840515)","('Selling_Practices_And_Product_Labeling', 0.2001914083957672)","('Customer_Welfare', 0.11393836885690689)","('NON-ESG', 0.41559430956840515)","('NON-ESG', 0.2001914083957672)","('NON-ESG', 0.11393836885690689)"
Line 245,"BD carefully considers the potential impact of the materials we  use in our products and packaging and considers customer  preferences related to chemicals of concern in finished goods.
","('Product_Design_And_Lifecycle_Management', 0.9421079158782959)","('Selling_Practices_And_Product_Labeling', 0.014688560739159584)","('Product_Quality_And_Safety', 0.005072475876659155)","(['Product Stewardship'], 0.9421079158782959)","('NON-ESG', 0.014688560739159584)","('NON-ESG', 0.005072475876659155)"
Line 246,"In  order to monitor the changing landscape around chemicals of  high concern among customers, regulatory bodies and advocacy  groups, BD established a Chemical Review Board in 2013.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8295629024505615)","('Ecological_Impacts', 0.02467908337712288)","('Product_Quality_And_Safety', 0.016700712963938713)","(['Corporate Governance'], 0.8295629024505615)","('NON-ESG', 0.02467908337712288)","('NON-ESG', 0.016700712963938713)"
Line 247,"This  internal board, led by our director of Global Product Stewardship,  includes representation from R&D for each of our business units  and functional expertise from toxicology and procurement.
","('Product_Design_And_Lifecycle_Management', 0.6404026746749878)","('Product_Quality_And_Safety', 0.19002006947994232)","('Customer_Welfare', 0.031623657792806625)","(['Product Stewardship'], 0.6404026746749878)","('NON-ESG', 0.19002006947994232)","('NON-ESG', 0.031623657792806625)"
Line 248,"This group is equipped to evaluate the feasibility of alternative  materials, provide guidance to R&D within the company and  leverage material expertise across the organization to accelerate  our work to reduce priority MOC from the portfolio.
","('Supply_Chain_Management', 0.5747692584991455)","('Product_Design_And_Lifecycle_Management', 0.18556782603263855)","('Waste_And_Hazardous_Materials_Management', 0.037941984832286835)","(['Supply Chain Management'], 0.5747692584991455)","('NON-ESG', 0.18556782603263855)","('NON-ESG', 0.037941984832286835)"
Line 249,"While our 2020 sustainability goals related to the reduction of  priority MOC do not specifically reference safer alternatives,  internal work processes (such as the Chemical Review Board)  exist to manage that aspect of chemicals management.
","('Product_Design_And_Lifecycle_Management', 0.3906109631061554)","('Product_Quality_And_Safety', 0.21314546465873718)","('Customer_Welfare', 0.10150270164012909)","('NON-ESG', 0.3906109631061554)","('NON-ESG', 0.21314546465873718)","('NON-ESG', 0.10150270164012909)"
Line 250,"At the corporate level, BD has a Global Product Stewardship  function, led by a director of Global Product Stewardship and director of Global Product Stewardship Compliance.
","('Product_Design_And_Lifecycle_Management', 0.8843586444854736)","('Product_Quality_And_Safety', 0.03662591055035591)","('Selling_Practices_And_Product_Labeling', 0.01707059144973755)","(['Product Stewardship'], 0.8843586444854736)","('NON-ESG', 0.03662591055035591)","('NON-ESG', 0.01707059144973755)"
Line 251,"The Global  Product Stewardship function reports to the VP of Environment,  Health & Safety and Sustainability (EHS&S); the VP EHS&S  reports to the company’s executive VP Integrated Supply Chain.
","('Product_Design_And_Lifecycle_Management', 0.661007821559906)","('Supply_Chain_Management', 0.11321057379245758)","('Product_Quality_And_Safety', 0.08301928639411926)","(['Product Stewardship'], 0.661007821559906)","('NON-ESG', 0.11321057379245758)","('NON-ESG', 0.08301928639411926)"
Line 252,"The Global Product Stewardship team is in place to monitor  changing global environmental regulations affecting our product  portfolio (including chemicals of high concern) and provide  governance over compliance activities carried out by our  business units.
","('Product_Design_And_Lifecycle_Management', 0.640282154083252)","('Product_Quality_And_Safety', 0.17796720564365387)","('Selling_Practices_And_Product_Labeling', 0.054181963205337524)","(['Product Stewardship'], 0.640282154083252)","('NON-ESG', 0.17796720564365387)","('NON-ESG', 0.054181963205337524)"
Line 253,"The Global Product Stewardship team also  administers our system of collecting information from suppliers  through a dedicated team of supply base compliance associates.
","('Supply_Chain_Management', 0.7391027212142944)","('Product_Design_And_Lifecycle_Management', 0.09609939903020859)","('Waste_And_Hazardous_Materials_Management', 0.021593725308775902)","(['Supply Chain Management'], 0.7391027212142944)","('NON-ESG', 0.09609939903020859)","('NON-ESG', 0.021593725308775902)"
Line 254,"The team also maintains our MOC list, and owns the central  database used to manage chemical information at the product  portfolio level.
","('Product_Design_And_Lifecycle_Management', 0.5334351658821106)","('Selling_Practices_And_Product_Labeling', 0.1958352029323578)","('Customer_Welfare', 0.0749991238117218)","(['Product Stewardship'], 0.5334351658821106)","('NON-ESG', 0.1958352029323578)","('NON-ESG', 0.0749991238117218)"
Line 255,"The Global Product Stewardship team, and in turn our EHS&S  function, are accountable for the company’s overall system of  chemicals management and are responsible for governance over  compliance with product environmental regulations, such as  REACH and RoHS.
","('Product_Design_And_Lifecycle_Management', 0.750212550163269)","('Product_Quality_And_Safety', 0.10124916583299637)","('Selling_Practices_And_Product_Labeling', 0.0383242592215538)","(['Product Stewardship'], 0.750212550163269)","('NON-ESG', 0.10124916583299637)","('NON-ESG', 0.0383242592215538)"
Line 256,"Following the acquisition of Bard, we are currently evaluating our  expanded portfolio against our 2020 product stewardship goals.
","('Product_Design_And_Lifecycle_Management', 0.9431185722351074)","('Product_Quality_And_Safety', 0.009806754998862743)","('Customer_Welfare', 0.0062536573968827724)","(['Product Stewardship'], 0.9431185722351074)","('NON-ESG', 0.009806754998862743)","('NON-ESG', 0.0062536573968827724)"
Line 257,"Our MOC list and materials for suppliers are available on the  Supplier Resources page on our website .
","('Supply_Chain_Management', 0.9336374998092651)","('Labor_Practices', 0.0060461233370006084)","('Product_Design_And_Lifecycle_Management', 0.005537873599678278)","(['Supply Chain Management'], 0.9336374998092651)","('NON-ESG', 0.0060461233370006084)","('NON-ESG', 0.005537873599678278)"
Line 258,"SASB disclosure: HC-MS-410a.1Management of Materials of Concern17BD belongs to a broad industry sector whose products include a  variety of medical devices, diagnostics, biotechnology and  pharmaceuticals.
","('Product_Design_And_Lifecycle_Management', 0.7116348147392273)","('Customer_Welfare', 0.08893068134784698)","('Selling_Practices_And_Product_Labeling', 0.04535071179270744)","(['Product Stewardship'], 0.7116348147392273)","('NON-ESG', 0.08893068134784698)","('NON-ESG', 0.04535071179270744)"
Line 259,"Products in this sector must meet very stringent  requirements for demonstration of safety, efficacy and suitability  for their intended use.
","('Product_Quality_And_Safety', 0.8487680554389954)","('Product_Design_And_Lifecycle_Management', 0.05367320030927658)","('Selling_Practices_And_Product_Labeling', 0.014250115491449833)","(['Product Quality & Recall Management'], 0.8487680554389954)","('NON-ESG', 0.05367320030927658)","('NON-ESG', 0.014250115491449833)"
Line 260,"As part of this work of ensuring ultimate  patient safety, existing regulations and standards require the use  of laboratory animals in research and product evaluation.
","('Product_Quality_And_Safety', 0.9204543828964233)","('Product_Design_And_Lifecycle_Management', 0.010923277586698532)","('Selling_Practices_And_Product_Labeling', 0.010534780099987984)","(['Product Quality & Recall Management'], 0.9204543828964233)","('NON-ESG', 0.010923277586698532)","('NON-ESG', 0.010534780099987984)"
Line 261,"This use of carefully selected and defined animal models is  required in the development and testing of certain products.
","('Product_Design_And_Lifecycle_Management', 0.579767644405365)","('Selling_Practices_And_Product_Labeling', 0.16998068988323212)","('Product_Quality_And_Safety', 0.07850177586078644)","(['Product Stewardship'], 0.579767644405365)","('NON-ESG', 0.16998068988323212)","('NON-ESG', 0.07850177586078644)"
Line 262,"Further, a defined scope of laboratory animal testing is required  for regulatory approval and market access of BD products for  human or veterinary applications.
","('Selling_Practices_And_Product_Labeling', 0.31489890813827515)","('Product_Quality_And_Safety', 0.22503532469272614)","('Customer_Welfare', 0.1476520299911499)","('NON-ESG', 0.31489890813827515)","('NON-ESG', 0.22503532469272614)","('NON-ESG', 0.1476520299911499)"
Line 263,"Throughout this essential  work, BD is committed to animal welfare, as good, sound animal  welfare is not only the right thing to do, it also leads to good  scientific data.
","('Ecological_Impacts', 0.4430975615978241)","('Human_Rights_And_Community_Relations', 0.10311666131019592)","('GHG_Emissions', 0.05594676360487938)","('NON-ESG', 0.4430975615978241)","('NON-ESG', 0.10311666131019592)","('NON-ESG', 0.05594676360487938)"
Line 264,"It is emphasized that any testing involving live  research animals is undertaken only when absolutely necessary,  and in keeping with all applicable regulations and current  best practices.
","('Management_Of_Legal_And_Regulatory_Framework', 0.46430566906929016)","('Product_Quality_And_Safety', 0.13148127496242523)","('Selling_Practices_And_Product_Labeling', 0.0640282854437828)","('NON-ESG', 0.46430566906929016)","('NON-ESG', 0.13148127496242523)","('NON-ESG', 0.0640282854437828)"
Line 265,"Our company’s Animal Research Program is led by a proactive,  committed team of animal care professionals, that employ best  practices to ensure all animal associates are treated humanely  and respectfully.
","('Waste_And_Hazardous_Materials_Management', 0.23013892769813538)","('Employee_Health_And_Safety', 0.1293513923883438)","('Employee_Engagement_Inclusion_And_Diversity', 0.08020059019327164)","('NON-ESG', 0.23013892769813538)","('NON-ESG', 0.1293513923883438)","('NON-ESG', 0.08020059019327164)"
Line 266,"Our program is a leader in animal welfare best  practices and is influencing the animal research community in  positive ways.
","('Management_Of_Legal_And_Regulatory_Framework', 0.14528711140155792)","('Ecological_Impacts', 0.11822367459535599)","('Access_And_Affordability', 0.1171363964676857)","('NON-ESG', 0.14528711140155792)","('NON-ESG', 0.11822367459535599)","('NON-ESG', 0.1171363964676857)"
Line 267,"Best practices include providing animal  acclimation, socialization, stress-free handling and  environmental enrichment; all to enable animals to display  natural behaviors and control over their environment.
","('Ecological_Impacts', 0.8573654890060425)","('Human_Rights_And_Community_Relations', 0.037865813821554184)","('Employee_Health_And_Safety', 0.014081907458603382)","(['Natural Capital'], 0.8573654890060425)","('NON-ESG', 0.037865813821554184)","('NON-ESG', 0.014081907458603382)"
Line 268,"BD makes every effort to minimize animal testing by practicing  the 4 Rs: Replacement (e.g., in vitro testing, literature review),  Refinement (e.g., approaches always considered to eliminate or  reduce potential pain and distress), Reduction (e.g., use minimal  number of animals to achieve scientific results) and Retirement  (e.g., approved program to adopt out retired laboratory animals  with attending veterinarian guidance).
","('Ecological_Impacts', 0.20995613932609558)","('Management_Of_Legal_And_Regulatory_Framework', 0.1224202960729599)","('GHG_Emissions', 0.12186359614133835)","('NON-ESG', 0.20995613932609558)","('NON-ESG', 0.1224202960729599)","('NON-ESG', 0.12186359614133835)"
Line 269,"Very significant effort is  applied to leveraging alternative information as much as  possible to preclude direct testing (e.g., historical testing results,  existing information on materials, history of safe clinical use,  chemical analysis and toxicologic risk assessment).
","('Product_Quality_And_Safety', 0.5767090320587158)","('Selling_Practices_And_Product_Labeling', 0.14102928340435028)","('Waste_And_Hazardous_Materials_Management', 0.0687514916062355)","(['Product Quality & Recall Management'], 0.5767090320587158)","('NON-ESG', 0.14102928340435028)","('NON-ESG', 0.0687514916062355)"
Line 270,"BD is also  committed to the pursuit of alternative methods to lab animal  testing, including in vitro alternatives, computer simulation and  modeling and application of anatomical models derived from 3D  printed facsimiles.
","('Customer_Welfare', 0.13902613520622253)","('GHG_Emissions', 0.13338690996170044)","('Ecological_Impacts', 0.10173869132995605)","('NON-ESG', 0.13902613520622253)","('NON-ESG', 0.13338690996170044)","('NON-ESG', 0.10173869132995605)"
Line 271,"Our approach is detailed in a BD company policy reviewed and  approved by senior management of the corporation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8505147099494934)","('Director_Removal', 0.047979507595300674)","('Business_Ethics', 0.015261858701705933)","(['Corporate Governance'], 0.8505147099494934)","('NON-ESG', 0.047979507595300674)","('NON-ESG', 0.015261858701705933)"
Line 272,"The  requirements of this policy apply not only to internal BD studies,  but we also require that any/all third parties who carry out animal  testing on our behalf are covered by our Expectations for Suppliers  (EFS) and our company policy.
","('Management_Of_Legal_And_Regulatory_Framework', 0.25140488147735596)","('GHG_Emissions', 0.1087755486369133)","('Selling_Practices_And_Product_Labeling', 0.1023096963763237)","('NON-ESG', 0.25140488147735596)","('NON-ESG', 0.1087755486369133)","('NON-ESG', 0.1023096963763237)"
Line 273,"We preferentially use AAALAC  accredited third parties, with limited exceptions when other  qualification information is considered sufficient and if unique  expertise limits options.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7242984771728516)","('Competitive_Behavior', 0.057806193828582764)","('Business_Ethics', 0.02777792327105999)","(['Corporate Governance'], 0.7242984771728516)","('NON-ESG', 0.057806193828582764)","('NON-ESG', 0.02777792327105999)"
Line 274,"Even in the latter case, the BD Animal  Research Program performs full supplier animal welfare audits to  ensure sound animal welfare among animal vendors and suppliers,  and adherence to our EFS and content of our policy.
","('Ecological_Impacts', 0.16623666882514954)","('Selling_Practices_And_Product_Labeling', 0.11176294088363647)","('Waste_And_Hazardous_Materials_Management', 0.0761437937617302)","('NON-ESG', 0.16623666882514954)","('NON-ESG', 0.11176294088363647)","('NON-ESG', 0.0761437937617302)"
Line 275,"BD maintains an ongoing focus on developments in the research  animal study and animal welfare communities, with senior staff  involved in numerous relevant governmental and academic  organizations.
","('Ecological_Impacts', 0.4259781539440155)","('GHG_Emissions', 0.09316040575504303)","('Management_Of_Legal_And_Regulatory_Framework', 0.06676013022661209)","('NON-ESG', 0.4259781539440155)","('NON-ESG', 0.09316040575504303)","('NON-ESG', 0.06676013022661209)"
Line 276,"As such, BD is striving to increase transparency in  this area, and address the potential questions or concerns of our  customers, shareholders and patients.
","('Business_Ethics', 0.966339647769928)","('Systemic_Risk_Management', 0.004549458622932434)","('Management_Of_Legal_And_Regulatory_Framework', 0.003988508600741625)","(['Business Ethics'], 0.966339647769928)","('NON-ESG', 0.004549458622932434)","('NON-ESG', 0.003988508600741625)"
Line 277,"As one example, BD will be  hosting its first BRAD (Biomedical Research Appreciation Day)  event in 2020 as part of an international effort to celebrate the  contributions of research animals in biomedical research.
","('Access_And_Affordability', 0.2371426373720169)","('Management_Of_Legal_And_Regulatory_Framework', 0.18027621507644653)","('Ecological_Impacts', 0.11151064187288284)","('NON-ESG', 0.2371426373720169)","('NON-ESG', 0.18027621507644653)","('NON-ESG', 0.11151064187288284)"
Line 278,"BD is  committed to honoring the contributions of animal research to  ensuring our products are safe and effective for use across human  and veterinary medicine.Laboratory animal welfare Replacement ReﬁnementReduction Retirementby in vitr o testing, liter ature review using appr oaches alw ays consider ed  to eliminate or reduce potential  pain and distr essuse minimal number  of animals to achie ve  scientiﬁc r esults utilizing an appr oved  program to adopt out   retired labor atory  animals with attending  veterinarian guidanc e4Rs18Cybersecurity At BD, our commitment to cybersecurity includes product security, manufacturing security and enterprise security.
","('Employee_Health_And_Safety', 0.6297153234481812)","('Product_Quality_And_Safety', 0.08370591700077057)","('Customer_Welfare', 0.05265895649790764)","(['Operational Eco-Efficiency'], 0.6297153234481812)","('NON-ESG', 0.08370591700077057)","('NON-ESG', 0.05265895649790764)"
Line 279,"BD is  committed to honoring the contributions of animal research to  ensuring our products are safe and effective for use across human  and veterinary medicine.Laboratory animal welfare Replacement ReﬁnementReduction Retirementby in vitr o testing, liter ature review using appr oaches alw ays consider ed  to eliminate or reduce potential  pain and distr essuse minimal number  of animals to achie ve  scientiﬁc r esults utilizing an appr oved  program to adopt out   retired labor atory  animals with attending  veterinarian guidanc e4Rs18Cybersecurity At BD, our commitment to cybersecurity includes product security, manufacturing security and enterprise security.
","('Data_Security', 0.95604407787323)","('Systemic_Risk_Management', 0.0051749092526733875)","('Physical_Impacts_Of_Climate_Change', 0.0034505859948694706)","(['Information Security/Cybersecurity & System Availability'], 0.95604407787323)","('NON-ESG', 0.0051749092526733875)","('NON-ESG', 0.0034505859948694706)"
Line 280,"We strive to ensure  our products, and the environments in which they are used, meet high security standards so our customers can focus on what  matters most: caring for patients.
","('Product_Design_And_Lifecycle_Management', 0.8998412489891052)","('Product_Quality_And_Safety', 0.0340774767100811)","('Selling_Practices_And_Product_Labeling', 0.010365546680986881)","(['Product Stewardship'], 0.8998412489891052)","('NON-ESG', 0.0340774767100811)","('NON-ESG', 0.010365546680986881)"
Line 281,"While we maintain robust security protocols, we also recognize that new security threats emerge  daily in the healthcare industry.
","('Data_Security', 0.9551874399185181)","('Systemic_Risk_Management', 0.004497986286878586)","('Physical_Impacts_Of_Climate_Change', 0.004155438859015703)","(['Information Security/Cybersecurity & System Availability'], 0.9551874399185181)","('NON-ESG', 0.004497986286878586)","('NON-ESG', 0.004155438859015703)"
Line 282,"That is why we believe transparency and collaboration are essential.
","('Business_Ethics', 0.9542851448059082)","('Data_Security', 0.005861109122633934)","('Management_Of_Legal_And_Regulatory_Framework', 0.004761459305882454)","(['Business Ethics'], 0.9542851448059082)","('NON-ESG', 0.005861109122633934)","('NON-ESG', 0.004761459305882454)"
Line 283,"Our strategic approach to cybersecurity includes: Secure by design BD products and systems are designed to  be secure and are developed using  industry-leading cybersecurity standards.Secure in use BD products and systems are secured  and maintained throughout their  intended life cycle, across all technologies  and sites.Secure through partnership BD ensures our strategic vendors also meet  or exceed our cybersecurity standards.
","('Data_Security', 0.9539178013801575)","('Systemic_Risk_Management', 0.005294978618621826)","('Business_Ethics', 0.004965226165950298)","(['Information Security/Cybersecurity & System Availability'], 0.9539178013801575)","('NON-ESG', 0.005294978618621826)","('NON-ESG', 0.004965226165950298)"
Line 284,"In an effort to continually improve cybersecurity, we regularly: • Adopt and update secure and certified standards to mature  our cybersecurity governance models; • Perform vulnerability scanning, risk assessments   and penetration testing for BD products and enterprise  systems; and  • Provide proactive and timely communications around  cybersecurity as it relates to our products, enabling customers  to understand and properly manage a potential risk through  awareness and guidance.
","('Data_Security', 0.9490827322006226)","('Systemic_Risk_Management', 0.009340334683656693)","('Business_Ethics', 0.00432810140773654)","(['Information Security/Cybersecurity & System Availability'], 0.9490827322006226)","('NON-ESG', 0.009340334683656693)","('NON-ESG', 0.00432810140773654)"
Line 285,"Certifications and attestations BD recognizes the value to our customers of independent  cybersecurity accreditation.
","('Data_Security', 0.2787722647190094)","('Business_Ethics', 0.20960886776447296)","('Product_Quality_And_Safety', 0.1307978332042694)","('NON-ESG', 0.2787722647190094)","('NON-ESG', 0.20960886776447296)","('NON-ESG', 0.1307978332042694)"
Line 286,"Each year, a range of third-party  audits are performed on BD products and internal cybersecurity  controls, including:  Service and Organization Controls (SOC 2®): SOC 2+ is a  technical audit developed by the American Institute of Certified  Public Accountants (AICPA) that focuses on the design and  operating effectiveness of a company’s controls and includes  compliance with the HIPAA security rule.
","('Data_Security', 0.8286042809486389)","('Business_Ethics', 0.06745677441358566)","('Systemic_Risk_Management', 0.02604152448475361)","(['Information Security/Cybersecurity & System Availability'], 0.8286042809486389)","('NON-ESG', 0.06745677441358566)","('NON-ESG', 0.02604152448475361)"
Line 287,"BD maintains a SOC 2+  program to provide controls assurance for those BD products and  platforms that collect and process patient health information.
","('Customer_Privacy', 0.6862087249755859)","('Employee_Health_And_Safety', 0.054991286247968674)","('Selling_Practices_And_Product_Labeling', 0.03984299302101135)","(['Privacy Protection'], 0.6862087249755859)","('NON-ESG', 0.054991286247968674)","('NON-ESG', 0.03984299302101135)"
Line 288,"These audit reports are prepared annually by an independent  third party and address the effectiveness of BD internal controls  and the security of our products.
","('Data_Security', 0.6517655849456787)","('Business_Ethics', 0.17064402997493744)","('Systemic_Risk_Management', 0.02448827587068081)","(['Information Security/Cybersecurity & System Availability'], 0.6517655849456787)","('NON-ESG', 0.17064402997493744)","('NON-ESG', 0.02448827587068081)"
Line 289,"Underwriters Laboratory Cybersecurity Assurance Program  (UL CAP):  BD cybersecurity programs and policies have been  evaluated by the Underwriters Laboratory Cybersecurity  Assurance Program (UL CAP), which is an independently audited  certification that demonstrates the cybersecurity of medical  device products through a rigorous program of analysis,  including penetration and vulnerability testing.19Collaborating to improve cybersecurity At BD, we believe industry collaboration makes us stronger.
","('Data_Security', 0.9523616433143616)","('Systemic_Risk_Management', 0.007987904362380505)","('Physical_Impacts_Of_Climate_Change', 0.003506345208734274)","(['Information Security/Cybersecurity & System Availability'], 0.9523616433143616)","('NON-ESG', 0.007987904362380505)","('NON-ESG', 0.003506345208734274)"
Line 290,"The following examples represent the types of collaborations   we engage in regularly.
","('Employee_Engagement_Inclusion_And_Diversity', 0.1529104858636856)","('Competitive_Behavior', 0.10943439602851868)","('Business_Model_Resilience', 0.10655225813388824)","('NON-ESG', 0.1529104858636856)","('NON-ESG', 0.10943439602851868)","('NON-ESG', 0.10655225813388824)"
Line 291,"The Biohacking Village Device Lab at DEF CON BD co-sponsored and participated in the medical device lab,  which allows medical device manufacturers to submit medical  devices to be tested by security researchers in a high-trust,   high-collaboration environment that includes manufacturers,  regulatory bodies and security researchers collaborating to  enhance medical device cybersecurity.
","('Data_Security', 0.9487778544425964)","('Systemic_Risk_Management', 0.00697121350094676)","('Business_Ethics', 0.004403718281537294)","(['Information Security/Cybersecurity & System Availability'], 0.9487778544425964)","('NON-ESG', 0.00697121350094676)","('NON-ESG', 0.004403718281537294)"
Line 292,"Forty medical devices  from ten manufacturers were tested, including four BD products.
","('Product_Design_And_Lifecycle_Management', 0.29563868045806885)","('Product_Quality_And_Safety', 0.23180001974105835)","('Customer_Welfare', 0.12521913647651672)","('NON-ESG', 0.29563868045806885)","('NON-ESG', 0.23180001974105835)","('NON-ESG', 0.12521913647651672)"
Line 293,"As a result, several third-party vulnerabilities, known as the  Interpeak IPNET TCP/IP stack , were confirmed.
","('Data_Security', 0.9159212708473206)","('Systemic_Risk_Management', 0.011942322365939617)","('Customer_Privacy', 0.007608744315803051)","(['Information Security/Cybersecurity & System Availability'], 0.9159212708473206)","('NON-ESG', 0.011942322365939617)","('NON-ESG', 0.007608744315803051)"
Line 294,"While these  third-party vulnerabilities were not limited to BD products, BD  shared them as part of our commitment to transparency and  participation in the Coordinated Vulnerability Disclosure process.
","('Data_Security', 0.8805742859840393)","('Systemic_Risk_Management', 0.03444840759038925)","('Business_Ethics', 0.020511437207460403)","(['Information Security/Cybersecurity & System Availability'], 0.8805742859840393)","('NON-ESG', 0.03444840759038925)","('NON-ESG', 0.020511437207460403)"
Line 295,"Healthcare & Public Health Sector Coordinating  Councils (HSCC) BD participated in the HSCC Med Tech Cybersecurity Risk  Management Task Group, co-chaired by Rob Suárez, VP, Chief  Information Security Officer for BD.
","('Data_Security', 0.9202262759208679)","('Systemic_Risk_Management', 0.015231447294354439)","('Physical_Impacts_Of_Climate_Change', 0.007291337009519339)","(['Information Security/Cybersecurity & System Availability'], 0.9202262759208679)","('NON-ESG', 0.015231447294354439)","('NON-ESG', 0.007291337009519339)"
Line 296,"In 2019, the task group  issued the seminal Medical Device and Healthcare  Information Technology Joint Security Plan (JSP) .
","('Data_Security', 0.9530254602432251)","('Customer_Privacy', 0.0060666752979159355)","('Director_Removal', 0.0035600801929831505)","(['Information Security/Cybersecurity & System Availability'], 0.9530254602432251)","('NON-ESG', 0.0060666752979159355)","('NON-ESG', 0.0035600801929831505)"
Line 297,"The JSP  outlines specific recommendations for developing, deploying  and supporting secure medical devices and health IT products.
","('Data_Security', 0.4639502763748169)","('Product_Design_And_Lifecycle_Management', 0.18107829988002777)","('Product_Quality_And_Safety', 0.04855173081159592)","('NON-ESG', 0.4639502763748169)","('NON-ESG', 0.18107829988002777)","('NON-ESG', 0.04855173081159592)"
Line 298,"Our contribution included a deidentified version of the BD  Product Security Framework, a schema that drives the security- by-design principle all medical device manufacturers now follow  in alignment with the JSP.International Medical Device Regulators Forum – Medical  Device Cybersecurity Working Group BD is one of seven nonregulatory members actively  participating in the International Medical Device Regulators  Forum (IMDRF) – Medical Device Cybersecurity Working  Group.
","('Data_Security', 0.9412565231323242)","('Systemic_Risk_Management', 0.009249212220311165)","('Business_Ethics', 0.0051056575030088425)","(['Information Security/Cybersecurity & System Availability'], 0.9412565231323242)","('NON-ESG', 0.009249212220311165)","('NON-ESG', 0.0051056575030088425)"
Line 299,"This is a collaborative effort with the shared goal of  harmonizing medical device cybersecurity around the world.
","('Data_Security', 0.9373666048049927)","('Systemic_Risk_Management', 0.009734779596328735)","('Physical_Impacts_Of_Climate_Change', 0.005212371703237295)","(['Information Security/Cybersecurity & System Availability'], 0.9373666048049927)","('NON-ESG', 0.009734779596328735)","('NON-ESG', 0.005212371703237295)"
Line 300,"BD made significant contributions to the IMDRF’s Principles  and Practices for Medical Device Cybersecurity , which was  developed in 2019 and finalized in March 2020.
","('Data_Security', 0.8957786560058594)","('Systemic_Risk_Management', 0.024508079513907433)","('Business_Model_Resilience', 0.009655468165874481)","(['Information Security/Cybersecurity & System Availability'], 0.8957786560058594)","('NON-ESG', 0.024508079513907433)","('NON-ESG', 0.009655468165874481)"
Line 301,"Cybersecurity bootcamps In 2019, BD partnered with the New Zealand Ministry of Health  and healthAlliance on a series of cybersecurity bootcamps in  collaboration with security researcher and co-founder of I Am  the Cavalry, Beau Woods.
","('Data_Security', 0.9474795460700989)","('Systemic_Risk_Management', 0.006975127849727869)","('Physical_Impacts_Of_Climate_Change', 0.005073299165815115)","(['Information Security/Cybersecurity & System Availability'], 0.9474795460700989)","('NON-ESG', 0.006975127849727869)","('NON-ESG', 0.005073299165815115)"
Line 302,"Over 50 clinicians, procurement  specialists, auditors, biomedical engineers and health IT leaders  met with security researchers, security experts and device  manufacturers to discuss how to better collaborate and  coordinate to protect patient safety.
","('Employee_Health_And_Safety', 0.6766199469566345)","('Product_Quality_And_Safety', 0.19220374524593353)","('Product_Design_And_Lifecycle_Management', 0.014104314148426056)","(['Operational Eco-Efficiency'], 0.6766199469566345)","('NON-ESG', 0.19220374524593353)","('NON-ESG', 0.014104314148426056)"
Line 303,"For more information about BD cybersecurity, visit the   Cybersecurity  section of our website.
","('Data_Security', 0.9023483991622925)","('Systemic_Risk_Management', 0.024764014407992363)","('Physical_Impacts_Of_Climate_Change', 0.007460290100425482)","(['Information Security/Cybersecurity & System Availability'], 0.9023483991622925)","('NON-ESG', 0.024764014407992363)","('NON-ESG', 0.007460290100425482)"
Line 304,"20Medical device sterilization is essential to a functioning and  effective healthcare system.
","('Employee_Health_And_Safety', 0.8457837104797363)","('Critical_Incident_Risk_Management', 0.026502707973122597)","('Access_And_Affordability', 0.023845164105296135)","(['Operational Eco-Efficiency'], 0.8457837104797363)","('NON-ESG', 0.026502707973122597)","('NON-ESG', 0.023845164105296135)"
Line 305,"Sterilization protects patients from  the risks of infectious diseases caused by bacteria, viruses and  fungi.
","('Access_And_Affordability', 0.1860649436712265)","('Employee_Health_And_Safety', 0.1174396350979805)","('Product_Quality_And_Safety', 0.09242527931928635)","('NON-ESG', 0.1860649436712265)","('NON-ESG', 0.1174396350979805)","('NON-ESG', 0.09242527931928635)"
Line 306,"At BD, we use a variety of methods to safely sterilize our  products, including ethylene oxide (or “EtO”), gamma radiation,  e-beam and moist heat.
","('Product_Design_And_Lifecycle_Management', 0.25995728373527527)","('Waste_And_Hazardous_Materials_Management', 0.2061421275138855)","('Product_Quality_And_Safety', 0.19156640768051147)","('NON-ESG', 0.25995728373527527)","('NON-ESG', 0.2061421275138855)","('NON-ESG', 0.19156640768051147)"
Line 307,"The appropriate method of sterilization depends on a variety of  factors.
","('Employee_Health_And_Safety', 0.4960823059082031)","('Product_Quality_And_Safety', 0.10836425423622131)","('Customer_Welfare', 0.05801377072930336)","('NON-ESG', 0.4960823059082031)","('NON-ESG', 0.10836425423622131)","('NON-ESG', 0.05801377072930336)"
Line 308,"For example, a large number of devices can be damaged  by moist heat, radiation and other modes of sterilization, making  EtO the only practical sterilization option for those devices.
","('Employee_Health_And_Safety', 0.3099365234375)","('Product_Quality_And_Safety', 0.2319524735212326)","('Product_Design_And_Lifecycle_Management', 0.09069565683603287)","('NON-ESG', 0.3099365234375)","('NON-ESG', 0.2319524735212326)","('NON-ESG', 0.09069565683603287)"
Line 309,"Further, viable sterilization methods must not only ensure the  safety of devices but also provide the ongoing capacity and  scale required to process the billions of medical devices needed by patients in today’s modern healthcare systems.
","('Product_Quality_And_Safety', 0.5262152552604675)","('Employee_Health_And_Safety', 0.23967012763023376)","('Product_Design_And_Lifecycle_Management', 0.033482618629932404)","(['Product Quality & Recall Management'], 0.5262152552604675)","('NON-ESG', 0.23967012763023376)","('NON-ESG', 0.033482618629932404)"
Line 310,"For these  reasons and others, EtO sterilization is the method used for  approximately 50% of our company’s sterile devices.
","('Waste_And_Hazardous_Materials_Management', 0.3880048096179962)","('Employee_Health_And_Safety', 0.2139768898487091)","('Water_And_Wastewater_Management', 0.04964107647538185)","('NON-ESG', 0.3880048096179962)","('NON-ESG', 0.2139768898487091)","('NON-ESG', 0.04964107647538185)"
Line 311,"We recognize the responsibility we have to safely use all modes  of sterilization in our operations.
","('Employee_Health_And_Safety', 0.7778798937797546)","('Waste_And_Hazardous_Materials_Management', 0.03809811919927597)","('Access_And_Affordability', 0.032091401517391205)","(['Operational Eco-Efficiency'], 0.7778798937797546)","('NON-ESG', 0.03809811919927597)","('NON-ESG', 0.032091401517391205)"
Line 312,"That is why for decades, BD has  invested in emission control technologies, process safety controls,  as well as subject matter expertise in process safety engineering,  environmental engineering, radiation safety, industrial hygiene,  sterility assurance and other disciplines.
","('Employee_Health_And_Safety', 0.4654984474182129)","('Air_Quality', 0.18370512127876282)","('Critical_Incident_Risk_Management', 0.10116890072822571)","('NON-ESG', 0.4654984474182129)","('NON-ESG', 0.18370512127876282)","('NON-ESG', 0.10116890072822571)"
Line 313,"Our Environmental  Health and Safety (EHS) standards ensure that all BD sterilization  facilities are designed and operate with a high level of process  safety and environmental controls.Sterilization In FY 2019, BD was selected as a participant in the U.S. FDA’s  innovation challenge to identify new sterilization methods and  technologies as alternatives to EtO and reduce EtO emissions.
","('Product_Quality_And_Safety', 0.7023757100105286)","('Employee_Health_And_Safety', 0.15901459753513336)","('Access_And_Affordability', 0.015270802192389965)","(['Product Quality & Recall Management'], 0.7023757100105286)","('NON-ESG', 0.15901459753513336)","('NON-ESG', 0.015270802192389965)"
Line 314,"We were 1 of 12 accepted proposals out of 46 applicants.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6239328384399414)","('Employee_Engagement_Inclusion_And_Diversity', 0.03958680480718613)","('Human_Rights_And_Community_Relations', 0.036813974380493164)","(['Corporate Governance'], 0.6239328384399414)","('NON-ESG', 0.03958680480718613)","('NON-ESG', 0.036813974380493164)"
Line 315,"The FDA’s selection of our proposal into the program marks a  critical step in our ongoing partnership with the FDA.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9006824493408203)","('Competitive_Behavior', 0.01658187434077263)","('GHG_Emissions', 0.008114351890981197)","(['Corporate Governance'], 0.9006824493408203)","('NON-ESG', 0.01658187434077263)","('NON-ESG', 0.008114351890981197)"
Line 316,"It demonstrates the company’s commitment to improve upon  and ensure the continued safe use of EtO, and to investigate  alternative sterilization methods that will provide the same  sterility assurance and result in the same device performance as  EtO, at the scale required.U.S. FDA Innovation Challenge Until there is a safe and effective replacement for EtO, BD will  continue to pursue our goal to reduce the amount of EtO used  and minimize emissions from the process.
","('Product_Quality_And_Safety', 0.3319065570831299)","('Employee_Health_And_Safety', 0.29138168692588806)","('Access_And_Affordability', 0.07617147266864777)","('NON-ESG', 0.3319065570831299)","('NON-ESG', 0.29138168692588806)","('NON-ESG', 0.07617147266864777)"
Line 317,"Optimizing EtO  sterilization cycles, evaluating new device packaging configurations and evaluating new approaches to validation are  examples of possible ways to minimize the amount of EtO used  in the sterilization process.Reducing EtO consumption21Enforcement action • Our infusion pump organizational unit is operating under an  amended consent decree entered into by CareFusion with  the FDA in 2007.
","('Customer_Welfare', 0.2237313836812973)","('Product_Quality_And_Safety', 0.1258208304643631)","('Employee_Health_And_Safety', 0.09035035967826843)","('NON-ESG', 0.2237313836812973)","('NON-ESG', 0.1258208304643631)","('NON-ESG', 0.09035035967826843)"
Line 318,"CareFusion’s consent decree with the FDA  related to its Alaris ™ SE infusion pumps.
","('Customer_Welfare', 0.28888294100761414)","('Selling_Practices_And_Product_Labeling', 0.15252360701560974)","('Energy_Management', 0.08470398187637329)","('NON-ESG', 0.28888294100761414)","('NON-ESG', 0.15252360701560974)","('NON-ESG', 0.08470398187637329)"
Line 319,"In February 2009,  CareFusion and the FDA amended the consent decree   to include all infusion pumps manufactured by or for  CareFusion 303, Inc., the organizational unit that  manufactures and sells infusion pumps in the United States.
","('Customer_Welfare', 0.2950027585029602)","('Energy_Management', 0.20784926414489746)","('Selling_Practices_And_Product_Labeling', 0.10032778233289719)","('NON-ESG', 0.2950027585029602)","('NON-ESG', 0.20784926414489746)","('NON-ESG', 0.10032778233289719)"
Line 320,"The amended consent decree does not apply to intravenous  administration sets and accessories.
","('Customer_Welfare', 0.21865814924240112)","('Competitive_Behavior', 0.09856767952442169)","('Management_Of_Legal_And_Regulatory_Framework', 0.0965351015329361)","('NON-ESG', 0.21865814924240112)","('NON-ESG', 0.09856767952442169)","('NON-ESG', 0.0965351015329361)"
Line 321,"While this BD organizational unit remains subject to the  amended consent decree, which includes the requirements of  the original consent decree, it has made substantial progress  in its compliance efforts.
","('Management_Of_Legal_And_Regulatory_Framework', 0.956737220287323)","('Business_Ethics', 0.004768270067870617)","('Director_Removal', 0.0037593336310237646)","(['Corporate Governance'], 0.956737220287323)","('NON-ESG', 0.004768270067870617)","('NON-ESG', 0.0037593336310237646)"
Line 322,"However, we cannot predict the  outcome of this matter, and the amended consent decree  authorizes the FDA, in the event of any violations in the  future, to order us to cease manufacturing and distributing  infusion pumps, recall products and take other actions.
","('Selling_Practices_And_Product_Labeling', 0.3659329116344452)","('Product_Quality_And_Safety', 0.2856743633747101)","('Customer_Welfare', 0.06671877950429916)","('NON-ESG', 0.3659329116344452)","('NON-ESG', 0.2856743633747101)","('NON-ESG', 0.06671877950429916)"
Line 323,"We may be required to pay damages of $15,000 per day   per violation if we fail to comply with any provision of the  amended consent decree, up to $15 million per year.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7339666485786438)","('Business_Ethics', 0.1701180338859558)","('Competitive_Behavior', 0.009008252993226051)","(['Corporate Governance'], 0.7339666485786438)","('NON-ESG', 0.1701180338859558)","('NON-ESG', 0.009008252993226051)"
Line 324,"We also cannot currently predict whether additional monetary  investment will be incurred to resolve this matter or the  matter’s ultimate impact on our business.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9329745173454285)","('Systemic_Risk_Management', 0.008652438409626484)","('Business_Ethics', 0.006120051722973585)","(['Corporate Governance'], 0.9329745173454285)","('NON-ESG', 0.008652438409626484)","('NON-ESG', 0.006120051722973585)"
Line 325,"We may be  obligated to pay more costs in the future because, among  other things, the FDA may determine that we are not fully  compliant with the amended consent decree and therefore  impose penalties under the amended consent decree, and/or  we may be subject to future proceedings and litigation relating  to the matters addressed in the amended consent decree.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9567520618438721)","('Business_Ethics', 0.008286017924547195)","('Competitive_Behavior', 0.004631073214113712)","(['Corporate Governance'], 0.9567520618438721)","('NON-ESG', 0.008286017924547195)","('NON-ESG', 0.004631073214113712)"
Line 326,"As of September 30, 2019, we do not believe that a loss is  probable in connection with the amended consent decree,  and accordingly, we have no accruals associated with  compliance with the amended consent decree.While we have implemented, and continue to improve upon, programs and management systems around product quality and safety,  we are on occasion subject to enforcement action.
","('Product_Quality_And_Safety', 0.9175402522087097)","('Product_Design_And_Lifecycle_Management', 0.014593789353966713)","('Selling_Practices_And_Product_Labeling', 0.008716486394405365)","(['Product Quality & Recall Management'], 0.9175402522087097)","('NON-ESG', 0.014593789353966713)","('NON-ESG', 0.008716486394405365)"
Line 327,"• In May 2017, the FDA conducted inspections at BD’s  Preanalytical Systems (“PAS”) facility in Franklin Lakes, New  Jersey.
","('Management_Of_Legal_And_Regulatory_Framework', 0.778667151927948)","('Product_Quality_And_Safety', 0.03992283716797829)","('Business_Ethics', 0.038514673709869385)","(['Corporate Governance'], 0.778667151927948)","('NON-ESG', 0.03992283716797829)","('NON-ESG', 0.038514673709869385)"
Line 328,"In July 2017, the FDA issued a Form 483 to BD PAS in  connection with these inspections that contained  observations of non-conformance relating to quality system  regulations and medical device reporting relating to certain  of our BD Vacutainer ™ EDTA blood collection tubes.
","('Product_Quality_And_Safety', 0.39514654874801636)","('Management_Of_Legal_And_Regulatory_Framework', 0.17135398089885712)","('Business_Ethics', 0.09886976331472397)","('NON-ESG', 0.39514654874801636)","('NON-ESG', 0.17135398089885712)","('NON-ESG', 0.09886976331472397)"
Line 329,"On January 11, 2018, BD received a Warning Letter from   the FDA, citing certain alleged violations of quality system  regulations and of law.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8424630761146545)","('Product_Quality_And_Safety', 0.02946738712489605)","('Business_Ethics', 0.019705254584550858)","(['Corporate Governance'], 0.8424630761146545)","('NON-ESG', 0.02946738712489605)","('NON-ESG', 0.019705254584550858)"
Line 330,"The Warning Letter states that,   until BD resolves the outstanding issues covered by the   Warning Letter, the FDA will not clear or approve any   premarket submissions for Class III devices to which the   non-conformances are reasonably related or grant requests  for certificates to foreign governments.
","('Product_Quality_And_Safety', 0.33964213728904724)","('Management_Of_Legal_And_Regulatory_Framework', 0.27083876729011536)","('Competitive_Behavior', 0.057581014931201935)","('NON-ESG', 0.33964213728904724)","('NON-ESG', 0.27083876729011536)","('NON-ESG', 0.057581014931201935)"
Line 331,"We submitted our  response to the Warning Letter on January 31, 2018.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2308656871318817)","('Product_Quality_And_Safety', 0.07948258519172668)","('GHG_Emissions', 0.0739978551864624)","('NON-ESG', 0.2308656871318817)","('NON-ESG', 0.07948258519172668)","('NON-ESG', 0.0739978551864624)"
Line 332,"BD is working closely with the FDA and intends to fully  implement corrective actions to address the concerns  identified in the Warning Letter.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7277061343193054)","('Selling_Practices_And_Product_Labeling', 0.05167621746659279)","('Product_Quality_And_Safety', 0.04206026345491409)","(['Corporate Governance'], 0.7277061343193054)","('NON-ESG', 0.05167621746659279)","('NON-ESG', 0.04206026345491409)"
Line 333,"However, BD cannot give any  assurances that the FDA will be satisfied with its responses to  the Warning Letter or as to the expected date of resolution of  matters included in the Warning Letter.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8780704140663147)","('Product_Quality_And_Safety', 0.018040381371974945)","('Selling_Practices_And_Product_Labeling', 0.01270123291760683)","(['Corporate Governance'], 0.8780704140663147)","('NON-ESG', 0.018040381371974945)","('NON-ESG', 0.01270123291760683)"
Line 334,"While BD does not  believe that the issues identified in the Warning Letter will  have a material impact on BD’s operation, no assurances can  be given that the resolution of this matter will not have a  material adverse effect on BD’s business, results of  operations, financial conditions and/or liquidity.
","('Systemic_Risk_Management', 0.9237473607063293)","('Business_Model_Resilience', 0.01587999053299427)","('Business_Ethics', 0.01091111358255148)","(['Risk & Crisis Management'], 0.9237473607063293)","('NON-ESG', 0.01587999053299427)","('NON-ESG', 0.01091111358255148)"
Line 335,"22COVID-19—How BD is mobilizing to help combat the virus The global pandemic resulting from the COVID-19 virus has brought about unprecedented change and challenges.
","('Physical_Impacts_Of_Climate_Change', 0.2576398253440857)","('Systemic_Risk_Management', 0.15726682543754578)","('Data_Security', 0.14396797120571136)","('NON-ESG', 0.2576398253440857)","('NON-ESG', 0.15726682543754578)","('NON-ESG', 0.14396797120571136)"
Line 336,"BD recognizes that worldwide, hospitals, physicians, laboratories  and clinics rely on our products to maintain the health of their  patients.
","('Product_Design_And_Lifecycle_Management', 0.7357130646705627)","('Customer_Welfare', 0.07469356805086136)","('Product_Quality_And_Safety', 0.04643573611974716)","(['Product Stewardship'], 0.7357130646705627)","('NON-ESG', 0.07469356805086136)","('NON-ESG', 0.04643573611974716)"
Line 337,"As a company with a global supply chain, we  understand the importance of ensuring that we can continue to  supply customers around the world with the products their  patients rely upon.
","('Product_Design_And_Lifecycle_Management', 0.7805786728858948)","('Supply_Chain_Management', 0.11301448941230774)","('Customer_Welfare', 0.00983252190053463)","(['Product Stewardship'], 0.7805786728858948)","('NON-ESG', 0.11301448941230774)","('NON-ESG', 0.00983252190053463)"
Line 338,"With over 65,000 associates, we have a  responsibility to provide safe working conditions, to ensure they,  their families and the communities they live in, remain healthy.
","('Human_Rights_And_Community_Relations', 0.41579464077949524)","('Access_And_Affordability', 0.22533702850341797)","('Employee_Health_And_Safety', 0.15895573794841766)","('NON-ESG', 0.41579464077949524)","('NON-ESG', 0.22533702850341797)","('NON-ESG', 0.15895573794841766)"
Line 339,"We have mobilized our product portfolio, to expand diagnostic  testing; to track and report COVID-19 data and impact; and  help accelerate discovery of potential therapies and vaccines.
","('Product_Design_And_Lifecycle_Management', 0.7050979137420654)","('Selling_Practices_And_Product_Labeling', 0.07531530410051346)","('Customer_Welfare', 0.0713130459189415)","(['Product Stewardship'], 0.7050979137420654)","('NON-ESG', 0.07531530410051346)","('NON-ESG', 0.0713130459189415)"
Line 340,"We have engaged on the front lines, by providing new training  on infection control practices; our service engineers are  installing and servicing medical instruments in hospitals caring  for COVID-19 patients; and we are supporting clinically trained  BD associates who wish to volunteer to support healthcare  facilities in their communities.
","('Access_And_Affordability', 0.3459938168525696)","('Employee_Health_And_Safety', 0.2349362075328827)","('Product_Quality_And_Safety', 0.09000507742166519)","('NON-ESG', 0.3459938168525696)","('NON-ESG', 0.2349362075328827)","('NON-ESG', 0.09000507742166519)"
Line 341,"The situation will continue to evolve, and we will continue to  prepare and respond.
","('Critical_Incident_Risk_Management', 0.7841846346855164)","('Physical_Impacts_Of_Climate_Change', 0.05651351809501648)","('Business_Model_Resilience', 0.01875719614326954)","(['Risk & Crisis Management'], 0.7841846346855164)","('NON-ESG', 0.05651351809501648)","('NON-ESG', 0.01875719614326954)"
Line 342,"For example, our full portfolio of  medication delivery devices can support rapid deployment of  novel COVID-19 treatments and vaccine trials.
","('Customer_Welfare', 0.41958314180374146)","('Competitive_Behavior', 0.11274191737174988)","('Product_Design_And_Lifecycle_Management', 0.08499643206596375)","('NON-ESG', 0.41958314180374146)","('NON-ESG', 0.11274191737174988)","('NON-ESG', 0.08499643206596375)"
Line 343,"We are committed to transparency on our response to the  pandemic and its impacts on our business.
","('Systemic_Risk_Management', 0.4732413589954376)","('Business_Ethics', 0.19384612143039703)","('Physical_Impacts_Of_Climate_Change', 0.11776059120893478)","('NON-ESG', 0.4732413589954376)","('NON-ESG', 0.19384612143039703)","('NON-ESG', 0.11776059120893478)"
Line 344,"Impacts as they  pertain to our business will be reported via our financial filings  and quarterly earnings calls, available on the Investors section  of our website.
","('Business_Model_Resilience', 0.4766855835914612)","('Systemic_Risk_Management', 0.21366442739963531)","('Physical_Impacts_Of_Climate_Change', 0.08211421966552734)","('NON-ESG', 0.4766855835914612)","('NON-ESG', 0.21366442739963531)","('NON-ESG', 0.08211421966552734)"
Line 345,"For current information on our response to COVID-19, please  visit our  website .
","('Management_Of_Legal_And_Regulatory_Framework', 0.29860883951187134)","('GHG_Emissions', 0.14120173454284668)","('Competitive_Behavior', 0.09420068562030792)","('NON-ESG', 0.29860883951187134)","('NON-ESG', 0.14120173454284668)","('NON-ESG', 0.09420068562030792)"
Line 346,"The information provided below outlines our response   up to July 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3749988079071045)","('Critical_Incident_Risk_Management', 0.0801268070936203)","('Physical_Impacts_Of_Climate_Change', 0.07795682549476624)","('NON-ESG', 0.3749988079071045)","('NON-ESG', 0.0801268070936203)","('NON-ESG', 0.07795682549476624)"
Line 347,"We will provide an update in our next  sustainability report.Mobilization to respond to  the pandemic has been  needed across the public,  private, nonprofit sectors  and civil society.
","('Physical_Impacts_Of_Climate_Change', 0.5563470125198364)","('Systemic_Risk_Management', 0.15092220902442932)","('Critical_Incident_Risk_Management', 0.04881037771701813)","(['Climate Change'], 0.5563470125198364)","('NON-ESG', 0.15092220902442932)","('NON-ESG', 0.04881037771701813)"
Line 348,"Enabled remote work  for office-based associatesEarly to implement visitor restrictions, travel restrictions, limits on group meetings Implemented screening, social distancing, enhanced cleaning and PPE  for essential  workers at BD facilities Enhanced healthcare benefits , including expanding access to telehealth services and  our Employee Assistance ProgramProvided pandemic pay  to support self-quarantine Increased paid volunteer leave  for medically trained professionals and created  Employee Assistance Fund  for furloughed associatesProtecting health   and safety Caring for   our associates Spotlight—COVID-Protecting the health, safety and well-being of BD associates Deployed PPE  to field-based associates supporting critical customer needs23Our more than 65,000 associates are essential to ensuring our  customers and their patients continue to receive our products  and support services.
","('Labor_Practices', 0.6510357856750488)","('Employee_Health_And_Safety', 0.17908534407615662)","('Access_And_Affordability', 0.02334349788725376)","(['Labor Practice Indicators'], 0.6510357856750488)","('NON-ESG', 0.17908534407615662)","('NON-ESG', 0.02334349788725376)"
Line 349,"Enabled remote work  for office-based associatesEarly to implement visitor restrictions, travel restrictions, limits on group meetings Implemented screening, social distancing, enhanced cleaning and PPE  for essential  workers at BD facilities Enhanced healthcare benefits , including expanding access to telehealth services and  our Employee Assistance ProgramProvided pandemic pay  to support self-quarantine Increased paid volunteer leave  for medically trained professionals and created  Employee Assistance Fund  for furloughed associatesProtecting health   and safety Caring for   our associates Spotlight—COVID-Protecting the health, safety and well-being of BD associates Deployed PPE  to field-based associates supporting critical customer needs23Our more than 65,000 associates are essential to ensuring our  customers and their patients continue to receive our products  and support services.
","('Employee_Health_And_Safety', 0.5196041464805603)","('Product_Quality_And_Safety', 0.34208065271377563)","('Product_Design_And_Lifecycle_Management', 0.026222867891192436)","(['Operational Eco-Efficiency'], 0.5196041464805603)","('NON-ESG', 0.34208065271377563)","('NON-ESG', 0.026222867891192436)"
Line 350,"We have taken numerous steps to ensure  the safety of our associates.
","('Employee_Health_And_Safety', 0.9261229038238525)","('Customer_Privacy', 0.009432638064026833)","('Critical_Incident_Risk_Management', 0.008303706534206867)","(['Operational Eco-Efficiency'], 0.9261229038238525)","('NON-ESG', 0.009432638064026833)","('NON-ESG', 0.008303706534206867)"
Line 351,"Leveraging technology, much of our global workforce has  successfully transitioned to working from home.
","('Employee_Engagement_Inclusion_And_Diversity', 0.47305241227149963)","('Labor_Practices', 0.31714463233947754)","('Employee_Health_And_Safety', 0.040992505848407745)","('NON-ESG', 0.47305241227149963)","('NON-ESG', 0.31714463233947754)","('NON-ESG', 0.040992505848407745)"
Line 352,"We continue to  provide a range of guidance and support to help our associates  maintain physical and mental health.
","('Employee_Health_And_Safety', 0.9297241568565369)","('Access_And_Affordability', 0.012859383597970009)","('Employee_Engagement_Inclusion_And_Diversity', 0.00984134990721941)","(['Operational Eco-Efficiency'], 0.9297241568565369)","('NON-ESG', 0.012859383597970009)","('NON-ESG', 0.00984134990721941)"
Line 353,"For associates who remain working at BD facilities, we have  implemented several protective measures, including: • Weekly calls are held with site and operations leaders to share  guidance and best practice.
","('Employee_Health_And_Safety', 0.41973134875297546)","('Supply_Chain_Management', 0.0828266516327858)","('Labor_Practices', 0.07044456154108047)","('NON-ESG', 0.41973134875297546)","('NON-ESG', 0.0828266516327858)","('NON-ESG', 0.07044456154108047)"
Line 354,"• Anyone entering a BD facility is temperature screened, and  only business-critical visitors are allowed on-site.
","('Ecological_Impacts', 0.14495207369327545)","('Waste_And_Hazardous_Materials_Management', 0.14215503633022308)","('Customer_Privacy', 0.11096759885549545)","('NON-ESG', 0.14495207369327545)","('NON-ESG', 0.14215503633022308)","('NON-ESG', 0.11096759885549545)"
Line 355,"• Physical distancing measures, tailored by facility, including  modifying break rooms to provide physical separation and  staggering break times and modifying workstations to create  physical distance.
","('Employee_Health_And_Safety', 0.1727495640516281)","('Energy_Management', 0.11365961283445358)","('Product_Design_And_Lifecycle_Management', 0.07399574667215347)","('NON-ESG', 0.1727495640516281)","('NON-ESG', 0.11365961283445358)","('NON-ESG', 0.07399574667215347)"
Line 356,"Where a physical distance of at least 6 feet  cannot be fully obtained, associates are provided with face  shields or masks.
","('Employee_Health_And_Safety', 0.7512883543968201)","('Employee_Engagement_Inclusion_And_Diversity', 0.09208423644304276)","('Product_Design_And_Lifecycle_Management', 0.01600249670445919)","(['Operational Eco-Efficiency'], 0.7512883543968201)","('NON-ESG', 0.09208423644304276)","('NON-ESG', 0.01600249670445919)"
Line 357,"• All associates performing field work have been issued PPE,  tailored to the risk level of their activities, along with training  and guidance on COVID-19 and PPE protocols.For field service associates, protocols have been implemented to  reduce the number of associates who are deployed, while  ensuring we meet overall continuity of care and meet customer  needs due to the COVID-19 pandemic.
","('Access_And_Affordability', 0.23119387030601501)","('Employee_Health_And_Safety', 0.17414051294326782)","('Systemic_Risk_Management', 0.09828488528728485)","('NON-ESG', 0.23119387030601501)","('NON-ESG', 0.17414051294326782)","('NON-ESG', 0.09828488528728485)"
Line 358,"Additional personal  protective equipment, along with guidance for use, has been  issued to any field service associate entering high-risk areas.
","('Employee_Health_And_Safety', 0.9226154685020447)","('Critical_Incident_Risk_Management', 0.023413503542542458)","('Product_Design_And_Lifecycle_Management', 0.007360938936471939)","(['Operational Eco-Efficiency'], 0.9226154685020447)","('NON-ESG', 0.023413503542542458)","('NON-ESG', 0.007360938936471939)"
Line 359,"Changes in demand across our portfolio has resulted in the  need to take temporary actions to reduce our costs so we can  continue to serve our customers now and into the future.
","('Product_Design_And_Lifecycle_Management', 0.22221878170967102)","('Energy_Management', 0.19360564649105072)","('Business_Model_Resilience', 0.10901995003223419)","('NON-ESG', 0.22221878170967102)","('NON-ESG', 0.19360564649105072)","('NON-ESG', 0.10901995003223419)"
Line 360,"Steps included temporary work reductions, by slowing or  suspending production at select manufacturing locations.
","('Labor_Practices', 0.41227954626083374)","('Supply_Chain_Management', 0.2364213913679123)","('Energy_Management', 0.0684075877070427)","('NON-ESG', 0.41227954626083374)","('NON-ESG', 0.2364213913679123)","('NON-ESG', 0.0684075877070427)"
Line 361,"This has led to furloughs, which allows us to retain BD associates  as employees.
","('Labor_Practices', 0.8690115213394165)","('Employee_Health_And_Safety', 0.02882811240851879)","('Management_Of_Legal_And_Regulatory_Framework', 0.01504586823284626)","(['Labor Practice Indicators'], 0.8690115213394165)","('NON-ESG', 0.02882811240851879)","('NON-ESG', 0.01504586823284626)"
Line 362,"While pay has been adjusted accordingly,   we recognize the disruption this can cause to our associates and  their families and we want to do everything we can to support  and care for associates—this includes affected associates  retaining their benefits, including medical benefits.
","('Employee_Health_And_Safety', 0.44179579615592957)","('Access_And_Affordability', 0.1599387675523758)","('Labor_Practices', 0.10472363978624344)","('NON-ESG', 0.44179579615592957)","('NON-ESG', 0.1599387675523758)","('NON-ESG', 0.10472363978624344)"
Line 363,"We also believe leaders in the company have the responsibility  to serve and act in the best interest of the company and our  associates, helping to ensure that we can emerge stronger.
","('Human_Rights_And_Community_Relations', 0.28568169474601746)","('Director_Removal', 0.14668026566505432)","('Business_Model_Resilience', 0.11235157400369644)","('NON-ESG', 0.28568169474601746)","('NON-ESG', 0.14668026566505432)","('NON-ESG', 0.11235157400369644)"
Line 364,"Therefore, all BD leaders globally, along with the chairman and  Board of Directors, are subject to a temporary reduction  in base pay.
","('Director_Removal', 0.50699383020401)","('Labor_Practices', 0.2593834102153778)","('Management_Of_Legal_And_Regulatory_Framework', 0.04806821793317795)","(['Anti-Crime Policy & Measures'], 0.50699383020401)","('NON-ESG', 0.2593834102153778)","('NON-ESG', 0.04806821793317795)"
Line 365,"* BD operations Leveraging our world-class manufacturing excellence to address critical  customer and patient needs Built for scale and impact • Significantly ramped production of all  critical-to-COVID devices, maintaining our  strong focus on quality and compliance • Reduced production of select products due  to lower demand: reinforced strong  liquidity position • Engaged governments to ensure business  and supply chain continuity *Subject to any required consultation process and local law where applicable Spotlight—COVID-1924 23In response to very high demand for our critical medical devices,  production was increased for many of our high-demand  products and we closely monitor inventory and customer  ordering to ensure supply continuity.
","('Product_Design_And_Lifecycle_Management', 0.5474048256874084)","('Supply_Chain_Management', 0.3057097792625427)","('Customer_Welfare', 0.016665998846292496)","(['Product Stewardship'], 0.5474048256874084)","('NON-ESG', 0.3057097792625427)","('NON-ESG', 0.016665998846292496)"
Line 366,"* BD operations Leveraging our world-class manufacturing excellence to address critical  customer and patient needs Built for scale and impact • Significantly ramped production of all  critical-to-COVID devices, maintaining our  strong focus on quality and compliance • Reduced production of select products due  to lower demand: reinforced strong  liquidity position • Engaged governments to ensure business  and supply chain continuity *Subject to any required consultation process and local law where applicable Spotlight—COVID-1924 23In response to very high demand for our critical medical devices,  production was increased for many of our high-demand  products and we closely monitor inventory and customer  ordering to ensure supply continuity.
","('Product_Design_And_Lifecycle_Management', 0.9210402369499207)","('Supply_Chain_Management', 0.014534275978803635)","('Selling_Practices_And_Product_Labeling', 0.009619556367397308)","(['Product Stewardship'], 0.9210402369499207)","('NON-ESG', 0.014534275978803635)","('NON-ESG', 0.009619556367397308)"
Line 367,"While we continued to  meet demand for the vast majority of our products, we saw  high demand in select product categories because of a  prolonged flu season and the coronavirus pandemic.
","('Product_Design_And_Lifecycle_Management', 0.7561788558959961)","('Product_Quality_And_Safety', 0.05311557278037071)","('Selling_Practices_And_Product_Labeling', 0.048831839114427567)","(['Product Stewardship'], 0.7561788558959961)","('NON-ESG', 0.05311557278037071)","('NON-ESG', 0.048831839114427567)"
Line 368,"As a result, a number of products were placed on manual  inventory allocation to supply our customers as much as  possible.
","('Product_Design_And_Lifecycle_Management', 0.9433924555778503)","('Selling_Practices_And_Product_Labeling', 0.007722776848822832)","('Supply_Chain_Management', 0.007229023613035679)","(['Product Stewardship'], 0.9433924555778503)","('NON-ESG', 0.007722776848822832)","('NON-ESG', 0.007229023613035679)"
Line 369,"Manual inventory allocation is an internal process that  allows BD to retain greater visibility and control of available  product to effectively serve our customers by ensuring an  equitable allocation of available inventory.
","('Product_Design_And_Lifecycle_Management', 0.805455207824707)","('Customer_Welfare', 0.04694640263915062)","('Selling_Practices_And_Product_Labeling', 0.030591024085879326)","(['Product Stewardship'], 0.805455207824707)","('NON-ESG', 0.04694640263915062)","('NON-ESG', 0.030591024085879326)"
Line 370,"This includes  reviewing orders for disproportionate quantities based on  historic demand.Product availability: supply and business continuityBD continues to closely monitor the COVID-19 situation across  the world and guidance from the CDC, the WHO and health  officials in a variety of affected countries to ensure the health  and safety of BD associates while ensuring continued  availability of our company’s critical medical devices.
","('Product_Quality_And_Safety', 0.5945404767990112)","('Product_Design_And_Lifecycle_Management', 0.19271297752857208)","('Selling_Practices_And_Product_Labeling', 0.05935746431350708)","(['Product Quality & Recall Management'], 0.5945404767990112)","('NON-ESG', 0.19271297752857208)","('NON-ESG', 0.05935746431350708)"
Line 371,"BD manufactures and sources product from multiple locations  around the world.
","('Product_Design_And_Lifecycle_Management', 0.9352189302444458)","('Product_Quality_And_Safety', 0.01113856304436922)","('Selling_Practices_And_Product_Labeling', 0.008410141803324223)","(['Product Stewardship'], 0.9352189302444458)","('NON-ESG', 0.01113856304436922)","('NON-ESG', 0.008410141803324223)"
Line 372,"Our manufacturing and distribution centers  remained operational and enacted business continuity plans to  minimize the risk of disruption to our customers.We have experienced volatile and unpredictable level of product  demand across our portfolio.
","('Product_Design_And_Lifecycle_Management', 0.9384552836418152)","('Supply_Chain_Management', 0.0077128843404352665)","('Customer_Welfare', 0.007381782401353121)","(['Product Stewardship'], 0.9384552836418152)","('NON-ESG', 0.0077128843404352665)","('NON-ESG', 0.007381782401353121)"
Line 373,"We have seen significant increases  in demand for products used in sample collection, diagnosis and  treatment of COVID-19.
","('Product_Design_And_Lifecycle_Management', 0.8748738169670105)","('Selling_Practices_And_Product_Labeling', 0.02836701273918152)","('Product_Quality_And_Safety', 0.02755207195878029)","(['Product Stewardship'], 0.8748738169670105)","('NON-ESG', 0.02836701273918152)","('NON-ESG', 0.02755207195878029)"
Line 374,"However, in other parts of our business,  we’ve experienced drops in demand as healthcare providers  followed guidance to slow or stop most other hospital visits,  non-urgent surgeries, elective procedures and other research.
","('Employee_Health_And_Safety', 0.32844212651252747)","('Access_And_Affordability', 0.27622857689857483)","('Critical_Incident_Risk_Management', 0.08454281836748123)","('NON-ESG', 0.32844212651252747)","('NON-ESG', 0.27622857689857483)","('NON-ESG', 0.08454281836748123)"
Line 375,"Spotlight—COVID-As one of the largest global medical technology companies in the world, BD has deployed our capabilities, expertise and scale to  address critical health needs related to coronavirus—from our diagnostic offerings to identify COVID-19, to real-time informatics and  electronic surveillance technology, to essential medical devices to support patient care.Our products: supporting a global response • BD announced multiple new products to help aid in the  detection and identification of COVID-19, including   a molecular test for the detection of COVID-19 for clinical  laboratories in countries recognizing the CE mark .
","('Product_Design_And_Lifecycle_Management', 0.5637718439102173)","('Customer_Welfare', 0.09579309076070786)","('Product_Quality_And_Safety', 0.05826091766357422)","(['Product Stewardship'], 0.5637718439102173)","('NON-ESG', 0.09579309076070786)","('NON-ESG', 0.05826091766357422)"
Line 376,"Spotlight—COVID-As one of the largest global medical technology companies in the world, BD has deployed our capabilities, expertise and scale to  address critical health needs related to coronavirus—from our diagnostic offerings to identify COVID-19, to real-time informatics and  electronic surveillance technology, to essential medical devices to support patient care.Our products: supporting a global response • BD announced multiple new products to help aid in the  detection and identification of COVID-19, including   a molecular test for the detection of COVID-19 for clinical  laboratories in countries recognizing the CE mark .
","('Competitive_Behavior', 0.31682154536247253)","('GHG_Emissions', 0.16046234965324402)","('Customer_Welfare', 0.12590345740318298)","('NON-ESG', 0.31682154536247253)","('NON-ESG', 0.16046234965324402)","('NON-ESG', 0.12590345740318298)"
Line 377,"• BD received CE mark and emergency use authorization  (EUA) from the FDA for an additional molecular  diagnostics test for COVID-19  that can return results in two  to three hours, helping to increase the availability of tests  around the world.
","('Critical_Incident_Risk_Management', 0.9487928748130798)","('Employee_Health_And_Safety', 0.011338584125041962)","('Air_Quality', 0.0063066789880394936)","(['Risk & Crisis Management'], 0.9487928748130798)","('NON-ESG', 0.011338584125041962)","('NON-ESG', 0.0063066789880394936)"
Line 378,"• BD partnered with BioGX to  launch a new diagnostic test  that will enable hospitals to screen for COVID-19 on-site   and get results in under three hours.
","('Access_And_Affordability', 0.2487211972475052)","('Product_Quality_And_Safety', 0.12688101828098297)","('Management_Of_Legal_And_Regulatory_Framework', 0.07374471426010132)","('NON-ESG', 0.2487211972475052)","('NON-ESG', 0.12688101828098297)","('NON-ESG', 0.07374471426010132)"
Line 379,"• BD was granted an EUA for a rapid, point-of-care,   SARS-CoV-2 diagnostic test for use with the BD Veritor ™  Plus System .
","('Access_And_Affordability', 0.3484250009059906)","('Product_Quality_And_Safety', 0.10251972824335098)","('Customer_Welfare', 0.08024440705776215)","('NON-ESG', 0.3484250009059906)","('NON-ESG', 0.10251972824335098)","('NON-ESG', 0.08024440705776215)"
Line 380,"This new assay delivers results in 15 minutes   on a highly portable instrument.
","('Competitive_Behavior', 0.6686640977859497)","('Customer_Welfare', 0.06310948729515076)","('Energy_Management', 0.036812860518693924)","(['Business Ethics'], 0.6686640977859497)","('NON-ESG', 0.06310948729515076)","('NON-ESG', 0.036812860518693924)"
Line 381,"Portability and ease of use   is critical for improving access to COVID-19 diagnostics,  providing real-time results and enabling decision-making  while the patient is still on-site.• BD collaborated with peers from across the industry, HHS,  FDA and private partners to identify and validate additional  swab types as well as transport medium options in order to  expand capacity and alternative collection methods.
","('Access_And_Affordability', 0.21069061756134033)","('Customer_Welfare', 0.20865067839622498)","('Selling_Practices_And_Product_Labeling', 0.08480849117040634)","('NON-ESG', 0.21069061756134033)","('NON-ESG', 0.20865067839622498)","('NON-ESG', 0.08480849117040634)"
Line 382,"• BD announced the launch of the Prevention Course in  HAI Knowledge and Control , developed independently by  the Society for Healthcare Epidemiology of America (SHEA)  and supported in full by an educational grant from BD.Specimen collection and  transport —used for the  collection and transport of clinical  specimens, including viruses.
","('Waste_And_Hazardous_Materials_Management', 0.332681804895401)","('Ecological_Impacts', 0.16246578097343445)","('Employee_Health_And_Safety', 0.05749345198273659)","('NON-ESG', 0.332681804895401)","('NON-ESG', 0.16246578097343445)","('NON-ESG', 0.05749345198273659)"
Line 383,"Swabs —used to collect clinical  specimens from various body sites.
","('Waste_And_Hazardous_Materials_Management', 0.4336232841014862)","('Employee_Health_And_Safety', 0.14164917171001434)","('Employee_Engagement_Inclusion_And_Diversity', 0.06919220834970474)","('NON-ESG', 0.4336232841014862)","('NON-ESG', 0.14164917171001434)","('NON-ESG', 0.06919220834970474)"
Line 384,"UVT medium vials —used for the  transport of clinical specimens,  including viruses.
","('Waste_And_Hazardous_Materials_Management', 0.6545898914337158)","('Selling_Practices_And_Product_Labeling', 0.058543913066387177)","('Water_And_Wastewater_Management', 0.03217808157205582)","(['Operational Eco-Efficiency'], 0.6545898914337158)","('NON-ESG', 0.058543913066387177)","('NON-ESG', 0.03217808157205582)"
Line 385,"UVT kit —a prepacked, individually  wrapped kit that includes swab(s)  and a vial for the collection and  transport of clinical specimens,  including viruses.BD MAX ™ System —an open  platform system that enables  exploratory development of rapid  tests for COVID-19.
","('Selling_Practices_And_Product_Labeling', 0.13032938539981842)","('Access_And_Affordability', 0.12749768793582916)","('Waste_And_Hazardous_Materials_Management', 0.12145087867975235)","('NON-ESG', 0.13032938539981842)","('NON-ESG', 0.12749768793582916)","('NON-ESG', 0.12145087867975235)"
Line 386,"BD Veritor ™ System —a rapid  point-of-care (POC) platform  used to diagnose Flu A, Flu B, RSV  and Strep in minutes.
","('Employee_Health_And_Safety', 0.40130192041397095)","('Product_Quality_And_Safety', 0.09070663154125214)","('Customer_Welfare', 0.0553748793900013)","('NON-ESG', 0.40130192041397095)","('NON-ESG', 0.09070663154125214)","('NON-ESG', 0.0553748793900013)"
Line 387,"Assay for  COVID-19 granted emergency  use authorization by the FDA.Injection devices —specific  needles and syringes used to  administer medications required  for COVID-19 treatment, as well  as vaccination clinical trials and  future campaigns.
","('Employee_Health_And_Safety', 0.5945804119110107)","('Access_And_Affordability', 0.06502652913331985)","('Product_Quality_And_Safety', 0.06364072114229202)","(['Operational Eco-Efficiency'], 0.5945804119110107)","('NON-ESG', 0.06502652913331985)","('NON-ESG', 0.06364072114229202)"
Line 388,"BD Alaris ™ System —controls  precise delivery of IV medication  for COVID-19 treatment.Foley Catheters —used to drain  urine from the bladder in acute care  settings.
","('Waste_And_Hazardous_Materials_Management', 0.3387536108493805)","('Water_And_Wastewater_Management', 0.20321251451969147)","('Customer_Welfare', 0.08790091425180435)","('NON-ESG', 0.3387536108493805)","('NON-ESG', 0.20321251451969147)","('NON-ESG', 0.08790091425180435)"
Line 389,"Peripherally inserted central  catheters (PICCs) and midlines — used to rapidly deliver drugs required  for COVID-19 treatment.
","('Access_And_Affordability', 0.44289231300354004)","('Customer_Welfare', 0.09798156470060349)","('Energy_Management', 0.0481938011944294)","('NON-ESG', 0.44289231300354004)","('NON-ESG', 0.09798156470060349)","('NON-ESG', 0.0481938011944294)"
Line 390,"Acute dialysis catheters —used to  administer immediate dialysis for  patients who enter acute renal failure.
","('Access_And_Affordability', 0.22618399560451508)","('Employee_Health_And_Safety', 0.12527671456336975)","('Critical_Incident_Risk_Management', 0.11593373119831085)","('NON-ESG', 0.22618399560451508)","('NON-ESG', 0.12527671456336975)","('NON-ESG', 0.11593373119831085)"
Line 391,"BD Vacutainer® Luer-Lok ™ Access  Devices —used specifically to  facilitate blood sample collection  from hospitalized patients who have  existing access lines.Real-time surveillance, reporting and understanding of geographic impact for COVID-19 along with medication use trackingSpecimen collection Diagnostic testing Drug delivery Treatment In response to the heightened need for trained clinical staff,  many individuals have chosen to re-enter the medical  profession, in some cases coming out of retirement.
","('Access_And_Affordability', 0.485226035118103)","('Customer_Welfare', 0.08035397529602051)","('Employee_Health_And_Safety', 0.06113441661000252)","('NON-ESG', 0.485226035118103)","('NON-ESG', 0.08035397529602051)","('NON-ESG', 0.06113441661000252)"
Line 392,"BD Vacutainer® Luer-Lok ™ Access  Devices —used specifically to  facilitate blood sample collection  from hospitalized patients who have  existing access lines.Real-time surveillance, reporting and understanding of geographic impact for COVID-19 along with medication use trackingSpecimen collection Diagnostic testing Drug delivery Treatment In response to the heightened need for trained clinical staff,  many individuals have chosen to re-enter the medical  profession, in some cases coming out of retirement.
","('Customer_Privacy', 0.10236068814992905)","('Director_Removal', 0.08989939838647842)","('Labor_Practices', 0.08451154083013535)","('NON-ESG', 0.10236068814992905)","('NON-ESG', 0.08989939838647842)","('NON-ESG', 0.08451154083013535)"
Line 393,"To enable  them to quickly and easily obtain access to information and  guidance about our products, we have added instructional  training videos to our  YouTube channel .
","('Product_Design_And_Lifecycle_Management', 0.3417878746986389)","('Selling_Practices_And_Product_Labeling', 0.13603365421295166)","('Product_Quality_And_Safety', 0.13576281070709229)","('NON-ESG', 0.3417878746986389)","('NON-ESG', 0.13603365421295166)","('NON-ESG', 0.13576281070709229)"
Line 394,"Spotlight—COVID-1926BD has long been known for its public-private partnerships to tackle global challenges.
","('Systemic_Risk_Management', 0.19730691611766815)","('Business_Model_Resilience', 0.15782120823860168)","('Human_Rights_And_Community_Relations', 0.11634302139282227)","('NON-ESG', 0.19730691611766815)","('NON-ESG', 0.15782120823860168)","('NON-ESG', 0.11634302139282227)"
Line 395,"On March 13, BD attended a White House  meeting with President Trump, Vice President Pence, HHS Secretary Azar and others, alongside CEOs of companies who have been  involved in the effort to expand access to COVID-19 testing and test development.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24079099297523499)","('Access_And_Affordability', 0.20862877368927002)","('Competitive_Behavior', 0.07916178554296494)","('NON-ESG', 0.24079099297523499)","('NON-ESG', 0.20862877368927002)","('NON-ESG', 0.07916178554296494)"
Line 396,"The meeting, which encouraged the private sector to continue innovating with full support from the U.S. government, was an  example of our long history of building relationships with the public sector to address and tackle global challenges, particularly in  times of crisis.Public-private partnerships The coronavirus pandemic demonstrates just how vulnerable the  world’s population is to infectious disease risks and outbreaks.
","('Physical_Impacts_Of_Climate_Change', 0.30138763785362244)","('Critical_Incident_Risk_Management', 0.2980253994464874)","('Systemic_Risk_Management', 0.07771684974431992)","('NON-ESG', 0.30138763785362244)","('NON-ESG', 0.2980253994464874)","('NON-ESG', 0.07771684974431992)"
Line 397,"We’ve seen natural parallels between the objectives for combating  COVID-19 and AMR—when medications commonly used to treat  infections stop working because the organism becomes  resistant to the drug.
","('Product_Quality_And_Safety', 0.17248134315013885)","('Selling_Practices_And_Product_Labeling', 0.16219472885131836)","('Customer_Welfare', 0.08486931025981903)","('NON-ESG', 0.17248134315013885)","('NON-ESG', 0.16219472885131836)","('NON-ESG', 0.08486931025981903)"
Line 398,"Both of these global health challenges rely heavily on effective  infection prevention and control, accessible testing, and  surveillance and reporting data to track prevalence, progression  and patient outcomes.Based on the fundamental premise that health challenges and  threats as large and encompassing as AMR and COVID-19  cannot ever be addressed by one sector alone, BD will continue  to engage in extensive cross-sector collaboration with leading  health agencies, foundations and other organizations around  the world, underpinned by common motives and goals.
","('Employee_Health_And_Safety', 0.5755674242973328)","('Access_And_Affordability', 0.11282730102539062)","('Critical_Incident_Risk_Management', 0.0608048178255558)","(['Operational Eco-Efficiency'], 0.5755674242973328)","('NON-ESG', 0.11282730102539062)","('NON-ESG', 0.0608048178255558)"
Line 399,"Both of these global health challenges rely heavily on effective  infection prevention and control, accessible testing, and  surveillance and reporting data to track prevalence, progression  and patient outcomes.Based on the fundamental premise that health challenges and  threats as large and encompassing as AMR and COVID-19  cannot ever be addressed by one sector alone, BD will continue  to engage in extensive cross-sector collaboration with leading  health agencies, foundations and other organizations around  the world, underpinned by common motives and goals.
","('Human_Rights_And_Community_Relations', 0.26203158497810364)","('Competitive_Behavior', 0.20622214674949646)","('Business_Model_Resilience', 0.12131880223751068)","('NON-ESG', 0.26203158497810364)","('NON-ESG', 0.20622214674949646)","('NON-ESG', 0.12131880223751068)"
Line 400,"Engagement at all levels of government to: Safeguard   operations Communicate   capabilities Mitigate   capacity   constraints• Partnered with the  White House Coronavirus Task   Force  to expand access to diagnostic testing  • Installed BD MAX ™ System at China CDC  and  universities in Japan  to support lab-developed tests • Worked with Health Canada  to ensure adequate  supply of injection devices for vaccination • Supported European Commission  efforts to defer  new regulations that could impede supply• Engaged the governors of six states in Mexico    to ensure the continuity of BD manufacturing • Coordinated with the governments of India ,  Malaysia  and Singapore  to ensure BD and our  suppliers can continue our manufacturing • Increased sterilization capacity for products critical  to COVID-19 response Spotlight—COVID-1927 26Grantmaking: funding frontline relief agencies in the U.S. and globally At the end of June, BD donated $1,245,000  in cash and  product to COVID-19 response efforts in the U.S. and  internationally.
","('Access_And_Affordability', 0.38401830196380615)","('Product_Quality_And_Safety', 0.14676691591739655)","('Employee_Health_And_Safety', 0.07368446886539459)","('NON-ESG', 0.38401830196380615)","('NON-ESG', 0.14676691591739655)","('NON-ESG', 0.07368446886539459)"
Line 401,"Engagement at all levels of government to: Safeguard   operations Communicate   capabilities Mitigate   capacity   constraints• Partnered with the  White House Coronavirus Task   Force  to expand access to diagnostic testing  • Installed BD MAX ™ System at China CDC  and  universities in Japan  to support lab-developed tests • Worked with Health Canada  to ensure adequate  supply of injection devices for vaccination • Supported European Commission  efforts to defer  new regulations that could impede supply• Engaged the governors of six states in Mexico    to ensure the continuity of BD manufacturing • Coordinated with the governments of India ,  Malaysia  and Singapore  to ensure BD and our  suppliers can continue our manufacturing • Increased sterilization capacity for products critical  to COVID-19 response Spotlight—COVID-1927 26Grantmaking: funding frontline relief agencies in the U.S. and globally At the end of June, BD donated $1,245,000  in cash and  product to COVID-19 response efforts in the U.S. and  internationally.
","('Product_Design_And_Lifecycle_Management', 0.8940651416778564)","('Product_Quality_And_Safety', 0.028937142342329025)","('Customer_Welfare', 0.010558070614933968)","(['Product Stewardship'], 0.8940651416778564)","('NON-ESG', 0.028937142342329025)","('NON-ESG', 0.010558070614933968)"
Line 402,"Engagement at all levels of government to: Safeguard   operations Communicate   capabilities Mitigate   capacity   constraints• Partnered with the  White House Coronavirus Task   Force  to expand access to diagnostic testing  • Installed BD MAX ™ System at China CDC  and  universities in Japan  to support lab-developed tests • Worked with Health Canada  to ensure adequate  supply of injection devices for vaccination • Supported European Commission  efforts to defer  new regulations that could impede supply• Engaged the governors of six states in Mexico    to ensure the continuity of BD manufacturing • Coordinated with the governments of India ,  Malaysia  and Singapore  to ensure BD and our  suppliers can continue our manufacturing • Increased sterilization capacity for products critical  to COVID-19 response Spotlight—COVID-1927 26Grantmaking: funding frontline relief agencies in the U.S. and globally At the end of June, BD donated $1,245,000  in cash and  product to COVID-19 response efforts in the U.S. and  internationally.
","('Management_Of_Legal_And_Regulatory_Framework', 0.15669463574886322)","('Human_Rights_And_Community_Relations', 0.07982499152421951)","('Employee_Engagement_Inclusion_And_Diversity', 0.06619337946176529)","('NON-ESG', 0.15669463574886322)","('NON-ESG', 0.07982499152421951)","('NON-ESG', 0.06619337946176529)"
Line 403,"The new funding is being deployed through  6 nonprofit partners, to support healthcare workers in the  United States, Europe, Latin America and China in their  collaborative battle against COVID-19.
","('Labor_Practices', 0.3434658646583557)","('Employee_Health_And_Safety', 0.20234419405460358)","('Access_And_Affordability', 0.09243659675121307)","('NON-ESG', 0.3434658646583557)","('NON-ESG', 0.20234419405460358)","('NON-ESG', 0.09243659675121307)"
Line 404,"Spotlight—COVID-Throughout the pandemic, we will continue to create and deliver value to all our stakeholders, by prioritizing the needs   of our associates and customers around the world, while remaining focused on our long-term strategy.
","('Business_Model_Resilience', 0.46951958537101746)","('Product_Design_And_Lifecycle_Management', 0.2862691283226013)","('Supply_Chain_Management', 0.047141183167696)","('NON-ESG', 0.46951958537101746)","('NON-ESG', 0.2862691283226013)","('NON-ESG', 0.047141183167696)"
Line 405,"Further details can be found at the  BD COVID-19 response webpage .
","('Management_Of_Legal_And_Regulatory_Framework', 0.21308845281600952)","('Access_And_Affordability', 0.1909131407737732)","('Systemic_Risk_Management', 0.06563614308834076)","('NON-ESG', 0.21308845281600952)","('NON-ESG', 0.1909131407737732)","('NON-ESG', 0.06563614308834076)"
Line 406,"28We center our sustainability strategy upon our Purpose— advancing the world of health ™—and integrally tie it to our  business strategy.
","('Business_Model_Resilience', 0.8010098934173584)","('Product_Design_And_Lifecycle_Management', 0.039999399334192276)","('Supply_Chain_Management', 0.030248252674937248)","(['Codes of Business Conduct'], 0.8010098934173584)","('NON-ESG', 0.039999399334192276)","('NON-ESG', 0.030248252674937248)"
Line 407,"We utilize a defined process to evaluate and prioritize the ESG  factors most relevant to our business and stakeholders.
","('Business_Model_Resilience', 0.7535578012466431)","('Systemic_Risk_Management', 0.04931331425905228)","('Human_Rights_And_Community_Relations', 0.025777660310268402)","(['Codes of Business Conduct'], 0.7535578012466431)","('NON-ESG', 0.04931331425905228)","('NON-ESG', 0.025777660310268402)"
Line 408,"By using  this process, we have defined four areas of focus that provide  the framework for our 2020 sustainability goals: • Innovation – How we contribute to more sustainable  healthcare systems by improving outcomes, reducing system  costs and protecting patients and healthcare workers • Access – How we support health system leapfrogging in  emerging and developing economies, and reach vulnerable  populations globally • Efficiency – How we work across our value chain to minimize  environmental impact and create positive social impact• Empowerment – How we advance our purpose-driven culture  through workforce and community engagements During FY 2019, we began developing our next generation  sustainability strategy.
","('Access_And_Affordability', 0.8543834686279297)","('Employee_Health_And_Safety', 0.021925657987594604)","('Human_Rights_And_Community_Relations', 0.016829760745167732)","(['Health Outcome Contribution'], 0.8543834686279297)","('NON-ESG', 0.021925657987594604)","('NON-ESG', 0.016829760745167732)"
Line 409,"By using  this process, we have defined four areas of focus that provide  the framework for our 2020 sustainability goals: • Innovation – How we contribute to more sustainable  healthcare systems by improving outcomes, reducing system  costs and protecting patients and healthcare workers • Access – How we support health system leapfrogging in  emerging and developing economies, and reach vulnerable  populations globally • Efficiency – How we work across our value chain to minimize  environmental impact and create positive social impact• Empowerment – How we advance our purpose-driven culture  through workforce and community engagements During FY 2019, we began developing our next generation  sustainability strategy.
","('Human_Rights_And_Community_Relations', 0.9187861084938049)","('Employee_Engagement_Inclusion_And_Diversity', 0.023242376744747162)","('Access_And_Affordability', 0.007726749405264854)","(['Community Relations'], 0.9187861084938049)","('NON-ESG', 0.023242376744747162)","('NON-ESG', 0.007726749405264854)"
Line 410,"The first two phases of this work were  conducted in parallel: 1) identifying our significant ESG issues  and 2) developing a climate change management program.
","('Physical_Impacts_Of_Climate_Change', 0.9294188022613525)","('Business_Model_Resilience', 0.01753862015902996)","('GHG_Emissions', 0.00858817994594574)","(['Climate Change'], 0.9294188022613525)","('NON-ESG', 0.01753862015902996)","('NON-ESG', 0.00858817994594574)"
Line 411,"In FY 2020, we will be taking the output of the first two  phases to develop our impact goals, which we expect to  announce in late 2020.
","('Business_Model_Resilience', 0.3440507650375366)","('GHG_Emissions', 0.1857612282037735)","('Physical_Impacts_Of_Climate_Change', 0.07815151661634445)","('NON-ESG', 0.3440507650375366)","('NON-ESG', 0.1857612282037735)","('NON-ESG', 0.07815151661634445)"
Line 412,"As with the current 2020 goals, our new impact goals will ensure  we remain focused on shared value creation—meaning how we  address unmet societal needs through business models and  initiatives that also contribute to the commercial success of BD.
","('Business_Model_Resilience', 0.6936946511268616)","('Human_Rights_And_Community_Relations', 0.08063656836748123)","('Product_Design_And_Lifecycle_Management', 0.024253884330391884)","(['Codes of Business Conduct'], 0.6936946511268616)","('NON-ESG', 0.08063656836748123)","('NON-ESG', 0.024253884330391884)"
Line 413,"Solar panels installed at the BD European Headquarters in Eysins, Switzerland.
","('Energy_Management', 0.8907828330993652)","('Management_Of_Legal_And_Regulatory_Framework', 0.02105947583913803)","('GHG_Emissions', 0.016827484592795372)","(['Operational Eco-Efficiency'], 0.8907828330993652)","('NON-ESG', 0.02105947583913803)","('NON-ESG', 0.016827484592795372)"
Line 414,"GRI disclosure: 102-47 Empowerment • Inclusion and diversity • Associate health   and safety • Attraction and  retention of talent • Transparent and ethical  business practicesSignificant ESG issues Our ESG issues are:  Innovation • Data security • Informatics and  innovation Access • Collaborations and  partnerships • Value-based outcomes • Patient-centric care • Healthcare access and  affordability Efficiency • Planetary health  • Sustainable supply chain • Product design and life  cycle management • Energy and GHG   management • Waste • WaterSustainability strategy29Sustainability governance The Environment, Health, Safety and Sustainability Team  manages our ESG reporting, as well as stakeholder engagement  activities relevant to our sustainability strategy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8376569151878357)","('Access_And_Affordability', 0.025695089250802994)","('Product_Design_And_Lifecycle_Management', 0.019741130992770195)","(['Human Capital Development'], 0.8376569151878357)","('NON-ESG', 0.025695089250802994)","('NON-ESG', 0.019741130992770195)"
Line 415,"GRI disclosure: 102-47 Empowerment • Inclusion and diversity • Associate health   and safety • Attraction and  retention of talent • Transparent and ethical  business practicesSignificant ESG issues Our ESG issues are:  Innovation • Data security • Informatics and  innovation Access • Collaborations and  partnerships • Value-based outcomes • Patient-centric care • Healthcare access and  affordability Efficiency • Planetary health  • Sustainable supply chain • Product design and life  cycle management • Energy and GHG   management • Waste • WaterSustainability strategy29Sustainability governance The Environment, Health, Safety and Sustainability Team  manages our ESG reporting, as well as stakeholder engagement  activities relevant to our sustainability strategy.
","('GHG_Emissions', 0.9667170643806458)","('Air_Quality', 0.0037814152892678976)","('Ecological_Impacts', 0.0032122768461704254)","(['Climate Change'], 0.9667170643806458)","('NON-ESG', 0.0037814152892678976)","('NON-ESG', 0.0032122768461704254)"
Line 416,"This group  reports directly to the executive vice president of Integrated  Supply Chain and engages directly with the Executive  Leadership team.
","('Supply_Chain_Management', 0.9449196457862854)","('Product_Design_And_Lifecycle_Management', 0.00524734565988183)","('Labor_Practices', 0.004967331420630217)","(['Supply Chain Management'], 0.9449196457862854)","('NON-ESG', 0.00524734565988183)","('NON-ESG', 0.004967331420630217)"
Line 417,"Our sustainability strategy is governed by the Executive  Leadership team, which maintains a dialogue with our  stakeholders, businesses and associates about issues relevant to  each group and monitors performance related to our 2020  sustainability goals.Our Board of Directors—as a board or through its  committees—also oversees several sustainability-related  issues, including: • Community relations • Employment practices • Environment, health and safety • Ethics and enterprise compliance In addition, the Corporate Governance and Nominating  Committee oversees matters that involve the company’s image,  reputation and our standing as a responsible corporate citizen.
","('Human_Rights_And_Community_Relations', 0.6227436065673828)","('Business_Ethics', 0.1166665107011795)","('Labor_Practices', 0.028795097023248672)","(['Community Relations'], 0.6227436065673828)","('NON-ESG', 0.1166665107011795)","('NON-ESG', 0.028795097023248672)"
Line 418,"Our sustainability strategy is governed by the Executive  Leadership team, which maintains a dialogue with our  stakeholders, businesses and associates about issues relevant to  each group and monitors performance related to our 2020  sustainability goals.Our Board of Directors—as a board or through its  committees—also oversees several sustainability-related  issues, including: • Community relations • Employment practices • Environment, health and safety • Ethics and enterprise compliance In addition, the Corporate Governance and Nominating  Committee oversees matters that involve the company’s image,  reputation and our standing as a responsible corporate citizen.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7209705710411072)","('Director_Removal', 0.07591409981250763)","('Business_Ethics', 0.043571531772613525)","(['Corporate Governance'], 0.7209705710411072)","('NON-ESG', 0.07591409981250763)","('NON-ESG', 0.043571531772613525)"
Line 419,"This includes ESG issues and initiatives relating to sustainability,  access to healthcare and other social topics.
","('Human_Rights_And_Community_Relations', 0.7337736487388611)","('Access_And_Affordability', 0.06380235403776169)","('Business_Model_Resilience', 0.03029487654566765)","(['Community Relations'], 0.7337736487388611)","('NON-ESG', 0.06380235403776169)","('NON-ESG', 0.03029487654566765)"
Line 420,"Because of our global reach and the nature of our work, we serve  and rely on a wide range of stakeholders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2834983766078949)","('Business_Model_Resilience', 0.18757587671279907)","('Human_Rights_And_Community_Relations', 0.13393381237983704)","('NON-ESG', 0.2834983766078949)","('NON-ESG', 0.18757587671279907)","('NON-ESG', 0.13393381237983704)"
Line 421,"Engaging with them  through a variety of channels across many parts of our  organization is critical to how we apply the principle of shared  value and therefore essential to our business success.
","('Business_Model_Resilience', 0.6491931080818176)","('Human_Rights_And_Community_Relations', 0.04106450080871582)","('Product_Design_And_Lifecycle_Management', 0.038364578038454056)","(['Codes of Business Conduct'], 0.6491931080818176)","('NON-ESG', 0.04106450080871582)","('NON-ESG', 0.038364578038454056)"
Line 422,"Often, we  work collaboratively with stakeholders who share our objectives,  and, in the process, we gain a deep understanding of their work.
","('Human_Rights_And_Community_Relations', 0.7262320518493652)","('Business_Model_Resilience', 0.04139060154557228)","('Director_Removal', 0.022870102897286415)","(['Community Relations'], 0.7262320518493652)","('NON-ESG', 0.04139060154557228)","('NON-ESG', 0.022870102897286415)"
Line 423,"We listen to our stakeholders’ views and suggestions, and use that  feedback to improve our products, services and business  practices.
","('Product_Design_And_Lifecycle_Management', 0.7161786556243896)","('Business_Model_Resilience', 0.10604595392942429)","('Supply_Chain_Management', 0.020336773246526718)","(['Product Stewardship'], 0.7161786556243896)","('NON-ESG', 0.10604595392942429)","('NON-ESG', 0.020336773246526718)"
Line 424,"During FY 2019, as we began development of our  future sustainability strategy, we consulted with our stakeholders  to understand which ESG factors are most important to them.
","('Business_Model_Resilience', 0.7726486921310425)","('Physical_Impacts_Of_Climate_Change', 0.027904225513339043)","('Systemic_Risk_Management', 0.02774612233042717)","(['Codes of Business Conduct'], 0.7726486921310425)","('NON-ESG', 0.027904225513339043)","('NON-ESG', 0.02774612233042717)"
Line 425,"Our stakeholders: • Customers: Our customers are at the center of everything that  we do.
","('Business_Model_Resilience', 0.1578957438468933)","('Product_Design_And_Lifecycle_Management', 0.1512109786272049)","('Competitive_Behavior', 0.13647602498531342)","('NON-ESG', 0.1578957438468933)","('NON-ESG', 0.1512109786272049)","('NON-ESG', 0.13647602498531342)"
Line 426,"In a fast-changing environment, it is vital for BD to  understand what our customers value most to develop  solutions that will best meet their needs.
","('Business_Model_Resilience', 0.3277241289615631)","('Product_Design_And_Lifecycle_Management', 0.26403024792671204)","('Supply_Chain_Management', 0.1607278287410736)","('NON-ESG', 0.3277241289615631)","('NON-ESG', 0.26403024792671204)","('NON-ESG', 0.1607278287410736)"
Line 427,"We create a deep  understanding of the healthcare market and its customers  through a fact-based approach across regions and strategically  engage with customers to develop and deploy our products  and solutions.
","('Product_Design_And_Lifecycle_Management', 0.9466136693954468)","('Customer_Welfare', 0.00837845727801323)","('Business_Model_Resilience', 0.005733420141041279)","(['Product Stewardship'], 0.9466136693954468)","('NON-ESG', 0.00837845727801323)","('NON-ESG', 0.005733420141041279)"
Line 428,"• Shareholders: Our focus on shareholders is to ensure that the  combination of our business and geographic diversity—our  balanced capital allocation and our drive for efficiency— provides a long-term pathway toward sustainable profit  growth that returns capital to shareholders.
","('Business_Model_Resilience', 0.3207944929599762)","('Employee_Engagement_Inclusion_And_Diversity', 0.2595127522945404)","('Competitive_Behavior', 0.11955820769071579)","('NON-ESG', 0.3207944929599762)","('NON-ESG', 0.2595127522945404)","('NON-ESG', 0.11955820769071579)"
Line 429,"We engage with  shareholders in a variety of forms, including quarterly calls and  in-person meetings, on specific topics that range from our  long-term growth and innovation strategy to how we integrate  ESG factors into our business.
","('Business_Model_Resilience', 0.8707330226898193)","('Systemic_Risk_Management', 0.02049919031560421)","('Supply_Chain_Management', 0.010667644441127777)","(['Codes of Business Conduct'], 0.8707330226898193)","('NON-ESG', 0.02049919031560421)","('NON-ESG', 0.010667644441127777)"
Line 430,"• BD associates: BD has grown to over 65,000 associates.
","('Business_Model_Resilience', 0.15843498706817627)","('Business_Ethics', 0.10933743417263031)","('Systemic_Risk_Management', 0.10888973623514175)","('NON-ESG', 0.15843498706817627)","('NON-ESG', 0.10933743417263031)","('NON-ESG', 0.10888973623514175)"
Line 431,"The  capabilities and dedication of these associates are critical to  achieving our strategy.
","('Business_Model_Resilience', 0.5308467149734497)","('Human_Rights_And_Community_Relations', 0.07995057851076126)","('Product_Design_And_Lifecycle_Management', 0.03937861695885658)","(['Codes of Business Conduct'], 0.5308467149734497)","('NON-ESG', 0.07995057851076126)","('NON-ESG', 0.03937861695885658)"
Line 432,"We engage and develop our associates  through a variety of mechanisms including internal social  networks, town hall meetings, leadership and mentoring  programs and associate resource groups.• Business partners:  Our suppliers, distributors and other  partners in the supply chain help us effectively serve our  customers.
","('Supply_Chain_Management', 0.9296280145645142)","('Product_Design_And_Lifecycle_Management', 0.008771730586886406)","('Labor_Practices', 0.006187228951603174)","(['Supply Chain Management'], 0.9296280145645142)","('NON-ESG', 0.008771730586886406)","('NON-ESG', 0.006187228951603174)"
Line 433,"We engage with them through a variety of  strategic programs, including through relationship managers  within our Integrated Supply Chain function.
","('Supply_Chain_Management', 0.9529046416282654)","('Product_Design_And_Lifecycle_Management', 0.0038739510346204042)","('Labor_Practices', 0.0035494256298989058)","(['Supply Chain Management'], 0.9529046416282654)","('NON-ESG', 0.0038739510346204042)","('NON-ESG', 0.0035494256298989058)"
Line 434,"• Communities: At the country level, our general managers  engage with a variety of community stakeholders to understand  the health system’s priorities and align our capabilities to them.
","('Human_Rights_And_Community_Relations', 0.939380943775177)","('Business_Model_Resilience', 0.005617077462375164)","('Access_And_Affordability', 0.00554502010345459)","(['Community Relations'], 0.939380943775177)","('NON-ESG', 0.005617077462375164)","('NON-ESG', 0.00554502010345459)"
Line 435,"In communities where we have manufacturing operations, we  engage with local government officials and civic organizations,  and often develop relationships with teaching institutions to  help develop the skill sets we require in our operations.
","('Human_Rights_And_Community_Relations', 0.5953226089477539)","('Management_Of_Legal_And_Regulatory_Framework', 0.18981599807739258)","('Access_And_Affordability', 0.048146553337574005)","(['Community Relations'], 0.5953226089477539)","('NON-ESG', 0.18981599807739258)","('NON-ESG', 0.048146553337574005)"
Line 436,"In addition, our associates engage in community-organized  volunteer efforts to support local programs.
","('Human_Rights_And_Community_Relations', 0.6379972100257874)","('Access_And_Affordability', 0.11928639560937881)","('Critical_Incident_Risk_Management', 0.03334788233041763)","(['Community Relations'], 0.6379972100257874)","('NON-ESG', 0.11928639560937881)","('NON-ESG', 0.03334788233041763)"
Line 437,"• Governments and policymakers:  We engage governments  and policymakers through various ways, primarily through our  public policy teams.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9144446849822998)","('Human_Rights_And_Community_Relations', 0.010232736356556416)","('Physical_Impacts_Of_Climate_Change', 0.009438132867217064)","(['Corporate Governance'], 0.9144446849822998)","('NON-ESG', 0.010232736356556416)","('NON-ESG', 0.009438132867217064)"
Line 438,"We engage at the agency and legislative  levels in many countries to enhance our understanding of the  priorities of governments.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9597513675689697)","('Human_Rights_And_Community_Relations', 0.004462079145014286)","('Director_Removal', 0.003837467869743705)","(['Corporate Governance'], 0.9597513675689697)","('NON-ESG', 0.004462079145014286)","('NON-ESG', 0.003837467869743705)"
Line 439,"From these engagements, we seek  ways to deploy our capabilities, products and solutions to help  support and achieve national health objectives.
","('Product_Design_And_Lifecycle_Management', 0.9256037473678589)","('Product_Quality_And_Safety', 0.013840878382325172)","('Customer_Welfare', 0.009731046855449677)","(['Product Stewardship'], 0.9256037473678589)","('NON-ESG', 0.013840878382325172)","('NON-ESG', 0.009731046855449677)"
Line 440,"We also share  our expertise and global experience in key focus areas.
","('Employee_Engagement_Inclusion_And_Diversity', 0.3800400197505951)","('Business_Model_Resilience', 0.18476808071136475)","('Systemic_Risk_Management', 0.07351794838905334)","('NON-ESG', 0.3800400197505951)","('NON-ESG', 0.18476808071136475)","('NON-ESG', 0.07351794838905334)"
Line 441,"• International agencies: We engage with UN agencies such  as the World Health Organization (WHO), the United Nations  InterAgency Coordinating Group (UN IACG) on Antimicrobial  Resistance, UNICEF, the Joint United Nations Programme on  HIV & AIDS (UNAIDS) and other international and  intergovernmental organizations through collaborations that  aim to address pressing global health needs.
","('Access_And_Affordability', 0.38164272904396057)","('Employee_Health_And_Safety', 0.09552624076604843)","('Product_Quality_And_Safety', 0.07388497143983841)","('NON-ESG', 0.38164272904396057)","('NON-ESG', 0.09552624076604843)","('NON-ESG', 0.07388497143983841)"
Line 442,"We routinely  pursue these types of collaborations as an integral part of our  business model in countries throughout the world.
","('Business_Model_Resilience', 0.6163151860237122)","('Systemic_Risk_Management', 0.04991624504327774)","('Product_Design_And_Lifecycle_Management', 0.03753264993429184)","(['Codes of Business Conduct'], 0.6163151860237122)","('NON-ESG', 0.04991624504327774)","('NON-ESG', 0.03753264993429184)"
Line 443,"• Nongovernmental organizations (NGOs):  In many cases,  NGOs and relief organizations are strategic partners in helping  us meet unmet health needs.
","('Critical_Incident_Risk_Management', 0.43320363759994507)","('Employee_Health_And_Safety', 0.2183975875377655)","('Access_And_Affordability', 0.1417153924703598)","('NON-ESG', 0.43320363759994507)","('NON-ESG', 0.2183975875377655)","('NON-ESG', 0.1417153924703598)"
Line 444,"We engage with them through  in-person meetings, collaborative initiatives and site visits to  strengthen how we serve those in need.Stakeholder engagement GRI disclosure: 102-4030Our sustainability strategy addresses a wide range of challenges  in our industry while helping to make a difference on relevant  issues that affect society and the planet.
","('Human_Rights_And_Community_Relations', 0.3522794842720032)","('Business_Model_Resilience', 0.2585426867008209)","('Management_Of_Legal_And_Regulatory_Framework', 0.050958938896656036)","('NON-ESG', 0.3522794842720032)","('NON-ESG', 0.2585426867008209)","('NON-ESG', 0.050958938896656036)"
Line 445,"We also actively  evaluate how we can mobilize and contribute to the  achievement of the UN SDGs through our product and   service offerings as well as collaborative efforts across various  sectors—most prominently around SDG #3, for good health  and well-being.
","('Access_And_Affordability', 0.19234699010849)","('Product_Design_And_Lifecycle_Management', 0.18506555259227753)","('Employee_Health_And_Safety', 0.17796887457370758)","('NON-ESG', 0.19234699010849)","('NON-ESG', 0.18506555259227753)","('NON-ESG', 0.17796887457370758)"
Line 446,"We launched our 2020 sustainability goals in July 2015,  reflecting a broader and more integrated agenda than previous years.
","('Business_Model_Resilience', 0.34431663155555725)","('Physical_Impacts_Of_Climate_Change', 0.1329503059387207)","('Human_Rights_And_Community_Relations', 0.10581639409065247)","('NON-ESG', 0.34431663155555725)","('NON-ESG', 0.1329503059387207)","('NON-ESG', 0.10581639409065247)"
Line 447,"In line with our significant sustainability issues, we  arranged our goals and programs around four strategic areas:  innovation, access, efficiency and empowerment.
","('Product_Design_And_Lifecycle_Management', 0.2290719598531723)","('Business_Model_Resilience', 0.206883504986763)","('Management_Of_Legal_And_Regulatory_Framework', 0.08134271949529648)","('NON-ESG', 0.2290719598531723)","('NON-ESG', 0.206883504986763)","('NON-ESG', 0.08134271949529648)"
Line 448,"We have also outlined alignment to our current strategy, core  activities and 2020 goal framework against the 17 SDGs and  associated 169 targets.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4254191815853119)","('Business_Model_Resilience', 0.14534679055213928)","('Human_Rights_And_Community_Relations', 0.10571695864200592)","('NON-ESG', 0.4254191815853119)","('NON-ESG', 0.14534679055213928)","('NON-ESG', 0.10571695864200592)"
Line 449,"Our analysis reviewed the type of  impact BD has on the SDG target, the location of impacts  within the value chain and our degree of control and relevant  ESG factors.
","('Business_Model_Resilience', 0.690041720867157)","('Systemic_Risk_Management', 0.1276557743549347)","('Supply_Chain_Management', 0.04253262281417847)","(['Codes of Business Conduct'], 0.690041720867157)","('NON-ESG', 0.1276557743549347)","('NON-ESG', 0.04253262281417847)"
Line 450,"For case studies of how BD is supporting the SDGs, visit the BD sustainability page .
","('Supply_Chain_Management', 0.2382318675518036)","('Business_Model_Resilience', 0.1455158144235611)","('Product_Design_And_Lifecycle_Management', 0.14468416571617126)","('NON-ESG', 0.2382318675518036)","('NON-ESG', 0.1455158144235611)","('NON-ESG', 0.14468416571617126)"
Line 451,"Innovation   Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safety  Access Develop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging countries  Efficiency Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products  Empowerment Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs2020 sustainability goals Innovation               Access                      Efficiency                Empowerment       31Innovation Healthcare safety, outcomes and cost  Introduction BD is on the forefront of helping healthcare systems balance four key priorities: increasing access,  improving outcomes, mitigating healthcare system cost pressures and protecting patients, and  healthcare workers.
","('Employee_Health_And_Safety', 0.9150576591491699)","('Access_And_Affordability', 0.01314992643892765)","('Product_Quality_And_Safety', 0.011116486974060535)","(['Operational Eco-Efficiency'], 0.9150576591491699)","('NON-ESG', 0.01314992643892765)","('NON-ESG', 0.011116486974060535)"
Line 452,"Innovation   Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safety  Access Develop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging countries  Efficiency Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products  Empowerment Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs2020 sustainability goals Innovation               Access                      Efficiency                Empowerment       31Innovation Healthcare safety, outcomes and cost  Introduction BD is on the forefront of helping healthcare systems balance four key priorities: increasing access,  improving outcomes, mitigating healthcare system cost pressures and protecting patients, and  healthcare workers.
","('Product_Design_And_Lifecycle_Management', 0.9312255382537842)","('Customer_Welfare', 0.00943803321570158)","('Supply_Chain_Management', 0.008272047154605389)","(['Product Stewardship'], 0.9312255382537842)","('NON-ESG', 0.00943803321570158)","('NON-ESG', 0.008272047154605389)"
Line 453,"Innovation   Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safety  Access Develop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging countries  Efficiency Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products  Empowerment Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs2020 sustainability goals Innovation               Access                      Efficiency                Empowerment       31Innovation Healthcare safety, outcomes and cost  Introduction BD is on the forefront of helping healthcare systems balance four key priorities: increasing access,  improving outcomes, mitigating healthcare system cost pressures and protecting patients, and  healthcare workers.
","('Product_Quality_And_Safety', 0.5929843187332153)","('Employee_Health_And_Safety', 0.2357143759727478)","('Access_And_Affordability', 0.028938619419932365)","(['Product Quality & Recall Management'], 0.5929843187332153)","('NON-ESG', 0.2357143759727478)","('NON-ESG', 0.028938619419932365)"
Line 454,"Innovation   Innovate  key healthcare processes such as medication management and lab automation Develop  innovations and informatics to enable disease management across the care continuum Enable  the transition from research into clinical practice Provide solutions that improve healthcare worker and patient safety  Access Develop  low-cost innovations to address leading causes of mortality and morbidity Collaborate  on health system strengthening with leading agencies and NGOs Further expand BD manufacturing, product array and employment in emerging countries  Efficiency Reduce  GHG emissions and increase climate resilience throughout operations and value chain Minimize our environmental footprint and conserve natural resources Establish  a supplier responsibility evaluation methodology Reduce  priority materials of concern in specified product categories Improve life cycle impacts of current and future products  Empowerment Increase  the diversity of our workforce, particularly in leadership roles Achieve  best-in-class associate safety performance Partner  with nonprofits to address unmet needs locally and globally Drive  social impact and associate engagement through volunteer programs2020 sustainability goals Innovation               Access                      Efficiency                Empowerment       31Innovation Healthcare safety, outcomes and cost  Introduction BD is on the forefront of helping healthcare systems balance four key priorities: increasing access,  improving outcomes, mitigating healthcare system cost pressures and protecting patients, and  healthcare workers.
","('Employee_Health_And_Safety', 0.4664592444896698)","('Critical_Incident_Risk_Management', 0.12191043049097061)","('Supply_Chain_Management', 0.08881626278162003)","('NON-ESG', 0.4664592444896698)","('NON-ESG', 0.12191043049097061)","('NON-ESG', 0.08881626278162003)"
Line 455,"A sustainable innovation system needs investment, discipline and  leadership to succeed.
","('Product_Design_And_Lifecycle_Management', 0.2778349220752716)","('Business_Model_Resilience', 0.1988561898469925)","('Competitive_Behavior', 0.06880734115839005)","('NON-ESG', 0.2778349220752716)","('NON-ESG', 0.1988561898469925)","('NON-ESG', 0.06880734115839005)"
Line 456,"Innovation requires diligence and partnering, and our capabilities span ideation through market  development.
","('Competitive_Behavior', 0.4087298810482025)","('Business_Model_Resilience', 0.3027053475379944)","('Systemic_Risk_Management', 0.05037642642855644)","('NON-ESG', 0.4087298810482025)","('NON-ESG', 0.3027053475379944)","('NON-ESG', 0.05037642642855644)"
Line 457,"Along this continuum, we can increase our impact through selective partnerships.
","('Human_Rights_And_Community_Relations', 0.14794465899467468)","('Access_And_Affordability', 0.11738084256649017)","('Business_Model_Resilience', 0.1066485196352005)","('NON-ESG', 0.14794465899467468)","('NON-ESG', 0.11738084256649017)","('NON-ESG', 0.1066485196352005)"
Line 458,"We think a broad definition of the term “innovation” is the best way to advance healthcare.
","('Business_Model_Resilience', 0.38855454325675964)","('Product_Design_And_Lifecycle_Management', 0.10096300393342972)","('Competitive_Behavior', 0.06837061047554016)","('NON-ESG', 0.38855454325675964)","('NON-ESG', 0.10096300393342972)","('NON-ESG', 0.06837061047554016)"
Line 459,"Whether it  is technology, processes, systems partnerships or any dimension of business, we pioneer new, relevant  ways to address healthcare’s most pressing problems.
","('Systemic_Risk_Management', 0.2280769944190979)","('Supply_Chain_Management', 0.17977018654346466)","('Business_Model_Resilience', 0.15462440252304077)","('NON-ESG', 0.2280769944190979)","('NON-ESG', 0.17977018654346466)","('NON-ESG', 0.15462440252304077)"
Line 460,"Our technologies and execution capabilities allow  BD to make a profound impact on the quality of care.
","('Access_And_Affordability', 0.4104657769203186)","('Product_Design_And_Lifecycle_Management', 0.10290601849555969)","('Product_Quality_And_Safety', 0.07740877568721771)","('NON-ESG', 0.4104657769203186)","('NON-ESG', 0.10290601849555969)","('NON-ESG', 0.07740877568721771)"
Line 461,"Our Purpose— advancing the world of health ™—and innovating  to solve major health problems are mutually reinforced goals.
","('Employee_Health_And_Safety', 0.8214318156242371)","('Access_And_Affordability', 0.021151522174477577)","('Product_Quality_And_Safety', 0.020356647670269012)","(['Operational Eco-Efficiency'], 0.8214318156242371)","('NON-ESG', 0.021151522174477577)","('NON-ESG', 0.020356647670269012)"
Line 462,"When we innovate to increase access to quality healthcare, it  benefits people and societies throughout the world and drives  our business performance.
","('Access_And_Affordability', 0.8894975185394287)","('Human_Rights_And_Community_Relations', 0.010687149129807949)","('Critical_Incident_Risk_Management', 0.01054481603205204)","(['Health Outcome Contribution'], 0.8894975185394287)","('NON-ESG', 0.010687149129807949)","('NON-ESG', 0.01054481603205204)"
Line 463,"BD conducts its R&D activities at its operating units and at BD  Technologies in Research Triangle Park, North Carolina.
","('Supply_Chain_Management', 0.34981203079223633)","('Business_Model_Resilience', 0.18031001091003418)","('Product_Design_And_Lifecycle_Management', 0.09472327679395676)","('NON-ESG', 0.34981203079223633)","('NON-ESG', 0.18031001091003418)","('NON-ESG', 0.09472327679395676)"
Line 464,"The  majority of the company’s R&D activities are conducted in  North America.
","('Business_Model_Resilience', 0.3331659436225891)","('Supply_Chain_Management', 0.22394078969955444)","('Systemic_Risk_Management', 0.0615418516099453)","('NON-ESG', 0.3331659436225891)","('NON-ESG', 0.22394078969955444)","('NON-ESG', 0.0615418516099453)"
Line 465,"Outside North America, BD primarily conducts  R&D activities in China, France, India, Ireland and Singapore.
","('Business_Model_Resilience', 0.29939156770706177)","('Supply_Chain_Management', 0.13244947791099548)","('Systemic_Risk_Management', 0.08592718094587326)","('NON-ESG', 0.29939156770706177)","('NON-ESG', 0.13244947791099548)","('NON-ESG', 0.08592718094587326)"
Line 466,"BD  also collaborates with certain universities, medical centers and  other entities on R&D programs and retains individual  consultants and partners to support its efforts in  specialized fields.
","('Access_And_Affordability', 0.3789554536342621)","('Employee_Engagement_Inclusion_And_Diversity', 0.08224660158157349)","('Management_Of_Legal_And_Regulatory_Framework', 0.07004082202911377)","('NON-ESG', 0.3789554536342621)","('NON-ESG', 0.08224660158157349)","('NON-ESG', 0.07004082202911377)"
Line 467,"Our investments in research and development led to 25 major  product launches in FY 2019, including: • Venovo ™ Venous Stent, the first stent indicated to treat  iliofemoral venous occlusive disease.• Purewick ™ Female External Catheter, a simple, noninvasive  option for managing female urinary incontinence.
","('Employee_Health_And_Safety', 0.6750352382659912)","('Employee_Engagement_Inclusion_And_Diversity', 0.04892469197511673)","('Access_And_Affordability', 0.034151602536439896)","(['Operational Eco-Efficiency'], 0.6750352382659912)","('NON-ESG', 0.04892469197511673)","('NON-ESG', 0.034151602536439896)"
Line 468,"• WavelinQ ™ 4F Arteriovenous Fistula Creation Device, which  offers an alternative to open surgery for patients being  treated for end-stage renal disease.
","('Access_And_Affordability', 0.19503948092460632)","('Employee_Health_And_Safety', 0.17163410782814026)","('Product_Quality_And_Safety', 0.08095324039459229)","('NON-ESG', 0.19503948092460632)","('NON-ESG', 0.17163410782814026)","('NON-ESG', 0.08095324039459229)"
Line 469,"• BD HealthSight ™ Data Manager 1.1, which was introduced as  part of a suite of technologies and services that are helping  make medication management safer, simpler and smarter.
","('Customer_Welfare', 0.21726678311824799)","('Product_Design_And_Lifecycle_Management', 0.20005911588668823)","('Product_Quality_And_Safety', 0.16973094642162323)","('NON-ESG', 0.21726678311824799)","('NON-ESG', 0.20005911588668823)","('NON-ESG', 0.16973094642162323)"
Line 470,"• BD Cor ™ System, a high-throughput solution for infectious  disease diagnostics, which launched in Europe and sets a new  standard in automation for molecular testing in core  laboratories and other large centralized laboratories.
","('Access_And_Affordability', 0.20477648079395294)","('Customer_Welfare', 0.11487524956464767)","('Competitive_Behavior', 0.07156919687986374)","('NON-ESG', 0.20477648079395294)","('NON-ESG', 0.11487524956464767)","('NON-ESG', 0.07156919687986374)"
Line 471,"• BD FACSDuet ™ Sample Preparation System, an automated  sample processing system for flow cytometry that enables  clinical laboratories to improve their efficiency by reducing  errors and limiting manual user interactions.
","('Competitive_Behavior', 0.2983919382095337)","('Customer_Welfare', 0.18741166591644287)","('Management_Of_Legal_And_Regulatory_Framework', 0.09847408533096313)","('NON-ESG', 0.2983919382095337)","('NON-ESG', 0.18741166591644287)","('NON-ESG', 0.09847408533096313)"
Line 472,"R&D expense   (USD, millions)FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY 472 494 550 632 828 770 * 1,004 * 1,*Numbers restated in FY 2019 10-K filing.R&D investmentsAccess                     Efficiency                Empowerment       Innovation               31 32For the fifth year in a  row, BD was included in  the Derwent Top 100  Global Innovators list.1  This list highlights  high-impact innovation  and the companies who rank among the world’s 100 most  successful innovators.
","('Business_Model_Resilience', 0.42941972613334656)","('Product_Design_And_Lifecycle_Management', 0.1431862860918045)","('Supply_Chain_Management', 0.08541029691696167)","('NON-ESG', 0.42941972613334656)","('NON-ESG', 0.1431862860918045)","('NON-ESG', 0.08541029691696167)"
Line 473,"The ranking celebrates innovation as measured by the number  and impact of the company’s patents, using data from the  Derwent World Patents Index ™.
","('Competitive_Behavior', 0.6874980330467224)","('Product_Design_And_Lifecycle_Management', 0.0794062688946724)","('Business_Model_Resilience', 0.03463224321603775)","(['Business Ethics'], 0.6874980330467224)","('NON-ESG', 0.0794062688946724)","('NON-ESG', 0.03463224321603775)"
Line 474,"In 2019, BD received more than  500 U.S. patents and more than 3,000 patents worldwide.
","('Competitive_Behavior', 0.7110881209373474)","('Management_Of_Legal_And_Regulatory_Framework', 0.10046295076608658)","('Business_Ethics', 0.02167349122464657)","(['Business Ethics'], 0.7110881209373474)","('NON-ESG', 0.10046295076608658)","('NON-ESG', 0.02167349122464657)"
Line 475,"BD spends more than $1 billion dollars each year on innovation  annually and has more than 250 new products in our  development pipeline, spread across our three business segments  and nine business units.Innovation awards BD remains focused on delivering sustainable growth and  shareholder value, while making appropriate investments for the  future.
","('Product_Design_And_Lifecycle_Management', 0.960465669631958)","('Product_Quality_And_Safety', 0.004366918466985226)","('Customer_Welfare', 0.004040093161165714)","(['Product Stewardship'], 0.960465669631958)","('NON-ESG', 0.004366918466985226)","('NON-ESG', 0.004040093161165714)"
Line 476,"We operate the business in a manner consistent with  various core strategies, including:  • Increasing revenue growth by focusing on our core products,  services and solutions that deliver greater benefits to  patients, healthcare workers and researchers;• Supplementing our internal growth through   strategic acquisitions; • Continuing investment in research and development   for platform extensions and innovative new products; and • Making investments in growing our operations in  emerging markets.
","('Product_Design_And_Lifecycle_Management', 0.9548235535621643)","('Customer_Welfare', 0.006996702402830124)","('Product_Quality_And_Safety', 0.005379476584494114)","(['Product Stewardship'], 0.9548235535621643)","('NON-ESG', 0.006996702402830124)","('NON-ESG', 0.005379476584494114)"
Line 477,"Reference 1 Derwent.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4075146019458771)","('Ecological_Impacts', 0.09521101415157318)","('Water_And_Wastewater_Management', 0.07067916542291641)","('NON-ESG', 0.4075146019458771)","('NON-ESG', 0.09521101415157318)","('NON-ESG', 0.07067916542291641)"
Line 478,"Derwent Top 100 Global Innovators 2020 Report.
","('Business_Model_Resilience', 0.6568226218223572)","('Product_Design_And_Lifecycle_Management', 0.06276051700115204)","('Supply_Chain_Management', 0.04295406490564346)","(['Codes of Business Conduct'], 0.6568226218223572)","('NON-ESG', 0.06276051700115204)","('NON-ESG', 0.04295406490564346)"
Line 479,"https://clarivate.com/derwent/top100innovators.
","('Business_Model_Resilience', 0.684867799282074)","('Systemic_Risk_Management', 0.07668951898813248)","('Supply_Chain_Management', 0.030337845906615257)","(['Codes of Business Conduct'], 0.684867799282074)","('NON-ESG', 0.07668951898813248)","('NON-ESG', 0.030337845906615257)"
Line 480,"Accessed April 20, 2020.Discovery Providing tools and technologies  to the research community that  facilitate the understanding of  the cell, cellular diagnostics, cell  therapy and immunologyDiagnostics Improving clinical outcomes   through new, more accurate   and faster diagnostics Medication   management Enabling safer, simpler and   more effective parenteral   drug deliveryTherapy   management Enhancing disease   management with our   product offeringsInnovation strategy Our strategy focuses on four specific areas within healthcare and life sciences:Access                     Efficiency                Empowerment       Innovation               332020 goal Innovate  key healthcare processes such as medication management and lab automation Medication management BD Pyxis ™ SupplyStation ™ RF Cabinet and BD Pyxis ™ KanBan RF System The BD Pyxis ™ SupplyStation ™ RF Cabinet  is a scalable and  secure cabinet that leverages ultra-high frequency (UHF)  radio-frequency identification (RFID) technology for touchless  inventory management of high-value inventory.
","('Customer_Welfare', 0.3606339693069458)","('Product_Design_And_Lifecycle_Management', 0.11243657022714615)","('Product_Quality_And_Safety', 0.10707813501358032)","('NON-ESG', 0.3606339693069458)","('NON-ESG', 0.11243657022714615)","('NON-ESG', 0.10707813501358032)"
Line 481,"Accessed April 20, 2020.Discovery Providing tools and technologies  to the research community that  facilitate the understanding of  the cell, cellular diagnostics, cell  therapy and immunologyDiagnostics Improving clinical outcomes   through new, more accurate   and faster diagnostics Medication   management Enabling safer, simpler and   more effective parenteral   drug deliveryTherapy   management Enhancing disease   management with our   product offeringsInnovation strategy Our strategy focuses on four specific areas within healthcare and life sciences:Access                     Efficiency                Empowerment       Innovation               332020 goal Innovate  key healthcare processes such as medication management and lab automation Medication management BD Pyxis ™ SupplyStation ™ RF Cabinet and BD Pyxis ™ KanBan RF System The BD Pyxis ™ SupplyStation ™ RF Cabinet  is a scalable and  secure cabinet that leverages ultra-high frequency (UHF)  radio-frequency identification (RFID) technology for touchless  inventory management of high-value inventory.
","('Energy_Management', 0.36568331718444824)","('Data_Security', 0.1274597942829132)","('Access_And_Affordability', 0.06649341434240341)","('NON-ESG', 0.36568331718444824)","('NON-ESG', 0.1274597942829132)","('NON-ESG', 0.06649341434240341)"
Line 482,"Accessed April 20, 2020.Discovery Providing tools and technologies  to the research community that  facilitate the understanding of  the cell, cellular diagnostics, cell  therapy and immunologyDiagnostics Improving clinical outcomes   through new, more accurate   and faster diagnostics Medication   management Enabling safer, simpler and   more effective parenteral   drug deliveryTherapy   management Enhancing disease   management with our   product offeringsInnovation strategy Our strategy focuses on four specific areas within healthcare and life sciences:Access                     Efficiency                Empowerment       Innovation               332020 goal Innovate  key healthcare processes such as medication management and lab automation Medication management BD Pyxis ™ SupplyStation ™ RF Cabinet and BD Pyxis ™ KanBan RF System The BD Pyxis ™ SupplyStation ™ RF Cabinet  is a scalable and  secure cabinet that leverages ultra-high frequency (UHF)  radio-frequency identification (RFID) technology for touchless  inventory management of high-value inventory.
","('Supply_Chain_Management', 0.3760071396827698)","('Product_Design_And_Lifecycle_Management', 0.13545460999011993)","('Waste_And_Hazardous_Materials_Management', 0.07261543720960617)","('NON-ESG', 0.3760071396827698)","('NON-ESG', 0.13545460999011993)","('NON-ESG', 0.07261543720960617)"
Line 483,"This solution  offers real-time updates for better control and enhanced  security.
","('Data_Security', 0.9449709057807922)","('Systemic_Risk_Management', 0.006213393062353134)","('Customer_Privacy', 0.00437195785343647)","(['Information Security/Cybersecurity & System Availability'], 0.9449709057807922)","('NON-ESG', 0.006213393062353134)","('NON-ESG', 0.00437195785343647)"
Line 484,"This product drives workflow optimization in a simple  process that links patient electronic medical records (EMRs) with  associated inventory usage with RFID technology, and provides  analytics on supply usage, helping to reduce documentation  error and increase compliance and charge capture.What’s more, the BD Pyxis ™ SupplyStation ™ RF Cabinet is  compliant with FDA regulations for device recall management  and unique device identification (UDI), which automatically  captures an item’s lot, serial number and expiration dates, helping  healthcare facilities to properly rotate about-to-expire items.
","('Supply_Chain_Management', 0.18095526099205017)","('Product_Design_And_Lifecycle_Management', 0.164837047457695)","('Waste_And_Hazardous_Materials_Management', 0.13359764218330383)","('NON-ESG', 0.18095526099205017)","('NON-ESG', 0.164837047457695)","('NON-ESG', 0.13359764218330383)"
Line 485,"This product drives workflow optimization in a simple  process that links patient electronic medical records (EMRs) with  associated inventory usage with RFID technology, and provides  analytics on supply usage, helping to reduce documentation  error and increase compliance and charge capture.What’s more, the BD Pyxis ™ SupplyStation ™ RF Cabinet is  compliant with FDA regulations for device recall management  and unique device identification (UDI), which automatically  captures an item’s lot, serial number and expiration dates, helping  healthcare facilities to properly rotate about-to-expire items.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4518895447254181)","('Labor_Practices', 0.06008361279964447)","('Director_Removal', 0.045196376740932465)","('NON-ESG', 0.4518895447254181)","('NON-ESG', 0.06008361279964447)","('NON-ESG', 0.045196376740932465)"
Line 486,"The BD Pyxis ™ SupplyStation ™ RF Cabinet is not only a flexible  platform that promotes safe and secure inventory  management, but it also paints a clear picture of inventory  visibility.
","('Supply_Chain_Management', 0.7206542491912842)","('Waste_And_Hazardous_Materials_Management', 0.06000392884016037)","('Energy_Management', 0.02632180042564869)","(['Supply Chain Management'], 0.7206542491912842)","('NON-ESG', 0.06000392884016037)","('NON-ESG', 0.02632180042564869)"
Line 487,"Such accurate reporting helps standardize par levels  and supply usage data, which in turn optimizes inventory control  and procedural costs.
","('Supply_Chain_Management', 0.9033506512641907)","('Waste_And_Hazardous_Materials_Management', 0.012865510769188404)","('Labor_Practices', 0.00781858991831541)","(['Supply Chain Management'], 0.9033506512641907)","('NON-ESG', 0.012865510769188404)","('NON-ESG', 0.00781858991831541)"
Line 488,"The BD Pyxis ™ SupplyStation ™ RF Cabinet also offers automatic and accurate charge capture by  interfacing with patient billing software.
","('Energy_Management', 0.2612314522266388)","('Management_Of_Legal_And_Regulatory_Framework', 0.10162785649299622)","('Water_And_Wastewater_Management', 0.08455059677362442)","('NON-ESG', 0.2612314522266388)","('NON-ESG', 0.10162785649299622)","('NON-ESG', 0.08455059677362442)"
Line 489,"By minimizing their  clinical supply chain engagement and maximizing access to the  right inventory at the right time, clinicians can focus on what  matters and deliver thorough patient care.
","('Supply_Chain_Management', 0.9014327526092529)","('Customer_Welfare', 0.011648907326161861)","('Product_Design_And_Lifecycle_Management', 0.009741690941154957)","(['Supply Chain Management'], 0.9014327526092529)","('NON-ESG', 0.011648907326161861)","('NON-ESG', 0.009741690941154957)"
Line 490,"The BD Pyxis ™ Kanban RF System  is an RFID-enabled  inventory management system that allows for easy tracking of  supply levels in healthcare facilities.
","('Supply_Chain_Management', 0.8854255080223083)","('Energy_Management', 0.01671397127211094)","('Water_And_Wastewater_Management', 0.014250398613512516)","(['Supply Chain Management'], 0.8854255080223083)","('NON-ESG', 0.01671397127211094)","('NON-ESG', 0.014250398613512516)"
Line 491,"Lack of usage tracking for  low-value and high-volume supply items can lead to skewed  inventory levels.
","('Supply_Chain_Management', 0.900137186050415)","('Energy_Management', 0.01416162308305502)","('Waste_And_Hazardous_Materials_Management', 0.009415501728653908)","(['Supply Chain Management'], 0.900137186050415)","('NON-ESG', 0.01416162308305502)","('NON-ESG', 0.009415501728653908)"
Line 492,"For materials management, this causes  ambiguity in procurement, constant over/under inventory levels  and can lead to an endless cycle of out-of-balance budgets.
","('Supply_Chain_Management', 0.7383710145950317)","('Product_Design_And_Lifecycle_Management', 0.0983835980296135)","('Waste_And_Hazardous_Materials_Management', 0.017551664263010025)","(['Supply Chain Management'], 0.7383710145950317)","('NON-ESG', 0.0983835980296135)","('NON-ESG', 0.017551664263010025)"
Line 493,"The  BD Pyxis ™ Kanban RF System is a modular, integrated and  automated end-to-end supply management solution that tracks  when inventory bins become empty through unique RFID tags,  and sends an alert to materials management to replenish  supplies.
","('Supply_Chain_Management', 0.8874491453170776)","('Waste_And_Hazardous_Materials_Management', 0.016462115570902824)","('Product_Design_And_Lifecycle_Management', 0.013934087008237839)","(['Supply Chain Management'], 0.8874491453170776)","('NON-ESG', 0.016462115570902824)","('NON-ESG', 0.013934087008237839)"
Line 494,"This helps minimize misplaced, expired or out-of-stock  inventory, ultimately helping to reduce supply inventory cost in  healthcare facilities.
","('Supply_Chain_Management', 0.8760790824890137)","('Waste_And_Hazardous_Materials_Management', 0.020410194993019104)","('Energy_Management', 0.013863143511116505)","(['Supply Chain Management'], 0.8760790824890137)","('NON-ESG', 0.020410194993019104)","('NON-ESG', 0.013863143511116505)"
Line 495,"Even though the product is called BD Pyxis ™  Kanban System in reference to a two-bin system, the BD Pyxis ™  Kanban RF System is not tied to a certain number of bins.
","('Product_Design_And_Lifecycle_Management', 0.5537161231040955)","('Customer_Welfare', 0.14826801419258118)","('Selling_Practices_And_Product_Labeling', 0.05715698003768921)","(['Product Stewardship'], 0.5537161231040955)","('NON-ESG', 0.14826801419258118)","('NON-ESG', 0.05715698003768921)"
Line 496,"The BD Pyxis ™ Kanban RF System can be used with an existing  shelving solution, one bin or multiple bins.
","('Waste_And_Hazardous_Materials_Management', 0.6802425980567932)","('Energy_Management', 0.06007314845919609)","('Product_Design_And_Lifecycle_Management', 0.036155641078948975)","(['Operational Eco-Efficiency'], 0.6802425980567932)","('NON-ESG', 0.06007314845919609)","('NON-ESG', 0.036155641078948975)"
Line 497,"The system can  support up to 150 RFID tags.
","('Data_Security', 0.20206832885742188)","('Air_Quality', 0.1817629635334015)","('Customer_Privacy', 0.14114096760749817)","('NON-ESG', 0.20206832885742188)","('NON-ESG', 0.1817629635334015)","('NON-ESG', 0.14114096760749817)"
Line 498,"The BD Pyxis ™ Kanban RF System  is a flexible solution that can be configured to any inventory  point in a customer’s facility.
","('Product_Design_And_Lifecycle_Management', 0.2301398068666458)","('Energy_Management', 0.19859763979911804)","('Customer_Privacy', 0.07627557963132858)","('NON-ESG', 0.2301398068666458)","('NON-ESG', 0.19859763979911804)","('NON-ESG', 0.07627557963132858)"
Line 499,"Making it a flexible solution for all  open nonpatient specific open clinical supply scenarios.
","('Access_And_Affordability', 0.22079026699066162)","('Supply_Chain_Management', 0.1456911265850067)","('Customer_Welfare', 0.09737776964902878)","('NON-ESG', 0.22079026699066162)","('NON-ESG', 0.1456911265850067)","('NON-ESG', 0.09737776964902878)"
Line 500,"The BD Pyxis ™ SupplyStation ™ RF Cabinet and BD Pyxis ™ Kanban  RF System innovate healthcare procedures by facilitating supply  through accurate usage tracking, billing and materials  management.
","('Supply_Chain_Management', 0.903763473033905)","('Waste_And_Hazardous_Materials_Management', 0.009916791692376137)","('Water_And_Wastewater_Management', 0.009866634383797646)","(['Supply Chain Management'], 0.903763473033905)","('NON-ESG', 0.009916791692376137)","('NON-ESG', 0.009866634383797646)"
Line 501,"By ensuring that supply closets are optimized for  usage, healthcare providers can free up time and capacity to  focus on what matters most, the patient.
","('Supply_Chain_Management', 0.8498113751411438)","('Energy_Management', 0.03785406053066254)","('Water_And_Wastewater_Management', 0.01996110938489437)","(['Supply Chain Management'], 0.8498113751411438)","('NON-ESG', 0.03785406053066254)","('NON-ESG', 0.01996110938489437)"
Line 502,"To learn more, contact pyxis_supply_solutions@bd.com 1 Clinicians log in  and select patient  and procedure3 Upon door closure, cabinet scans  for removed items in real time4 Patient record automatically  updates with removed supplies2 Access cabinet and select  associate suppliesAccess                     Efficiency                Empowerment       Innovation               33 34Lab automation and efficiency The BD COR ™ System is the company’s newest solution for  high volume molecular laboratories.
","('Supply_Chain_Management', 0.45351642370224)","('Product_Design_And_Lifecycle_Management', 0.1276262104511261)","('Waste_And_Hazardous_Materials_Management', 0.10819943249225616)","('NON-ESG', 0.45351642370224)","('NON-ESG', 0.1276262104511261)","('NON-ESG', 0.10819943249225616)"
Line 503,"The high throughput  solution for infectious disease diagnostics sets a new standard  in automation for molecular testing in core laboratories and  other large centralized laboratories.
","('Access_And_Affordability', 0.1853393018245697)","('Customer_Welfare', 0.13805824518203735)","('Competitive_Behavior', 0.10841956734657288)","('NON-ESG', 0.1853393018245697)","('NON-ESG', 0.13805824518203735)","('NON-ESG', 0.10841956734657288)"
Line 504,"The system’s initial launch  occurred in June 2019 with CE-Marking for the BD COR ™ PX  and GX Instruments, automating the testing for BD Onclarity ™  HPV Assay used for the detection and extended genotyping of  human papillomavirus (HPV).
","('Ecological_Impacts', 0.19549204409122467)","('Data_Security', 0.08860691636800766)","('GHG_Emissions', 0.07917692512273788)","('NON-ESG', 0.19549204409122467)","('NON-ESG', 0.08860691636800766)","('NON-ESG', 0.07917692512273788)"
Line 505,"The system enables the  processing of samples directly from liquid-based cytology vials,  the creation of molecular aliquot tubes and assay testing,  replacing labor-intensive and error-prone manual processes  with automated ones.
","('Competitive_Behavior', 0.20383599400520325)","('Customer_Welfare', 0.09621599316596985)","('Product_Quality_And_Safety', 0.08222640305757523)","('NON-ESG', 0.20383599400520325)","('NON-ESG', 0.09621599316596985)","('NON-ESG', 0.08222640305757523)"
Line 506,"The BD COR ™ System integrates and automates the complete  molecular laboratory workflow from preanalytical processing  to diagnostic test result.
","('Access_And_Affordability', 0.2059214860200882)","('Management_Of_Legal_And_Regulatory_Framework', 0.13145479559898376)","('Customer_Welfare', 0.07541275024414062)","('NON-ESG', 0.2059214860200882)","('NON-ESG', 0.13145479559898376)","('NON-ESG', 0.07541275024414062)"
Line 507,"The system includes three  instruments, the PX, GX and MX instruments that can be used  in multiple configurations.
","('GHG_Emissions', 0.433503657579422)","('Management_Of_Legal_And_Regulatory_Framework', 0.2373601645231247)","('Competitive_Behavior', 0.05586859956383705)","('NON-ESG', 0.433503657579422)","('NON-ESG', 0.2373601645231247)","('NON-ESG', 0.05586859956383705)"
Line 508,"The BD COR ™ PX Instrument is the  system’s preanalytical module—processing samples and  sending to either the GX or MX for testing.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3002026081085205)","('Competitive_Behavior', 0.19606861472129822)","('GHG_Emissions', 0.06275071948766708)","('NON-ESG', 0.3002026081085205)","('NON-ESG', 0.19606861472129822)","('NON-ESG', 0.06275071948766708)"
Line 509,"The GX instrument  performs the BD Onclarity ™ HPV Assay and the MX instrument  will perform other molecular assays that will be available in  the future.
","('GHG_Emissions', 0.4167141318321228)","('Competitive_Behavior', 0.12265345454216003)","('Ecological_Impacts', 0.07061026245355606)","('NON-ESG', 0.4167141318321228)","('NON-ESG', 0.12265345454216003)","('NON-ESG', 0.07061026245355606)"
Line 510,"The BD COR ™ System was designed to meet the needs of  centralized testing laboratories, helping address many of   the challenges they face in high-volume molecular testing.
","('Competitive_Behavior', 0.16857685148715973)","('Customer_Welfare', 0.15121805667877197)","('GHG_Emissions', 0.10565071552991867)","('NON-ESG', 0.16857685148715973)","('NON-ESG', 0.15121805667877197)","('NON-ESG', 0.10565071552991867)"
Line 511,"The system design provides: • Complete automation with a fully integrated preanalytical  solution for samples requiring additional processing prior  to analysis; • High capacity for samples and reagents resulting in minimal  intervention for laboratory staff enabling resource allocation  where needed; • Ready-to-load reagents in bulk format to reduce hands on  time and possible errors; • Continuous access for loading samples and consumables   for flexible workflow; and • Multiple configurations to meet the needs of   multiple laboratories.
","('Customer_Welfare', 0.3202645182609558)","('Energy_Management', 0.07909387350082397)","('Product_Design_And_Lifecycle_Management', 0.07502104341983795)","('NON-ESG', 0.3202645182609558)","('NON-ESG', 0.07909387350082397)","('NON-ESG', 0.07502104341983795)"
Line 512,"The system design provides: • Complete automation with a fully integrated preanalytical  solution for samples requiring additional processing prior  to analysis; • High capacity for samples and reagents resulting in minimal  intervention for laboratory staff enabling resource allocation  where needed; • Ready-to-load reagents in bulk format to reduce hands on  time and possible errors; • Continuous access for loading samples and consumables   for flexible workflow; and • Multiple configurations to meet the needs of   multiple laboratories.
","('Access_And_Affordability', 0.5279627442359924)","('Supply_Chain_Management', 0.07236790657043457)","('Customer_Welfare', 0.04720882326364517)","(['Health Outcome Contribution'], 0.5279627442359924)","('NON-ESG', 0.07236790657043457)","('NON-ESG', 0.04720882326364517)"
Line 513,"Over the coming years, BD plans to continue seeking  regulatory authorizations to sell the BD COR ™ System   around the world while expanding the instrument  configurations and content.BD COR ™ System Access                     Efficiency                Empowerment       Innovation               352020 goal Develop  innovations and informatics to enable disease management across the care continuum BD HealthSight ™ Diversion Management Analytics Addiction to prescription narcotics in the U.S. has reached  epidemic proportions, contributing to the opioid crisis and  becoming a major driver of drug diversion within healthcare  settings.2 Diversion of drugs, for personal use or illegal  distribution, can cause significant financial loss3 and potentially  impact care to patients and staff safety.As part of the BD HealthSight ™ Platform  that is designed to  support enterprise-wide medication management, the   BD HealthSight ™ Diversion Management Analytics Application  assists with opioid drug diversion investigations by creating an  investigation workflow to monitor, triage and assign potential  diversion cases to specific investigators.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5498411655426025)","('Access_And_Affordability', 0.10775120556354523)","('Product_Quality_And_Safety', 0.051705725491046906)","(['Corporate Governance'], 0.5498411655426025)","('NON-ESG', 0.10775120556354523)","('NON-ESG', 0.051705725491046906)"
Line 514,"Over the coming years, BD plans to continue seeking  regulatory authorizations to sell the BD COR ™ System   around the world while expanding the instrument  configurations and content.BD COR ™ System Access                     Efficiency                Empowerment       Innovation               352020 goal Develop  innovations and informatics to enable disease management across the care continuum BD HealthSight ™ Diversion Management Analytics Addiction to prescription narcotics in the U.S. has reached  epidemic proportions, contributing to the opioid crisis and  becoming a major driver of drug diversion within healthcare  settings.2 Diversion of drugs, for personal use or illegal  distribution, can cause significant financial loss3 and potentially  impact care to patients and staff safety.As part of the BD HealthSight ™ Platform  that is designed to  support enterprise-wide medication management, the   BD HealthSight ™ Diversion Management Analytics Application  assists with opioid drug diversion investigations by creating an  investigation workflow to monitor, triage and assign potential  diversion cases to specific investigators.
","('Business_Ethics', 0.27601152658462524)","('Customer_Welfare', 0.12008969485759735)","('Product_Quality_And_Safety', 0.09680601209402084)","('NON-ESG', 0.27601152658462524)","('NON-ESG', 0.12008969485759735)","('NON-ESG', 0.09680601209402084)"
Line 515,"Over the coming years, BD plans to continue seeking  regulatory authorizations to sell the BD COR ™ System   around the world while expanding the instrument  configurations and content.BD COR ™ System Access                     Efficiency                Empowerment       Innovation               352020 goal Develop  innovations and informatics to enable disease management across the care continuum BD HealthSight ™ Diversion Management Analytics Addiction to prescription narcotics in the U.S. has reached  epidemic proportions, contributing to the opioid crisis and  becoming a major driver of drug diversion within healthcare  settings.2 Diversion of drugs, for personal use or illegal  distribution, can cause significant financial loss3 and potentially  impact care to patients and staff safety.As part of the BD HealthSight ™ Platform  that is designed to  support enterprise-wide medication management, the   BD HealthSight ™ Diversion Management Analytics Application  assists with opioid drug diversion investigations by creating an  investigation workflow to monitor, triage and assign potential  diversion cases to specific investigators.
","('Business_Ethics', 0.2493712306022644)","('Management_Of_Legal_And_Regulatory_Framework', 0.16785196959972382)","('Critical_Incident_Risk_Management', 0.10742108523845673)","('NON-ESG', 0.2493712306022644)","('NON-ESG', 0.16785196959972382)","('NON-ESG', 0.10742108523845673)"
Line 516,"Compared to  traditional, statistically based analytical tools that only look at  opioid amounts dispensed to identify potential diversion, BD  utilizes machine learning algorithms and multiple dispensing  behaviors—such as overrides, canceled transactions, delays in  dispense, administration or waste—to surface clinicians whose  behavior indicates higher risk for diversion.BD has partnered with Microsoft, who brings industry-leading  expertise in artificial intelligence (AI) and data science  methodologies, to support development of these machine  learning based algorithms.
","('Waste_And_Hazardous_Materials_Management', 0.7480669021606445)","('Business_Ethics', 0.0561559796333313)","('Water_And_Wastewater_Management', 0.02245606668293476)","(['Operational Eco-Efficiency'], 0.7480669021606445)","('NON-ESG', 0.0561559796333313)","('NON-ESG', 0.02245606668293476)"
Line 517,"Compared to  traditional, statistically based analytical tools that only look at  opioid amounts dispensed to identify potential diversion, BD  utilizes machine learning algorithms and multiple dispensing  behaviors—such as overrides, canceled transactions, delays in  dispense, administration or waste—to surface clinicians whose  behavior indicates higher risk for diversion.BD has partnered with Microsoft, who brings industry-leading  expertise in artificial intelligence (AI) and data science  methodologies, to support development of these machine  learning based algorithms.
","('Competitive_Behavior', 0.6703182458877563)","('Customer_Welfare', 0.04054967314004898)","('Systemic_Risk_Management', 0.028216728940606117)","(['Business Ethics'], 0.6703182458877563)","('NON-ESG', 0.04054967314004898)","('NON-ESG', 0.028216728940606117)"
Line 518,"Importantly, the application also  aggregates EMR and dispensing cabinet data to automate a  normally time consuming and tedious manual review process to  reconcile and automatically flag anomalous dispense  administration and waste transactions.
","('Waste_And_Hazardous_Materials_Management', 0.9744808673858643)","('Water_And_Wastewater_Management', 0.0021860685665160418)","('Data_Security', 0.0017606081673875451)","(['Operational Eco-Efficiency'], 0.9744808673858643)","('NON-ESG', 0.0021860685665160418)","('NON-ESG', 0.0017606081673875451)"
Line 519,"To enable analytics and support data normalization, BD  introduced the BD HealthSight ™ Data Manager, which is a  hosted, cloud-based solution that provides a single platform to  normalize medication data.
","('Data_Security', 0.41583096981048584)","('Customer_Privacy', 0.10884615033864975)","('Systemic_Risk_Management', 0.09832325577735901)","('NON-ESG', 0.41583096981048584)","('NON-ESG', 0.10884615033864975)","('NON-ESG', 0.09832325577735901)"
Line 520,"The tool can map disparate med  IDs to enable analytics, including BD HealthSight ™ Diversion  Analytics risk algorithm, while simplifying formulary  maintenance across a health system.
","('Systemic_Risk_Management', 0.728163480758667)","('Business_Ethics', 0.07640807330608368)","('Competitive_Behavior', 0.04054538905620575)","(['Risk & Crisis Management'], 0.728163480758667)","('NON-ESG', 0.07640807330608368)","('NON-ESG', 0.04054538905620575)"
Line 521,"References 2 Cicero TJ, Ellis MS.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5011083483695984)","('Business_Ethics', 0.11146926134824753)","('Competitive_Behavior', 0.06287388503551483)","(['Corporate Governance'], 0.5011083483695984)","('NON-ESG', 0.11146926134824753)","('NON-ESG', 0.06287388503551483)"
Line 522,"The prescription opioid epidemic: a review of qualitative studies on the progression from initial use to abuse.
","('Access_And_Affordability', 0.15856315195560455)","('Competitive_Behavior', 0.11601048707962036)","('Business_Ethics', 0.11166242510080338)","('NON-ESG', 0.15856315195560455)","('NON-ESG', 0.11601048707962036)","('NON-ESG', 0.11166242510080338)"
Line 523,"Dialogues Clin Neurosci .
","('Competitive_Behavior', 0.17893095314502716)","('Access_And_Affordability', 0.10944969952106476)","('Ecological_Impacts', 0.07537775486707687)","('NON-ESG', 0.17893095314502716)","('NON-ESG', 0.10944969952106476)","('NON-ESG', 0.07537775486707687)"
Line 524,"2017;19(3):259-269.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24475479125976562)","('Systemic_Risk_Management', 0.11884944885969162)","('Competitive_Behavior', 0.09813131392002106)","('NON-ESG', 0.24475479125976562)","('NON-ESG', 0.11884944885969162)","('NON-ESG', 0.09813131392002106)"
Line 525,"3 Bouffard K.
","('Management_Of_Legal_And_Regulatory_Framework', 0.20069192349910736)","('Competitive_Behavior', 0.16216178238391876)","('Business_Ethics', 0.10256568342447281)","('NON-ESG', 0.20069192349910736)","('NON-ESG', 0.16216178238391876)","('NON-ESG', 0.10256568342447281)"
Line 526,"UM pays 4.3M to settle federal charges for stolen drugs, but criminal charges possible.
","('Business_Ethics', 0.8814780712127686)","('Management_Of_Legal_And_Regulatory_Framework', 0.026263965293765068)","('Data_Security', 0.026228806003928185)","(['Business Ethics'], 0.8814780712127686)","('NON-ESG', 0.026263965293765068)","('NON-ESG', 0.026228806003928185)"
Line 527,"The Detroit News.
","('Customer_Privacy', 0.10448423773050308)","('Data_Security', 0.09419398009777069)","('Employee_Engagement_Inclusion_And_Diversity', 0.06495664268732071)","('NON-ESG', 0.10448423773050308)","('NON-ESG', 0.09419398009777069)","('NON-ESG', 0.06495664268732071)"
Line 528,"August 30, 2018.
","('Management_Of_Legal_And_Regulatory_Framework', 0.13029111921787262)","('Director_Removal', 0.1243603453040123)","('Data_Security', 0.06237196922302246)","('NON-ESG', 0.13029111921787262)","('NON-ESG', 0.1243603453040123)","('NON-ESG', 0.06237196922302246)"
Line 529,"https://www.detroitnews.com/story/news/local/ michigan/2018/08/30/university-michigan-3-million-settle-federal-drug-diversion-lawsuit/1145373002/; Accessed October 30, 2018.
","('Competitive_Behavior', 0.2630486786365509)","('Business_Ethics', 0.22258654236793518)","('Management_Of_Legal_And_Regulatory_Framework', 0.13859252631664276)","('NON-ESG', 0.2630486786365509)","('NON-ESG', 0.22258654236793518)","('NON-ESG', 0.13859252631664276)"
Line 530,"4 Hospital tech who spread hepatitis C through drug use sentenced to 39 years.
","('Business_Ethics', 0.16384854912757874)","('Access_And_Affordability', 0.11673024296760559)","('Systemic_Risk_Management', 0.07741349935531616)","('NON-ESG', 0.16384854912757874)","('NON-ESG', 0.11673024296760559)","('NON-ESG', 0.07741349935531616)"
Line 531,"CBS News.
","('Critical_Incident_Risk_Management', 0.08944766223430634)","('Customer_Privacy', 0.08649824559688568)","('Business_Model_Resilience', 0.08173110336065292)","('NON-ESG', 0.08944766223430634)","('NON-ESG', 0.08649824559688568)","('NON-ESG', 0.08173110336065292)"
Line 532,"December 2, 2013.
","('Management_Of_Legal_And_Regulatory_Framework', 0.11775071173906326)","('Director_Removal', 0.0996101126074791)","('Business_Ethics', 0.07915577292442322)","('NON-ESG', 0.11775071173906326)","('NON-ESG', 0.0996101126074791)","('NON-ESG', 0.07915577292442322)"
Line 533,"https://www.cbsnews.com/news/lab-tech-hepatitis-c-kwiatkowski-sentenced-39- years.
","('Business_Ethics', 0.3584393262863159)","('Management_Of_Legal_And_Regulatory_Framework', 0.25459998846054077)","('Competitive_Behavior', 0.05459227412939072)","('NON-ESG', 0.3584393262863159)","('NON-ESG', 0.25459998846054077)","('NON-ESG', 0.05459227412939072)"
Line 534,"Accessed October 30, 2018.BD P yxis™ CIISafe SystemBD Pyxis™ ES System +  BD Pyxis™ ES RefrigeratorBD P yxis™ IV Prep SystemBD P yxis™ Logistics Software BD HealthSight™ Pl atform EMRPharma cy Patient care Patient Enterprise master data management enabling  analytics and simplifying formulary managementOperations dashboard with real-time viewsBD Alaris™  Infusion SystemInve ntory opt imiza tion | Diversio n manageme nt | Me dication safetyAccess                     Efficiency                Empowerment       Innovation               35 362020 goal Enable  the transition from research into clinical practice The BD FACSLyric ™ Clinical Flow Cytometer is a standardized,  easy-to-use in vitro diagnostic (IVD) system, for use with BD  Multitest ™ Assays for immunological assessment of individuals  and patients having, or suspected of having, immune  deficiency.
","('Access_And_Affordability', 0.2534694969654083)","('Customer_Welfare', 0.14067263901233673)","('Energy_Management', 0.10214422643184662)","('NON-ESG', 0.2534694969654083)","('NON-ESG', 0.14067263901233673)","('NON-ESG', 0.10214422643184662)"
Line 535,"Accessed October 30, 2018.BD P yxis™ CIISafe SystemBD Pyxis™ ES System +  BD Pyxis™ ES RefrigeratorBD P yxis™ IV Prep SystemBD P yxis™ Logistics Software BD HealthSight™ Pl atform EMRPharma cy Patient care Patient Enterprise master data management enabling  analytics and simplifying formulary managementOperations dashboard with real-time viewsBD Alaris™  Infusion SystemInve ntory opt imiza tion | Diversio n manageme nt | Me dication safetyAccess                     Efficiency                Empowerment       Innovation               35 362020 goal Enable  the transition from research into clinical practice The BD FACSLyric ™ Clinical Flow Cytometer is a standardized,  easy-to-use in vitro diagnostic (IVD) system, for use with BD  Multitest ™ Assays for immunological assessment of individuals  and patients having, or suspected of having, immune  deficiency.
","('Customer_Welfare', 0.10870660841464996)","('Product_Quality_And_Safety', 0.10609075427055359)","('Access_And_Affordability', 0.10329638421535492)","('NON-ESG', 0.10870660841464996)","('NON-ESG', 0.10609075427055359)","('NON-ESG', 0.10329638421535492)"
Line 536,"BD FACSLyric ™ Flow Cytometer is available in  4-color to 12-colors with on-site upgradeable features to adapt  to a lab’s changing needs.
","('Energy_Management', 0.32746613025665283)","('Product_Design_And_Lifecycle_Management', 0.1774384081363678)","('Customer_Welfare', 0.09834441542625427)","('NON-ESG', 0.32746613025665283)","('NON-ESG', 0.1774384081363678)","('NON-ESG', 0.09834441542625427)"
Line 537,"It supports the BD Multitest ™  4-Color Assays and the BD Multitest ™ 6-Color TBNK Assay,  which are some of the most used flow-based IVD assays.
","('Competitive_Behavior', 0.31045249104499817)","('Customer_Welfare', 0.12449906766414642)","('GHG_Emissions', 0.11605816334486008)","('NON-ESG', 0.31045249104499817)","('NON-ESG', 0.12449906766414642)","('NON-ESG', 0.11605816334486008)"
Line 538,"These tests determine the percentages and absolute counts of  T, B and natural killer (NK) cells, as well as the CD4 and CD8  subsets of T cells.
","('Customer_Welfare', 0.12145788222551346)","('Ecological_Impacts', 0.10644766688346863)","('Systemic_Risk_Management', 0.08565843850374222)","('NON-ESG', 0.12145788222551346)","('NON-ESG', 0.10644766688346863)","('NON-ESG', 0.08565843850374222)"
Line 539,"Together, these metrics can be used in the  immunological assessment of individuals and patients having,  or suspected of having, immune deficiency.
","('Systemic_Risk_Management', 0.13279248774051666)","('Product_Quality_And_Safety', 0.11939460784196854)","('Employee_Health_And_Safety', 0.11195071041584015)","('NON-ESG', 0.13279248774051666)","('NON-ESG', 0.11939460784196854)","('NON-ESG', 0.11195071041584015)"
Line 540,"BD FACSLyric ™  Clinical Flow Cytometer capabilities enable standardization  and collaboration through consistent results and unique assay  portability across labs, in the same site or across the globe.
","('Competitive_Behavior', 0.3694235682487488)","('Customer_Welfare', 0.11272678524255753)","('Management_Of_Legal_And_Regulatory_Framework', 0.09239435195922852)","('NON-ESG', 0.3694235682487488)","('NON-ESG', 0.11272678524255753)","('NON-ESG', 0.09239435195922852)"
Line 541,"The BD FACSDuet ™ Automated Flow Cytometry System is a  fully automated sample preparation instrument that enables clinical laboratories to improve their efficiency by reducing errors  and limiting the manual user interactions required to run assays  on the BD FACSLyric ™ Clinical Flow Cytometer.
","('Competitive_Behavior', 0.27271732687950134)","('Customer_Welfare', 0.21602627635002136)","('Management_Of_Legal_And_Regulatory_Framework', 0.08283776789903641)","('NON-ESG', 0.27271732687950134)","('NON-ESG', 0.21602627635002136)","('NON-ESG', 0.08283776789903641)"
Line 542,"These solutions  may help clinical laboratories improve accuracy and  repeatability of their assays by minimizing manual steps that  can introduce errors.
","('Competitive_Behavior', 0.7537649869918823)","('Customer_Welfare', 0.047128334641456604)","('Business_Ethics', 0.030807754024863243)","(['Business Ethics'], 0.7537649869918823)","('NON-ESG', 0.047128334641456604)","('NON-ESG', 0.030807754024863243)"
Line 543,"With complete workflow traceability, it  supports the labs to be compliant with ISO-15189 accreditation.
","('Product_Quality_And_Safety', 0.32269537448883057)","('Systemic_Risk_Management', 0.08614729344844818)","('Product_Design_And_Lifecycle_Management', 0.07853325456380844)","('NON-ESG', 0.32269537448883057)","('NON-ESG', 0.08614729344844818)","('NON-ESG', 0.07853325456380844)"
Line 544,"Physical integration between the BD FACSDuet ™ System and  the BD FACSLyric ™ Clinical Flow Cytometer allows technicians  to load samples and reagents onto the BD FACSDuet ™ System  and receive data once the samples are fully processed from  the BD FACSLyric ™ Clinical Flow Cytometer—a complete  walkaway sample to answer solution.
","('Customer_Welfare', 0.31677955389022827)","('Water_And_Wastewater_Management', 0.10553516447544098)","('Energy_Management', 0.07589507102966309)","('NON-ESG', 0.31677955389022827)","('NON-ESG', 0.10553516447544098)","('NON-ESG', 0.07589507102966309)"
Line 545,"Data integration using  the BD FACSLink ™ Middleware Solution offers bidirectional  communication between the instruments and connectivity  with laboratory information systems (LISs).
","('Data_Security', 0.8910947442054749)","('Customer_Privacy', 0.03902020305395126)","('Systemic_Risk_Management', 0.0053614419884979725)","(['Information Security/Cybersecurity & System Availability'], 0.8910947442054749)","('NON-ESG', 0.03902020305395126)","('NON-ESG', 0.0053614419884979725)"
Line 546,"Visit our biosciences site  to learn more about the company’s  portfolio of clinical flow cytometry products.BD FACSLyric ™ Clinical Flow Cytometer and BD FACSDuet ™ System Access                     Efficiency                Empowerment       Innovation               372020 goal Provide  solutions that improve healthcare worker and patient safety Technology is advancing capabilities for how clinicians and patients manage disease across the care continuum.
","('Employee_Health_And_Safety', 0.6482086777687073)","('Product_Quality_And_Safety', 0.18575599789619446)","('Access_And_Affordability', 0.02227468602359295)","(['Operational Eco-Efficiency'], 0.6482086777687073)","('NON-ESG', 0.18575599789619446)","('NON-ESG', 0.02227468602359295)"
Line 547,"We work closely with  healthcare systems to improve safety, costs and outcomes.
","('Employee_Health_And_Safety', 0.941157877445221)","('Product_Quality_And_Safety', 0.01789148710668087)","('Access_And_Affordability', 0.004768573213368654)","(['Operational Eco-Efficiency'], 0.941157877445221)","('NON-ESG', 0.01789148710668087)","('NON-ESG', 0.004768573213368654)"
Line 548,"We continue to invest in new technologies and leverage informatics to  enhance our product and solution offerings.
","('Product_Design_And_Lifecycle_Management', 0.9408780336380005)","('Customer_Welfare', 0.009240727871656418)","('Product_Quality_And_Safety', 0.00490278797224164)","(['Product Stewardship'], 0.9408780336380005)","('NON-ESG', 0.009240727871656418)","('NON-ESG', 0.00490278797224164)"
Line 549,"As we pursue new digital technologies, we are committed to providing secure products  to our customers.
","('Product_Design_And_Lifecycle_Management', 0.4035198986530304)","('Data_Security', 0.23633572459220886)","('Customer_Privacy', 0.047055765986442566)","('NON-ESG', 0.4035198986530304)","('NON-ESG', 0.23633572459220886)","('NON-ESG', 0.047055765986442566)"
Line 550,"OptiFix ™ AT Absorbable Fixation System The OptiFix ™ AT Fixation System is an articulating mesh fixation  device that allows for traditional straight fixation plus the option  to articulate the tip to better access areas where mesh fixation  may otherwise be difficult, such as locations close to the trocar.
","('Customer_Welfare', 0.15447206795215607)","('Access_And_Affordability', 0.08089222759008408)","('Competitive_Behavior', 0.08053507655858994)","('NON-ESG', 0.15447206795215607)","('NON-ESG', 0.08089222759008408)","('NON-ESG', 0.08053507655858994)"
Line 551,"OptiFix ™ AT Fixation System helps address some of the  challenges associated with traditional straight fixation devices  which includes technical limitations that may result in nonideal  fastener placement, which is a mechanism for mesh shift,  migration, inadequate mesh overlap, folding and fastener  engagement.
","('Competitive_Behavior', 0.16791842877864838)","('Product_Design_And_Lifecycle_Management', 0.15240857005119324)","('Customer_Welfare', 0.10014445334672928)","('NON-ESG', 0.16791842877864838)","('NON-ESG', 0.15240857005119324)","('NON-ESG', 0.10014445334672928)"
Line 552,"The ergonomic OptiFix ™ AT Fixation System is  designed to provide full mesh access from one side of the  patient, deliver more consistent perpendicular fastener  deployment and enhance surgeon comfort.
","('Access_And_Affordability', 0.45732423663139343)","('Employee_Health_And_Safety', 0.19589795172214508)","('Customer_Welfare', 0.04567471519112587)","('NON-ESG', 0.45732423663139343)","('NON-ESG', 0.19589795172214508)","('NON-ESG', 0.04567471519112587)"
Line 553,"Improved access  may reduce the total number of trocars needed.
","('Access_And_Affordability', 0.8511157035827637)","('Management_Of_Legal_And_Regulatory_Framework', 0.015414344146847725)","('Product_Quality_And_Safety', 0.014180034399032593)","(['Health Outcome Contribution'], 0.8511157035827637)","('NON-ESG', 0.015414344146847725)","('NON-ESG', 0.014180034399032593)"
Line 554,"Studies demonstrate that reducing trocars can result in cost savings,  reduced risk of infections and reduced trocar site herniation.
","('Employee_Health_And_Safety', 0.8027804493904114)","('Product_Quality_And_Safety', 0.021378332749009132)","('Business_Ethics', 0.01570177637040615)","(['Operational Eco-Efficiency'], 0.8027804493904114)","('NON-ESG', 0.021378332749009132)","('NON-ESG', 0.01570177637040615)"
Line 555,"Further, consistent perpendicular fastener deployment enables  secure fixation across the entire mesh, leading to improved  fastener tissue purchase and fixation strength, as well as  facilitating mesh positioning and reducing the chance for mesh  to be pulled away during fastening.
","('Product_Design_And_Lifecycle_Management', 0.6415966153144836)","('Employee_Health_And_Safety', 0.05400147661566734)","('Product_Quality_And_Safety', 0.03724154829978943)","(['Product Stewardship'], 0.6415966153144836)","('NON-ESG', 0.05400147661566734)","('NON-ESG', 0.03724154829978943)"
Line 556,"PureWick ™ Female External Catheter Kit An estimated 35,6005 patients experience catheter-associated  urinary tract infections each year, also known as CAUTIs—which  lead to increased costs and longer hospitals stays.6 The #1 risk  factor for CAUTI is prolonged catheterization.6,7 The #2 risk  factor is female gender and 61% of catheterized patients are  women.8 Until recently, external catheters were only available   for men—leaving women with no external catheter option for  urine output.
","('Employee_Health_And_Safety', 0.17702758312225342)","('Customer_Welfare', 0.10931569337844849)","('Access_And_Affordability', 0.10677918046712875)","('NON-ESG', 0.17702758312225342)","('NON-ESG', 0.10931569337844849)","('NON-ESG', 0.10677918046712875)"
Line 557,"The PureWick ™ Female External Catheter was the first female  external catheter that allowed for simple, noninvasive urine  management for women.
","('Water_And_Wastewater_Management', 0.15182824432849884)","('Employee_Health_And_Safety', 0.12056662887334824)","('Customer_Welfare', 0.09630031883716583)","('NON-ESG', 0.15182824432849884)","('NON-ESG', 0.12056662887334824)","('NON-ESG', 0.09630031883716583)"
Line 558,"The PureWick ™ Female External  Catheter helps lower CAUTI risk by providing an alternative for  urine management and helps facilitate approximate urine  measurement when utilizing an appropriate collection canister.
","('Water_And_Wastewater_Management', 0.3001635670661926)","('Waste_And_Hazardous_Materials_Management', 0.13968060910701752)","('Customer_Welfare', 0.08195565640926361)","('NON-ESG', 0.3001635670661926)","('NON-ESG', 0.13968060910701752)","('NON-ESG', 0.08195565640926361)"
Line 559,"First used in a hospital in January 2016, the PureWick ™ Female  External Catheter uses low pressure wall suction and wicks away  urine from the patient and into a designated collection canister.
","('Waste_And_Hazardous_Materials_Management', 0.3959541618824005)","('Water_And_Wastewater_Management', 0.1486343890428543)","('Customer_Welfare', 0.06300687044858932)","('NON-ESG', 0.3959541618824005)","('NON-ESG', 0.1486343890428543)","('NON-ESG', 0.06300687044858932)"
Line 560,"Today, PureWick ™ Female External Catheter is used in over 2,200 hospitals in the United States and has also recently become  available in Canada, Japan, the U.K., Brazil, Chile and China.
","('Access_And_Affordability', 0.3106733560562134)","('Employee_Health_And_Safety', 0.18706238269805908)","('Product_Quality_And_Safety', 0.053581204265356064)","('NON-ESG', 0.3106733560562134)","('NON-ESG', 0.18706238269805908)","('NON-ESG', 0.053581204265356064)"
Line 561,"The latest PureWick ™ Female External Catheter platform  innovation is the launch of a new user-friendly kit.
","('Product_Design_And_Lifecycle_Management', 0.35735249519348145)","('Access_And_Affordability', 0.08299001306295395)","('Customer_Welfare', 0.07627641409635544)","('NON-ESG', 0.35735249519348145)","('NON-ESG', 0.08299001306295395)","('NON-ESG', 0.07627641409635544)"
Line 562,"The PureWick ™  Female External Catheter Kit is a solution designed to help with  consistent practice of noninvasive urine management for  women.
","('Water_And_Wastewater_Management', 0.14681968092918396)","('Customer_Welfare', 0.12141556292772293)","('Waste_And_Hazardous_Materials_Management', 0.11042428761720657)","('NON-ESG', 0.14681968092918396)","('NON-ESG', 0.12141556292772293)","('NON-ESG', 0.11042428761720657)"
Line 563,"A duration label assists nursing staff in determining how  long the device has been in place and standardized SureStep ™  Peri-Care Wipes help facilitate patient cleaning practice through  step-by-step instructions.
","('Waste_And_Hazardous_Materials_Management', 0.22306416928768158)","('Product_Quality_And_Safety', 0.15454190969467163)","('Product_Design_And_Lifecycle_Management', 0.12160826474428177)","('NON-ESG', 0.22306416928768158)","('NON-ESG', 0.15454190969467163)","('NON-ESG', 0.12160826474428177)"
Line 564,"These aspects of device and patient  care play a vital role in patient hygiene and skin integrity.
","('Employee_Health_And_Safety', 0.7616778612136841)","('Product_Quality_And_Safety', 0.041447870433330536)","('Product_Design_And_Lifecycle_Management', 0.03438810259103775)","(['Operational Eco-Efficiency'], 0.7616778612136841)","('NON-ESG', 0.041447870433330536)","('NON-ESG', 0.03438810259103775)"
Line 565,"References 5 Magill SS, Edwards JR, Bamberg W, et al.
","('Management_Of_Legal_And_Regulatory_Framework', 0.43666231632232666)","('Ecological_Impacts', 0.13893532752990723)","('GHG_Emissions', 0.05644428730010986)","('NON-ESG', 0.43666231632232666)","('NON-ESG', 0.13893532752990723)","('NON-ESG', 0.05644428730010986)"
Line 566,"Multistate point-prevalence survey of health care–associated infections.
","('Employee_Health_And_Safety', 0.43045133352279663)","('Product_Quality_And_Safety', 0.08578918874263763)","('Access_And_Affordability', 0.07117172330617905)","('NON-ESG', 0.43045133352279663)","('NON-ESG', 0.08578918874263763)","('NON-ESG', 0.07117172330617905)"
Line 567,"N Engl J Med .
","('Management_Of_Legal_And_Regulatory_Framework', 0.14448323845863342)","('Ecological_Impacts', 0.12128008902072906)","('Access_And_Affordability', 0.07286673784255981)","('NON-ESG', 0.14448323845863342)","('NON-ESG', 0.12128008902072906)","('NON-ESG', 0.07286673784255981)"
Line 568,"2014;370:1198-1208.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5102283358573914)","('Ecological_Impacts', 0.07153607904911041)","('Competitive_Behavior', 0.05253300070762634)","(['Corporate Governance'], 0.5102283358573914)","('NON-ESG', 0.07153607904911041)","('NON-ESG', 0.05253300070762634)"
Line 569,"6 Scott RD 2nd; Centers for Disease Control and Prevention.
","('Systemic_Risk_Management', 0.1336536556482315)","('Access_And_Affordability', 0.12242456525564194)","('Physical_Impacts_Of_Climate_Change', 0.09817491471767426)","('NON-ESG', 0.1336536556482315)","('NON-ESG', 0.12242456525564194)","('NON-ESG', 0.09817491471767426)"
Line 570,"The direct medical costs of healthcare-associated infections in U.S. hospitals and the benefits of prevention.
","('Employee_Health_And_Safety', 0.46418559551239014)","('Access_And_Affordability', 0.06947723776102066)","('Product_Quality_And_Safety', 0.05991524085402489)","('NON-ESG', 0.46418559551239014)","('NON-ESG', 0.06947723776102066)","('NON-ESG', 0.05991524085402489)"
Line 571,"https://www.cdc.gov/ HAI/pdfs/hai/scott_costpaper.pdf.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8222195506095886)","('Energy_Management', 0.029200725257396698)","('Access_And_Affordability', 0.02011585235595703)","(['Corporate Governance'], 0.8222195506095886)","('NON-ESG', 0.029200725257396698)","('NON-ESG', 0.02011585235595703)"
Line 572,"Published March 2009.
","('Ecological_Impacts', 0.12626846134662628)","('Management_Of_Legal_And_Regulatory_Framework', 0.11697546392679214)","('Data_Security', 0.11428957432508469)","('NON-ESG', 0.12626846134662628)","('NON-ESG', 0.11697546392679214)","('NON-ESG', 0.11428957432508469)"
Line 573,"Accessed June 19, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2509731352329254)","('Ecological_Impacts', 0.10193179547786713)","('Competitive_Behavior', 0.09474756568670273)","('NON-ESG', 0.2509731352329254)","('NON-ESG', 0.10193179547786713)","('NON-ESG', 0.09474756568670273)"
Line 574,"7 Maki D, Tambyah P.
","('Business_Ethics', 0.24809737503528595)","('Management_Of_Legal_And_Regulatory_Framework', 0.11071372032165527)","('Human_Rights_And_Community_Relations', 0.06288992613554001)","('NON-ESG', 0.24809737503528595)","('NON-ESG', 0.11071372032165527)","('NON-ESG', 0.06288992613554001)"
Line 575,"Engineering out the risk for infection with urinary catheters.
","('Employee_Health_And_Safety', 0.6277036070823669)","('Critical_Incident_Risk_Management', 0.03781077638268471)","('Access_And_Affordability', 0.037640176713466644)","(['Operational Eco-Efficiency'], 0.6277036070823669)","('NON-ESG', 0.03781077638268471)","('NON-ESG', 0.037640176713466644)"
Line 576,"Emerg Infect Dis .
","('Water_And_Wastewater_Management', 0.19398236274719238)","('Ecological_Impacts', 0.08457721769809723)","('Systemic_Risk_Management', 0.08302414417266846)","('NON-ESG', 0.19398236274719238)","('NON-ESG', 0.08457721769809723)","('NON-ESG', 0.08302414417266846)"
Line 577,"2001;7(2):342-347.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3291940987110138)","('Data_Security', 0.11576180905103683)","('Systemic_Risk_Management', 0.08607327938079834)","('NON-ESG', 0.3291940987110138)","('NON-ESG', 0.11576180905103683)","('NON-ESG', 0.08607327938079834)"
Line 578,"8 Daniels KR, Lee GC, Frei CR.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5730764865875244)","('Business_Ethics', 0.10605191439390182)","('Competitive_Behavior', 0.06572046130895615)","(['Corporate Governance'], 0.5730764865875244)","('NON-ESG', 0.10605191439390182)","('NON-ESG', 0.06572046130895615)"
Line 579,"Trends in CAUTIs among a national cohort of hospitalized adults.
","('Ecological_Impacts', 0.2984554171562195)","('Water_And_Wastewater_Management', 0.09878971427679062)","('Systemic_Risk_Management', 0.09056934714317322)","('NON-ESG', 0.2984554171562195)","('NON-ESG', 0.09878971427679062)","('NON-ESG', 0.09056934714317322)"
Line 580,"Am J Infect Control.
","('Systemic_Risk_Management', 0.1420809030532837)","('Ecological_Impacts', 0.10704108327627182)","('Water_And_Wastewater_Management', 0.05907585844397545)","('NON-ESG', 0.1420809030532837)","('NON-ESG', 0.10704108327627182)","('NON-ESG', 0.05907585844397545)"
Line 581,"2014;41(1):17-22.
","('Management_Of_Legal_And_Regulatory_Framework', 0.32400158047676086)","('Competitive_Behavior', 0.07991158962249756)","('Systemic_Risk_Management', 0.07329703867435455)","('NON-ESG', 0.32400158047676086)","('NON-ESG', 0.07991158962249756)","('NON-ESG', 0.07329703867435455)"
Line 582,"Access                     Efficiency                Empowerment       Innovation               37 38WavelinQ ™ 4F EndoAVF System Chronic kidney disease affects millions of people worldwide.
","('Access_And_Affordability', 0.7162547707557678)","('Employee_Health_And_Safety', 0.0537848137319088)","('Product_Quality_And_Safety', 0.03970292583107948)","(['Health Outcome Contribution'], 0.7162547707557678)","('NON-ESG', 0.0537848137319088)","('NON-ESG', 0.03970292583107948)"
Line 583,"The  final stage of kidney disease is called end-stage kidney disease  (ESKD).
","('Employee_Health_And_Safety', 0.25790518522262573)","('Employee_Engagement_Inclusion_And_Diversity', 0.08922284841537476)","('Waste_And_Hazardous_Materials_Management', 0.06433195620775223)","('NON-ESG', 0.25790518522262573)","('NON-ESG', 0.08922284841537476)","('NON-ESG', 0.06433195620775223)"
Line 584,"Patients with ESKD require dialysis treatments or a  kidney transplant to sustain life.
","('Employee_Health_And_Safety', 0.26912328600883484)","('Access_And_Affordability', 0.15899516642093658)","('Employee_Engagement_Inclusion_And_Diversity', 0.11091761291027069)","('NON-ESG', 0.26912328600883484)","('NON-ESG', 0.15899516642093658)","('NON-ESG', 0.11091761291027069)"
Line 585,"Globally, there are more than   2 million patients on hemodialysis with the majority depending  on a fistula as their lifeline for dialysis therapy.To administer hemodialysis treatment, an “access” to the  bloodstream is required.
","('Access_And_Affordability', 0.3307095170021057)","('Customer_Welfare', 0.10603587329387665)","('Employee_Health_And_Safety', 0.07911789417266846)","('NON-ESG', 0.3307095170021057)","('NON-ESG', 0.10603587329387665)","('NON-ESG', 0.07911789417266846)"
Line 586,"Arteriovenous fistulas (AVF) are the  preferred access method.
","('Access_And_Affordability', 0.35760197043418884)","('Product_Quality_And_Safety', 0.0960058644413948)","('Employee_Health_And_Safety', 0.09190718084573746)","('NON-ESG', 0.35760197043418884)","('NON-ESG', 0.0960058644413948)","('NON-ESG', 0.09190718084573746)"
Line 587,"An AVF is a connection between an  artery and a vein, most often created surgically.
","('Employee_Health_And_Safety', 0.34533199667930603)","('Access_And_Affordability', 0.1006498783826828)","('Critical_Incident_Risk_Management', 0.08599042892456055)","('NON-ESG', 0.34533199667930603)","('NON-ESG', 0.1006498783826828)","('NON-ESG', 0.08599042892456055)"
Line 588,"This connection  increases blood flow in the vein, providing a method to perform  hemodialysis.
","('Water_And_Wastewater_Management', 0.2689213454723358)","('Access_And_Affordability', 0.11474993079900742)","('Customer_Welfare', 0.07731795310974121)","('NON-ESG', 0.2689213454723358)","('NON-ESG', 0.11474993079900742)","('NON-ESG', 0.07731795310974121)"
Line 589,"Surgical AVFs have been the standard of care for  hemodialysis patients for over 50 years, until now.
","('Access_And_Affordability', 0.32209956645965576)","('Customer_Welfare', 0.1096659004688263)","('Employee_Health_And_Safety', 0.05949114263057709)","('NON-ESG', 0.32209956645965576)","('NON-ESG', 0.1096659004688263)","('NON-ESG', 0.05949114263057709)"
Line 590,"The WavelinQ ™ 4F EndoAVF System is designed to create an  endovascular AVF (endoAVF) for hemodialysis access in patients  who have ESKD and need dialysis.
","('Access_And_Affordability', 0.7022388577461243)","('Customer_Welfare', 0.03593182936310768)","('Critical_Incident_Risk_Management', 0.028686555102467537)","(['Health Outcome Contribution'], 0.7022388577461243)","('NON-ESG', 0.03593182936310768)","('NON-ESG', 0.028686555102467537)"
Line 591,"This innovative technology is  one of the first to provide a nonsurgical option to create an AVF.
","('Access_And_Affordability', 0.28168627619743347)","('Employee_Health_And_Safety', 0.15598832070827484)","('Product_Design_And_Lifecycle_Management', 0.07066173851490021)","('NON-ESG', 0.28168627619743347)","('NON-ESG', 0.15598832070827484)","('NON-ESG', 0.07066173851490021)"
Line 592,"The WavelinQ ™ 4F EndoAVF System is comprised of two  4-French (4F) single-use, disposable, magnetic,  hydrophilic-coated catheters: a venous catheter and arterial  catheter.
","('Employee_Health_And_Safety', 0.25938162207603455)","('Access_And_Affordability', 0.14467822015285492)","('Critical_Incident_Risk_Management', 0.1307092159986496)","('NON-ESG', 0.25938162207603455)","('NON-ESG', 0.14467822015285492)","('NON-ESG', 0.1307092159986496)"
Line 593,"The venous catheter contains a radiofrequency (RF)  electrode for the delivery of RF energy.
","('Energy_Management', 0.8096361756324768)","('Air_Quality', 0.0393957756459713)","('Water_And_Wastewater_Management', 0.02081892639398575)","(['Operational Eco-Efficiency'], 0.8096361756324768)","('NON-ESG', 0.0393957756459713)","('NON-ESG', 0.02081892639398575)"
Line 594,"The arterial catheter  contains a ceramic backstop for receiving the electrode.
","('Employee_Health_And_Safety', 0.2557559609413147)","('Access_And_Affordability', 0.18676835298538208)","('Critical_Incident_Risk_Management', 0.09330432116985321)","('NON-ESG', 0.2557559609413147)","('NON-ESG', 0.18676835298538208)","('NON-ESG', 0.09330432116985321)"
Line 595,"Each  catheter is equipped with 36 square magnets, which allow for  flexibility and coaptation while navigating in the vessels.
","('Access_And_Affordability', 0.34899577498435974)","('Air_Quality', 0.10254472494125366)","('Energy_Management', 0.08741363883018494)","('NON-ESG', 0.34899577498435974)","('NON-ESG', 0.10254472494125366)","('NON-ESG', 0.08741363883018494)"
Line 596,"When  placed in proximity, the magnets attract to each other, pulling  the vessels together and aligning the electrode with  the backstop.
","('Energy_Management', 0.3826037347316742)","('Competitive_Behavior', 0.20268802344799042)","('Product_Design_And_Lifecycle_Management', 0.03674707189202309)","('NON-ESG', 0.3826037347316742)","('NON-ESG', 0.20268802344799042)","('NON-ESG', 0.03674707189202309)"
Line 597,"Once the catheters are aligned, a small burst of RF energy is  used to create a channel between the artery and vein to create  the endoAVF.
","('Energy_Management', 0.2726600766181946)","('Access_And_Affordability', 0.19203637540340424)","('Critical_Incident_Risk_Management', 0.0886475220322609)","('NON-ESG', 0.2726600766181946)","('NON-ESG', 0.19203637540340424)","('NON-ESG', 0.0886475220322609)"
Line 598,"The catheters are then removed, and blood will  flow from the artery into the vein, creating an enhanced blood  flow that can support hemodialysis.
","('Access_And_Affordability', 0.16501934826374054)","('Water_And_Wastewater_Management', 0.11101120710372925)","('Customer_Welfare', 0.09059903770685196)","('NON-ESG', 0.16501934826374054)","('NON-ESG', 0.11101120710372925)","('NON-ESG', 0.09059903770685196)"
Line 599,"For more information, visit the WaveLinQ ™ 4F EndoAVF  System webpage .Venovo ™ Venous Stent System The Venovo ™ Venous Stent System is indicated for the treatment  of symptomatic iliofemoral venous outflow obstruction.
","('Employee_Health_And_Safety', 0.6320258975028992)","('Critical_Incident_Risk_Management', 0.04305266588926315)","('Water_And_Wastewater_Management', 0.03860228881239891)","(['Operational Eco-Efficiency'], 0.6320258975028992)","('NON-ESG', 0.04305266588926315)","('NON-ESG', 0.03860228881239891)"
Line 600,"The  stent is designed with the balance of radial strength,  compression resistance and flexibility needed for the treatment  of symptomatic postthrombotic and nonthrombotic iliofemoral  lesions.
","('Employee_Health_And_Safety', 0.40549421310424805)","('Product_Quality_And_Safety', 0.07924548536539078)","('Systemic_Risk_Management', 0.06760688126087189)","('NON-ESG', 0.40549421310424805)","('NON-ESG', 0.07924548536539078)","('NON-ESG', 0.06760688126087189)"
Line 601,"Key product features include 3-mm flared ends designed  to prevent stent migration, broad size range (10- to 20-mm  diameters, 40- to 160-mm lengths) and a triaxial delivery  system designed for placement accuracy.
","('Product_Design_And_Lifecycle_Management', 0.9208848476409912)","('Product_Quality_And_Safety', 0.013939832337200642)","('Customer_Welfare', 0.011028834618628025)","(['Product Stewardship'], 0.9208848476409912)","('NON-ESG', 0.013939832337200642)","('NON-ESG', 0.011028834618628025)"
Line 602,"One-year results from the product’s prospective, multicenter,  single-arm VERNACULAR trial * involving 170 patients  demonstrated the safety and effectiveness of the Venovo ™  Venous Stent for the treatment of symptomatic iliofemoral  venous outflow obstruction.
","('Employee_Health_And_Safety', 0.6833277344703674)","('Customer_Welfare', 0.028624629601836205)","('Product_Design_And_Lifecycle_Management', 0.02815980277955532)","(['Operational Eco-Efficiency'], 0.6833277344703674)","('NON-ESG', 0.028624629601836205)","('NON-ESG', 0.02815980277955532)"
Line 603,"The clinical findings showed a  weighted primary patency rate of 88.3%, with a 96.9% patency  rate in nonthrombotic lesions and an 81.3% patency rate in  postthrombotic lesions, a statistically significant difference from  the performance goal of 74%.
","('Employee_Health_And_Safety', 0.5166640281677246)","('Employee_Engagement_Inclusion_And_Diversity', 0.0695403441786766)","('Systemic_Risk_Management', 0.051444705575704575)","(['Operational Eco-Efficiency'], 0.5166640281677246)","('NON-ESG', 0.0695403441786766)","('NON-ESG', 0.051444705575704575)"
Line 604,"For more information regarding  Venovo ™ Venous Stent System, visit the product webpage .*The Venovo ™ Venous Stent System was studied in the global  VERNACULAR clinical trial, which was a prospective, multicenter,  nonrandomized, single-arm study of 170 patients.
","('Employee_Health_And_Safety', 0.4367534816265106)","('Customer_Welfare', 0.08231747150421143)","('Water_And_Wastewater_Management', 0.04942014068365097)","('NON-ESG', 0.4367534816265106)","('NON-ESG', 0.08231747150421143)","('NON-ESG', 0.04942014068365097)"
Line 605,"The primary  effectiveness endpoint of the study was primary patency (PP) at  12 months post-index procedure.
","('Access_And_Affordability', 0.5522955060005188)","('Management_Of_Legal_And_Regulatory_Framework', 0.11304300278425217)","('Product_Quality_And_Safety', 0.08787912875413895)","(['Health Outcome Contribution'], 0.5522955060005188)","('NON-ESG', 0.11304300278425217)","('NON-ESG', 0.08787912875413895)"
Line 606,"Patients who received a  Venovo ™ Venous Stent had a weighted PP rate of 88.3%,  demonstrating a statistically significant difference from a  literature-derived performance goal (PG) of 74%, with an 81.3%  PP rate for subjects with postthrombotic syndrome and 96.9%  PP rate for subjects with nonthrombotic iliac vein lesions.References 9 Data on file.
","('Employee_Health_And_Safety', 0.517450749874115)","('Access_And_Affordability', 0.06933781504631042)","('Product_Quality_And_Safety', 0.04589186608791351)","(['Operational Eco-Efficiency'], 0.517450749874115)","('NON-ESG', 0.06933781504631042)","('NON-ESG', 0.04589186608791351)"
Line 607,"Bard Peripheral Vascular Inc., Tempe, AZ.
","('Employee_Health_And_Safety', 0.12442713975906372)","('Supply_Chain_Management', 0.09390734136104584)","('Customer_Welfare', 0.08750616759061813)","('NON-ESG', 0.12442713975906372)","('NON-ESG', 0.09390734136104584)","('NON-ESG', 0.08750616759061813)"
Line 608,"10 National Kidney Foundation.
","('Business_Ethics', 0.16289807856082916)","('Customer_Welfare', 0.08939404785633087)","('Access_And_Affordability', 0.07341074198484421)","('NON-ESG', 0.16289807856082916)","('NON-ESG', 0.08939404785633087)","('NON-ESG', 0.07341074198484421)"
Line 609,"Global facts about kidney disease.
","('Employee_Health_And_Safety', 0.4176454544067383)","('Waste_And_Hazardous_Materials_Management', 0.06702578067779541)","('Employee_Engagement_Inclusion_And_Diversity', 0.05529022216796875)","('NON-ESG', 0.4176454544067383)","('NON-ESG', 0.06702578067779541)","('NON-ESG', 0.05529022216796875)"
Line 610,"https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease.
","('Employee_Health_And_Safety', 0.20932717621326447)","('Employee_Engagement_Inclusion_And_Diversity', 0.11890838295221329)","('Waste_And_Hazardous_Materials_Management', 0.09002351015806198)","('NON-ESG', 0.20932717621326447)","('NON-ESG', 0.11890838295221329)","('NON-ESG', 0.09002351015806198)"
Line 611,"Accessed June 23, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.26857659220695496)","('Ecological_Impacts', 0.0988227128982544)","('Competitive_Behavior', 0.09471891075372696)","('NON-ESG', 0.26857659220695496)","('NON-ESG', 0.0988227128982544)","('NON-ESG', 0.09471891075372696)"
Line 612,"*The VENOVO® Venous Stent System was studied in the global VERNACULAR clinical trial, which was a prospective, multicenter, nonrandomized, single-arm study of 170 patients.
","('Employee_Health_And_Safety', 0.4390312135219574)","('Customer_Welfare', 0.06776710599660873)","('Water_And_Wastewater_Management', 0.057068224996328354)","('NON-ESG', 0.4390312135219574)","('NON-ESG', 0.06776710599660873)","('NON-ESG', 0.057068224996328354)"
Line 613,"The primary  effectiveness endpoint of the study was primary patency (PP) at 12 months postindex procedure.
","('Access_And_Affordability', 0.574006199836731)","('Product_Quality_And_Safety', 0.08924481272697449)","('Management_Of_Legal_And_Regulatory_Framework', 0.08508646488189697)","(['Health Outcome Contribution'], 0.574006199836731)","('NON-ESG', 0.08924481272697449)","('NON-ESG', 0.08508646488189697)"
Line 614,"Patients who received a VENOVO® Venous Stent had a weighted PP rate of 88.3%,  demonstrating a statistically significant difference from a literature-derived performance goal (PG) of 74%, with an 81.3% PP rate for subjects with post-thrombotic syndrome and 96.9% PP  rate for subjects with nonthrombotic iliac vein lesions.9Access                     Efficiency                Empowerment       Innovation               39AMR Antimicrobial resistance, or AMR for short, is among the greatest  threats to the health and well-being of the world’s population.
","('Customer_Welfare', 0.2078874111175537)","('Product_Quality_And_Safety', 0.16305257380008698)","('Selling_Practices_And_Product_Labeling', 0.07097672671079636)","('NON-ESG', 0.2078874111175537)","('NON-ESG', 0.16305257380008698)","('NON-ESG', 0.07097672671079636)"
Line 615,"Patients who received a VENOVO® Venous Stent had a weighted PP rate of 88.3%,  demonstrating a statistically significant difference from a literature-derived performance goal (PG) of 74%, with an 81.3% PP rate for subjects with post-thrombotic syndrome and 96.9% PP  rate for subjects with nonthrombotic iliac vein lesions.9Access                     Efficiency                Empowerment       Innovation               39AMR Antimicrobial resistance, or AMR for short, is among the greatest  threats to the health and well-being of the world’s population.
","('Access_And_Affordability', 0.35754284262657166)","('Human_Rights_And_Community_Relations', 0.26717162132263184)","('Employee_Health_And_Safety', 0.0750558078289032)","('NON-ESG', 0.35754284262657166)","('NON-ESG', 0.26717162132263184)","('NON-ESG', 0.0750558078289032)"
Line 616,"If  present trends continue, by 2050 AMR will become a greater cause  of mortality than heart disease or cancer.11 As the bacteria that  cause infections become increasingly drug resistant, even  common medical procedures—including surgery, childbirth and  chemotherapy—will become increasingly life-threatening.
","('Employee_Health_And_Safety', 0.6468439698219299)","('Product_Quality_And_Safety', 0.04470422491431236)","('Access_And_Affordability', 0.042702291160821915)","(['Operational Eco-Efficiency'], 0.6468439698219299)","('NON-ESG', 0.04470422491431236)","('NON-ESG', 0.042702291160821915)"
Line 617,"This is  not a theoretical future risk; it is already happening.
","('Systemic_Risk_Management', 0.8070610761642456)","('Business_Model_Resilience', 0.04336448758840561)","('Physical_Impacts_Of_Climate_Change', 0.04008650407195091)","(['Risk & Crisis Management'], 0.8070610761642456)","('NON-ESG', 0.04336448758840561)","('NON-ESG', 0.04008650407195091)"
Line 618,"In 2019, the  CDC released updated estimates for the toll of drug-resistant  infections in the United States, demonstrating that the risk is  greater than previously believed, affecting over 2.8 million  patients annually.
","('Employee_Health_And_Safety', 0.1368919312953949)","('Systemic_Risk_Management', 0.1315866857767105)","('Data_Security', 0.08917870372533798)","('NON-ESG', 0.1368919312953949)","('NON-ESG', 0.1315866857767105)","('NON-ESG', 0.08917870372533798)"
Line 619,"And as the COVID-19 pandemic has  demonstrated, the threat of untreatable infections  remains very real.Antimicrobials are a mainstay of modern medicine, but  decades of outmoded prescribing practices and extensive use  of antimicrobials in food production have driven a rise in  organisms that are resistant to these life-saving drugs.
","('Systemic_Risk_Management', 0.1273512989282608)","('Selling_Practices_And_Product_Labeling', 0.11239999532699585)","('Product_Quality_And_Safety', 0.08612468838691711)","('NON-ESG', 0.1273512989282608)","('NON-ESG', 0.11239999532699585)","('NON-ESG', 0.08612468838691711)"
Line 620,"While  much of the focus on AMR has highlighted the need for a  renewed pipeline of new antimicrobials, experts including the  WHO and CDC recognize the need for a multipronged  approach which includes improved infection prevention,  increased utilization of diagnostic testing and antibiotic  stewardship to preserve our current antibiotics.
","('Customer_Welfare', 0.13484959304332733)","('Selling_Practices_And_Product_Labeling', 0.12961705029010773)","('Product_Quality_And_Safety', 0.10880574584007263)","('NON-ESG', 0.13484959304332733)","('NON-ESG', 0.12961705029010773)","('NON-ESG', 0.10880574584007263)"
Line 621,"$20 billion annually in  the United States700,000 preventable  deaths worldwide  annually10 million deaths and  more than $1 trillion  per year by 2050Cost12Impact13ProjectionsSome bacteria are  resistant to  antibioticsResistant bacteria  pass between peopleDrug-resistant bacteria  become dominant and  spreadDrug-resistant  bacteria survive   and multiplyAntibiotics kill both  good and bad  bacteria References 11 O’Neill J; The Review on Antimicrobial Resistance.
","('Selling_Practices_And_Product_Labeling', 0.10605625808238983)","('Systemic_Risk_Management', 0.10423840582370758)","('Customer_Welfare', 0.10291144996881485)","('NON-ESG', 0.10605625808238983)","('NON-ESG', 0.10423840582370758)","('NON-ESG', 0.10291144996881485)"
Line 622,"Tackling drug-resistant infections globally: final report and recommendations.
","('Product_Quality_And_Safety', 0.12719738483428955)","('Access_And_Affordability', 0.10885042697191238)","('Employee_Health_And_Safety', 0.09051090478897095)","('NON-ESG', 0.12719738483428955)","('NON-ESG', 0.10885042697191238)","('NON-ESG', 0.09051090478897095)"
Line 623,"https://amr-review.org/sites/default/files/160518_Final%paper_with%20cover.pdf.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6739134788513184)","('Competitive_Behavior', 0.06066800653934479)","('Business_Ethics', 0.03158043324947357)","(['Corporate Governance'], 0.6739134788513184)","('NON-ESG', 0.06066800653934479)","('NON-ESG', 0.03158043324947357)"
Line 624,"Published May 2016.
","('Ecological_Impacts', 0.14013248682022095)","('Data_Security', 0.11780740320682526)","('Management_Of_Legal_And_Regulatory_Framework', 0.11637801676988602)","('NON-ESG', 0.14013248682022095)","('NON-ESG', 0.11780740320682526)","('NON-ESG', 0.11637801676988602)"
Line 625,"Accessed March 15, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21158811450004578)","('Ecological_Impacts', 0.09045995026826859)","('Competitive_Behavior', 0.07761534303426743)","('NON-ESG', 0.21158811450004578)","('NON-ESG', 0.09045995026826859)","('NON-ESG', 0.07761534303426743)"
Line 626,"12 Centers for Disease Control and Prevention.
","('Access_And_Affordability', 0.17744559049606323)","('Systemic_Risk_Management', 0.1247548907995224)","('Physical_Impacts_Of_Climate_Change', 0.079123854637146)","('NON-ESG', 0.17744559049606323)","('NON-ESG', 0.1247548907995224)","('NON-ESG', 0.079123854637146)"
Line 627,"Antibiotic threats in the United States 2013.
","('Systemic_Risk_Management', 0.13218773901462555)","('Customer_Welfare', 0.11764978617429733)","('Selling_Practices_And_Product_Labeling', 0.09101270884275436)","('NON-ESG', 0.13218773901462555)","('NON-ESG', 0.11764978617429733)","('NON-ESG', 0.09101270884275436)"
Line 628,"https://www.cdc.gov/drugresistance/ threat-report-2013/index.html.
","('Systemic_Risk_Management', 0.3407447338104248)","('Data_Security', 0.2494679093360901)","('Physical_Impacts_Of_Climate_Change', 0.048729393631219864)","('NON-ESG', 0.3407447338104248)","('NON-ESG', 0.2494679093360901)","('NON-ESG', 0.048729393631219864)"
Line 629,"Accessed March 15, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21158811450004578)","('Ecological_Impacts', 0.09045995026826859)","('Competitive_Behavior', 0.07761534303426743)","('NON-ESG', 0.21158811450004578)","('NON-ESG', 0.09045995026826859)","('NON-ESG', 0.07761534303426743)"
Line 630,"13 O’Neill J; Tackling drug-resistant infections globally: final report and recommendations.
","('Product_Quality_And_Safety', 0.1237100288271904)","('Selling_Practices_And_Product_Labeling', 0.09500386565923691)","('Access_And_Affordability', 0.08934716135263443)","('NON-ESG', 0.1237100288271904)","('NON-ESG', 0.09500386565923691)","('NON-ESG', 0.08934716135263443)"
Line 631,"https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5015742778778076)","('Competitive_Behavior', 0.13711990416049957)","('Business_Ethics', 0.053799647837877274)","(['Corporate Governance'], 0.5015742778778076)","('NON-ESG', 0.13711990416049957)","('NON-ESG', 0.053799647837877274)"
Line 632,"Published May  2016.
","('Ecological_Impacts', 0.14013248682022095)","('Data_Security', 0.11780740320682526)","('Management_Of_Legal_And_Regulatory_Framework', 0.11637801676988602)","('NON-ESG', 0.14013248682022095)","('NON-ESG', 0.11780740320682526)","('NON-ESG', 0.11637801676988602)"
Line 633,"Accessed March 15, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21158811450004578)","('Ecological_Impacts', 0.09045995026826859)","('Competitive_Behavior', 0.07761534303426743)","('NON-ESG', 0.21158811450004578)","('NON-ESG', 0.09045995026826859)","('NON-ESG', 0.07761534303426743)"
Line 634,"14 O’Neill J; Antimicrobial resistance: tackling a crisis for the health and wealth of nations.
","('Customer_Welfare', 0.20488479733467102)","('Systemic_Risk_Management', 0.12293713539838791)","('Product_Quality_And_Safety', 0.09144816547632217)","('NON-ESG', 0.20488479733467102)","('NON-ESG', 0.12293713539838791)","('NON-ESG', 0.09144816547632217)"
Line 635,"https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%and%20wealth%20of%20nations_1.pdf.
","('Business_Ethics', 0.19657878577709198)","('Systemic_Risk_Management', 0.12977834045886993)","('Competitive_Behavior', 0.11745292693376541)","('NON-ESG', 0.19657878577709198)","('NON-ESG', 0.12977834045886993)","('NON-ESG', 0.11745292693376541)"
Line 636,"Published December 2014.
","('Management_Of_Legal_And_Regulatory_Framework', 0.17285142838954926)","('Ecological_Impacts', 0.1565685272216797)","('Data_Security', 0.09452242404222488)","('NON-ESG', 0.17285142838954926)","('NON-ESG', 0.1565685272216797)","('NON-ESG', 0.09452242404222488)"
Line 637,"Accessed March 15, 2020.40BD is leveraging its extensive global capabilities to meaningfully engage around each of the five key strategies outlined in the WHO’s  Global Action Plan on AMR and adopted by the United Nations Interagency Coordination Group on Antimicrobial Resistance: Improving awareness and education remain a critical  component of efforts to combat AMR.
","('Customer_Welfare', 0.1322382539510727)","('Access_And_Affordability', 0.08299040049314499)","('Selling_Practices_And_Product_Labeling', 0.07149547338485718)","('NON-ESG', 0.1322382539510727)","('NON-ESG', 0.08299040049314499)","('NON-ESG', 0.07149547338485718)"
Line 638,"The Antimicrobial  Resistance Fighter Coalition (ARFC) , mobilized by BD, aims to  raise awareness and emphasize the need for a broad array of  stakeholders to take personal responsibility in combating AMR.
","('Human_Rights_And_Community_Relations', 0.30067014694213867)","('Access_And_Affordability', 0.12006040662527084)","('Critical_Incident_Risk_Management', 0.07585547119379044)","('NON-ESG', 0.30067014694213867)","('NON-ESG', 0.12006040662527084)","('NON-ESG', 0.07585547119379044)"
Line 639,"The Coalition continues to grow with over 200 participants from  43 countries, including government and nongovernment  organization leaders, patient advocacy groups, clinicians,  researchers, patients and family members.
","('Access_And_Affordability', 0.41275015473365784)","('Management_Of_Legal_And_Regulatory_Framework', 0.19168981909751892)","('Human_Rights_And_Community_Relations', 0.12112950533628464)","('NON-ESG', 0.41275015473365784)","('NON-ESG', 0.19168981909751892)","('NON-ESG', 0.12112950533628464)"
Line 640,"With the launch of a  new website and social media channels, the Coalition engages  globally to provide information and updates with videos, online  education and news articles.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5695174336433411)","('Access_And_Affordability', 0.13641861081123352)","('Human_Rights_And_Community_Relations', 0.040791045874357224)","(['Corporate Governance'], 0.5695174336433411)","('NON-ESG', 0.13641861081123352)","('NON-ESG', 0.040791045874357224)"
Line 641,"In September 2019, the Coalition  co-hosted a side event during the United Nations General  Assembly week with the CDC, Wellcome Trust, the American  Society of Microbiology and the Bill and Melinda Gates  Foundation.
","('Ecological_Impacts', 0.3070284128189087)","('Management_Of_Legal_And_Regulatory_Framework', 0.2678886651992798)","('Access_And_Affordability', 0.09374376386404037)","('NON-ESG', 0.3070284128189087)","('NON-ESG', 0.2678886651992798)","('NON-ESG', 0.09374376386404037)"
Line 642,"An international audience attended the event to  hear from global leaders and were invited to view the U.S.  premiere of a full-length documentary on AMR titled  Antimicrobial Resistance Fighters.
","('Customer_Welfare', 0.1590033620595932)","('GHG_Emissions', 0.12083282321691513)","('Selling_Practices_And_Product_Labeling', 0.1188151016831398)","('NON-ESG', 0.1590033620595932)","('NON-ESG', 0.12083282321691513)","('NON-ESG', 0.1188151016831398)"
Line 643,"To reinforce appropriate infection prevention and control  behaviors, BD partnered with SHEA to launch Prevention CHKC,  an online course for frontline providers reinforcing the  importance of infection prevention practices in healthcare.
","('Employee_Health_And_Safety', 0.8533965945243835)","('Critical_Incident_Risk_Management', 0.01625833846628666)","('Product_Quality_And_Safety', 0.012639825232326984)","(['Operational Eco-Efficiency'], 0.8533965945243835)","('NON-ESG', 0.01625833846628666)","('NON-ESG', 0.012639825232326984)"
Line 644,"To support understanding of the role of diagnostics in the  appropriate use of antimicrobials, BD partnered to create and  launch new training and assessment tools.
","('Customer_Welfare', 0.1703062355518341)","('Ecological_Impacts', 0.14070795476436615)","('Selling_Practices_And_Product_Labeling', 0.12081718444824219)","('NON-ESG', 0.1703062355518341)","('NON-ESG', 0.14070795476436615)","('NON-ESG', 0.12081718444824219)"
Line 645,"Read more about the  massive online open course on AMR diagnostics and AMR  scorecard in the Access  section of this report.
","('Management_Of_Legal_And_Regulatory_Framework', 0.27955880761146545)","('Access_And_Affordability', 0.2556678056716919)","('Product_Quality_And_Safety', 0.08524710685014725)","('NON-ESG', 0.27955880761146545)","('NON-ESG', 0.2556678056716919)","('NON-ESG', 0.08524710685014725)"
Line 646,"Strategy 1: Improve awareness, education and training Strengthening surveillance and reporting are necessary to better understand the  scale of the challenge and develop an appropriate response.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2652786672115326)","('Human_Rights_And_Community_Relations', 0.21635447442531586)","('Access_And_Affordability', 0.10715772956609726)","('NON-ESG', 0.2652786672115326)","('NON-ESG', 0.21635447442531586)","('NON-ESG', 0.10715772956609726)"
Line 647,"In 2019, BD provided  extensive data and analytics to the CDC utilizing insights from our proprietary  hospital surveillance and analytics platforms.
","('Data_Security', 0.4512973129749298)","('Customer_Privacy', 0.16612884402275085)","('Energy_Management', 0.04838952794671059)","('NON-ESG', 0.4512973129749298)","('NON-ESG', 0.16612884402275085)","('NON-ESG', 0.04838952794671059)"
Line 648,"These data were integrated in the  CDC Antibiotic Resistance Threats Report,15 released last year, which highlights  the prevalence and impact of antibiotic-resistant bacteria and fungi on patients  in the United States.Strategy 2: Strengthen evidence via surveillance Reference 15 Centers for Disease Control and Prevention.
","('Selling_Practices_And_Product_Labeling', 0.2524307072162628)","('Customer_Welfare', 0.1177435889840126)","('Systemic_Risk_Management', 0.07522808760404587)","('NON-ESG', 0.2524307072162628)","('NON-ESG', 0.1177435889840126)","('NON-ESG', 0.07522808760404587)"
Line 649,"Antibiotic resistance threats in the United States: 2019.
","('Systemic_Risk_Management', 0.13147152960300446)","('Customer_Welfare', 0.12566497921943665)","('Competitive_Behavior', 0.08885035663843155)","('NON-ESG', 0.13147152960300446)","('NON-ESG', 0.12566497921943665)","('NON-ESG', 0.08885035663843155)"
Line 650,"https://www.cdc.gov/drugresistance/pdf/ threats-report/2019-ar-threats-report-508.pdf.
","('Systemic_Risk_Management', 0.3869794011116028)","('Data_Security', 0.25139179825782776)","('Physical_Impacts_Of_Climate_Change', 0.09248662739992142)","('NON-ESG', 0.3869794011116028)","('NON-ESG', 0.25139179825782776)","('NON-ESG', 0.09248662739992142)"
Line 651,"Updated December 2019.
","('Business_Model_Resilience', 0.13221727311611176)","('Director_Removal', 0.09736453741788864)","('Data_Security', 0.09468705207109451)","('NON-ESG', 0.13221727311611176)","('NON-ESG', 0.09736453741788864)","('NON-ESG', 0.09468705207109451)"
Line 652,"Accessed March 15, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21158811450004578)","('Ecological_Impacts', 0.09045995026826859)","('Competitive_Behavior', 0.07761534303426743)","('NON-ESG', 0.21158811450004578)","('NON-ESG', 0.09045995026826859)","('NON-ESG', 0.07761534303426743)"
Line 653,"41 40Reducing risk of infection is an essential component of the global  effort to combat AMR.
","('Employee_Health_And_Safety', 0.5153850317001343)","('Systemic_Risk_Management', 0.06478175520896912)","('Critical_Incident_Risk_Management', 0.042682647705078125)","(['Operational Eco-Efficiency'], 0.5153850317001343)","('NON-ESG', 0.06478175520896912)","('NON-ESG', 0.042682647705078125)"
Line 654,"When selecting, placing and maintaining  medical devices, proper hand hygiene, aseptic technique and  compliance to guidelines are necessary to reduce risks to  patients from healthcare-associated infections (HAIs).
","('Employee_Health_And_Safety', 0.537975549697876)","('Product_Quality_And_Safety', 0.11830759048461914)","('Customer_Welfare', 0.04945380985736847)","(['Operational Eco-Efficiency'], 0.537975549697876)","('NON-ESG', 0.11830759048461914)","('NON-ESG', 0.04945380985736847)"
Line 655,"And since  resistant infections spread easily among patients in healthcare  facilities, patient screening and universal precautions may  reduce transmission of infections.
","('Employee_Health_And_Safety', 0.37420758605003357)","('Critical_Incident_Risk_Management', 0.0808216780424118)","('Data_Security', 0.07194487005472183)","('NON-ESG', 0.37420758605003357)","('NON-ESG', 0.0808216780424118)","('NON-ESG', 0.07194487005472183)"
Line 656,"BD is leveraging our expertise  in diagnostics, vascular access, surgical preparation and critical  care to support hospitals’ infection prevention and  control programs.
","('Employee_Health_And_Safety', 0.6906261444091797)","('Access_And_Affordability', 0.06544418632984161)","('Product_Quality_And_Safety', 0.03710532560944557)","(['Operational Eco-Efficiency'], 0.6906261444091797)","('NON-ESG', 0.06544418632984161)","('NON-ESG', 0.03710532560944557)"
Line 657,"In addition to deploying these programs at an individual health  facility level, BD has worked in collaboration with national  governments in multiple countries, including the U.S., China,  Kenya, Cambodia and India, via public-private partnerships to  improve infection prevention and control capabilities in hospitals.
","('Employee_Health_And_Safety', 0.5237822532653809)","('Access_And_Affordability', 0.09821850806474686)","('Product_Quality_And_Safety', 0.05806422233581543)","(['Operational Eco-Efficiency'], 0.5237822532653809)","('NON-ESG', 0.09821850806474686)","('NON-ESG', 0.05806422233581543)"
Line 658,"See the Access  section for additional details on our programs to  improve infection prevention practices.Strategy 3: Reduce incidence of infection Diagnostic tests classify infections and guide therapies, enabling  clinicians to implement effective antimicrobial stewardship  interventions.
","('Employee_Health_And_Safety', 0.8168188333511353)","('Product_Quality_And_Safety', 0.022039547562599182)","('Critical_Incident_Risk_Management', 0.020731287077069283)","(['Operational Eco-Efficiency'], 0.8168188333511353)","('NON-ESG', 0.022039547562599182)","('NON-ESG', 0.020731287077069283)"
Line 659,"In 2019, BD announced a collaboration with the  Fleming Fund to equip more than 70 labs in developing and  emerging countries with diagnostic instruments, tests and  training to help aid in the diagnosis of infections and guide  physicians on appropriate antimicrobial prescribing and use.
","('Selling_Practices_And_Product_Labeling', 0.17515183985233307)","('Product_Quality_And_Safety', 0.14994686841964722)","('Employee_Health_And_Safety', 0.1489279419183731)","('NON-ESG', 0.17515183985233307)","('NON-ESG', 0.14994686841964722)","('NON-ESG', 0.1489279419183731)"
Line 660,"In the U.S. and other industrialized countries, BD introduced the  BD HealthSight ™ Clinical Advisor Platform to identify when an  inappropriate and potentially ineffective antibiotic has been prescribed.
","('Customer_Welfare', 0.3027113080024719)","('Selling_Practices_And_Product_Labeling', 0.2725372910499573)","('Product_Quality_And_Safety', 0.08152198791503906)","('NON-ESG', 0.3027113080024719)","('NON-ESG', 0.2725372910499573)","('NON-ESG', 0.08152198791503906)"
Line 661,"Actionable alerts are delivered to clinicians involved  in the medication management process to assist with selection  of antibiotics and avoid waste of resources associated with  compounding of unnecessary medications.
","('Waste_And_Hazardous_Materials_Management', 0.8279537558555603)","('Customer_Welfare', 0.019477708265185356)","('Selling_Practices_And_Product_Labeling', 0.015103601850569248)","(['Operational Eco-Efficiency'], 0.8279537558555603)","('NON-ESG', 0.019477708265185356)","('NON-ESG', 0.015103601850569248)"
Line 662,"BD HealthSight ™  Clinical Advisor is a key component of our connected medication  management system, which includes automated dispensing and  infusion technologies that help pharmacies efficiently dispense,  track and deliver medications.
","('Customer_Welfare', 0.49947768449783325)","('Selling_Practices_And_Product_Labeling', 0.10703840851783752)","('Product_Design_And_Lifecycle_Management', 0.060029804706573486)","('NON-ESG', 0.49947768449783325)","('NON-ESG', 0.10703840851783752)","('NON-ESG', 0.060029804706573486)"
Line 663,"Strategy 4: Optimize the use of antimicrobials Minimizing risk of infections is the first step in combating AMR.
","('Systemic_Risk_Management', 0.12834450602531433)","('Data_Security', 0.10419351607561111)","('Employee_Health_And_Safety', 0.08606690168380737)","('NON-ESG', 0.12834450602531433)","('NON-ESG', 0.10419351607561111)","('NON-ESG', 0.08606690168380737)"
Line 664,"BD ChloraPrep ™ Skin Preparation is the leading standard of care  for preoperative antiseptic skin preparations.
","('Product_Design_And_Lifecycle_Management', 0.17283418774604797)","('Product_Quality_And_Safety', 0.16596484184265137)","('Employee_Health_And_Safety', 0.14577163755893707)","('NON-ESG', 0.17283418774604797)","('NON-ESG', 0.16596484184265137)","('NON-ESG', 0.14577163755893707)"
Line 665,"In 2019, BD  announced it received FDA approval for BD ChloraPrep ™ Skin  Preparation with sterile solution, the only fully sterile  chlorhexidine gluconate (CHG) antiseptic skin preparation  commercially available in the U.S. This new BD ChloraPrep ™ Skin  Preparation product uses a proprietary and patented process to  sterilize the antiseptic solution inside the sealed ampoules  located in the BD applicator.
","('Product_Quality_And_Safety', 0.20965458452701569)","('Customer_Welfare', 0.201813206076622)","('Waste_And_Hazardous_Materials_Management', 0.1404266059398651)","('NON-ESG', 0.20965458452701569)","('NON-ESG', 0.201813206076622)","('NON-ESG', 0.1404266059398651)"
Line 666,"“Outbreaks of highly resistant bacteria and spore  contamination have been reported with contaminated  antiseptic products in the past.
","('Waste_And_Hazardous_Materials_Management', 0.7879557609558105)","('Product_Quality_And_Safety', 0.027069853618741035)","('Business_Ethics', 0.021751662716269493)","(['Operational Eco-Efficiency'], 0.7879557609558105)","('NON-ESG', 0.027069853618741035)","('NON-ESG', 0.021751662716269493)"
Line 667,"Now with a fully sterilized skin  preparation product, BD is assisting healthcare providers with a  tool to enhance patient safety by the reduction of risk from  intrinsic contamination in antiseptic solutions,” said Donald E.
","('Product_Quality_And_Safety', 0.629305899143219)","('Employee_Health_And_Safety', 0.07933644950389862)","('Waste_And_Hazardous_Materials_Management', 0.07525042444467545)","(['Product Quality & Recall Management'], 0.629305899143219)","('NON-ESG', 0.07933644950389862)","('NON-ESG', 0.07525042444467545)"
Line 668,"Fry, M.D., a nationally recognized expert in infection prevention.Strategy 5: Innovations to help combat AMR In response to the global threat of AMR and under the guidance of the UN AMR Interagency Coordination Group, most  countries throughout the world have established AMR national action plans.
","('Employee_Health_And_Safety', 0.4542599022388458)","('Critical_Incident_Risk_Management', 0.08778191357851028)","('Systemic_Risk_Management', 0.055964380502700806)","('NON-ESG', 0.4542599022388458)","('NON-ESG', 0.08778191357851028)","('NON-ESG', 0.055964380502700806)"
Line 669,"BD is engaging with ministries of health,  international agencies and other partners to integrate our AMR capabilities and initiatives within these country-level  plans.
","('Access_And_Affordability', 0.5180690288543701)","('Management_Of_Legal_And_Regulatory_Framework', 0.10269202291965485)","('Human_Rights_And_Community_Relations', 0.07358346879482269)","(['Health Outcome Contribution'], 0.5180690288543701)","('NON-ESG', 0.10269202291965485)","('NON-ESG', 0.07358346879482269)"
Line 670,"We are doing so in a manner that appropriately aligns our actions to the stage of development of the countries  and the hospitals we are working in.
","('Management_Of_Legal_And_Regulatory_Framework', 0.25334471464157104)","('Human_Rights_And_Community_Relations', 0.18508753180503845)","('Access_And_Affordability', 0.16536346077919006)","('NON-ESG', 0.25334471464157104)","('NON-ESG', 0.18508753180503845)","('NON-ESG', 0.16536346077919006)"
Line 671,"These actions and activities reflect the company’s strong commitment to combating  the global risk of drug-resistant infections.
","('Access_And_Affordability', 0.1350807398557663)","('Systemic_Risk_Management', 0.09727746248245239)","('Selling_Practices_And_Product_Labeling', 0.0946127325296402)","('NON-ESG', 0.1350807398557663)","('NON-ESG', 0.09727746248245239)","('NON-ESG', 0.0946127325296402)"
Line 672,"And as the COVID-19 pandemic has reminded all of us, untreatable infectious  diseases remain a very real threat to all of us.
","('Physical_Impacts_Of_Climate_Change', 0.34999942779541016)","('Critical_Incident_Risk_Management', 0.17258460819721222)","('Systemic_Risk_Management', 0.09505724906921387)","('NON-ESG', 0.34999942779541016)","('NON-ESG', 0.17258460819721222)","('NON-ESG', 0.09505724906921387)"
Line 673,"42Introduction BD believes in the vision of a world free of disease and needless suffering.
","('Employee_Health_And_Safety', 0.65916907787323)","('Access_And_Affordability', 0.10521694272756577)","('Human_Rights_And_Community_Relations', 0.05057516321539879)","(['Operational Eco-Efficiency'], 0.65916907787323)","('NON-ESG', 0.10521694272756577)","('NON-ESG', 0.05057516321539879)"
Line 674,"We think healthcare is   so fundamental that it can create more productive, educated and equitable societies.
","('Access_And_Affordability', 0.5834833979606628)","('Human_Rights_And_Community_Relations', 0.15308693051338196)","('Employee_Engagement_Inclusion_And_Diversity', 0.05637722462415695)","(['Health Outcome Contribution'], 0.5834833979606628)","('NON-ESG', 0.15308693051338196)","('NON-ESG', 0.05637722462415695)"
Line 675,"BD Global Health works to expand access and drive capacity building through partnerships with  leading organizations and governments.
","('Access_And_Affordability', 0.8975521922111511)","('Human_Rights_And_Community_Relations', 0.010286640375852585)","('Critical_Incident_Risk_Management', 0.009610929526388645)","(['Health Outcome Contribution'], 0.8975521922111511)","('NON-ESG', 0.010286640375852585)","('NON-ESG', 0.009610929526388645)"
Line 676,"We engage in advocacy with governments, donors and  health agencies to advance innovations around the world to address the world’s leading public  health needs, which are highly aligned with the UN SDGs. The business model for emerging markets encourages our country leaders to understand the health  system priorities in their country and engage with key opinion leaders responsible for health policies  and practices.
","('Access_And_Affordability', 0.48399242758750916)","('Employee_Health_And_Safety', 0.1306741088628769)","('Critical_Incident_Risk_Management', 0.0634705126285553)","('NON-ESG', 0.48399242758750916)","('NON-ESG', 0.1306741088628769)","('NON-ESG', 0.0634705126285553)"
Line 677,"This enables BD to engage at earlier stages in the healthcare decision-making process  and adapt our strategic plans for product array, manufacturing and talent accordingly.Access Healthcare in resource-limited  populations 2020 goal Develop  low-cost innovations to address leading causes of mortality and morbidity In FY 2019, the first feasibility clinical trial of the BD Odon Device ™  was completed in the U.K. and two safety and efficacy clinical  trials received ethics and regulatory approvals and started in   the U.K. and France.
","('Product_Quality_And_Safety', 0.6248230338096619)","('Customer_Welfare', 0.06491228938102722)","('Selling_Practices_And_Product_Labeling', 0.05986342579126358)","(['Product Quality & Recall Management'], 0.6248230338096619)","('NON-ESG', 0.06491228938102722)","('NON-ESG', 0.05986342579126358)"
Line 678,"This enables BD to engage at earlier stages in the healthcare decision-making process  and adapt our strategic plans for product array, manufacturing and talent accordingly.Access Healthcare in resource-limited  populations 2020 goal Develop  low-cost innovations to address leading causes of mortality and morbidity In FY 2019, the first feasibility clinical trial of the BD Odon Device ™  was completed in the U.K. and two safety and efficacy clinical  trials received ethics and regulatory approvals and started in   the U.K. and France.
","('Management_Of_Legal_And_Regulatory_Framework', 0.553942859172821)","('Access_And_Affordability', 0.06627102941274643)","('Human_Rights_And_Community_Relations', 0.028888283297419548)","(['Corporate Governance'], 0.553942859172821)","('NON-ESG', 0.06627102941274643)","('NON-ESG', 0.028888283297419548)"
Line 679,"This investigative device is intended to  provide a safe and effective alternative for assisted vaginal   birth (AVB) when labor is prolonged or complicated, a condition  that occurs in approximately 10% of pregnancies.
","('Employee_Health_And_Safety', 0.2993577718734741)","('Access_And_Affordability', 0.18937286734580994)","('Employee_Engagement_Inclusion_And_Diversity', 0.11946187913417816)","('NON-ESG', 0.2993577718734741)","('NON-ESG', 0.18937286734580994)","('NON-ESG', 0.11946187913417816)"
Line 680,"Untreated,  prolonged/complicated labor can lead to serious complications  for mothers and babies, including postpartum hemorrhage,  birth asphyxia, maternal infection, fistulas or even death.16   In addition, increased access to AVB could reduce the use of  cesarean delivery and its associated higher costs for the health  system and the inherent risks of severe complications   (e.g., hemorrhage, stillbirth, abnormally invasive placenta)   in the current and subsequent pregnancies.17-20 Maternal and newborn health is a key component of UN  Sustainable Development Goal 3 for good health and   well-being.
","('Employee_Health_And_Safety', 0.8129180669784546)","('Access_And_Affordability', 0.029476355761289597)","('Employee_Engagement_Inclusion_And_Diversity', 0.027870003134012222)","(['Operational Eco-Efficiency'], 0.8129180669784546)","('NON-ESG', 0.029476355761289597)","('NON-ESG', 0.027870003134012222)"
Line 681,"Untreated,  prolonged/complicated labor can lead to serious complications  for mothers and babies, including postpartum hemorrhage,  birth asphyxia, maternal infection, fistulas or even death.16   In addition, increased access to AVB could reduce the use of  cesarean delivery and its associated higher costs for the health  system and the inherent risks of severe complications   (e.g., hemorrhage, stillbirth, abnormally invasive placenta)   in the current and subsequent pregnancies.17-20 Maternal and newborn health is a key component of UN  Sustainable Development Goal 3 for good health and   well-being.
","('Employee_Health_And_Safety', 0.8338018655776978)","('Access_And_Affordability', 0.04072830453515053)","('Product_Quality_And_Safety', 0.014090179465711117)","(['Operational Eco-Efficiency'], 0.8338018655776978)","('NON-ESG', 0.04072830453515053)","('NON-ESG', 0.014090179465711117)"
Line 682,"Although WHO guidelines call for access to AVB   at all facilities that provide basic management of obstetric  emergencies, a recent study in sub-Saharan Africa showed  that only 54% of hospitals and 6% of health centers were able  to conduct AVB in the past year.21 By driving forward the  investigative BD Odon Device ™, this partnership is moving this  technology closer to in-field use.Maternal and newborn health; investigative BD Odon Device™ References 16 O’Mahony F, Hofmeyer GJ, Menon V.
","('Employee_Health_And_Safety', 0.39704856276512146)","('Access_And_Affordability', 0.30961838364601135)","('Critical_Incident_Risk_Management', 0.09623321145772934)","('NON-ESG', 0.39704856276512146)","('NON-ESG', 0.30961838364601135)","('NON-ESG', 0.09623321145772934)"
Line 683,"Choice of instruments for assisted vaginal delivery.
","('Access_And_Affordability', 0.2684491276741028)","('Employee_Health_And_Safety', 0.18643976747989655)","('Employee_Engagement_Inclusion_And_Diversity', 0.090345598757267)","('NON-ESG', 0.2684491276741028)","('NON-ESG', 0.18643976747989655)","('NON-ESG', 0.090345598757267)"
Line 684,"Cochrane Database Syst Rev .
","('Ecological_Impacts', 0.20898036658763885)","('Management_Of_Legal_And_Regulatory_Framework', 0.17709098756313324)","('GHG_Emissions', 0.08984953910112381)","('NON-ESG', 0.20898036658763885)","('NON-ESG', 0.17709098756313324)","('NON-ESG', 0.08984953910112381)"
Line 685,"2010;(11):CD005455.
","('Management_Of_Legal_And_Regulatory_Framework', 0.277824729681015)","('Ecological_Impacts', 0.16604623198509216)","('Systemic_Risk_Management', 0.055244721472263336)","('NON-ESG', 0.277824729681015)","('NON-ESG', 0.16604623198509216)","('NON-ESG', 0.055244721472263336)"
Line 686,"17 Clark EA, Silver RM.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5814666152000427)","('Business_Ethics', 0.05986041575670242)","('Ecological_Impacts', 0.031672991812229156)","(['Corporate Governance'], 0.5814666152000427)","('NON-ESG', 0.05986041575670242)","('NON-ESG', 0.031672991812229156)"
Line 687,"Long-term maternal morbidity associated with repeat cesarean delivery.
","('Employee_Health_And_Safety', 0.8231540322303772)","('Critical_Incident_Risk_Management', 0.03362076357007027)","('Access_And_Affordability', 0.024756506085395813)","(['Operational Eco-Efficiency'], 0.8231540322303772)","('NON-ESG', 0.03362076357007027)","('NON-ESG', 0.024756506085395813)"
Line 688,"Am J Obstet Gynecol .
","('Access_And_Affordability', 0.26461848616600037)","('Customer_Welfare', 0.09612667560577393)","('Employee_Engagement_Inclusion_And_Diversity', 0.07366354018449783)","('NON-ESG', 0.26461848616600037)","('NON-ESG', 0.09612667560577393)","('NON-ESG', 0.07366354018449783)"
Line 689,"2011;205:S2-S10.
","('Management_Of_Legal_And_Regulatory_Framework', 0.29741400480270386)","('Competitive_Behavior', 0.11141542345285416)","('GHG_Emissions', 0.10445071011781693)","('NON-ESG', 0.29741400480270386)","('NON-ESG', 0.11141542345285416)","('NON-ESG', 0.10445071011781693)"
Line 690,"18 Moraitis AA, Oliver-Williams C, Wood AM, Fleming M, Pell JP, Smith G.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4649910628795624)","('Business_Ethics', 0.07658495754003525)","('Competitive_Behavior', 0.05459475889801979)","('NON-ESG', 0.4649910628795624)","('NON-ESG', 0.07658495754003525)","('NON-ESG', 0.05459475889801979)"
Line 691,"Previous caesarean delivery and the risk of unexplained stillbirth: retrospective cohort study and meta-analysis.
","('Employee_Health_And_Safety', 0.3582390546798706)","('Access_And_Affordability', 0.24830934405326843)","('Employee_Engagement_Inclusion_And_Diversity', 0.057820986956357956)","('NON-ESG', 0.3582390546798706)","('NON-ESG', 0.24830934405326843)","('NON-ESG', 0.057820986956357956)"
Line 692,"BJOG .
","('Business_Model_Resilience', 0.10833107680082321)","('Product_Design_And_Lifecycle_Management', 0.09222494065761566)","('Ecological_Impacts', 0.09122404456138611)","('NON-ESG', 0.10833107680082321)","('NON-ESG', 0.09222494065761566)","('NON-ESG', 0.09122404456138611)"
Line 693,"2015;122:1467-1474.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3275500535964966)","('Ecological_Impacts', 0.07265838235616684)","('Data_Security', 0.047516290098428726)","('NON-ESG', 0.3275500535964966)","('NON-ESG', 0.07265838235616684)","('NON-ESG', 0.047516290098428726)"
Line 694,"19 Murphy DJ, Liebling RE, Verity L, Swingler R, Patel R.
","('Management_Of_Legal_And_Regulatory_Framework', 0.33074936270713806)","('Competitive_Behavior', 0.15161804854869843)","('Business_Ethics', 0.10900221765041351)","('NON-ESG', 0.33074936270713806)","('NON-ESG', 0.15161804854869843)","('NON-ESG', 0.10900221765041351)"
Line 695,"Early maternal and neonatal morbidity associated with operative delivery in second stage of labour: a cohort study.
","('Employee_Health_And_Safety', 0.9005846381187439)","('Access_And_Affordability', 0.022253086790442467)","('Employee_Engagement_Inclusion_And_Diversity', 0.010809793137013912)","(['Operational Eco-Efficiency'], 0.9005846381187439)","('NON-ESG', 0.022253086790442467)","('NON-ESG', 0.010809793137013912)"
Line 696,"Lancet .
","('Management_Of_Legal_And_Regulatory_Framework', 0.1365494728088379)","('Business_Ethics', 0.12134969979524612)","('Product_Design_And_Lifecycle_Management', 0.07224299013614655)","('NON-ESG', 0.1365494728088379)","('NON-ESG', 0.12134969979524612)","('NON-ESG', 0.07224299013614655)"
Line 697,"2001;358:1203-1207.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6260035037994385)","('Ecological_Impacts', 0.045808084309101105)","('Competitive_Behavior', 0.03209748864173889)","(['Corporate Governance'], 0.6260035037994385)","('NON-ESG', 0.045808084309101105)","('NON-ESG', 0.03209748864173889)"
Line 698,"20 Bailey PE.
","('Employee_Engagement_Inclusion_And_Diversity', 0.2148384153842926)","('Competitive_Behavior', 0.12290028482675552)","('Labor_Practices', 0.0689643919467926)","('NON-ESG', 0.2148384153842926)","('NON-ESG', 0.12290028482675552)","('NON-ESG', 0.0689643919467926)"
Line 699,"The disappearing art of instrumental delivery: time to reverse the trend.
","('Business_Model_Resilience', 0.16419267654418945)","('Systemic_Risk_Management', 0.15128262341022491)","('Product_Design_And_Lifecycle_Management', 0.13170750439167023)","('NON-ESG', 0.16419267654418945)","('NON-ESG', 0.15128262341022491)","('NON-ESG', 0.13170750439167023)"
Line 700,"Int J Gynaecol Obstet .
","('Access_And_Affordability', 0.18636780977249146)","('Competitive_Behavior', 0.10639067739248276)","('Employee_Engagement_Inclusion_And_Diversity', 0.08359906822443008)","('NON-ESG', 0.18636780977249146)","('NON-ESG', 0.10639067739248276)","('NON-ESG', 0.08359906822443008)"
Line 701,"2005;91:89-96.
","('Management_Of_Legal_And_Regulatory_Framework', 0.17384056746959686)","('Waste_And_Hazardous_Materials_Management', 0.07415115833282471)","('Director_Removal', 0.06868188083171844)","('NON-ESG', 0.17384056746959686)","('NON-ESG', 0.07415115833282471)","('NON-ESG', 0.06868188083171844)"
Line 702,"21 Bailey PE, van Roosmalen J, Mola G, Evans C, de Bernis L, Dao B.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3228645920753479)","('Business_Ethics', 0.0756831094622612)","('Competitive_Behavior', 0.07197260111570358)","('NON-ESG', 0.3228645920753479)","('NON-ESG', 0.0756831094622612)","('NON-ESG', 0.07197260111570358)"
Line 703,"Assisted vaginal delivery in low and middle income countries: an overview.
","('Access_And_Affordability', 0.2541765868663788)","('Employee_Health_And_Safety', 0.22394300997257233)","('Employee_Engagement_Inclusion_And_Diversity', 0.06214926764369011)","('NON-ESG', 0.2541765868663788)","('NON-ESG', 0.22394300997257233)","('NON-ESG', 0.06214926764369011)"
Line 704,"Br J Obstet Gynaecol .
","('Access_And_Affordability', 0.3516887128353119)","('Employee_Engagement_Inclusion_And_Diversity', 0.07871124893426895)","('Competitive_Behavior', 0.07144686579704285)","('NON-ESG', 0.3516887128353119)","('NON-ESG', 0.07871124893426895)","('NON-ESG', 0.07144686579704285)"
Line 705,"2017;124(9):1335-1344.Innovation               Efficiency                Empowerment       Access                     42 432020 goal Collaborate  on strengthening health systems with leading agencies and NGOs AMR is among the most significant threats to health and  well-being of the world’s population.
","('Employee_Health_And_Safety', 0.528597891330719)","('Access_And_Affordability', 0.2637682855129242)","('Critical_Incident_Risk_Management', 0.03709902986884117)","(['Operational Eco-Efficiency'], 0.528597891330719)","('NON-ESG', 0.2637682855129242)","('NON-ESG', 0.03709902986884117)"
Line 706,"If present trends continue,  AMR is projected to become one of the leading causes of  human mortality and may cause 10 million deaths each year by  2050.
","('Employee_Health_And_Safety', 0.8738488554954529)","('Critical_Incident_Risk_Management', 0.047782961279153824)","('Access_And_Affordability', 0.012068863958120346)","(['Operational Eco-Efficiency'], 0.8738488554954529)","('NON-ESG', 0.047782961279153824)","('NON-ESG', 0.012068863958120346)"
Line 707,"AMR is a global concern that endangers people in every  region and country around the world—and is a particular threat  to low- and middle-income countries.BD has formed several innovative partnerships with leading  health agencies and NGOs, each of which aims to raise  awareness of this growing global threat; better understand the  scale and scope of the challenge; help reduce the risk of  infection and drive optimal antimicrobial use—particularly in  low- and middle-income countries.
","('Employee_Health_And_Safety', 0.3451007008552551)","('Systemic_Risk_Management', 0.09648770838975906)","('Access_And_Affordability', 0.0847197026014328)","('NON-ESG', 0.3451007008552551)","('NON-ESG', 0.09648770838975906)","('NON-ESG', 0.0847197026014328)"
Line 708,"Global experts have identified several challenges that low- and  middle-income countries face when addressing AMR.
","('Access_And_Affordability', 0.26460516452789307)","('Human_Rights_And_Community_Relations', 0.2284679114818573)","('Supply_Chain_Management', 0.08917609602212906)","('NON-ESG', 0.26460516452789307)","('NON-ESG', 0.2284679114818573)","('NON-ESG', 0.08917609602212906)"
Line 709,"There are  too few trained microbiologists, few health facilities that  routinely undertake bacterial culture and still fewer facilities that  meet the requirements for accreditation.
","('Product_Quality_And_Safety', 0.12401029467582703)","('Ecological_Impacts', 0.1165437400341034)","('Customer_Welfare', 0.11408606916666031)","('NON-ESG', 0.12401029467582703)","('NON-ESG', 0.1165437400341034)","('NON-ESG', 0.11408606916666031)"
Line 710,"To respond to these challenges, BD and The London School of  Hygiene & Tropical Medicine, together with a global advisory  group of experts, have partnered to create the Massive Open  Online Course (MOOC) that educates participants about how  diagnostics can be leveraged to reduce the inappropriate use of  antibiotics, screen patients with resistant bacteria in healthcare  settings, and monitor AMR trends and the effectiveness of  antibiotic stewardship strategies.
","('Customer_Welfare', 0.2886642813682556)","('Selling_Practices_And_Product_Labeling', 0.1645888388156891)","('Access_And_Affordability', 0.08970102667808533)","('NON-ESG', 0.2886642813682556)","('NON-ESG', 0.1645888388156891)","('NON-ESG', 0.08970102667808533)"
Line 711,"By the end of FY 2019, this curriculum had reached 9,000  participants; 97% of whom said they gained new knowledge;  and 87% said they have applied what they learned.
","('Employee_Engagement_Inclusion_And_Diversity', 0.24071340262889862)","('Access_And_Affordability', 0.19662250578403473)","('Ecological_Impacts', 0.06435701251029968)","('NON-ESG', 0.24071340262889862)","('NON-ESG', 0.19662250578403473)","('NON-ESG', 0.06435701251029968)"
Line 712,"Two new  courses will be launched in 2020.Six weekly modules that focus on WHO priority pathogens Module 1:  Introduction Module 2:  Common clinical syndromes Module 3:  Healthcare-associated infections by pathogens Module 4:  Enteric infections and One Health Module 5:  TB/Neisseria gonorrhea Module 6:  The path forward and certification *Innovative partnerships to strengthen lab systems and combat AMR Educating and advocating for AMR *Certification is optional, at a cost.
","('Product_Quality_And_Safety', 0.14802156388759613)","('Employee_Health_And_Safety', 0.13685263693332672)","('Access_And_Affordability', 0.12065192312002182)","('NON-ESG', 0.14802156388759613)","('NON-ESG', 0.13685263693332672)","('NON-ESG', 0.12065192312002182)"
Line 713,"Innovation               Innovation               Efficiency                Empowerment        Access                     Access                     43 44The Fleming Fund, a U.K. aid program, provides grants to improve  the surveillance of AMR and generate relevant data that is shared  nationally and globally.
","('Management_Of_Legal_And_Regulatory_Framework', 0.593579888343811)","('Access_And_Affordability', 0.09810318052768707)","('Business_Ethics', 0.03414342552423477)","(['Corporate Governance'], 0.593579888343811)","('NON-ESG', 0.09810318052768707)","('NON-ESG', 0.03414342552423477)"
Line 714,"In 2019, The Fleming Fund awarded  grants to diagnostic sector companies for strengthening  laboratory systems in 24 countries.
","('Access_And_Affordability', 0.3169455826282501)","('Management_Of_Legal_And_Regulatory_Framework', 0.09953528642654419)","('Product_Quality_And_Safety', 0.08940429240465164)","('NON-ESG', 0.3169455826282501)","('NON-ESG', 0.09953528642654419)","('NON-ESG', 0.08940429240465164)"
Line 715,"BD was awarded grants to  expand its automated blood culture and identification and antimicrobial susceptibility testing (ID/AST) technologies to help  strengthen laboratory systems’ ability to combat AMR in 19 of the  24 countries.
","('Selling_Practices_And_Product_Labeling', 0.17058376967906952)","('Customer_Welfare', 0.16060645878314972)","('Product_Quality_And_Safety', 0.14998012781143188)","('NON-ESG', 0.17058376967906952)","('NON-ESG', 0.16060645878314972)","('NON-ESG', 0.14998012781143188)"
Line 716,"This broad-based award includes application of the  company’s collaborative program initiatives for strengthening  laboratory systems.
","('Management_Of_Legal_And_Regulatory_Framework', 0.45361143350601196)","('Access_And_Affordability', 0.22758561372756958)","('Human_Rights_And_Community_Relations', 0.05786827951669693)","('NON-ESG', 0.45361143350601196)","('NON-ESG', 0.22758561372756958)","('NON-ESG', 0.05786827951669693)"
Line 717,"To strengthen capacities to combat AMR at an individual  laboratory level and across the national laboratory system, in   FY 2019 BD partnered with the Foundation for Innovative New  Diagnostics (FIND), a Geneva-based NGO, to develop the AMR  Scorecard for Lab Quality Improvement.
","('Product_Quality_And_Safety', 0.3728207051753998)","('Access_And_Affordability', 0.08193317800760269)","('Employee_Health_And_Safety', 0.07773828506469727)","('NON-ESG', 0.3728207051753998)","('NON-ESG', 0.08193317800760269)","('NON-ESG', 0.07773828506469727)"
Line 718,"The program, which will be launched in FY 2020, will utilize a stepwise evaluation  methodology to assess AMR-related laboratory capabilities and  address the specific gaps through mentorship and training.
","('Employee_Engagement_Inclusion_And_Diversity', 0.5295979380607605)","('Access_And_Affordability', 0.16926810145378113)","('Human_Rights_And_Community_Relations', 0.031655047088861465)","(['Human Capital Development'], 0.5295979380607605)","('NON-ESG', 0.16926810145378113)","('NON-ESG', 0.031655047088861465)"
Line 719,"Lack of access to reliable drug-susceptibility testing (DST) is a  critical public health challenge posed by drug resistant forms  of TB.
","('Product_Quality_And_Safety', 0.2895132005214691)","('Access_And_Affordability', 0.20079360902309418)","('Customer_Welfare', 0.08182039856910706)","('NON-ESG', 0.2895132005214691)","('NON-ESG', 0.20079360902309418)","('NON-ESG', 0.08182039856910706)"
Line 720,"On average, it is estimated that 50% of those in need of  second-line drug-susceptibility testing in high-burden countries do  not receive it.
","('Product_Quality_And_Safety', 0.38014712929725647)","('Customer_Welfare', 0.0983203873038292)","('Access_And_Affordability', 0.08396679162979126)","('NON-ESG', 0.38014712929725647)","('NON-ESG', 0.0983203873038292)","('NON-ESG', 0.08396679162979126)"
Line 721,"To better understand the barriers that stand in the way of patient  access to this life-saving testing, BD and USAID formed a  partnership, called STRIDES (Strengthen TB Resistance Testing  and Diagnostic Systems).
","('Access_And_Affordability', 0.6835920810699463)","('Product_Quality_And_Safety', 0.06521853059530258)","('Employee_Health_And_Safety', 0.033559564501047134)","(['Health Outcome Contribution'], 0.6835920810699463)","('NON-ESG', 0.06521853059530258)","('NON-ESG', 0.033559564501047134)"
Line 722,"As part of the partnership, BD and USAID are working in India  with the National TB Elimination Program (NTEP) to strengthen  liquid culture and drug-susceptibility testing across all 55 labs in  the national network to improve detection and appropriate  treatment for multidrug-resistant TB patients across the country.
","('Access_And_Affordability', 0.17215746641159058)","('Product_Quality_And_Safety', 0.11977329105138779)","('Systemic_Risk_Management', 0.10189062356948853)","('NON-ESG', 0.17215746641159058)","('NON-ESG', 0.11977329105138779)","('NON-ESG', 0.10189062356948853)"
Line 723,"Key FY 2019 highlights of this partnership include: • the development of a first-of-its-kind lab assessment tool for  liquid culture and drug-susceptibility testing for TB; • the completion of an assessment of the specimen referral  system (SRS) for sputum samples;  • work toward an integrated, GIS-enabled, barcode-enabled  software for tracking specimen to help reduce the turnaround  time from sample collection to diagnosis and treatment; and • strengthening data management systems for tracking  specimen results and optimizing lab workflow.
","('Waste_And_Hazardous_Materials_Management', 0.32006675004959106)","('Ecological_Impacts', 0.12845636904239655)","('Employee_Health_And_Safety', 0.058950167149305344)","('NON-ESG', 0.32006675004959106)","('NON-ESG', 0.12845636904239655)","('NON-ESG', 0.058950167149305344)"
Line 724,"Key FY 2019 highlights of this partnership include: • the development of a first-of-its-kind lab assessment tool for  liquid culture and drug-susceptibility testing for TB; • the completion of an assessment of the specimen referral  system (SRS) for sputum samples;  • work toward an integrated, GIS-enabled, barcode-enabled  software for tracking specimen to help reduce the turnaround  time from sample collection to diagnosis and treatment; and • strengthening data management systems for tracking  specimen results and optimizing lab workflow.
","('Product_Design_And_Lifecycle_Management', 0.2708083391189575)","('Business_Model_Resilience', 0.23053738474845886)","('Supply_Chain_Management', 0.07525995373725891)","('NON-ESG', 0.2708083391189575)","('NON-ESG', 0.23053738474845886)","('NON-ESG', 0.07525995373725891)"
Line 725,"At the 50th Union World Conference on Lung Health in  Hyderabad, USAID honored BD for its commitment to  strengthening the national TB program in India.
","('Employee_Health_And_Safety', 0.5705129504203796)","('Access_And_Affordability', 0.15552161633968353)","('Product_Quality_And_Safety', 0.029755525290966034)","(['Operational Eco-Efficiency'], 0.5705129504203796)","('NON-ESG', 0.15552161633968353)","('NON-ESG', 0.029755525290966034)"
Line 726,"“The BD-USAID STRIDES partnership has enabled us to conduct  lab assessments and lab staff trainings at our public sector Liquid  Culture and Drug Susceptibility Testing sites, which are critical to our National Tuberculosis Elimination Program.
","('Product_Quality_And_Safety', 0.20023195445537567)","('Management_Of_Legal_And_Regulatory_Framework', 0.1121305301785469)","('Competitive_Behavior', 0.10976123064756393)","('NON-ESG', 0.20023195445537567)","('NON-ESG', 0.1121305301785469)","('NON-ESG', 0.10976123064756393)"
Line 727,"The BD-USAID  STRIDES team brings innovation and technical expertise to the  table, and we look forward to continuing to collaborate with them  to achieve the goal of eliminating TB from India by 2025,” states  Dr. Nishant Kumar, Deputy Director, Central TB Division, Ministry  of Health and Family Welfare, Govt.
","('Access_And_Affordability', 0.43916308879852295)","('Employee_Health_And_Safety', 0.17152097821235657)","('Product_Quality_And_Safety', 0.0451628752052784)","('NON-ESG', 0.43916308879852295)","('NON-ESG', 0.17152097821235657)","('NON-ESG', 0.0451628752052784)"
Line 728,"of India In FY 2019, BD signed a memorandum of understanding with  USAID to expand the STRIDES program to Indonesia—with the  goal of working across 4 national labs and 15 labs that are part of  the country’s TB diagnostics network.Making STRIDES against drug-resistant TB in high-burden countriesEvaluating AMR-related lab capabilitiesScaling technologies to combat AMR Innovation               Innovation               Efficiency                Empowerment        Access                     Access                     45The year 2019 marked the 12th year of the company’s  collaboration with PEPFAR and the CDC on the Labs for Life  program, which seeks to strengthen laboratory systems and  upgrade clinical practices in phlebotomy, infusion  and injection.
","('Access_And_Affordability', 0.32929423451423645)","('Systemic_Risk_Management', 0.09254561364650726)","('Product_Quality_And_Safety', 0.08275306969881058)","('NON-ESG', 0.32929423451423645)","('NON-ESG', 0.09254561364650726)","('NON-ESG', 0.08275306969881058)"
Line 729,"of India In FY 2019, BD signed a memorandum of understanding with  USAID to expand the STRIDES program to Indonesia—with the  goal of working across 4 national labs and 15 labs that are part of  the country’s TB diagnostics network.Making STRIDES against drug-resistant TB in high-burden countriesEvaluating AMR-related lab capabilitiesScaling technologies to combat AMR Innovation               Innovation               Efficiency                Empowerment        Access                     Access                     45The year 2019 marked the 12th year of the company’s  collaboration with PEPFAR and the CDC on the Labs for Life  program, which seeks to strengthen laboratory systems and  upgrade clinical practices in phlebotomy, infusion  and injection.
","('Access_And_Affordability', 0.3954271078109741)","('Customer_Welfare', 0.16120174527168274)","('Product_Quality_And_Safety', 0.04763881117105484)","('NON-ESG', 0.3954271078109741)","('NON-ESG', 0.16120174527168274)","('NON-ESG', 0.04763881117105484)"
Line 730,"Through this program, BD has deployed more than 300  associates, called BD Global Health Fellows, for short-term,  in-country assignments, to strengthen and support 38  laboratories in India, Kenya, Ethiopia, Rwanda, Uganda and  Haiti.
","('Access_And_Affordability', 0.5046745538711548)","('Human_Rights_And_Community_Relations', 0.05760195851325989)","('Customer_Welfare', 0.04431957006454468)","(['Health Outcome Contribution'], 0.5046745538711548)","('NON-ESG', 0.05760195851325989)","('NON-ESG', 0.04431957006454468)"
Line 731,"In some participating laboratories, lab assessment  scores have improved by as much as 150% and average  turnaround time for select diagnostic tests have been   reduced by as much as 75%.BD, PEPFAR and CDC public-private partnerships to strengthen  lab effectiveness Infusion-related infections pose a significant threat to  healthcare workers and patients.
","('Employee_Health_And_Safety', 0.3454032242298126)","('Product_Quality_And_Safety', 0.10489355772733688)","('Access_And_Affordability', 0.0984094887971878)","('NON-ESG', 0.3454032242298126)","('NON-ESG', 0.10489355772733688)","('NON-ESG', 0.0984094887971878)"
Line 732,"China has one of the highest  rates of infusion per person in the world, and treatment via  intravenous therapy is commonplace.
","('Employee_Health_And_Safety', 0.16440771520137787)","('Customer_Welfare', 0.1396302878856659)","('Access_And_Affordability', 0.13733626902103424)","('NON-ESG', 0.16440771520137787)","('NON-ESG', 0.1396302878856659)","('NON-ESG', 0.13733626902103424)"
Line 733,"However, in Western  China, nearly 42% of procedures are still conducted using a steel  needle rather than the best practice IV catheter.22 Improper use  of steel needles for IV therapy can lead to increased pain and  higher rates of health complications.
","('Employee_Health_And_Safety', 0.9189932346343994)","('Product_Quality_And_Safety', 0.00826654676347971)","('Access_And_Affordability', 0.006536498665809631)","(['Operational Eco-Efficiency'], 0.9189932346343994)","('NON-ESG', 0.00826654676347971)","('NON-ESG', 0.006536498665809631)"
Line 734,"To address this challenge, BD signed a multiyear agreement in  FY 2018 with long-term partner, Project HOPE, to reduce  infusion-related infections among healthcare workers and  patients in four provinces in Western China.
","('Employee_Health_And_Safety', 0.8001346588134766)","('Access_And_Affordability', 0.032178133726119995)","('Critical_Incident_Risk_Management', 0.022737011313438416)","(['Operational Eco-Efficiency'], 0.8001346588134766)","('NON-ESG', 0.032178133726119995)","('NON-ESG', 0.022737011313438416)"
Line 735,"In FY 2019, BD and Project HOPE recruited and trained 25  master trainers to conduct 8 training workshops in 4 provinces,  training a total of 241 nurses and 36 nursing students.
","('Access_And_Affordability', 0.6446253061294556)","('Employee_Engagement_Inclusion_And_Diversity', 0.05688529461622238)","('Employee_Health_And_Safety', 0.04715948924422264)","(['Health Outcome Contribution'], 0.6446253061294556)","('NON-ESG', 0.05688529461622238)","('NON-ESG', 0.04715948924422264)"
Line 736,"To increase the number of healthcare workers reached, the  trained nurses then conducted cascade training for a total of  1,555 nurses, with the goal of reaching 90% of the target units  (outpatient, surgery, obstetrics and ICU) at 12 hospitals.
","('Employee_Health_And_Safety', 0.4467184543609619)","('Labor_Practices', 0.3091787099838257)","('Employee_Engagement_Inclusion_And_Diversity', 0.04041532427072525)","('NON-ESG', 0.4467184543609619)","('NON-ESG', 0.3091787099838257)","('NON-ESG', 0.04041532427072525)"
Line 737,"Educational materials were also developed and distributed   to participating hospitals.
","('Access_And_Affordability', 0.8219087719917297)","('Management_Of_Legal_And_Regulatory_Framework', 0.01670634001493454)","('Product_Quality_And_Safety', 0.01490275003015995)","(['Health Outcome Contribution'], 0.8219087719917297)","('NON-ESG', 0.01670634001493454)","('NON-ESG', 0.01490275003015995)"
Line 738,"Infection prevention in China Reference 22 Zhang M, Li WP, Cheng WP, et al.
","('Employee_Health_And_Safety', 0.5849674940109253)","('Product_Quality_And_Safety', 0.04351425915956497)","('Employee_Engagement_Inclusion_And_Diversity', 0.039140406996011734)","(['Operational Eco-Efficiency'], 0.5849674940109253)","('NON-ESG', 0.04351425915956497)","('NON-ESG', 0.039140406996011734)"
Line 739,"Investigation and analysis of the medical practices of the standardized nursing practices for  intravenous therapy in western region hospitals in China.
","('Access_And_Affordability', 0.17037037014961243)","('Employee_Health_And_Safety', 0.1692103147506714)","('Customer_Welfare', 0.15650363266468048)","('NON-ESG', 0.17037037014961243)","('NON-ESG', 0.1692103147506714)","('NON-ESG', 0.15650363266468048)"
Line 740,"Chinese Nurs Manager.
","('Employee_Engagement_Inclusion_And_Diversity', 0.19381672143936157)","('Competitive_Behavior', 0.08125324547290802)","('Human_Rights_And_Community_Relations', 0.0630524531006813)","('NON-ESG', 0.19381672143936157)","('NON-ESG', 0.08125324547290802)","('NON-ESG', 0.0630524531006813)"
Line 741,"2018;18(5): 623-635.
","('Management_Of_Legal_And_Regulatory_Framework', 0.39188170433044434)","('Systemic_Risk_Management', 0.08145353943109512)","('Data_Security', 0.055751875042915344)","('NON-ESG', 0.39188170433044434)","('NON-ESG', 0.08145353943109512)","('NON-ESG', 0.055751875042915344)"
Line 742,"Innovation               Efficiency                Empowerment       Access                     45 46More than 20% of needlestick injuries in Kenya occur from  starting IVs or connecting a syringe into an IV line.
","('Employee_Health_And_Safety', 0.973065197467804)","('Critical_Incident_Risk_Management', 0.005307250656187534)","('Employee_Engagement_Inclusion_And_Diversity', 0.002156224101781845)","(['Operational Eco-Efficiency'], 0.973065197467804)","('NON-ESG', 0.005307250656187534)","('NON-ESG', 0.002156224101781845)"
Line 743,"To address  these patient safety risks, BD signed a memorandum of  understanding with the CDC and PEPFAR in FY 2018 to create  an infection prevention partnership, called KINGA (the Kenya  Infection Prevention Global Collaboration for Advancement).
","('Employee_Health_And_Safety', 0.7153405547142029)","('Product_Quality_And_Safety', 0.050838518887758255)","('Critical_Incident_Risk_Management', 0.026248246431350708)","(['Operational Eco-Efficiency'], 0.7153405547142029)","('NON-ESG', 0.050838518887758255)","('NON-ESG', 0.026248246431350708)"
Line 744,"In FY 2019, as part of this partnership, BD Global Health Fellows  conducted baseline observational and quality improvement  assessments to document key gaps in infusion practices.
","('Product_Quality_And_Safety', 0.289227157831192)","('Access_And_Affordability', 0.1972075253725052)","('Employee_Health_And_Safety', 0.06138578802347183)","('NON-ESG', 0.289227157831192)","('NON-ESG', 0.1972075253725052)","('NON-ESG', 0.06138578802347183)"
Line 745,"During  this time, nearly 1,000 unique catheters and their associated  procedures were observed.
","('Employee_Health_And_Safety', 0.3315156102180481)","('Access_And_Affordability', 0.16297966241836548)","('Critical_Incident_Risk_Management', 0.06791146844625473)","('NON-ESG', 0.3315156102180481)","('NON-ESG', 0.16297966241836548)","('NON-ESG', 0.06791146844625473)"
Line 746,"BD Global Health Fellows then developed a training program,  tailored to address the gaps in infusion practice that were  identified during the assessments.
","('Access_And_Affordability', 0.627389669418335)","('Employee_Engagement_Inclusion_And_Diversity', 0.06527385860681534)","('Product_Quality_And_Safety', 0.03720945864915848)","(['Health Outcome Contribution'], 0.627389669418335)","('NON-ESG', 0.06527385860681534)","('NON-ESG', 0.03720945864915848)"
Line 747,"BD Global Health Fellows will  be deployed for short-term assignments in FY 2020 to  implement this training, train others to deliver it and provide  mentorship in hospitals across Kenya.
","('Access_And_Affordability', 0.8113104701042175)","('Product_Quality_And_Safety', 0.02058357000350952)","('Employee_Engagement_Inclusion_And_Diversity', 0.019026579335331917)","(['Health Outcome Contribution'], 0.8113104701042175)","('NON-ESG', 0.02058357000350952)","('NON-ESG', 0.019026579335331917)"
Line 748,"In FY 2019, BD business leaders joined together in The Hague,  Netherlands with more than 50 global health thought leaders  and key partners from international agencies, academia,  governments and other private sectors for a multiday BD Global  Health Summit.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4053683876991272)","('Access_And_Affordability', 0.09344764798879623)","('Systemic_Risk_Management', 0.08773886412382126)","('NON-ESG', 0.4053683876991272)","('NON-ESG', 0.09344764798879623)","('NON-ESG', 0.08773886412382126)"
Line 749,"Attendees engaged in valuable dialogue about  the current priorities and challenges in healthcare delivery in the  developing and developed world, and identified opportunities  through which BD and its partners can make a greater impact.
","('Access_And_Affordability', 0.5269981622695923)","('Human_Rights_And_Community_Relations', 0.11683400720357895)","('Business_Model_Resilience', 0.04198524355888367)","(['Health Outcome Contribution'], 0.5269981622695923)","('NON-ESG', 0.11683400720357895)","('NON-ESG', 0.04198524355888367)"
Line 750,"BD global health experts also participated in several key  international events to raise awareness of the importance of  public-private partnerships in addressing global health  challenges, including: • The Public-Private Partnership Forum of the National  Academies in Washington DC • The Union Conference on Lung Health in Hyderabad, India • The International Conference on AIDS and Sexually  Transmitted Infections in Africa Driving a global conversation about…safety  BD partnered with Devex International Development to launch a  dedicated digital platform called “ Safety First ,” to drive a global  conversation about healthcare worker and patient safety.
","('Employee_Health_And_Safety', 0.5202628374099731)","('Access_And_Affordability', 0.13793893158435822)","('Product_Quality_And_Safety', 0.057301465421915054)","(['Operational Eco-Efficiency'], 0.5202628374099731)","('NON-ESG', 0.13793893158435822)","('NON-ESG', 0.057301465421915054)"
Line 751,"BD global health experts also participated in several key  international events to raise awareness of the importance of  public-private partnerships in addressing global health  challenges, including: • The Public-Private Partnership Forum of the National  Academies in Washington DC • The Union Conference on Lung Health in Hyderabad, India • The International Conference on AIDS and Sexually  Transmitted Infections in Africa Driving a global conversation about…safety  BD partnered with Devex International Development to launch a  dedicated digital platform called “ Safety First ,” to drive a global  conversation about healthcare worker and patient safety.
","('Employee_Health_And_Safety', 0.9669469594955444)","('Product_Quality_And_Safety', 0.00646224245429039)","('Employee_Engagement_Inclusion_And_Diversity', 0.0028411082457751036)","(['Operational Eco-Efficiency'], 0.9669469594955444)","('NON-ESG', 0.00646224245429039)","('NON-ESG', 0.0028411082457751036)"
Line 752,"The  integrated series of online content features a series of portraits of  individuals who have experienced needlestick injuries and have  become advocates for healthcare provider and patient safety.
","('Employee_Health_And_Safety', 0.9808527827262878)","('Critical_Incident_Risk_Management', 0.003857939736917615)","('Employee_Engagement_Inclusion_And_Diversity', 0.0014608559431508183)","(['Operational Eco-Efficiency'], 0.9808527827262878)","('NON-ESG', 0.003857939736917615)","('NON-ESG', 0.0014608559431508183)"
Line 753,"Driving a global conversation about…drug-resistant TB  BD and USAID also partnered with an award-winning  documentary filmmaker in India to launch “ TB Talk, Unmasked ,”  a platform through which policymakers, TB survivors and treating  physicians can share their unique stories and perspectives.
","('Systemic_Risk_Management', 0.14149878919124603)","('Access_And_Affordability', 0.08951754122972488)","('Employee_Health_And_Safety', 0.08481976389884949)","('NON-ESG', 0.14149878919124603)","('NON-ESG', 0.08951754122972488)","('NON-ESG', 0.08481976389884949)"
Line 754,"Infection prevention in Kenya Driving global conversations about key global health issues BD Global Health Summit ""I am extremely proud that BD has taken the  initiative to support this program.
","('Employee_Health_And_Safety', 0.5835713148117065)","('Access_And_Affordability', 0.14157629013061523)","('Product_Quality_And_Safety', 0.05692999064922333)","(['Operational Eco-Efficiency'], 0.5835713148117065)","('NON-ESG', 0.14157629013061523)","('NON-ESG', 0.05692999064922333)"
Line 755,"I did not  realize the magnitude of impact we make on  patient care in these developing countries until  this trip.
","('Access_And_Affordability', 0.8066015243530273)","('Human_Rights_And_Community_Relations', 0.028779610991477966)","('Critical_Incident_Risk_Management', 0.01864779181778431)","(['Health Outcome Contribution'], 0.8066015243530273)","('NON-ESG', 0.028779610991477966)","('NON-ESG', 0.01864779181778431)"
Line 756,"We help bridge the gap in knowledge  of lab personnel and overall lab system quality  that translates into an improved patient  experience—that is reliable test results and  patient satisfaction.
","('Access_And_Affordability', 0.3097184896469116)","('Employee_Health_And_Safety', 0.17984221875667572)","('Employee_Engagement_Inclusion_And_Diversity', 0.1265186220407486)","('NON-ESG', 0.3097184896469116)","('NON-ESG', 0.17984221875667572)","('NON-ESG', 0.1265186220407486)"
Line 757,"I have not worked for or  known any other company that goes to this  extent to help without any hidden agendas.""   —Kokeb Tefera, Senior Program Manager, who served  as a BD Global Health Fellow through the Labs for Life  program in Ethiopia in June Innovation               Innovation               Efficiency                Empowerment        Access                     Access                     46 47BD is committed to bringing the world’s leading products,  technologies and manufacturing processes to China.
","('Product_Design_And_Lifecycle_Management', 0.937305212020874)","('Product_Quality_And_Safety', 0.006855659652501345)","('Supply_Chain_Management', 0.00679514417424798)","(['Product Stewardship'], 0.937305212020874)","('NON-ESG', 0.006855659652501345)","('NON-ESG', 0.00679514417424798)"
Line 758,"I have not worked for or  known any other company that goes to this  extent to help without any hidden agendas.""   —Kokeb Tefera, Senior Program Manager, who served  as a BD Global Health Fellow through the Labs for Life  program in Ethiopia in June Innovation               Innovation               Efficiency                Empowerment        Access                     Access                     46 47BD is committed to bringing the world’s leading products,  technologies and manufacturing processes to China.
","('Product_Design_And_Lifecycle_Management', 0.07696884870529175)","('Competitive_Behavior', 0.06801982969045639)","('Energy_Management', 0.06453041732311249)","('NON-ESG', 0.07696884870529175)","('NON-ESG', 0.06801982969045639)","('NON-ESG', 0.06453041732311249)"
Line 759,"In FY 2019  BD continued to expand our manufacturing array in our Suzhou  plants by introducing two new manufacturing lines, BD Hypak ™  Pre-Fillable Syringes and BD OptiBuild ™ Reagents.
","('Product_Design_And_Lifecycle_Management', 0.7653273940086365)","('Energy_Management', 0.06174159422516823)","('Customer_Welfare', 0.030831854790449142)","(['Product Stewardship'], 0.7653273940086365)","('NON-ESG', 0.06174159422516823)","('NON-ESG', 0.030831854790449142)"
Line 760,"These new  manufacturing capabilities have employed an additional 40  associates, and will employ another 150 associates after all the  BD Hypak ™ Pre-Fillable Syringe lines are completed.
","('Product_Design_And_Lifecycle_Management', 0.8101978898048401)","('Energy_Management', 0.038666628301143646)","('Customer_Welfare', 0.02591913565993309)","(['Product Stewardship'], 0.8101978898048401)","('NON-ESG', 0.038666628301143646)","('NON-ESG', 0.02591913565993309)"
Line 761,"In 2016, BD initiated work to equip one of our plants in Suzhou,  China with a BD Hypak ™ Pre-Fillable Syringes production line.
","('Product_Design_And_Lifecycle_Management', 0.4847264587879181)","('Energy_Management', 0.15262049436569214)","('Waste_And_Hazardous_Materials_Management', 0.07511549443006516)","('NON-ESG', 0.4847264587879181)","('NON-ESG', 0.15262049436569214)","('NON-ESG', 0.07511549443006516)"
Line 762,"This work included a multiphased concept to design process for  clean rooms, utility systems and laboratories.
","('Energy_Management', 0.45843973755836487)","('Product_Design_And_Lifecycle_Management', 0.22803713381290436)","('Water_And_Wastewater_Management', 0.06632883101701736)","('NON-ESG', 0.45843973755836487)","('NON-ESG', 0.22803713381290436)","('NON-ESG', 0.06632883101701736)"
Line 763,"BD invested   $25 million in Phase I of this installation project that will be  ready for launch production in FY 2020, and the other two  subsequent phases, several times larger than one, will be  completed in the next few years.
","('Energy_Management', 0.4151414930820465)","('Product_Design_And_Lifecycle_Management', 0.17209146916866302)","('GHG_Emissions', 0.07323609292507172)","('NON-ESG', 0.4151414930820465)","('NON-ESG', 0.17209146916866302)","('NON-ESG', 0.07323609292507172)"
Line 764,"As a world leader in prefillable  injection technology, BD will accelerate the development and  transformation of drug delivery systems in China through  this project.
","('Customer_Welfare', 0.3097383677959442)","('Access_And_Affordability', 0.13147291541099548)","('Energy_Management', 0.1172119751572609)","('NON-ESG', 0.3097383677959442)","('NON-ESG', 0.13147291541099548)","('NON-ESG', 0.1172119751572609)"
Line 765,"BD has always attached great importance to providing a total  solution, combining flow cytometry and reagents for scientific  researchers.
","('Energy_Management', 0.320523202419281)","('Water_And_Wastewater_Management', 0.1401037573814392)","('Product_Design_And_Lifecycle_Management', 0.13725793361663818)","('NON-ESG', 0.320523202419281)","('NON-ESG', 0.1401037573814392)","('NON-ESG', 0.13725793361663818)"
Line 766,"BD OptiBuild ™ Custom Reagents offer more  fluorochrome options with the antibodies the researchers need.
","('Customer_Welfare', 0.24684280157089233)","('Energy_Management', 0.21695967018604279)","('Product_Design_And_Lifecycle_Management', 0.17384955286979675)","('NON-ESG', 0.24684280157089233)","('NON-ESG', 0.21695967018604279)","('NON-ESG', 0.17384955286979675)"
Line 767,"Whether they want to minimize compensation or add new  markers to complex experiments, BD OptiBuild ™ Custom  Reagents provide flexibility to evaluate new colors and simplify  panel design.
","('Product_Design_And_Lifecycle_Management', 0.5705390572547913)","('Customer_Welfare', 0.11757811158895493)","('Competitive_Behavior', 0.08367379754781723)","(['Product Stewardship'], 0.5705390572547913)","('NON-ESG', 0.11757811158895493)","('NON-ESG', 0.08367379754781723)"
Line 768,"The 2019 completion of a new production line of  BD OptiBuild ™ Custom Reagents in our BD factory located in  Suzhou, China can significantly shorten the delivery cycle and  deliver products from the factory to the customer in as little as 4  days, providing more options for scientific research and greatly  improving research efficiency which will directly benefit  scientists in China and Pan-Asia.BD expands manufacturing site in China In June of 2019, BD opened a technology campus in Bangalore,  India (BDTCI).
","('Product_Design_And_Lifecycle_Management', 0.9472556710243225)","('Product_Quality_And_Safety', 0.006325501017272472)","('Customer_Welfare', 0.006166128907352686)","(['Product Stewardship'], 0.9472556710243225)","('NON-ESG', 0.006325501017272472)","('NON-ESG', 0.006166128907352686)"
Line 769,"The 2019 completion of a new production line of  BD OptiBuild ™ Custom Reagents in our BD factory located in  Suzhou, China can significantly shorten the delivery cycle and  deliver products from the factory to the customer in as little as 4  days, providing more options for scientific research and greatly  improving research efficiency which will directly benefit  scientists in China and Pan-Asia.BD expands manufacturing site in China In June of 2019, BD opened a technology campus in Bangalore,  India (BDTCI).
","('Management_Of_Legal_And_Regulatory_Framework', 0.6638572216033936)","('Business_Ethics', 0.09357109665870667)","('Director_Removal', 0.026797402650117874)","(['Corporate Governance'], 0.6638572216033936)","('NON-ESG', 0.09357109665870667)","('NON-ESG', 0.026797402650117874)"
Line 770,"BDTCI is positioned as an extension of global  R&D to support sustaining engineering initially, with a long-term  vision to own the product life cycle management for BD products.
","('Product_Design_And_Lifecycle_Management', 0.9652940630912781)","('Product_Quality_And_Safety', 0.0033909056801348925)","('Business_Model_Resilience', 0.0030405668076127768)","(['Product Stewardship'], 0.9652940630912781)","('NON-ESG', 0.0033909056801348925)","('NON-ESG', 0.0030405668076127768)"
Line 771,"As BDTCI becomes fluent with the life cycle management, the  center will be positioned to drive design  and innovation for global products and global markets.
","('Product_Design_And_Lifecycle_Management', 0.9665666818618774)","('Product_Quality_And_Safety', 0.0031321521382778883)","('Business_Model_Resilience', 0.002845791634172201)","(['Product Stewardship'], 0.9665666818618774)","('NON-ESG', 0.0031321521382778883)","('NON-ESG', 0.002845791634172201)"
Line 772,"BD has further plans to expand this site to provide   cross-functional support to support this work, as well as to  provide full capabilities to support product testing.
","('Product_Design_And_Lifecycle_Management', 0.8555546998977661)","('Product_Quality_And_Safety', 0.05664483830332756)","('Customer_Welfare', 0.017031151801347733)","(['Product Stewardship'], 0.8555546998977661)","('NON-ESG', 0.05664483830332756)","('NON-ESG', 0.017031151801347733)"
Line 773,"Currently  there are 80 associates at BDTCI, with a planned addition of  another 200 associates in the next 2 years.BD Technology Campus in India 2020 goal Further expand  BD manufacturing, product array and employment in emerging countries Innovation               Innovation               Efficiency                Empowerment        Access                     Access                     48Introduction We understand that the health of the planet is linked to the health of people, and reducing our impact  on the environment supports our Purpose of advancing the world of health™.
","('Product_Design_And_Lifecycle_Management', 0.7870623469352722)","('Product_Quality_And_Safety', 0.049293678253889084)","('Access_And_Affordability', 0.028221268206834793)","(['Product Stewardship'], 0.7870623469352722)","('NON-ESG', 0.049293678253889084)","('NON-ESG', 0.028221268206834793)"
Line 774,"Currently  there are 80 associates at BDTCI, with a planned addition of  another 200 associates in the next 2 years.BD Technology Campus in India 2020 goal Further expand  BD manufacturing, product array and employment in emerging countries Innovation               Innovation               Efficiency                Empowerment        Access                     Access                     48Introduction We understand that the health of the planet is linked to the health of people, and reducing our impact  on the environment supports our Purpose of advancing the world of health™.
","('Human_Rights_And_Community_Relations', 0.2832256853580475)","('Ecological_Impacts', 0.22926358878612518)","('GHG_Emissions', 0.08798855543136597)","('NON-ESG', 0.2832256853580475)","('NON-ESG', 0.22926358878612518)","('NON-ESG', 0.08798855543136597)"
Line 775,"With continuing pressure  on natural resources and the predicted impacts of climate change, it is imperative that we continue to  increase the resilience of our operations and explore opportunities for environmental improvements  across our value chain.
","('Physical_Impacts_Of_Climate_Change', 0.5619404911994934)","('Business_Model_Resilience', 0.28684118390083313)","('Ecological_Impacts', 0.031597595661878586)","(['Climate Change'], 0.5619404911994934)","('NON-ESG', 0.28684118390083313)","('NON-ESG', 0.031597595661878586)"
Line 776,"By partnering more closely with suppliers, customers and peers, we can address  some of the world’s most pressing environmental issues more broadly than we could on our own.Efficiency Environmentally sound products  and resilient operations 2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain Despite an increase in revenues, absolute Scope 1  and 2 GHG emissions have been reduced by 48%  from our baseline year of FY 2008.
","('GHG_Emissions', 0.938912570476532)","('Physical_Impacts_Of_Climate_Change', 0.011619209311902523)","('Air_Quality', 0.0055100759491324425)","(['Climate Change'], 0.938912570476532)","('NON-ESG', 0.011619209311902523)","('NON-ESG', 0.0055100759491324425)"
Line 777,"After normalization, we have reduced emissions   by 67% from our baseline year.
","('GHG_Emissions', 0.7202592492103577)","('Air_Quality', 0.11508730053901672)","('Energy_Management', 0.06139497831463814)","(['Climate Change'], 0.7202592492103577)","('NON-ESG', 0.11508730053901672)","('NON-ESG', 0.06139497831463814)"
Line 778,"Facilities continue to identify  carbon reduction opportunities on-site by utilizing best available  technology where feasible.
","('GHG_Emissions', 0.3921702802181244)","('Energy_Management', 0.3695632219314575)","('Management_Of_Legal_And_Regulatory_Framework', 0.028385646641254425)","('NON-ESG', 0.3921702802181244)","('NON-ESG', 0.3695632219314575)","('NON-ESG', 0.028385646641254425)"
Line 779,"We also continued our commitment  to increasing our use of on-site generation and renewable energy  sources, when feasible.
","('Energy_Management', 0.9765382409095764)","('Product_Design_And_Lifecycle_Management', 0.0031920988112688065)","('Management_Of_Legal_And_Regulatory_Framework', 0.0019805869087576866)","(['Operational Eco-Efficiency'], 0.9765382409095764)","('NON-ESG', 0.0031920988112688065)","('NON-ESG', 0.0019805869087576866)"
Line 780,"We provided limited reporting of Scope 3 emissions in previous  years, and in FY 2019 we continued to work with external  partners to establish baseline Scope 3 emissions across all  relevant categories.
","('GHG_Emissions', 0.8474371433258057)","('Air_Quality', 0.07917752861976624)","('Management_Of_Legal_And_Regulatory_Framework', 0.010747067630290985)","(['Climate Change'], 0.8474371433258057)","('NON-ESG', 0.07917752861976624)","('NON-ESG', 0.010747067630290985)"
Line 781,"Our largest sources of Scope 3 emissions are  estimated to be from purchased of goods, distribution and the  use and disposal of products.
","('Product_Design_And_Lifecycle_Management', 0.9599510431289673)","('Energy_Management', 0.004620734602212906)","('Product_Quality_And_Safety', 0.004284037742763758)","(['Product Stewardship'], 0.9599510431289673)","('NON-ESG', 0.004620734602212906)","('NON-ESG', 0.004284037742763758)"
Line 782,"Therefore, these sources represent  the largest areas for opportunity and will be subject of our focus  in our future sustainability strategy.GHG emissionsIn FY 2019, BD continued to make progress toward our 2020  efficiency goals.
","('GHG_Emissions', 0.9661150574684143)","('Air_Quality', 0.005018174182623625)","('Management_Of_Legal_And_Regulatory_Framework', 0.0031177622731775045)","(['Climate Change'], 0.9661150574684143)","('NON-ESG', 0.005018174182623625)","('NON-ESG', 0.0031177622731775045)"
Line 783,"This year we have integrated Bard operations  into our environmental performance reporting process.
","('Business_Model_Resilience', 0.2972216010093689)","('Physical_Impacts_Of_Climate_Change', 0.13084134459495544)","('Supply_Chain_Management', 0.10269252210855484)","('NON-ESG', 0.2972216010093689)","('NON-ESG', 0.13084134459495544)","('NON-ESG', 0.10269252210855484)"
Line 784,"The data  reported here is inclusive of the former-Bard operations.
","('Systemic_Risk_Management', 0.23181113600730896)","('Business_Model_Resilience', 0.10333750396966934)","('Competitive_Behavior', 0.07586709409952164)","('NON-ESG', 0.23181113600730896)","('NON-ESG', 0.10333750396966934)","('NON-ESG', 0.07586709409952164)"
Line 785,"The addition of Bard operations into our portfolio has impacted  performance to our 2020 goals (set prior to the acquisition).
","('Business_Model_Resilience', 0.7941001653671265)","('Systemic_Risk_Management', 0.04692692309617996)","('Employee_Engagement_Inclusion_And_Diversity', 0.01728200726211071)","(['Codes of Business Conduct'], 0.7941001653671265)","('NON-ESG', 0.04692692309617996)","('NON-ESG', 0.01728200726211071)"
Line 786,"While we have achieved our targets for Scope 1 and 2 greenhouse  gas (GHG) reduction and water reduction, we have more work to  do in reducing waste and air emissions.Status of performance against 2020 goals Further information about our climate change strategy and programs to reduce GHG emissions can be found in our separate Climate  Change Management report, available August 2020 on our website , as well as in our responses to the CDP  (formerly the Carbon  Disclosure Project).
","('GHG_Emissions', 0.9470374584197998)","('Air_Quality', 0.014367187395691872)","('Physical_Impacts_Of_Climate_Change', 0.007558927405625582)","(['Climate Change'], 0.9470374584197998)","('NON-ESG', 0.014367187395691872)","('NON-ESG', 0.007558927405625582)"
Line 787,"BD has reported to the CDP since its inception in 2003.Click here to view the GHG data tables .All data relating to our performance can be found at the end  of this section in the  Efficiency data tables section .
","('GHG_Emissions', 0.9583100080490112)","('Air_Quality', 0.004509332589805126)","('Water_And_Wastewater_Management', 0.00438061635941267)","(['Climate Change'], 0.9583100080490112)","('NON-ESG', 0.004509332589805126)","('NON-ESG', 0.00438061635941267)"
Line 788,"GRI disclosure: 201-2Innovation               Access                     Empowerment       Efficiency                49Our energy consumption decreased in absolute  terms and normalized terms for FY 19.
","('Energy_Management', 0.980665385723114)","('Air_Quality', 0.001844484475441277)","('Critical_Incident_Risk_Management', 0.0015003862790763378)","(['Operational Eco-Efficiency'], 0.980665385723114)","('NON-ESG', 0.001844484475441277)","('NON-ESG', 0.0015003862790763378)"
Line 789,"We have  focused on identifying opportunities by assessing  and incorporating new available technology to  further reduce energy consumption.
","('Energy_Management', 0.9807723760604858)","('Product_Design_And_Lifecycle_Management', 0.0019306160975247622)","('Air_Quality', 0.0016271114582195878)","(['Operational Eco-Efficiency'], 0.9807723760604858)","('NON-ESG', 0.0019306160975247622)","('NON-ESG', 0.0016271114582195878)"
Line 790,"While the amount of green energy increased in FY 2019, the  overall percentage of power from renewable sources fell slightly.
","('Energy_Management', 0.9747276902198792)","('Management_Of_Legal_And_Regulatory_Framework', 0.0038584310095757246)","('Product_Design_And_Lifecycle_Management', 0.002054637297987938)","(['Operational Eco-Efficiency'], 0.9747276902198792)","('NON-ESG', 0.0038584310095757246)","('NON-ESG', 0.002054637297987938)"
Line 791,"This was due to budget constraints caused by the COVID-19  pandemic that limited the number of supplemental renewable  energy credits that we could purchase.
","('Energy_Management', 0.8852288126945496)","('Management_Of_Legal_And_Regulatory_Framework', 0.055260464549064636)","('GHG_Emissions', 0.009003317914903164)","(['Operational Eco-Efficiency'], 0.8852288126945496)","('NON-ESG', 0.055260464549064636)","('NON-ESG', 0.009003317914903164)"
Line 792,"However, we remain  committed to renewable energy and expect to continue progress  set in previous years.
","('Energy_Management', 0.9294296503067017)","('Management_Of_Legal_And_Regulatory_Framework', 0.026453234255313873)","('Physical_Impacts_Of_Climate_Change', 0.0045270612463355064)","(['Operational Eco-Efficiency'], 0.9294296503067017)","('NON-ESG', 0.026453234255313873)","('NON-ESG', 0.0045270612463355064)"
Line 793,"Over the course of FY 2019, BD identified over 204 energy  reduction projects that will amount to over $5 million in energy  savings, once completed.
","('Energy_Management', 0.9795634150505066)","('Air_Quality', 0.0020754875149577856)","('Management_Of_Legal_And_Regulatory_Framework', 0.0017569445772096515)","(['Operational Eco-Efficiency'], 0.9795634150505066)","('NON-ESG', 0.0020754875149577856)","('NON-ESG', 0.0017569445772096515)"
Line 794,"The Utilities Center of Excellence  worked closely with sites around the world to identify key projects that will reduce energy usage and improve efficiency of  plant operations.
","('Energy_Management', 0.9807120561599731)","('Product_Design_And_Lifecycle_Management', 0.0018098984146490693)","('Air_Quality', 0.0016849559033289552)","(['Operational Eco-Efficiency'], 0.9807120561599731)","('NON-ESG', 0.0018098984146490693)","('NON-ESG', 0.0016849559033289552)"
Line 795,"Many of these projects will be completed in the  coming years, but work has already begun with some projects  being completed in 2019.
","('Management_Of_Legal_And_Regulatory_Framework', 0.38240084052085876)","('Energy_Management', 0.0768045037984848)","('Business_Model_Resilience', 0.0669928789138794)","('NON-ESG', 0.38240084052085876)","('NON-ESG', 0.0768045037984848)","('NON-ESG', 0.0669928789138794)"
Line 796,"Those projects completed saw savings  of $1.5 million in FY 2019—approximately 15 million kWh.  Projects include the replacement of existing lighting with LED  lighting; recommissioning of an ice plant; combined heat and  power projects, installation of solar panel projects and various  equipment upgrades.Energy2020 goal Minimize  our environmental footprint and conserve natural resources In FY 2019, we continued to invest in on-site power generation and identify opportunities to reduce our environmental footprint  across all sites.
","('Energy_Management', 0.9683989882469177)","('Management_Of_Legal_And_Regulatory_Framework', 0.0033251196146011353)","('Product_Design_And_Lifecycle_Management', 0.0030028808396309614)","(['Operational Eco-Efficiency'], 0.9683989882469177)","('NON-ESG', 0.0033251196146011353)","('NON-ESG', 0.0030028808396309614)"
Line 797,"Those projects completed saw savings  of $1.5 million in FY 2019—approximately 15 million kWh.  Projects include the replacement of existing lighting with LED  lighting; recommissioning of an ice plant; combined heat and  power projects, installation of solar panel projects and various  equipment upgrades.Energy2020 goal Minimize  our environmental footprint and conserve natural resources In FY 2019, we continued to invest in on-site power generation and identify opportunities to reduce our environmental footprint  across all sites.
","('Competitive_Behavior', 0.3010925352573395)","('Systemic_Risk_Management', 0.1357278823852539)","('Business_Ethics', 0.12978222966194153)","('NON-ESG', 0.3010925352573395)","('NON-ESG', 0.1357278823852539)","('NON-ESG', 0.12978222966194153)"
Line 798,"The second phase of the on-site solar installation for the BD  manufacturing plant in Canaan, CT was completed.
","('Energy_Management', 0.9380022883415222)","('GHG_Emissions', 0.006919624283909798)","('Management_Of_Legal_And_Regulatory_Framework', 0.006794259883463383)","(['Operational Eco-Efficiency'], 0.9380022883415222)","('NON-ESG', 0.006919624283909798)","('NON-ESG', 0.006794259883463383)"
Line 799,"The system  was expanded from a 2,655-kilowatt system with 6,400 ground and roof mounted panels to a 3,350-kilowatt system with 7,650  ground and roof mounted panels.
","('Energy_Management', 0.9566585421562195)","('Management_Of_Legal_And_Regulatory_Framework', 0.00450136186555028)","('Air_Quality', 0.004298647399991751)","(['Operational Eco-Efficiency'], 0.9566585421562195)","('NON-ESG', 0.00450136186555028)","('NON-ESG', 0.004298647399991751)"
Line 800,"Solar The combined heat and power (CHP) generation continues to be  utilized at BD sites.
","('Energy_Management', 0.9694356322288513)","('Water_And_Wastewater_Management', 0.005490131676197052)","('Air_Quality', 0.0024084614124149084)","(['Operational Eco-Efficiency'], 0.9694356322288513)","('NON-ESG', 0.005490131676197052)","('NON-ESG', 0.0024084614124149084)"
Line 801,"The latest CHP installation was completed in  Drogheda, Ireland where it will provide 75% of the site’s electrical  usage.
","('Energy_Management', 0.96107417345047)","('Air_Quality', 0.004999165888875723)","('Management_Of_Legal_And_Regulatory_Framework', 0.004940594546496868)","(['Operational Eco-Efficiency'], 0.96107417345047)","('NON-ESG', 0.004999165888875723)","('NON-ESG', 0.004940594546496868)"
Line 802,"On-site generation increases site’s resilience and is a more efficient use of energy, therefore reducing GHG emissions.
","('GHG_Emissions', 0.8560503125190735)","('Energy_Management', 0.035730283707380295)","('Physical_Impacts_Of_Climate_Change', 0.017036298289895058)","(['Climate Change'], 0.8560503125190735)","('NON-ESG', 0.035730283707380295)","('NON-ESG', 0.017036298289895058)"
Line 803,"Solutions such as combined heat and power continue to be  assessed to achieve our sustainability goals and build energy  resilience into our sites.Combined heat and powerClick here to view the Energy data tables .Innovation               Access                     Empowerment       Efficiency                50Water consumption decreased slightly in FY 2019 as a result of  continued water conservation efforts and we exceeded our  target of 40% reduction of water use (normalized by COPS).
","('Water_And_Wastewater_Management', 0.773613691329956)","('Energy_Management', 0.15445610880851746)","('GHG_Emissions', 0.008472541347146034)","(['Operational Eco-Efficiency'], 0.773613691329956)","('NON-ESG', 0.15445610880851746)","('NON-ESG', 0.008472541347146034)"
Line 804,"We  will continue to identify and implement viable water reduction projects.
","('Water_And_Wastewater_Management', 0.9740366339683533)","('GHG_Emissions', 0.003209501039236784)","('Ecological_Impacts', 0.0025678419042378664)","(['Operational Eco-Efficiency'], 0.9740366339683533)","('NON-ESG', 0.003209501039236784)","('NON-ESG', 0.0025678419042378664)"
Line 805,"Of the amount of water consumed, the percentage of  wastewater discharge also increased reflecting efforts to  improve system efficiencies.
","('Water_And_Wastewater_Management', 0.974926769733429)","('Energy_Management', 0.0026105535216629505)","('GHG_Emissions', 0.0025397264398634434)","(['Operational Eco-Efficiency'], 0.974926769733429)","('NON-ESG', 0.0026105535216629505)","('NON-ESG', 0.0025397264398634434)"
Line 806,"Water useWater is essential to human life, the environment  and the planet.
","('Water_And_Wastewater_Management', 0.962868332862854)","('Ecological_Impacts', 0.008957949467003345)","('GHG_Emissions', 0.0041083768010139465)","(['Operational Eco-Efficiency'], 0.962868332862854)","('NON-ESG', 0.008957949467003345)","('NON-ESG', 0.0041083768010139465)"
Line 807,"BD recognizes the importance of  water in our manufacturing processes, for our  products, our suppliers, in our environment, and to  our associates and their communities.
","('Water_And_Wastewater_Management', 0.9541018009185791)","('Waste_And_Hazardous_Materials_Management', 0.005971482023596764)","('GHG_Emissions', 0.00440047075971961)","(['Operational Eco-Efficiency'], 0.9541018009185791)","('NON-ESG', 0.005971482023596764)","('NON-ESG', 0.00440047075971961)"
Line 808,"Maintaining a clean and  ample supply of water is imperative both to the future of our  company, supply chain and to the future of the communities  where we live, work and do business.
","('Water_And_Wastewater_Management', 0.9088769555091858)","('Supply_Chain_Management', 0.024626443162560463)","('Energy_Management', 0.01157008670270443)","(['Operational Eco-Efficiency'], 0.9088769555091858)","('NON-ESG', 0.024626443162560463)","('NON-ESG', 0.01157008670270443)"
Line 809,"Water quality and quantity is fundamental to ensure that  highest healthcare product safety standards are met.
","('Product_Quality_And_Safety', 0.9298436045646667)","('Employee_Health_And_Safety', 0.008357115089893341)","('Product_Design_And_Lifecycle_Management', 0.006669456139206886)","(['Product Quality & Recall Management'], 0.9298436045646667)","('NON-ESG', 0.008357115089893341)","('NON-ESG', 0.006669456139206886)"
Line 810,"A key focus  is the efficient use of water, especially as some of our company’s  products contain purified water.
","('Water_And_Wastewater_Management', 0.8841395974159241)","('Energy_Management', 0.024185674265027046)","('Product_Design_And_Lifecycle_Management', 0.015772009268403053)","(['Operational Eco-Efficiency'], 0.8841395974159241)","('NON-ESG', 0.024185674265027046)","('NON-ESG', 0.015772009268403053)"
Line 811,"Freshwater is used in  manufacturing, sanitation, sterilization, processing and cooling  for our direct operations.
","('Water_And_Wastewater_Management', 0.9741137623786926)","('Waste_And_Hazardous_Materials_Management', 0.0028081159107387066)","('GHG_Emissions', 0.0026786276139318943)","(['Operational Eco-Efficiency'], 0.9741137623786926)","('NON-ESG', 0.0028081159107387066)","('NON-ESG', 0.0026786276139318943)"
Line 812,"Indirect water is used in the  manufacturing and/or processing of many raw materials used in  our products, such as resins, steel, packaging and electrical  components.
","('Product_Design_And_Lifecycle_Management', 0.5936320424079895)","('Water_And_Wastewater_Management', 0.12649187445640564)","('Waste_And_Hazardous_Materials_Management', 0.080732062458992)","(['Product Stewardship'], 0.5936320424079895)","('NON-ESG', 0.12649187445640564)","('NON-ESG', 0.080732062458992)"
Line 813,"Recycled and brackish water is used in ancillary operations, such  as cooling towers, because it does not meet quality standards for  most other uses.
","('Water_And_Wastewater_Management', 0.969187319278717)","('GHG_Emissions', 0.0036853933706879616)","('Ecological_Impacts', 0.003451404394581914)","(['Operational Eco-Efficiency'], 0.969187319278717)","('NON-ESG', 0.0036853933706879616)","('NON-ESG', 0.003451404394581914)"
Line 814,"Operating in accordance with local regulations that protect  people and the environment, approximately 97% of water used  at our facilities comes from, and is discharged to, third-party  sources (such as local municipal water sources).
","('Water_And_Wastewater_Management', 0.9766472578048706)","('Waste_And_Hazardous_Materials_Management', 0.002118850825354457)","('GHG_Emissions', 0.0021128468215465546)","(['Operational Eco-Efficiency'], 0.9766472578048706)","('NON-ESG', 0.002118850825354457)","('NON-ESG', 0.0021128468215465546)"
Line 815,"We collect  water-related data for total withdrawals from our sites worldwide  through an online system.
","('Water_And_Wastewater_Management', 0.9720472097396851)","('Energy_Management', 0.0035640045534819365)","('GHG_Emissions', 0.0026514914352446795)","(['Operational Eco-Efficiency'], 0.9720472097396851)","('NON-ESG', 0.0035640045534819365)","('NON-ESG', 0.0026514914352446795)"
Line 816,"This data is monitored and reviewed  on an ongoing basis.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3019430339336395)","('Access_And_Affordability', 0.09513375163078308)","('Customer_Privacy', 0.07279512286186218)","('NON-ESG', 0.3019430339336395)","('NON-ESG', 0.09513375163078308)","('NON-ESG', 0.07279512286186218)"
Line 817,"We are committed to responsible and sustainable use of water  and strive to include water sustainability considerations in  business decisions.
","('Water_And_Wastewater_Management', 0.975741982460022)","('GHG_Emissions', 0.0027963353786617517)","('Energy_Management', 0.0022402866743505)","(['Operational Eco-Efficiency'], 0.975741982460022)","('NON-ESG', 0.0027963353786617517)","('NON-ESG', 0.0022402866743505)"
Line 818,"We seek to achieve efficient use of water  resources at our operational locations by investing in and using  new technologies when feasible and implementing water conservation and water management practices.
","('Water_And_Wastewater_Management', 0.9756465554237366)","('Ecological_Impacts', 0.002946726977825165)","('GHG_Emissions', 0.00241179415024817)","(['Operational Eco-Efficiency'], 0.9756465554237366)","('NON-ESG', 0.002946726977825165)","('NON-ESG', 0.00241179415024817)"
Line 819,"Our facilities  conduct audits that include water usage, particularly in areas of  concern for water quality and quantity.
","('Water_And_Wastewater_Management', 0.9778202176094055)","('GHG_Emissions', 0.0020878680516034365)","('Energy_Management', 0.0017047427827492356)","(['Operational Eco-Efficiency'], 0.9778202176094055)","('NON-ESG', 0.0020878680516034365)","('NON-ESG', 0.0017047427827492356)"
Line 820,"Water risks are considered part of business continuity planning  and are assessed as part of an enterprise risk management  framework on an annual basis, using established water risk tools  to evaluate overall water stress areas.
","('Water_And_Wastewater_Management', 0.975465714931488)","('Waste_And_Hazardous_Materials_Management', 0.0023810777347534895)","('GHG_Emissions', 0.0018083327449858189)","(['Operational Eco-Efficiency'], 0.975465714931488)","('NON-ESG', 0.0023810777347534895)","('NON-ESG', 0.0018083327449858189)"
Line 821,"Water-related issues (such as resilience from water scarcity and  internal water efficiencies) are integrated into our long-term  business objectives.
","('Water_And_Wastewater_Management', 0.9731844663619995)","('Energy_Management', 0.0028168284334242344)","('GHG_Emissions', 0.002116488292813301)","(['Operational Eco-Efficiency'], 0.9731844663619995)","('NON-ESG', 0.0028168284334242344)","('NON-ESG', 0.002116488292813301)"
Line 822,"We see opportunities to continue to improve  operational efficiencies.
","('Energy_Management', 0.305921345949173)","('Business_Model_Resilience', 0.12885873019695282)","('Supply_Chain_Management', 0.11278699338436127)","('NON-ESG', 0.305921345949173)","('NON-ESG', 0.12885873019695282)","('NON-ESG', 0.11278699338436127)"
Line 823,"These are strategic opportunities that  will contribute to long-term resiliency and operational  cost savings.
","('Business_Model_Resilience', 0.8951035737991333)","('Product_Design_And_Lifecycle_Management', 0.015293377451598644)","('Physical_Impacts_Of_Climate_Change', 0.013031257316470146)","(['Codes of Business Conduct'], 0.8951035737991333)","('NON-ESG', 0.015293377451598644)","('NON-ESG', 0.013031257316470146)"
Line 824,"Further information about our water management strategy and  programs can be found in our responses to the CDP  (formerly  the Carbon Disclosure Project).
","('Water_And_Wastewater_Management', 0.9721633791923523)","('Ecological_Impacts', 0.003179759718477726)","('GHG_Emissions', 0.0026488006114959717)","(['Operational Eco-Efficiency'], 0.9721633791923523)","('NON-ESG', 0.003179759718477726)","('NON-ESG', 0.0026488006114959717)"
Line 825,"BD has reported to the CDP since  its inception in 2003.
","('Management_Of_Legal_And_Regulatory_Framework', 0.39219558238983154)","('Access_And_Affordability', 0.10834136605262756)","('Systemic_Risk_Management', 0.09819518774747849)","('NON-ESG', 0.39219558238983154)","('NON-ESG', 0.10834136605262756)","('NON-ESG', 0.09819518774747849)"
Line 826,"Clean water plays a role in global health.
","('Water_And_Wastewater_Management', 0.973884642124176)","('GHG_Emissions', 0.002892732387408614)","('Ecological_Impacts', 0.0028265404980629683)","(['Operational Eco-Efficiency'], 0.973884642124176)","('NON-ESG', 0.002892732387408614)","('NON-ESG', 0.0028265404980629683)"
Line 827,"Damaged ecosystems  affect the quantity and quality of water available for human  consumption.
","('Water_And_Wastewater_Management', 0.9524697661399841)","('Ecological_Impacts', 0.01479022391140461)","('GHG_Emissions', 0.005270843859761953)","(['Operational Eco-Efficiency'], 0.9524697661399841)","('NON-ESG', 0.01479022391140461)","('NON-ESG', 0.005270843859761953)"
Line 828,"Extreme weather events are impacting water  availability and quality.
","('Water_And_Wastewater_Management', 0.9690715670585632)","('Ecological_Impacts', 0.004500418435782194)","('GHG_Emissions', 0.0035491727758198977)","(['Operational Eco-Efficiency'], 0.9690715670585632)","('NON-ESG', 0.004500418435782194)","('NON-ESG', 0.0035491727758198977)"
Line 829,"Today, 2.1 billion people live without safe drinking water at  home, which can affect their health, education and livelihoods.23  Children under-five are on average more than 20 times more  likely to die from illnesses linked to unsafe water and bad  sanitation, than from conflict.BD has partnered with Charity: Water and Planet Water in  previous years to provide clean drinking to communities around  the world.
","('Water_And_Wastewater_Management', 0.9535422921180725)","('Energy_Management', 0.0045277210883796215)","('Critical_Incident_Risk_Management', 0.003870946355164051)","(['Operational Eco-Efficiency'], 0.9535422921180725)","('NON-ESG', 0.0045277210883796215)","('NON-ESG', 0.003870946355164051)"
Line 830,"You can read more about our work with Planet Water  in 2019 in the Empowerment  section of this report.Water managementWater References 23 World Health Organization.
","('Water_And_Wastewater_Management', 0.9758382439613342)","('Ecological_Impacts', 0.002645733766257763)","('GHG_Emissions', 0.0023519215174019337)","(['Operational Eco-Efficiency'], 0.9758382439613342)","('NON-ESG', 0.002645733766257763)","('NON-ESG', 0.0023519215174019337)"
Line 831,"2.1 billion people lack safe drinking water at home, more than twice as many lack safe sanitation.
","('Water_And_Wastewater_Management', 0.9498694539070129)","('Energy_Management', 0.005333528853952885)","('Waste_And_Hazardous_Materials_Management', 0.005297933239489794)","(['Operational Eco-Efficiency'], 0.9498694539070129)","('NON-ESG', 0.005333528853952885)","('NON-ESG', 0.005297933239489794)"
Line 832,"https://www.who.int/news-room/detail/12-07-2017-2-1-billion- people-lack-safe-drinking-water-at-home-more-than-twice-as-many-lack-safe-sanitation.
","('Water_And_Wastewater_Management', 0.9447259306907654)","('Energy_Management', 0.007512057665735483)","('Waste_And_Hazardous_Materials_Management', 0.006405446212738752)","(['Operational Eco-Efficiency'], 0.9447259306907654)","('NON-ESG', 0.007512057665735483)","('NON-ESG', 0.006405446212738752)"
Line 833,"Published July 12, 2017.
","('Management_Of_Legal_And_Regulatory_Framework', 0.15178805589675903)","('Data_Security', 0.14191299676895142)","('Ecological_Impacts', 0.08058846741914749)","('NON-ESG', 0.15178805589675903)","('NON-ESG', 0.14191299676895142)","('NON-ESG', 0.08058846741914749)"
Line 834,"Accessed May 8, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21498218178749084)","('Ecological_Impacts', 0.10841754078865051)","('Competitive_Behavior', 0.095762237906456)","('NON-ESG', 0.21498218178749084)","('NON-ESG', 0.10841754078865051)","('NON-ESG', 0.095762237906456)"
Line 835,"24 UN News.
","('Physical_Impacts_Of_Climate_Change', 0.11110740154981613)","('Management_Of_Legal_And_Regulatory_Framework', 0.09536462277173996)","('Data_Security', 0.07284471392631531)","('NON-ESG', 0.11110740154981613)","('NON-ESG', 0.09536462277173996)","('NON-ESG', 0.07284471392631531)"
Line 836,"More children killed by unsafe water, than bullets, says UNICEF chief.
","('Water_And_Wastewater_Management', 0.658164381980896)","('Waste_And_Hazardous_Materials_Management', 0.09354283660650253)","('Employee_Health_And_Safety', 0.044288549572229385)","(['Operational Eco-Efficiency'], 0.658164381980896)","('NON-ESG', 0.09354283660650253)","('NON-ESG', 0.044288549572229385)"
Line 837,"https://news.un.org/en/story/2019/03/1035171.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2425128072500229)","('Human_Rights_And_Community_Relations', 0.16557970643043518)","('Physical_Impacts_Of_Climate_Change', 0.07852230221033096)","('NON-ESG', 0.2425128072500229)","('NON-ESG', 0.16557970643043518)","('NON-ESG', 0.07852230221033096)"
Line 838,"March 21, 2019.
","('Business_Model_Resilience', 0.11457522958517075)","('Physical_Impacts_Of_Climate_Change', 0.07708924263715744)","('Director_Removal', 0.06710047274827957)","('NON-ESG', 0.11457522958517075)","('NON-ESG', 0.07708924263715744)","('NON-ESG', 0.06710047274827957)"
Line 839,"Accessed May 8, 2020.
","('Management_Of_Legal_And_Regulatory_Framework', 0.21498218178749084)","('Ecological_Impacts', 0.10841754078865051)","('Competitive_Behavior', 0.095762237906456)","('NON-ESG', 0.21498218178749084)","('NON-ESG', 0.10841754078865051)","('NON-ESG', 0.095762237906456)"
Line 840,"Click here to view the Water data table .Innovation               Access                     Empowerment       Efficiency                51While we continue to assess and implement waste reduction  projects, our performance in this area indicates there is  opportunity for improvement.
","('Water_And_Wastewater_Management', 0.8006334900856018)","('Waste_And_Hazardous_Materials_Management', 0.11395852267742157)","('Energy_Management', 0.013957556337118149)","(['Operational Eco-Efficiency'], 0.8006334900856018)","('NON-ESG', 0.11395852267742157)","('NON-ESG', 0.013957556337118149)"
Line 841,"Disposal methods have remained  largely unchanged from previous years, and we continue to face challenges with recycling waste streams.
","('Waste_And_Hazardous_Materials_Management', 0.9780365824699402)","('Water_And_Wastewater_Management', 0.0022761456202715635)","('Product_Design_And_Lifecycle_Management', 0.0019729090854525566)","(['Operational Eco-Efficiency'], 0.9780365824699402)","('NON-ESG', 0.0022761456202715635)","('NON-ESG', 0.0019729090854525566)"
Line 842,"However, hazardous  waste generation saw a decrease due to operational  improvements.Waste performanceEffective waste prevention and management  practices are critical for protecting human health  and the environment.
","('Waste_And_Hazardous_Materials_Management', 0.9850172400474548)","('Data_Security', 0.001210628543049097)","('Water_And_Wastewater_Management', 0.0010685607558116317)","(['Operational Eco-Efficiency'], 0.9850172400474548)","('NON-ESG', 0.001210628543049097)","('NON-ESG', 0.0010685607558116317)"
Line 843,"BD acknowledges the  importance of responsible end disposal  management for the various types of waste generated from our  operations.
","('Waste_And_Hazardous_Materials_Management', 0.9840286374092102)","('Water_And_Wastewater_Management', 0.0014774483861401677)","('Data_Security', 0.0011163655435666442)","(['Operational Eco-Efficiency'], 0.9840286374092102)","('NON-ESG', 0.0014774483861401677)","('NON-ESG', 0.0011163655435666442)"
Line 844,"Recognizing the current and future potential  liabilities associated with waste disposal is necessary to  safeguard our company, communities and planet.
","('Waste_And_Hazardous_Materials_Management', 0.9844693541526794)","('Water_And_Wastewater_Management', 0.0013878562022000551)","('Data_Security', 0.0010429196991026402)","(['Operational Eco-Efficiency'], 0.9844693541526794)","('NON-ESG', 0.0013878562022000551)","('NON-ESG', 0.0010429196991026402)"
Line 845,"We follow the waste management hierarchy for waste  generated.
","('Waste_And_Hazardous_Materials_Management', 0.9840081930160522)","('Data_Security', 0.0011920325923711061)","('Air_Quality', 0.0011738003231585026)","(['Operational Eco-Efficiency'], 0.9840081930160522)","('NON-ESG', 0.0011920325923711061)","('NON-ESG', 0.0011738003231585026)"
Line 846,"Source reduction and waste minimization practices  are utilized when feasible.
","('Waste_And_Hazardous_Materials_Management', 0.9769474267959595)","('Water_And_Wastewater_Management', 0.0033558716531842947)","('Air_Quality', 0.001979377120733261)","(['Operational Eco-Efficiency'], 0.9769474267959595)","('NON-ESG', 0.0033558716531842947)","('NON-ESG', 0.001979377120733261)"
Line 847,"End disposal site risk is evaluated by  using audits, vendor management and risk assessment tools.
","('Waste_And_Hazardous_Materials_Management', 0.5315459370613098)","('Systemic_Risk_Management', 0.1324845403432846)","('Supply_Chain_Management', 0.07094109058380127)","(['Operational Eco-Efficiency'], 0.5315459370613098)","('NON-ESG', 0.1324845403432846)","('NON-ESG', 0.07094109058380127)"
Line 848,"We are committed to reducing nonhazardous and hazardous  waste generated.
","('Waste_And_Hazardous_Materials_Management', 0.9845081567764282)","('Data_Security', 0.0011557621182873845)","('Water_And_Wastewater_Management', 0.0010910795535892248)","(['Operational Eco-Efficiency'], 0.9845081567764282)","('NON-ESG', 0.0011557621182873845)","('NON-ESG', 0.0010910795535892248)"
Line 849,"Waste generation is tracked through an online  system with the data collected being reviewed and monitored on  an ongoing basis.
","('Waste_And_Hazardous_Materials_Management', 0.978137731552124)","('Water_And_Wastewater_Management', 0.0031844337936490774)","('Air_Quality', 0.002211444079875946)","(['Operational Eco-Efficiency'], 0.978137731552124)","('NON-ESG', 0.0031844337936490774)","('NON-ESG', 0.002211444079875946)"
Line 850,"We partner with disposal vendors to evaluate  areas for waste reduction.Waste managementWaste  While our facilities continued to make absolute  reductions in VOC and HAP emissions through  process improvement projects and installation   of emission control equipment, data  demonstrates areas for opportunity remain.We continue to make progress on the reduction of ozone-depleting  substances, which are used at several of our legacy BD facilities.
","('Waste_And_Hazardous_Materials_Management', 0.9799291491508484)","('Air_Quality', 0.002757870126515627)","('Water_And_Wastewater_Management', 0.0020854694303125143)","(['Operational Eco-Efficiency'], 0.9799291491508484)","('NON-ESG', 0.002757870126515627)","('NON-ESG', 0.0020854694303125143)"
Line 851,"Conversion plans to eliminate the use of HCFC141b remain in  progress and are expected to be completed as scheduled.Air emissionsClick here to view the  Waste data tables .
","('Air_Quality', 0.978743851184845)","('Critical_Incident_Risk_Management', 0.0017671756213530898)","('GHG_Emissions', 0.0017542880959808826)","(['Operational Eco-Efficiency'], 0.978743851184845)","('NON-ESG', 0.0017671756213530898)","('NON-ESG', 0.0017542880959808826)"
Line 852,"Click here to view the Air emissions data tables .
","('Air_Quality', 0.9753995537757874)","('Waste_And_Hazardous_Materials_Management', 0.002099535660818219)","('GHG_Emissions', 0.002076941542327404)","(['Operational Eco-Efficiency'], 0.9753995537757874)","('NON-ESG', 0.002099535660818219)","('NON-ESG', 0.002076941542327404)"
Line 853,"Our EtO sterilization facilities in Covington and Madison,  Georgia (U.S.) are among the first in the industry to install dry  bed scrubber systems, a new innovative emission control  system designed to reduce fugitive (i.e., trace) emissions that  occur from product off-gassing after the sterilization process is  complete.
","('Air_Quality', 0.9624621272087097)","('Critical_Incident_Risk_Management', 0.00494654756039381)","('Energy_Management', 0.004826192278414965)","(['Operational Eco-Efficiency'], 0.9624621272087097)","('NON-ESG', 0.00494654756039381)","('NON-ESG', 0.004826192278414965)"
Line 854,"Both facilities are already equipped with  regenerative thermal oxidizers (RTOs), the best available  emission control technology, to destroy EtO emitted from the sterilization process.
","('Air_Quality', 0.967441976070404)","('Energy_Management', 0.005653930827975273)","('GHG_Emissions', 0.003218208672478795)","(['Operational Eco-Efficiency'], 0.967441976070404)","('NON-ESG', 0.005653930827975273)","('NON-ESG', 0.003218208672478795)"
Line 855,"The combination of the new dry bed  scrubber systems to control fugitive emissions and the existing  RTOs to control point source emissions makes the Covington  and Madison facilities two of the most sophisticated EtO  sterilization facilities in the world.
","('Air_Quality', 0.8115414977073669)","('GHG_Emissions', 0.11494819819927216)","('Energy_Management', 0.013343212194740772)","(['Operational Eco-Efficiency'], 0.8115414977073669)","('NON-ESG', 0.11494819819927216)","('NON-ESG', 0.013343212194740772)"
Line 856,"At our Covington facility, for  example, these new upgrades have reduced EtO emissions at  the facility by an additional 94%.Reducing EtO emissions For more information about our EtO facilities in Georgia, please  visit the EtO safety page on our website .Innovation               Access                     Empowerment       Efficiency                52Environment, Health and Safety (EHS) management We set expectations of EHS management via three  key documents: • Our EHS policy • Our Code of Conduct • Our Expectation for Suppliers At the corporate level, BD has an EHS team, led by the VP of  EHS&S; the VP EHS&S reports to the company’s executive VP  Integrated Supply Chain (EVP ISC).
","('Air_Quality', 0.4535510838031769)","('Product_Quality_And_Safety', 0.27919745445251465)","('Employee_Health_And_Safety', 0.06009334698319435)","('NON-ESG', 0.4535510838031769)","('NON-ESG', 0.27919745445251465)","('NON-ESG', 0.06009334698319435)"
Line 857,"At our Covington facility, for  example, these new upgrades have reduced EtO emissions at  the facility by an additional 94%.Reducing EtO emissions For more information about our EtO facilities in Georgia, please  visit the EtO safety page on our website .Innovation               Access                     Empowerment       Efficiency                52Environment, Health and Safety (EHS) management We set expectations of EHS management via three  key documents: • Our EHS policy • Our Code of Conduct • Our Expectation for Suppliers At the corporate level, BD has an EHS team, led by the VP of  EHS&S; the VP EHS&S reports to the company’s executive VP  Integrated Supply Chain (EVP ISC).
","('Supply_Chain_Management', 0.9425496459007263)","('Labor_Practices', 0.004624588880687952)","('Physical_Impacts_Of_Climate_Change', 0.0039412230253219604)","(['Supply Chain Management'], 0.9425496459007263)","('NON-ESG', 0.004624588880687952)","('NON-ESG', 0.0039412230253219604)"
Line 858,"Reporting to the VP EHS&S  are the following individuals with responsibility for EHS activities.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7086873650550842)","('Human_Rights_And_Community_Relations', 0.04409833997488022)","('Director_Removal', 0.02592250518500805)","(['Corporate Governance'], 0.7086873650550842)","('NON-ESG', 0.04409833997488022)","('NON-ESG', 0.02592250518500805)"
Line 859,"• Director, EHS Governance & Compliance.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7202921509742737)","('Business_Ethics', 0.052320320159196854)","('Business_Model_Resilience', 0.02628283016383648)","(['Corporate Governance'], 0.7202921509742737)","('NON-ESG', 0.052320320159196854)","('NON-ESG', 0.02628283016383648)"
Line 860,"This individual is  responsible for governance and compliance activities,  including the company’s internal EHS audit program, EHS  standards and training programs and communicating EHS  matters to relevant stakeholders throughout the organization.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6173533797264099)","('Business_Ethics', 0.24063964188098907)","('Product_Quality_And_Safety', 0.030241569504141808)","(['Corporate Governance'], 0.6173533797264099)","('NON-ESG', 0.24063964188098907)","('NON-ESG', 0.030241569504141808)"
Line 861,"This individual also oversees the Global EHS Advisory Council  (see the Empowerment  section for further information).
","('Management_Of_Legal_And_Regulatory_Framework', 0.8659992218017578)","('Director_Removal', 0.017517687752842903)","('Business_Ethics', 0.012878227978944778)","(['Corporate Governance'], 0.8659992218017578)","('NON-ESG', 0.017517687752842903)","('NON-ESG', 0.012878227978944778)"
Line 862,"• Director, Sustainability.
","('Product_Design_And_Lifecycle_Management', 0.15307851135730743)","('Business_Model_Resilience', 0.14870105683803558)","('Supply_Chain_Management', 0.10639584064483643)","('NON-ESG', 0.15307851135730743)","('NON-ESG', 0.14870105683803558)","('NON-ESG', 0.10639584064483643)"
Line 863,"In addition to stakeholder  engagement and development of the company’s  sustainability strategy, this individual is responsible for the  development of the company’s water stewardship and waste  management programs; and management of the company’s  EHS information management systems.
","('Water_And_Wastewater_Management', 0.9265426993370056)","('Ecological_Impacts', 0.018898779526352882)","('GHG_Emissions', 0.007385217119008303)","(['Operational Eco-Efficiency'], 0.9265426993370056)","('NON-ESG', 0.018898779526352882)","('NON-ESG', 0.007385217119008303)"
Line 864,"The VP EHS&S engages directly with the executive leadership  team and provides a report on EHS activities to the Board on an  annual basis.
","('Director_Removal', 0.6824329495429993)","('Management_Of_Legal_And_Regulatory_Framework', 0.04421653971076012)","('Business_Model_Resilience', 0.04144256189465523)","(['Anti-Crime Policy & Measures'], 0.6824329495429993)","('NON-ESG', 0.04421653971076012)","('NON-ESG', 0.04144256189465523)"
Line 865,"The Corporate Governance and Nominating  Committee oversees matters that involve the company’s image,  reputation and our standing as a responsible corporate citizen;  this includes EHS matters.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7378113269805908)","('Director_Removal', 0.06564266979694366)","('Business_Ethics', 0.04555574432015419)","(['Corporate Governance'], 0.7378113269805908)","('NON-ESG', 0.06564266979694366)","('NON-ESG', 0.04555574432015419)"
Line 866,"Training At a corporate level, we provide various training to our associates,  including new hire orientation to EHS professionals; training on  new or revised corporate EHS standards, internal EHS auditor  training and ongoing training for our EHS management of  information systems.
","('Product_Quality_And_Safety', 0.2569907307624817)","('Management_Of_Legal_And_Regulatory_Framework', 0.21734347939491272)","('Access_And_Affordability', 0.09642007201910019)","('NON-ESG', 0.2569907307624817)","('NON-ESG', 0.21734347939491272)","('NON-ESG', 0.09642007201910019)"
Line 867,"We use a variety of training mediums,  including classroom training, webinars and on-demand  compliance training via our online training system.
","('Access_And_Affordability', 0.18979960680007935)","('Management_Of_Legal_And_Regulatory_Framework', 0.17695684731006622)","('Product_Quality_And_Safety', 0.1253242939710617)","('NON-ESG', 0.18979960680007935)","('NON-ESG', 0.17695684731006622)","('NON-ESG', 0.1253242939710617)"
Line 868,"In 2020, we  are enhancing governance structures around our training  programs to consider our expanded operations following the  acquisition of Bard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8562922477722168)","('Director_Removal', 0.030565237626433372)","('Business_Ethics', 0.012549661099910736)","(['Corporate Governance'], 0.8562922477722168)","('NON-ESG', 0.030565237626433372)","('NON-ESG', 0.012549661099910736)"
Line 869,"Individual sites are responsible for identifying site-specific EHS  training needs and implementing training programs on a variety  of EHS topics, taking into consideration the risks that are present  and any local regulatory requirements.
","('Management_Of_Legal_And_Regulatory_Framework', 0.9619016647338867)","('Product_Quality_And_Safety', 0.004087002016603947)","('Access_And_Affordability', 0.002848547650501132)","(['Corporate Governance'], 0.9619016647338867)","('NON-ESG', 0.004087002016603947)","('NON-ESG', 0.002848547650501132)"
Line 870,"EHS Management Information Systems Internal Audits We have a global internal audit program covering all BD  locations.
","('Business_Ethics', 0.8644827604293823)","('Management_Of_Legal_And_Regulatory_Framework', 0.031130492687225342)","('Systemic_Risk_Management', 0.021999888122081757)","(['Business Ethics'], 0.8644827604293823)","('NON-ESG', 0.031130492687225342)","('NON-ESG', 0.021999888122081757)"
Line 871,"Audits are typically carried out by a third party and are  occasionally supported by associates from the corporate EHS  team.
","('Business_Ethics', 0.5744137763977051)","('Management_Of_Legal_And_Regulatory_Framework', 0.2563430964946747)","('Systemic_Risk_Management', 0.03528881445527077)","(['Business Ethics'], 0.5744137763977051)","('NON-ESG', 0.2563430964946747)","('NON-ESG', 0.03528881445527077)"
Line 872,"Frequency of audits are on a risk basis, determined by  factors such as type, size and scale of operations and previous  audit findings.
","('Business_Ethics', 0.38149309158325195)","('Management_Of_Legal_And_Regulatory_Framework', 0.24070383608341217)","('Systemic_Risk_Management', 0.16285352408885956)","('NON-ESG', 0.38149309158325195)","('NON-ESG', 0.24070383608341217)","('NON-ESG', 0.16285352408885956)"
Line 873,"Audit reports from each audit are provided to site  management, operational leaders, EVP ISC and the CEO.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6166304349899292)","('Business_Ethics', 0.18585486710071564)","('Systemic_Risk_Management', 0.040550485253334045)","(['Corporate Governance'], 0.6166304349899292)","('NON-ESG', 0.18585486710071564)","('NON-ESG', 0.040550485253334045)"
Line 874,"All  corrective actions are tracked to closure, with a follow-up audit  carried out approximately 12 months later.We use global EHS Management Information Systems,   provided by third-party vendors, to collect and manage   EHS information, including:• EHS incident reporting (including near misses) and corrective  action tracking • EHS performance metric reporting and tracking • Safety data sheet management EHS Management Systems To ensure continuous improvement of environmental  performance at a facility level, BD is implementing ISO  14001-certified environmental management systems at our  manufacturing sites around the world.
","('Employee_Health_And_Safety', 0.5723304748535156)","('Critical_Incident_Risk_Management', 0.35403579473495483)","('Air_Quality', 0.007778584491461515)","(['Operational Eco-Efficiency'], 0.5723304748535156)","('NON-ESG', 0.35403579473495483)","('NON-ESG', 0.007778584491461515)"
Line 875,"All  corrective actions are tracked to closure, with a follow-up audit  carried out approximately 12 months later.We use global EHS Management Information Systems,   provided by third-party vendors, to collect and manage   EHS information, including:• EHS incident reporting (including near misses) and corrective  action tracking • EHS performance metric reporting and tracking • Safety data sheet management EHS Management Systems To ensure continuous improvement of environmental  performance at a facility level, BD is implementing ISO  14001-certified environmental management systems at our  manufacturing sites around the world.
","('Product_Design_And_Lifecycle_Management', 0.7757706046104431)","('Energy_Management', 0.06187047064304352)","('Product_Quality_And_Safety', 0.02959022857248783)","(['Product Stewardship'], 0.7757706046104431)","('NON-ESG', 0.06187047064304352)","('NON-ESG', 0.02959022857248783)"
Line 876,"Currently, 46 BD sites  have ISO 14001-certified environmental management systems;  most of these sites are manufacturing locations, but also  includes HQ offices and some sales offices in Europe.
","('Product_Design_And_Lifecycle_Management', 0.4104142189025879)","('Product_Quality_And_Safety', 0.22226566076278687)","('Supply_Chain_Management', 0.04781441017985344)","('NON-ESG', 0.4104142189025879)","('NON-ESG', 0.22226566076278687)","('NON-ESG', 0.04781441017985344)"
Line 877,"Around two-thirds of these certified locations are part of a group  certificate, where we have established standardized procedures  and methods for program implementation.
","('Management_Of_Legal_And_Regulatory_Framework', 0.48568496108055115)","('Product_Quality_And_Safety', 0.14489391446113586)","('Human_Rights_And_Community_Relations', 0.0647311881184578)","('NON-ESG', 0.48568496108055115)","('NON-ESG', 0.14489391446113586)","('NON-ESG', 0.0647311881184578)"
Line 878,"This standardized  approach allows sites to work together in a collaborative way  with extensive sharing and interaction to enhance program  effectiveness.
","('Access_And_Affordability', 0.39337578415870667)","('Management_Of_Legal_And_Regulatory_Framework', 0.22261810302734375)","('Human_Rights_And_Community_Relations', 0.10423155128955841)","('NON-ESG', 0.39337578415870667)","('NON-ESG', 0.22261810302734375)","('NON-ESG', 0.10423155128955841)"
Line 879,"For example, all corrective actions are logged and  shared with all sites in the respective group certificates to  facilitate learning from each other’s experience and to take  proactive actions to prevent similar issues happening at other Innovation               Access                     Empowerment       Efficiency                532020 goal Establish  supplier responsibility evaluation methodology Supplier risk management is a major focus area for BD.
","('Supply_Chain_Management', 0.9474470615386963)","('Labor_Practices', 0.005233062896877527)","('Product_Design_And_Lifecycle_Management', 0.003994239494204521)","(['Supply Chain Management'], 0.9474470615386963)","('NON-ESG', 0.005233062896877527)","('NON-ESG', 0.003994239494204521)"
Line 880,"The overarching strategy of the risk program is to enable  processes and procedures that reduce or eliminate the likelihood  and minimize the impact of a supplier event that could affect  the company’s continuity of supply.
","('Supply_Chain_Management', 0.9516933560371399)","('Labor_Practices', 0.004318085964769125)","('Water_And_Wastewater_Management', 0.0039258250035345554)","(['Supply Chain Management'], 0.9516933560371399)","('NON-ESG', 0.004318085964769125)","('NON-ESG', 0.0039258250035345554)"
Line 881,"We have developed a robust  assessment process to identify our ”critical to healthcare”  products, which has allowed us to prioritize preventative risk  management best practices for not only our significant financial  impacting products but also those critical to the healthcare  market.
","('Product_Design_And_Lifecycle_Management', 0.9088985323905945)","('Product_Quality_And_Safety', 0.015648100525140762)","('Supply_Chain_Management', 0.011721791699528694)","(['Product Stewardship'], 0.9088985323905945)","('NON-ESG', 0.015648100525140762)","('NON-ESG', 0.011721791699528694)"
Line 882,"With a top-down directive on risk management, we are  implementing an enhanced risk model with a consistent  framework across all of our business units to assess, identify, prioritize, mitigate and monitor top risks.
","('Systemic_Risk_Management', 0.9451141357421875)","('Business_Model_Resilience', 0.012471199966967106)","('Physical_Impacts_Of_Climate_Change', 0.006238951813429594)","(['Risk & Crisis Management'], 0.9451141357421875)","('NON-ESG', 0.012471199966967106)","('NON-ESG', 0.006238951813429594)"
Line 883,"The program takes a  quantifiable approach to assess multiple risk factors, including  direct supplier-driven risks, such as operational and financial risk,  as well as indirect or market-driven risks, such as natural  disasters and geopolitical risks.
","('Supply_Chain_Management', 0.5656440854072571)","('Systemic_Risk_Management', 0.30521684885025024)","('Physical_Impacts_Of_Climate_Change', 0.03445185348391533)","(['Supply Chain Management'], 0.5656440854072571)","('NON-ESG', 0.30521684885025024)","('NON-ESG', 0.03445185348391533)"
Line 884,"Additionally, we have formed a   cross-functional crisis management team to proactively  monitor and respond to events around the world that may  impact our supply chain.
","('Supply_Chain_Management', 0.9527315497398376)","('Physical_Impacts_Of_Climate_Change', 0.004490721505135298)","('Systemic_Risk_Management', 0.0038124453276395798)","(['Supply Chain Management'], 0.9527315497398376)","('NON-ESG', 0.004490721505135298)","('NON-ESG', 0.0038124453276395798)"
Line 885,"The program will continue to evolve   as we leverage sophisticated technologies to aid us in our  journey to resiliency.sites.
","('Business_Model_Resilience', 0.9148818254470825)","('Physical_Impacts_Of_Climate_Change', 0.010587470605969429)","('Supply_Chain_Management', 0.008842295967042446)","(['Codes of Business Conduct'], 0.9148818254470825)","('NON-ESG', 0.010587470605969429)","('NON-ESG', 0.008842295967042446)"
Line 886,"Furthermore, every EMS-certified site sets environmental  improvement objectives on an annual basis and these are  reviewed for progress quarterly.
","('Product_Design_And_Lifecycle_Management', 0.17544886469841003)","('Ecological_Impacts', 0.16547144949436188)","('Human_Rights_And_Community_Relations', 0.11133745312690735)","('NON-ESG', 0.17544886469841003)","('NON-ESG', 0.16547144949436188)","('NON-ESG', 0.11133745312690735)"
Line 887,"Our plan is to continue ISO 14001 certification of remaining BD  manufacturing plants over the coming years.
","('Product_Quality_And_Safety', 0.42622697353363037)","('Product_Design_And_Lifecycle_Management', 0.28931209444999695)","('Management_Of_Legal_And_Regulatory_Framework', 0.026488138362765312)","('NON-ESG', 0.42622697353363037)","('NON-ESG', 0.28931209444999695)","('NON-ESG', 0.026488138362765312)"
Line 888,"The ISO 50001 energy management standard provides a  framework of requirements to measure and use data for better  understanding of energy use, set objectives for energy use  reduction and continually improve energy management.
","('Energy_Management', 0.9808021783828735)","('Management_Of_Legal_And_Regulatory_Framework', 0.0019610102754086256)","('Air_Quality', 0.001750160357914865)","(['Operational Eco-Efficiency'], 0.9808021783828735)","('NON-ESG', 0.0019610102754086256)","('NON-ESG', 0.001750160357914865)"
Line 889,"Many  BD facilities have a strong focus on energy management and  reduction and are pursuing many aspects of a responsible  energy management program.
","('Energy_Management', 0.9798905849456787)","('Air_Quality', 0.002157552633434534)","('Critical_Incident_Risk_Management', 0.001936158281750977)","(['Operational Eco-Efficiency'], 0.9798905849456787)","('NON-ESG', 0.002157552633434534)","('NON-ESG', 0.001936158281750977)"
Line 890,"We currently have four facilities  in Spain, Hungary and Germany that have implemented energy  management systems which are certified to ISO 50001.
","('Energy_Management', 0.9459044337272644)","('Product_Design_And_Lifecycle_Management', 0.009713645093142986)","('Management_Of_Legal_And_Regulatory_Framework', 0.004759298171848059)","(['Operational Eco-Efficiency'], 0.9459044337272644)","('NON-ESG', 0.009713645093142986)","('NON-ESG', 0.004759298171848059)"
Line 891,"All BD manufacturing locations have strong focus on  Occupational Health & Safety (OHS) management for injury reduction and prevention.
","('Employee_Health_And_Safety', 0.9849081039428711)","('Employee_Engagement_Inclusion_And_Diversity', 0.0017357275355607271)","('Critical_Incident_Risk_Management', 0.001354640698991716)","(['Operational Eco-Efficiency'], 0.9849081039428711)","('NON-ESG', 0.0017357275355607271)","('NON-ESG', 0.001354640698991716)"
Line 892,"Significant OHS risks associated with  our activities are identified and reviewed for elimination and/or  control to minimize their potential effects on our employees.
","('Systemic_Risk_Management', 0.6387709379196167)","('Employee_Health_And_Safety', 0.10514277964830399)","('Supply_Chain_Management', 0.06784985214471817)","(['Risk & Crisis Management'], 0.6387709379196167)","('NON-ESG', 0.10514277964830399)","('NON-ESG', 0.06784985214471817)"
Line 893,"The  most accepted OHS management system in the past has been  the OHSAS-18001 standard and two BD sites in Spain and China  are certified in this standard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4410908818244934)","('Product_Quality_And_Safety', 0.08857810497283936)","('Systemic_Risk_Management', 0.07776784896850586)","('NON-ESG', 0.4410908818244934)","('NON-ESG', 0.08857810497283936)","('NON-ESG', 0.07776784896850586)"
Line 894,"OHSAS-18001 standard is currently  being replaced by ISO-45001 and both of our sites will convert to  this new standard before the deadline of March 2021.
","('Management_Of_Legal_And_Regulatory_Framework', 0.35212135314941406)","('Product_Quality_And_Safety', 0.32271143794059753)","('Product_Design_And_Lifecycle_Management', 0.0297049842774868)","('NON-ESG', 0.35212135314941406)","('NON-ESG', 0.32271143794059753)","('NON-ESG', 0.0297049842774868)"
Line 895,"Although  our other sites are currently not formally certified in any OHS  standard, their site safety programs follow many of the elements  included in the OHSAS-18001/ISO-45001 standards.
","('Product_Quality_And_Safety', 0.6205521821975708)","('Employee_Health_And_Safety', 0.21340572834014893)","('Business_Ethics', 0.031633976846933365)","(['Product Quality & Recall Management'], 0.6205521821975708)","('NON-ESG', 0.21340572834014893)","('NON-ESG', 0.031633976846933365)"
Line 896,"For additional details on work carried out in FY 2019 related to  associate safety, please see our goal around achieving best-in- class associate safety performance in the Empowerment   section of this report.
","('Product_Quality_And_Safety', 0.8005437850952148)","('Employee_Health_And_Safety', 0.08797203749418259)","('Access_And_Affordability', 0.013298955745995045)","(['Product Quality & Recall Management'], 0.8005437850952148)","('NON-ESG', 0.08797203749418259)","('NON-ESG', 0.013298955745995045)"
Line 897,"GRI disclosures: 403-1, 403-5Innovation               Access                     Empowerment       Efficiency                54Supplier Diversity Program: percent of spend by designation 50% 0%40% 30% 20% 10% FY 2013 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014Total div erse spend Disability owne d Veteran owne d Woman owne dMinority/W oman owne d Minority owne dDiversity per cent of eligible spend by designations tr acke dSupplier diversity encompasses more than simply tracking  spending or “doing the right thing”—it supports our business  objectives.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9680136442184448)","('Business_Model_Resilience', 0.002770761726424098)","('Employee_Health_And_Safety', 0.002271378645673394)","(['Human Capital Development'], 0.9680136442184448)","('NON-ESG', 0.002770761726424098)","('NON-ESG', 0.002271378645673394)"
Line 898,"GRI disclosures: 403-1, 403-5Innovation               Access                     Empowerment       Efficiency                54Supplier Diversity Program: percent of spend by designation 50% 0%40% 30% 20% 10% FY 2013 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014Total div erse spend Disability owne d Veteran owne d Woman owne dMinority/W oman owne d Minority owne dDiversity per cent of eligible spend by designations tr acke dSupplier diversity encompasses more than simply tracking  spending or “doing the right thing”—it supports our business  objectives.
","('Business_Model_Resilience', 0.6026897430419922)","('Human_Rights_And_Community_Relations', 0.06185256317257881)","('Management_Of_Legal_And_Regulatory_Framework', 0.04366633668541908)","(['Codes of Business Conduct'], 0.6026897430419922)","('NON-ESG', 0.06185256317257881)","('NON-ESG', 0.04366633668541908)"
Line 899,"Being committed to supplier diversity entails  developing and implementing strategies that ensure our supply  base aligns with the diverse customers and communities we  serve, as well as the diverse markets we seek.
","('Supply_Chain_Management', 0.5135791301727295)","('Employee_Engagement_Inclusion_And_Diversity', 0.22565330564975739)","('Labor_Practices', 0.040263909846544266)","(['Supply Chain Management'], 0.5135791301727295)","('NON-ESG', 0.22565330564975739)","('NON-ESG', 0.040263909846544266)"
Line 900,"Further details on our Supplier Diversity Program can be found  on our website .
","('Employee_Engagement_Inclusion_And_Diversity', 0.885101318359375)","('Supply_Chain_Management', 0.015128434635698795)","('Human_Rights_And_Community_Relations', 0.008765670470893383)","(['Human Capital Development'], 0.885101318359375)","('NON-ESG', 0.015128434635698795)","('NON-ESG', 0.008765670470893383)"
Line 901,"While we remain committed to increasing the number of small  and diverse-owned businesses in our supply chain, our supplier  diversity performance was negatively impacted in FY 2019 due  to a number of factors.
","('Supply_Chain_Management', 0.9090504050254822)","('Labor_Practices', 0.01412672083824873)","('Employee_Engagement_Inclusion_And_Diversity', 0.007988089695572853)","(['Supply Chain Management'], 0.9090504050254822)","('NON-ESG', 0.01412672083824873)","('NON-ESG', 0.007988089695572853)"
Line 902,"Firstly, total reported procurement spend increased due to the  inclusion of Bard.
","('Supply_Chain_Management', 0.2752893567085266)","('Energy_Management', 0.19502195715904236)","('Product_Design_And_Lifecycle_Management', 0.12008611112833023)","('NON-ESG', 0.2752893567085266)","('NON-ESG', 0.19502195715904236)","('NON-ESG', 0.12008611112833023)"
Line 903,"However, as Bard supplier diversity data was not aligned with legacy BD data, we have been unable to include  Bard data in our FY 2019 performance data.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6129238605499268)","('Supply_Chain_Management', 0.09031602740287781)","('Labor_Practices', 0.046970486640930176)","(['Human Capital Development'], 0.6129238605499268)","('NON-ESG', 0.09031602740287781)","('NON-ESG', 0.046970486640930176)"
Line 904,"Secondly, as part of efforts to reduce overall procurement spend,  work continued in FY 2019 to implement a managed service  provider strategy.
","('Supply_Chain_Management', 0.522722065448761)","('Product_Design_And_Lifecycle_Management', 0.09141545742750168)","('Energy_Management', 0.08337363600730896)","(['Supply Chain Management'], 0.522722065448761)","('NON-ESG', 0.09141545742750168)","('NON-ESG', 0.08337363600730896)"
Line 905,"This has reduced the number of small and  diverse-owned businesses who are our tier 1 suppliers.
","('Supply_Chain_Management', 0.9005540609359741)","('Product_Design_And_Lifecycle_Management', 0.013521121814846992)","('Labor_Practices', 0.008777765557169914)","(['Supply Chain Management'], 0.9005540609359741)","('NON-ESG', 0.013521121814846992)","('NON-ESG', 0.008777765557169914)"
Line 906,"At this  time, we are only able to capture spend with our tier 1 suppliers  and this is reflected in the data presented.
","('Supply_Chain_Management', 0.9189834594726562)","('Systemic_Risk_Management', 0.010120242834091187)","('GHG_Emissions', 0.007577244192361832)","(['Supply Chain Management'], 0.9189834594726562)","('NON-ESG', 0.010120242834091187)","('NON-ESG', 0.007577244192361832)"
Line 907,"We are in the process of revising our data tracking and  management systems.
","('Customer_Privacy', 0.5538322329521179)","('Data_Security', 0.2577051520347595)","('Business_Model_Resilience', 0.024902628734707832)","(['Privacy Protection'], 0.5538322329521179)","('NON-ESG', 0.2577051520347595)","('NON-ESG', 0.024902628734707832)"
Line 908,"This will allow us to capture, track and  report spend with small and diverse-owned businesses who are  tier 2 suppliers, via our managed service providers.
","('Supply_Chain_Management', 0.8937091827392578)","('Product_Design_And_Lifecycle_Management', 0.014353415928781033)","('Customer_Welfare', 0.011166485957801342)","(['Supply Chain Management'], 0.8937091827392578)","('NON-ESG', 0.014353415928781033)","('NON-ESG', 0.011166485957801342)"
Line 909,"We will also  close remaining gaps in tracking and reporting supplier diversity  spend from legacy Bard.Supplier Diversity ProgramInnovation               Access                     Empowerment       Efficiency                55BD actively engages in dialogue with our customers and  advocacy groups to understand their position on the use of safer  chemicals for consideration in our work to eliminate priority  MOC.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8751335144042969)","('Supply_Chain_Management', 0.01865638606250286)","('Labor_Practices', 0.012677658349275589)","(['Human Capital Development'], 0.8751335144042969)","('NON-ESG', 0.01865638606250286)","('NON-ESG', 0.012677658349275589)"
Line 910,"This engagement includes our continued response to the  Chemical Footprint Project.
","('GHG_Emissions', 0.48228445649147034)","('Supply_Chain_Management', 0.08977629989385605)","('Business_Model_Resilience', 0.06736260652542114)","('NON-ESG', 0.48228445649147034)","('NON-ESG', 0.08977629989385605)","('NON-ESG', 0.06736260652542114)"
Line 911,"The mission of the Chemical  Footprint Project  is to transform global chemical use by measuring and disclosing data on business progress to safer  chemicals.
","('Waste_And_Hazardous_Materials_Management', 0.24760866165161133)","('Selling_Practices_And_Product_Labeling', 0.16026994585990906)","('Product_Quality_And_Safety', 0.12957389652729034)","('NON-ESG', 0.24760866165161133)","('NON-ESG', 0.16026994585990906)","('NON-ESG', 0.12957389652729034)"
Line 912,"It provides a tool for benchmarking companies as  they select safer alternatives and reduce their use of chemicals  of high concern.
","('Product_Quality_And_Safety', 0.2760327160358429)","('Customer_Welfare', 0.19458262622356415)","('Product_Design_And_Lifecycle_Management', 0.1930207759141922)","('NON-ESG', 0.2760327160358429)","('NON-ESG', 0.19458262622356415)","('NON-ESG', 0.1930207759141922)"
Line 913,"As in previous years, we have chosen to make  our response public.Chemical Footprint Project2020 goal Reduce  priority materials of concern in specified product categories As part of the BD portfolio of IV products, we introduced a  variety of IV solutions in different sizes for intravenous  administration.
","('Product_Design_And_Lifecycle_Management', 0.5963512659072876)","('Customer_Welfare', 0.16696079075336456)","('Product_Quality_And_Safety', 0.06090656667947769)","(['Product Stewardship'], 0.5963512659072876)","('NON-ESG', 0.16696079075336456)","('NON-ESG', 0.06090656667947769)"
Line 914,"These products also help move forward our  broader goal of reducing priority materials of concern in  specified product categories.
","('Product_Design_And_Lifecycle_Management', 0.9581425786018372)","('Product_Quality_And_Safety', 0.0060404459945857525)","('Selling_Practices_And_Product_Labeling', 0.005164969712495804)","(['Product Stewardship'], 0.9581425786018372)","('NON-ESG', 0.0060404459945857525)","('NON-ESG', 0.005164969712495804)"
Line 915,"The free flex® bag * is a multilayer  polyolefin film that is non-PVC and non-DEHP.
","('Product_Design_And_Lifecycle_Management', 0.37054145336151123)","('Energy_Management', 0.2270042896270752)","('Water_And_Wastewater_Management', 0.04901541396975517)","('NON-ESG', 0.37054145336151123)","('NON-ESG', 0.2270042896270752)","('NON-ESG', 0.04901541396975517)"
Line 916,"The bag is not  made with natural rubber latex.
","('Product_Design_And_Lifecycle_Management', 0.39527785778045654)","('Waste_And_Hazardous_Materials_Management', 0.08195023238658905)","('Access_And_Affordability', 0.06166243553161621)","('NON-ESG', 0.39527785778045654)","('NON-ESG', 0.08195023238658905)","('NON-ESG', 0.06166243553161621)"
Line 917,"The container closures are also  not made with natural rubber latex and are non-PVC  and non-DEHP.
","('Product_Design_And_Lifecycle_Management', 0.6136727333068848)","('Waste_And_Hazardous_Materials_Management', 0.13193263113498688)","('Product_Quality_And_Safety', 0.04356943815946579)","(['Product Stewardship'], 0.6136727333068848)","('NON-ESG', 0.13193263113498688)","('NON-ESG', 0.04356943815946579)"
Line 918,"These IV solution products include various sizes of 0.9% sodium  chloride injection, Lactated Ringer’s injection, 5% dextrose  injection and 0.45% sodium chloride injection, as listed on  our website .BD® IV Fluids *free flex® is a registered trademark of Fresenius Kabi.
","('Customer_Welfare', 0.24601732194423676)","('Water_And_Wastewater_Management', 0.12857800722122192)","('Waste_And_Hazardous_Materials_Management', 0.0981835275888443)","('NON-ESG', 0.24601732194423676)","('NON-ESG', 0.12857800722122192)","('NON-ESG', 0.0981835275888443)"
Line 919,"Manufactured by Fresenius Kabi.
","('Product_Design_And_Lifecycle_Management', 0.7350758910179138)","('Energy_Management', 0.036186978220939636)","('Supply_Chain_Management', 0.02746814489364624)","(['Product Stewardship'], 0.7350758910179138)","('NON-ESG', 0.036186978220939636)","('NON-ESG', 0.02746814489364624)"
Line 920,"BD is working to reduce priority materials   of concern * in each of the following  product categories: Devices:    PVC and phthalates Instruments:    Phthalates, brominated flame retardants (BFRs)   and heavy metals Packaging: PVC and expanded polystyrene *Intentionally addedInnovation               Access                     Empowerment       Efficiency                56BD continues to focus efforts on improving the life cycle impacts  of our products.
","('Product_Design_And_Lifecycle_Management', 0.9636498689651489)","('Energy_Management', 0.004774740897119045)","('Product_Quality_And_Safety', 0.0037405637558549643)","(['Product Stewardship'], 0.9636498689651489)","('NON-ESG', 0.004774740897119045)","('NON-ESG', 0.0037405637558549643)"
Line 921,"In 2019, we continued our engagement with the Healthcare  Plastics Recycling Council (HPRC) both in the United States and the European Union, and the Sustainable Healthcare Coalition  (SHC) in Europe.
","('Product_Design_And_Lifecycle_Management', 0.6502111554145813)","('Waste_And_Hazardous_Materials_Management', 0.05642043054103851)","('Energy_Management', 0.048436082899570465)","(['Product Stewardship'], 0.6502111554145813)","('NON-ESG', 0.05642043054103851)","('NON-ESG', 0.048436082899570465)"
Line 922,"The activities we undertake as part of our  engagement with these entities support, among other projects,  our efforts to limit and minimize waste produced during the life  cycle of our products.
","('Waste_And_Hazardous_Materials_Management', 0.7911936044692993)","('Product_Design_And_Lifecycle_Management', 0.1207590401172638)","('Product_Quality_And_Safety', 0.00963145587593317)","(['Operational Eco-Efficiency'], 0.7911936044692993)","('NON-ESG', 0.1207590401172638)","('NON-ESG', 0.00963145587593317)"
Line 923,"Product takeback2020 goal Improve  life cycle impacts of current and future products GRI disclosure: 301.3   SASB disclosure: HC-MS-410a.2Where required by law, we participate in compliance schemes to  ensure responsible collection, management and disposal  (including recycling) of packaging, batteries and waste electrical  and electronic equipment.
","('Product_Design_And_Lifecycle_Management', 0.9299889206886292)","('Waste_And_Hazardous_Materials_Management', 0.01626506634056568)","('Product_Quality_And_Safety', 0.008546697907149792)","(['Product Stewardship'], 0.9299889206886292)","('NON-ESG', 0.01626506634056568)","('NON-ESG', 0.008546697907149792)"
Line 924,"For details regarding product donation, please refer to the  Empowerment  section of this report.
","('Product_Design_And_Lifecycle_Management', 0.7228053212165833)","('Selling_Practices_And_Product_Labeling', 0.12364093214273453)","('Product_Quality_And_Safety', 0.033097803592681885)","(['Product Stewardship'], 0.7228053212165833)","('NON-ESG', 0.12364093214273453)","('NON-ESG', 0.033097803592681885)"
Line 925,"As noted in our FY 2018 Sustainability Report, we have  established a process at our facility in San Diego to manage the  end-of-life disposal of products from the BD Pyxis ™ Portfolio, by  recovering materials and components for refurbishment  or recycling.
","('Product_Design_And_Lifecycle_Management', 0.9641566276550293)","('Product_Quality_And_Safety', 0.003543280763551593)","('Selling_Practices_And_Product_Labeling', 0.0025673559866845608)","(['Product Stewardship'], 0.9641566276550293)","('NON-ESG', 0.003543280763551593)","('NON-ESG', 0.0025673559866845608)"
Line 926,"In FY 2019, 19,213 units were processed through our facility,  representing 2,750 metric tonnes of materials that were either  refurbished, reused or recycled.
","('Product_Design_And_Lifecycle_Management', 0.5938411951065063)","('Energy_Management', 0.14645600318908691)","('Waste_And_Hazardous_Materials_Management', 0.07564185559749603)","(['Product Stewardship'], 0.5938411951065063)","('NON-ESG', 0.14645600318908691)","('NON-ESG', 0.07564185559749603)"
Line 927,"We will continue to explore opportunities to improve the end-of- life disposal options for products through programs such as this.
","('Product_Design_And_Lifecycle_Management', 0.9643149971961975)","('Product_Quality_And_Safety', 0.004060199949890375)","('Selling_Practices_And_Product_Labeling', 0.0036518669221550226)","(['Product Stewardship'], 0.9643149971961975)","('NON-ESG', 0.004060199949890375)","('NON-ESG', 0.0036518669221550226)"
Line 928,"Where product take-back is not appropriate or viable, we will look  to alternatives—such cross-industry partnerships found in  HPRC—to make progress on our goal of improving the life cycle  impacts of our products.
","('Product_Design_And_Lifecycle_Management', 0.9656340479850769)","('Product_Quality_And_Safety', 0.00429571745917201)","('Selling_Practices_And_Product_Labeling', 0.003395318752154708)","(['Product Stewardship'], 0.9656340479850769)","('NON-ESG', 0.00429571745917201)","('NON-ESG', 0.003395318752154708)"
Line 929,"Innovation               Access                     Empowerment       Efficiency                57FY 2019 efficiency targets— performance data tables For most performance indicators, we have included data for legacy Bard back to our baseline year of FY 2008; however, in a few  instances, no historical data was available.
","('Energy_Management', 0.9557572603225708)","('Product_Design_And_Lifecycle_Management', 0.0071376049891114235)","('Management_Of_Legal_And_Regulatory_Framework', 0.0037676456850022078)","(['Operational Eco-Efficiency'], 0.9557572603225708)","('NON-ESG', 0.0071376049891114235)","('NON-ESG', 0.0037676456850022078)"
Line 930,"This is noted where applicable.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7064068913459778)","('Competitive_Behavior', 0.04938843101263046)","('Business_Ethics', 0.038861338049173355)","(['Corporate Governance'], 0.7064068913459778)","('NON-ESG', 0.04938843101263046)","('NON-ESG', 0.038861338049173355)"
Line 931,"We have strengthened our data collection processes by reviewing our reporting threshold.
","('Customer_Privacy', 0.3517003655433655)","('Data_Security', 0.20468029379844666)","('Management_Of_Legal_And_Regulatory_Framework', 0.05672586336731911)","('NON-ESG', 0.3517003655433655)","('NON-ESG', 0.20468029379844666)","('NON-ESG', 0.05672586336731911)"
Line 932,"This has increased the number of facilities  included in our reporting boundary.
","('Supply_Chain_Management', 0.16195718944072723)","('Customer_Welfare', 0.10481978952884674)","('Energy_Management', 0.08875688165426254)","('NON-ESG', 0.16195718944072723)","('NON-ESG', 0.10481978952884674)","('NON-ESG', 0.08875688165426254)"
Line 933,"Therefore, data has been restated.
","('Systemic_Risk_Management', 0.1994059830904007)","('Data_Security', 0.12078697234392166)","('Customer_Privacy', 0.10599340498447418)","('NON-ESG', 0.1994059830904007)","('NON-ESG', 0.12078697234392166)","('NON-ESG', 0.10599340498447418)"
Line 934,"To allow for year-on-year comparability and transparency, we are reporting performance data separately for both legacy BD and  Bard organizations across all performance indicators, in addition to combined performance data.
","('Business_Ethics', 0.8611953258514404)","('Systemic_Risk_Management', 0.03643890842795372)","('Management_Of_Legal_And_Regulatory_Framework', 0.01763583905994892)","(['Business Ethics'], 0.8611953258514404)","('NON-ESG', 0.03643890842795372)","('NON-ESG', 0.01763583905994892)"
Line 935,"Notes on data Efficiency data tables Solar panels installed at Canaan, CT site.
","('Energy_Management', 0.968306303024292)","('Management_Of_Legal_And_Regulatory_Framework', 0.004131434019654989)","('Product_Design_And_Lifecycle_Management', 0.003585312282666564)","(['Operational Eco-Efficiency'], 0.968306303024292)","('NON-ESG', 0.004131434019654989)","('NON-ESG', 0.003585312282666564)"
Line 936,"A total of 2.9 mega-watts are generated from solar panels at this site.
","('Energy_Management', 0.9637007117271423)","('Management_Of_Legal_And_Regulatory_Framework', 0.007780542131513357)","('GHG_Emissions', 0.002647659508511424)","(['Operational Eco-Efficiency'], 0.9637007117271423)","('NON-ESG', 0.007780542131513357)","('NON-ESG', 0.002647659508511424)"
Line 937,"Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope 1 and GRI disclosures: 305-1, 305-2, 305-4, 305-5Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,345 11,345 11,345 11,317 14,932 16,869 20,727 17,486 16,434 23,856 36,781 16,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 17 13 12 17 36 Scope 1 absolute (metric tonnes  CO2-e), legacy BD87,852 88,809 91,327 85,931 84,125 80,251 77,505 76,850 74,989 88,730 100,402 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 19 18 16 15 14 13 14 12 14 13 Scope 1 absolute (metric tonnes  CO2-e), combined99,197 100,154 102,672 97,249 99,057 97,120 98,232 94,336 91,424 112,585 137,183 118,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 18 17 15 15 14 13 14 12 15 16 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard65,713 65,800 62,976 63,338 62,380 63,281 68,212 75,016 73,554 78,335 70,006 65,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard70 70 62 59 56 54 55 58 55 54 69 Scope 2 absolute (metric tonnes  CO2-e), legacy BD530,133 511,114 430,824 377,152 310,580 249,722 266,936 226,888 169,073 164,483 145,002 175,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD112 108 84 71 56 44 44 41 26 27 19 Scope 2 absolute (metric tonnes  CO2-e), combined595,846 576,914 493,800 440,490 372,959 313,003 335,148 301,904 242,627 242,818 215,007 241,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined105 101 81 69 56 46 46 44 31 32 25 Total absolute (metric tonnes CO2-e),  legacy Bard77,058 77,145 74,320 74,656 77,312 80,150 88,939 92,502 89,989 102,190 106,787 82,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard83 82 73 69 69 68 71 71 67 71 105 % reduction from baseline -28% Total absolute (metric tonnes CO2-e),  legacy BD617,985 599,923 522,151 463,083 394,705 329,973 344,441 303,738 244,062 253,213 245,404 277,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD130 127 102 87 71 58 57 54 38 41 32 % reduction from baseline -72% Total absolute (metric tonnes CO2-e),  combined695,043 677,068 596,472 537,739 472,017 410,123 433,380 396,240 334,051 355,403 352,191 359,Total normalized (metric tonnes  CO2-e per $M COPS), combined122 119 97 84 71 60 59 58 43 47 40  2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.9591843485832214)","('Air_Quality', 0.010087057948112488)","('Ecological_Impacts', 0.0031666727736592293)","(['Climate Change'], 0.9591843485832214)","('NON-ESG', 0.010087057948112488)","('NON-ESG', 0.0031666727736592293)"
Line 938,"Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope 1 and GRI disclosures: 305-1, 305-2, 305-4, 305-5Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,345 11,345 11,345 11,317 14,932 16,869 20,727 17,486 16,434 23,856 36,781 16,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 17 13 12 17 36 Scope 1 absolute (metric tonnes  CO2-e), legacy BD87,852 88,809 91,327 85,931 84,125 80,251 77,505 76,850 74,989 88,730 100,402 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 19 18 16 15 14 13 14 12 14 13 Scope 1 absolute (metric tonnes  CO2-e), combined99,197 100,154 102,672 97,249 99,057 97,120 98,232 94,336 91,424 112,585 137,183 118,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 18 17 15 15 14 13 14 12 15 16 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard65,713 65,800 62,976 63,338 62,380 63,281 68,212 75,016 73,554 78,335 70,006 65,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard70 70 62 59 56 54 55 58 55 54 69 Scope 2 absolute (metric tonnes  CO2-e), legacy BD530,133 511,114 430,824 377,152 310,580 249,722 266,936 226,888 169,073 164,483 145,002 175,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD112 108 84 71 56 44 44 41 26 27 19 Scope 2 absolute (metric tonnes  CO2-e), combined595,846 576,914 493,800 440,490 372,959 313,003 335,148 301,904 242,627 242,818 215,007 241,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined105 101 81 69 56 46 46 44 31 32 25 Total absolute (metric tonnes CO2-e),  legacy Bard77,058 77,145 74,320 74,656 77,312 80,150 88,939 92,502 89,989 102,190 106,787 82,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard83 82 73 69 69 68 71 71 67 71 105 % reduction from baseline -28% Total absolute (metric tonnes CO2-e),  legacy BD617,985 599,923 522,151 463,083 394,705 329,973 344,441 303,738 244,062 253,213 245,404 277,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD130 127 102 87 71 58 57 54 38 41 32 % reduction from baseline -72% Total absolute (metric tonnes CO2-e),  combined695,043 677,068 596,472 537,739 472,017 410,123 433,380 396,240 334,051 355,403 352,191 359,Total normalized (metric tonnes  CO2-e per $M COPS), combined122 119 97 84 71 60 59 58 43 47 40  2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.726572573184967)","('Air_Quality', 0.029401293024420738)","('Water_And_Wastewater_Management', 0.02476639859378338)","(['Climate Change'], 0.726572573184967)","('NON-ESG', 0.029401293024420738)","('NON-ESG', 0.02476639859378338)"
Line 939,"Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope 1 and GRI disclosures: 305-1, 305-2, 305-4, 305-5Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,345 11,345 11,345 11,317 14,932 16,869 20,727 17,486 16,434 23,856 36,781 16,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 17 13 12 17 36 Scope 1 absolute (metric tonnes  CO2-e), legacy BD87,852 88,809 91,327 85,931 84,125 80,251 77,505 76,850 74,989 88,730 100,402 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 19 18 16 15 14 13 14 12 14 13 Scope 1 absolute (metric tonnes  CO2-e), combined99,197 100,154 102,672 97,249 99,057 97,120 98,232 94,336 91,424 112,585 137,183 118,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 18 17 15 15 14 13 14 12 15 16 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard65,713 65,800 62,976 63,338 62,380 63,281 68,212 75,016 73,554 78,335 70,006 65,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard70 70 62 59 56 54 55 58 55 54 69 Scope 2 absolute (metric tonnes  CO2-e), legacy BD530,133 511,114 430,824 377,152 310,580 249,722 266,936 226,888 169,073 164,483 145,002 175,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD112 108 84 71 56 44 44 41 26 27 19 Scope 2 absolute (metric tonnes  CO2-e), combined595,846 576,914 493,800 440,490 372,959 313,003 335,148 301,904 242,627 242,818 215,007 241,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined105 101 81 69 56 46 46 44 31 32 25 Total absolute (metric tonnes CO2-e),  legacy Bard77,058 77,145 74,320 74,656 77,312 80,150 88,939 92,502 89,989 102,190 106,787 82,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard83 82 73 69 69 68 71 71 67 71 105 % reduction from baseline -28% Total absolute (metric tonnes CO2-e),  legacy BD617,985 599,923 522,151 463,083 394,705 329,973 344,441 303,738 244,062 253,213 245,404 277,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD130 127 102 87 71 58 57 54 38 41 32 % reduction from baseline -72% Total absolute (metric tonnes CO2-e),  combined695,043 677,068 596,472 537,739 472,017 410,123 433,380 396,240 334,051 355,403 352,191 359,Total normalized (metric tonnes  CO2-e per $M COPS), combined122 119 97 84 71 60 59 58 43 47 40  2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.6984577775001526)","('Air_Quality', 0.033786725252866745)","('Water_And_Wastewater_Management', 0.029503924772143364)","(['Climate Change'], 0.6984577775001526)","('NON-ESG', 0.033786725252866745)","('NON-ESG', 0.029503924772143364)"
Line 940,"Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope 1 and GRI disclosures: 305-1, 305-2, 305-4, 305-5Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,345 11,345 11,345 11,317 14,932 16,869 20,727 17,486 16,434 23,856 36,781 16,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 17 13 12 17 36 Scope 1 absolute (metric tonnes  CO2-e), legacy BD87,852 88,809 91,327 85,931 84,125 80,251 77,505 76,850 74,989 88,730 100,402 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 19 18 16 15 14 13 14 12 14 13 Scope 1 absolute (metric tonnes  CO2-e), combined99,197 100,154 102,672 97,249 99,057 97,120 98,232 94,336 91,424 112,585 137,183 118,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 18 17 15 15 14 13 14 12 15 16 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard65,713 65,800 62,976 63,338 62,380 63,281 68,212 75,016 73,554 78,335 70,006 65,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard70 70 62 59 56 54 55 58 55 54 69 Scope 2 absolute (metric tonnes  CO2-e), legacy BD530,133 511,114 430,824 377,152 310,580 249,722 266,936 226,888 169,073 164,483 145,002 175,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD112 108 84 71 56 44 44 41 26 27 19 Scope 2 absolute (metric tonnes  CO2-e), combined595,846 576,914 493,800 440,490 372,959 313,003 335,148 301,904 242,627 242,818 215,007 241,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined105 101 81 69 56 46 46 44 31 32 25 Total absolute (metric tonnes CO2-e),  legacy Bard77,058 77,145 74,320 74,656 77,312 80,150 88,939 92,502 89,989 102,190 106,787 82,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard83 82 73 69 69 68 71 71 67 71 105 % reduction from baseline -28% Total absolute (metric tonnes CO2-e),  legacy BD617,985 599,923 522,151 463,083 394,705 329,973 344,441 303,738 244,062 253,213 245,404 277,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD130 127 102 87 71 58 57 54 38 41 32 % reduction from baseline -72% Total absolute (metric tonnes CO2-e),  combined695,043 677,068 596,472 537,739 472,017 410,123 433,380 396,240 334,051 355,403 352,191 359,Total normalized (metric tonnes  CO2-e per $M COPS), combined122 119 97 84 71 60 59 58 43 47 40  2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.6480740904808044)","('Waste_And_Hazardous_Materials_Management', 0.03203294053673744)","('Energy_Management', 0.031158100813627243)","(['Climate Change'], 0.6480740904808044)","('NON-ESG', 0.03203294053673744)","('NON-ESG', 0.031158100813627243)"
Line 941,"Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope 1 and GRI disclosures: 305-1, 305-2, 305-4, 305-5Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,345 11,345 11,345 11,317 14,932 16,869 20,727 17,486 16,434 23,856 36,781 16,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 17 13 12 17 36 Scope 1 absolute (metric tonnes  CO2-e), legacy BD87,852 88,809 91,327 85,931 84,125 80,251 77,505 76,850 74,989 88,730 100,402 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 19 18 16 15 14 13 14 12 14 13 Scope 1 absolute (metric tonnes  CO2-e), combined99,197 100,154 102,672 97,249 99,057 97,120 98,232 94,336 91,424 112,585 137,183 118,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 18 17 15 15 14 13 14 12 15 16 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard65,713 65,800 62,976 63,338 62,380 63,281 68,212 75,016 73,554 78,335 70,006 65,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard70 70 62 59 56 54 55 58 55 54 69 Scope 2 absolute (metric tonnes  CO2-e), legacy BD530,133 511,114 430,824 377,152 310,580 249,722 266,936 226,888 169,073 164,483 145,002 175,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD112 108 84 71 56 44 44 41 26 27 19 Scope 2 absolute (metric tonnes  CO2-e), combined595,846 576,914 493,800 440,490 372,959 313,003 335,148 301,904 242,627 242,818 215,007 241,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined105 101 81 69 56 46 46 44 31 32 25 Total absolute (metric tonnes CO2-e),  legacy Bard77,058 77,145 74,320 74,656 77,312 80,150 88,939 92,502 89,989 102,190 106,787 82,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard83 82 73 69 69 68 71 71 67 71 105 % reduction from baseline -28% Total absolute (metric tonnes CO2-e),  legacy BD617,985 599,923 522,151 463,083 394,705 329,973 344,441 303,738 244,062 253,213 245,404 277,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD130 127 102 87 71 58 57 54 38 41 32 % reduction from baseline -72% Total absolute (metric tonnes CO2-e),  combined695,043 677,068 596,472 537,739 472,017 410,123 433,380 396,240 334,051 355,403 352,191 359,Total normalized (metric tonnes  CO2-e per $M COPS), combined122 119 97 84 71 60 59 58 43 47 40  2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('GHG_Emissions', 0.9574030041694641)","('Air_Quality', 0.009483533911406994)","('Ecological_Impacts', 0.0032826063688844442)","(['Climate Change'], 0.9574030041694641)","('NON-ESG', 0.009483533911406994)","('NON-ESG', 0.0032826063688844442)"
Line 942,"Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope 1 and GRI disclosures: 305-1, 305-2, 305-4, 305-5Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total GHG emissions Scope 1 absolute (metric tonnes  CO2-e), legacy Bard11,345 11,345 11,345 11,317 14,932 16,869 20,727 17,486 16,434 23,856 36,781 16,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard12 12 11 10 13 14 17 13 12 17 36 Scope 1 absolute (metric tonnes  CO2-e), legacy BD87,852 88,809 91,327 85,931 84,125 80,251 77,505 76,850 74,989 88,730 100,402 101,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), legacy BD18 19 18 16 15 14 13 14 12 14 13 Scope 1 absolute (metric tonnes  CO2-e), combined99,197 100,154 102,672 97,249 99,057 97,120 98,232 94,336 91,424 112,585 137,183 118,Scope 1 normalized (metric tonnes  CO2-e per $M COPS), combined17 18 17 15 15 14 13 14 12 15 16 Scope 2 absolute (metric tonnes  CO2-e), legacy Bard65,713 65,800 62,976 63,338 62,380 63,281 68,212 75,016 73,554 78,335 70,006 65,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy Bard70 70 62 59 56 54 55 58 55 54 69 Scope 2 absolute (metric tonnes  CO2-e), legacy BD530,133 511,114 430,824 377,152 310,580 249,722 266,936 226,888 169,073 164,483 145,002 175,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), legacy BD112 108 84 71 56 44 44 41 26 27 19 Scope 2 absolute (metric tonnes  CO2-e), combined595,846 576,914 493,800 440,490 372,959 313,003 335,148 301,904 242,627 242,818 215,007 241,Scope 2 normalized (metric tonnes  CO2-e per $M COPS), combined105 101 81 69 56 46 46 44 31 32 25 Total absolute (metric tonnes CO2-e),  legacy Bard77,058 77,145 74,320 74,656 77,312 80,150 88,939 92,502 89,989 102,190 106,787 82,Total normalized (metric tonnes  CO2-e per $M COPS), legacy Bard83 82 73 69 69 68 71 71 67 71 105 % reduction from baseline -28% Total absolute (metric tonnes CO2-e),  legacy BD617,985 599,923 522,151 463,083 394,705 329,973 344,441 303,738 244,062 253,213 245,404 277,Total normalized (metric tonnes  CO2-e per $M COPS), legacy BD130 127 102 87 71 58 57 54 38 41 32 % reduction from baseline -72% Total absolute (metric tonnes CO2-e),  combined695,043 677,068 596,472 537,739 472,017 410,123 433,380 396,240 334,051 355,403 352,191 359,Total normalized (metric tonnes  CO2-e per $M COPS), combined122 119 97 84 71 60 59 58 43 47 40  2020 goal: Reduce Scope 1 and 2 GHG emissions by 50% (normalized to COPS).
","('Business_Ethics', 0.34208565950393677)","('Management_Of_Legal_And_Regulatory_Framework', 0.15603891015052795)","('Competitive_Behavior', 0.1041182354092598)","('NON-ESG', 0.34208565950393677)","('NON-ESG', 0.15603891015052795)","('NON-ESG', 0.1041182354092598)"
Line 943,"Current status: reduced by 67% TARGET ACHIEVED   Data represents Scope 1 (direct) and Scope 2 (indirect from electricity) energy sources.
","('Energy_Management', 0.9787951111793518)","('Management_Of_Legal_And_Regulatory_Framework', 0.002669033594429493)","('Water_And_Wastewater_Management', 0.0019929083064198494)","(['Operational Eco-Efficiency'], 0.9787951111793518)","('NON-ESG', 0.002669033594429493)","('NON-ESG', 0.0019929083064198494)"
Line 944,"BD uses emission factors that are temporally, geographically and technologically accurate for each site and source within its operational boundary as specified by the WRI/WBCSD GHG Protocol.
","('GHG_Emissions', 0.9346151351928711)","('Air_Quality', 0.025699397549033165)","('Energy_Management', 0.004813638981431723)","(['Climate Change'], 0.9346151351928711)","('NON-ESG', 0.025699397549033165)","('NON-ESG', 0.004813638981431723)"
Line 945,"This includes updating electric power emission factors to reflect changes in the  grid mix for areas in which BD operates.
","('Air_Quality', 0.9431355595588684)","('Energy_Management', 0.013641816563904285)","('Critical_Incident_Risk_Management', 0.005777369253337383)","(['Operational Eco-Efficiency'], 0.9431355595588684)","('NON-ESG', 0.013641816563904285)","('NON-ESG', 0.005777369253337383)"
Line 946,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,Capital goods  42,728 37,691 39,602 21,Fuel-and-energy-related activities (not included in Scope 1 or 2)3 106,340  103,995  106,451  106,360 101,856 105,617 111,946 101,392  Upstream transportation and distribution  72,640 125,904 280,636 286,Waste generated in operations1 15,266  15,302  13,789  13,071 15,465 15,380 19,239 19,359  Business travel4 35,273  38,230  41,171  68,259 107,049 95,612 117,116 147,795  Employee commuting  1,743  9,157  13,061  4,888 102,232 73,195 83,829 138,Upstream leased assets  27,094 47,011 32,299 1,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,End-of-life treatment of sold products 87,558 97,082 191,821 192,Downstream leased assets Not relevant6Not relevant6Not relevant61,Franchises Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('GHG_Emissions', 0.9592547416687012)","('Air_Quality', 0.011875968426465988)","('Physical_Impacts_Of_Climate_Change', 0.003110711695626378)","(['Climate Change'], 0.9592547416687012)","('NON-ESG', 0.011875968426465988)","('NON-ESG', 0.003110711695626378)"
Line 947,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,Capital goods  42,728 37,691 39,602 21,Fuel-and-energy-related activities (not included in Scope 1 or 2)3 106,340  103,995  106,451  106,360 101,856 105,617 111,946 101,392  Upstream transportation and distribution  72,640 125,904 280,636 286,Waste generated in operations1 15,266  15,302  13,789  13,071 15,465 15,380 19,239 19,359  Business travel4 35,273  38,230  41,171  68,259 107,049 95,612 117,116 147,795  Employee commuting  1,743  9,157  13,061  4,888 102,232 73,195 83,829 138,Upstream leased assets  27,094 47,011 32,299 1,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,End-of-life treatment of sold products 87,558 97,082 191,821 192,Downstream leased assets Not relevant6Not relevant6Not relevant61,Franchises Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('Energy_Management', 0.4245617389678955)","('Waste_And_Hazardous_Materials_Management', 0.2676220238208771)","('Water_And_Wastewater_Management', 0.08393048495054245)","('NON-ESG', 0.4245617389678955)","('NON-ESG', 0.2676220238208771)","('NON-ESG', 0.08393048495054245)"
Line 948,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,Capital goods  42,728 37,691 39,602 21,Fuel-and-energy-related activities (not included in Scope 1 or 2)3 106,340  103,995  106,451  106,360 101,856 105,617 111,946 101,392  Upstream transportation and distribution  72,640 125,904 280,636 286,Waste generated in operations1 15,266  15,302  13,789  13,071 15,465 15,380 19,239 19,359  Business travel4 35,273  38,230  41,171  68,259 107,049 95,612 117,116 147,795  Employee commuting  1,743  9,157  13,061  4,888 102,232 73,195 83,829 138,Upstream leased assets  27,094 47,011 32,299 1,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,End-of-life treatment of sold products 87,558 97,082 191,821 192,Downstream leased assets Not relevant6Not relevant6Not relevant61,Franchises Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('Product_Design_And_Lifecycle_Management', 0.8857657313346863)","('Selling_Practices_And_Product_Labeling', 0.025525564327836037)","('Customer_Welfare', 0.018462248146533966)","(['Product Stewardship'], 0.8857657313346863)","('NON-ESG', 0.025525564327836037)","('NON-ESG', 0.018462248146533966)"
Line 949,"In general, historical emission factors remain consistent with the publication that was most recent at the time of original reporting.2020 goal Reduce  GHG emissions and increase climate resilience throughout operations and value chain  Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesGHG emissions—Scope Measurement and UOM  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY GHG (absolute) (metric tonnes Co2-e) Purchased goods and services  966,282 1,069,505 1,065,132 1,147,Capital goods  42,728 37,691 39,602 21,Fuel-and-energy-related activities (not included in Scope 1 or 2)3 106,340  103,995  106,451  106,360 101,856 105,617 111,946 101,392  Upstream transportation and distribution  72,640 125,904 280,636 286,Waste generated in operations1 15,266  15,302  13,789  13,071 15,465 15,380 19,239 19,359  Business travel4 35,273  38,230  41,171  68,259 107,049 95,612 117,116 147,795  Employee commuting  1,743  9,157  13,061  4,888 102,232 73,195 83,829 138,Upstream leased assets  27,094 47,011 32,299 1,Downstream transportation and distribution Not relevant6Not relevant6Not relevant6Not relevantProcessing of sold products Not relevant6Not relevant6Not relevant6Not relevantUse of sold products 263,924 298,638 326,682 415,End-of-life treatment of sold products 87,558 97,082 191,821 192,Downstream leased assets Not relevant6Not relevant6Not relevant61,Franchises Not relevant6Not relevant6Not relevant6Not relevantInvestments Not relevant6Not relevant6Not relevant6Not relevant2020 goal: Establish Scope 3 GHG emission baselines for categories applicable to BD.
","('GHG_Emissions', 0.9521371126174927)","('Air_Quality', 0.015282174572348595)","('Physical_Impacts_Of_Climate_Change', 0.0038453086744993925)","(['Climate Change'], 0.9521371126174927)","('NON-ESG', 0.015282174572348595)","('NON-ESG', 0.0038453086744993925)"
Line 950,"Current status: We provided limited reporting of Scope 3 emissions in previous years, and in FY 2019 we continued to work with external partners to  establish baseline Scope 3 emissions across all categories.
","('GHG_Emissions', 0.8655070066452026)","('Air_Quality', 0.06963314116001129)","('Management_Of_Legal_And_Regulatory_Framework', 0.008679292164742947)","(['Climate Change'], 0.8655070066452026)","('NON-ESG', 0.06963314116001129)","('NON-ESG', 0.008679292164742947)"
Line 951,"This information will be used to inform future strategy.
","('Business_Model_Resilience', 0.4873407483100891)","('Management_Of_Legal_And_Regulatory_Framework', 0.09035134315490723)","('Access_And_Affordability', 0.04940538480877876)","('NON-ESG', 0.4873407483100891)","('NON-ESG', 0.09035134315490723)","('NON-ESG', 0.04940538480877876)"
Line 952,"2020 goal: Initiate climate resilience planning for BD facilities.
","('Business_Model_Resilience', 0.8625092506408691)","('Physical_Impacts_Of_Climate_Change', 0.03531722351908684)","('Supply_Chain_Management', 0.01560039073228836)","(['Codes of Business Conduct'], 0.8625092506408691)","('NON-ESG', 0.03531722351908684)","('NON-ESG', 0.01560039073228836)"
Line 953,"Current status: As the devastating hurricanes across the U.S. in 2017 demonstrated, resilience planning for extreme weather events is essential to ensure operations are  restored as quickly as possible.
","('Business_Model_Resilience', 0.8068100214004517)","('Physical_Impacts_Of_Climate_Change', 0.08828447759151459)","('Systemic_Risk_Management', 0.01106006558984518)","(['Codes of Business Conduct'], 0.8068100214004517)","('NON-ESG', 0.08828447759151459)","('NON-ESG', 0.01106006558984518)"
Line 954,"Work has been carried to deepen our understanding of potential risks to our supply chain and operations, to ensure potential impacts are mitigated or reduced.
","('Supply_Chain_Management', 0.9525927305221558)","('Physical_Impacts_Of_Climate_Change', 0.004570788238197565)","('Systemic_Risk_Management', 0.003548087552189827)","(['Supply Chain Management'], 0.9525927305221558)","('NON-ESG', 0.004570788238197565)","('NON-ESG', 0.003548087552189827)"
Line 955,"Further work was carried out in FY 2019 to  understand risks and opportunities associated with climate change and will be reported on in future reports.
","('Physical_Impacts_Of_Climate_Change', 0.9571439623832703)","('Business_Model_Resilience', 0.007252230774611235)","('GHG_Emissions', 0.004488595761358738)","(['Climate Change'], 0.9571439623832703)","('NON-ESG', 0.007252230774611235)","('NON-ESG', 0.004488595761358738)"
Line 956,"1 Includes CR Bard.
","('Competitive_Behavior', 0.12985645234584808)","('Management_Of_Legal_And_Regulatory_Framework', 0.09353578090667725)","('Systemic_Risk_Management', 0.06726787239313126)","('NON-ESG', 0.12985645234584808)","('NON-ESG', 0.09353578090667725)","('NON-ESG', 0.06726787239313126)"
Line 957,"2 Includes CR Bard.
","('Competitive_Behavior', 0.18719924986362457)","('Management_Of_Legal_And_Regulatory_Framework', 0.0887489914894104)","('Customer_Welfare', 0.06663014739751816)","('NON-ESG', 0.18719924986362457)","('NON-ESG', 0.0887489914894104)","('NON-ESG', 0.06663014739751816)"
Line 958,"Reduction is driven by change in sector classification, which have lower capital goods emission intensities.
","('GHG_Emissions', 0.42597585916519165)","('Air_Quality', 0.2025928646326065)","('Systemic_Risk_Management', 0.06559787690639496)","('NON-ESG', 0.42597585916519165)","('NON-ESG', 0.2025928646326065)","('NON-ESG', 0.06559787690639496)"
Line 959,"3 Data for all years reported has been recalculated to include legacy CR Bard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.34617844223976135)","('Systemic_Risk_Management', 0.13358721137046814)","('Energy_Management', 0.08147674798965454)","('NON-ESG', 0.34617844223976135)","('NON-ESG', 0.13358721137046814)","('NON-ESG', 0.08147674798965454)"
Line 960,"Data for all years also now includes emissions related to transmission and distribution losses and well to tank emissions from all energy sources, not just electric power.
","('Air_Quality', 0.8807607293128967)","('Energy_Management', 0.03637471795082092)","('GHG_Emissions', 0.03210925683379173)","(['Operational Eco-Efficiency'], 0.8807607293128967)","('NON-ESG', 0.03637471795082092)","('NON-ESG', 0.03210925683379173)"
Line 961,"(In prior years, we disclosed emissions  related to transmission and distribution losses from electric power only.)   4 FY 2019 includes CR Bard.
","('Air_Quality', 0.8035955429077148)","('GHG_Emissions', 0.10333088040351868)","('Energy_Management', 0.02983693592250347)","(['Operational Eco-Efficiency'], 0.8035955429077148)","('NON-ESG', 0.10333088040351868)","('NON-ESG', 0.02983693592250347)"
Line 962,"FY 2016 and FY 2017 have been restated due to error in earlier calculations.
","('Management_Of_Legal_And_Regulatory_Framework', 0.24710704386234283)","('Business_Model_Resilience', 0.10994674265384674)","('Systemic_Risk_Management', 0.09995220601558685)","('NON-ESG', 0.24710704386234283)","('NON-ESG', 0.10994674265384674)","('NON-ESG', 0.09995220601558685)"
Line 963,"5 Includes CR Bard.
","('Competitive_Behavior', 0.19340631365776062)","('Management_Of_Legal_And_Regulatory_Framework', 0.09386622905731201)","('Customer_Welfare', 0.09138175845146179)","('NON-ESG', 0.19340631365776062)","('NON-ESG', 0.09386622905731201)","('NON-ESG', 0.09138175845146179)"
Line 964,"Significant decrease due to more accurate data used in calculations.
","('Customer_Privacy', 0.24698230624198914)","('Management_Of_Legal_And_Regulatory_Framework', 0.1181187555193901)","('Data_Security', 0.08335629105567932)","('NON-ESG', 0.24698230624198914)","('NON-ESG', 0.1181187555193901)","('NON-ESG', 0.08335629105567932)"
Line 965,"6 Relevance based on 1% threshold relative to total Scope 3 emissions inventory.
","('Air_Quality', 0.47932422161102295)","('GHG_Emissions', 0.3245503306388855)","('Energy_Management', 0.0694194957613945)","('NON-ESG', 0.47932422161102295)","('NON-ESG', 0.3245503306388855)","('NON-ESG', 0.0694194957613945)"
Line 966,"Determined this category to be not relevant to the company’s business activities and did not estimate the associated GHG emissions.
","('GHG_Emissions', 0.9688921570777893)","('Ecological_Impacts', 0.004027440678328276)","('Air_Quality', 0.0027539548464119434)","(['Climate Change'], 0.9688921570777893)","('NON-ESG', 0.004027440678328276)","('NON-ESG', 0.0027539548464119434)"
Line 967,"7 Emissions are for a subset of our portfolio only.
","('GHG_Emissions', 0.5120233297348022)","('Air_Quality', 0.35282015800476074)","('Energy_Management', 0.040738966315984726)","(['Climate Change'], 0.5120233297348022)","('NON-ESG', 0.35282015800476074)","('NON-ESG', 0.040738966315984726)"
Line 968,"GRI disclosure: 305-3Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 219,899 219,899 219,899 219,899 270,744 302,468 381,073 332,693 316,465 413,807 620,237 311,Scope 1 normalized (GJ per $M  COPS), legacy Bard236 232 217 204 242 258 305 256 236 287 610 Scope 1 absolute (GJ), legacy BD 1,640,772 1,663,840 1,707,033 1,615,278 1,568,897 1,442,703 1,459,149 1,447,472 1,410,399 1,695,223 1,922,421 1,953,Scope 1 normalized (GJ per $M  COPS), legacy BD345 351 334 303 284 256 240 259 217 277 250 Scope 1 absolute (GJ), combined 1,860,671 1,883,740 1,926,933 1,835,178 1,839,641 1,745,171 1,840,221 1,780,165 1,726,864 2,109,030 2,542,658 2,265,Scope 1 normalized (GJ per $M  COPS), combined327 331 315 286 277 256 251 258 220 279 292 Scope 2 absolute (GJ), legacy Bard 449,174 450,250 450,346 450,346 463,907 475,639 495,386 560,506 575,758 623,298 612,855 587,Scope 2 normalized (GJ per $M  COPS), legacy Bard482 476 445 417 414 406 396 431 429 432 603 Scope 2 absolute (GJ), legacy BD 3,654,412 3,651,153 3,773,760 3,740,213 3,689,441 3,605,946 3,660,163 3,620,781 3,647,823 3,597,540 3,725,284 3,782,Scope 2 normalized (GJ per $M  COPS), legacy BD769 770 738 702 668 639 602 648 562 587 484 Scope 2 absolute (GJ), combined 4,103,586 4,101,402 4,224,106 4,190,559 4,153,349 4,081,585 4,155,548 4,181,287 4,223,582 4,220,837 4,338,138 4,370,Scope 2 normalized (GJ per $M  COPS), combined722 721 690 654 625 599 567 607 539 558 498 Total absolute (GJ), legacy Bard 669,073 670,149 670,245 670,245 734,651 778,107 876,458 893,199 892,223 1,037,105 1,233,092 899,Total normalized (GJ per $M COPS),  legacy Bard718 708 663 621 656 664 701 687 664 719 1,214 % reduction from baseline 9% Total absolute (GJ), legacy BD 5,295,183 5,314,993 5,480,794 5,355,491 5,258,338 5,048,649 5,119,311 5,068,253 5,058,223 5,292,763 5,647,705 5,736,Total normalized (GJ per $M COPS),  legacy BD1,114 1,121 1,072 1,005 952 895 842 907 779 864 734 % reduction from baseline 32% Total absolute (GJ), combined 5,964,257 5,985,142 6,151,039 6,025,737 5,992,990 5,826,756 5,995,770 5,961,452 5,950,446 6,329,868 6,880,797 6,635,Total normalized (GJ per $M COPS),  combined1,049 1,053 1,004 941 902 855 818 866 759 836 790 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Energy_Management', 0.9786887168884277)","('Product_Design_And_Lifecycle_Management', 0.0019581278320401907)","('Air_Quality', 0.0019102676305919886)","(['Operational Eco-Efficiency'], 0.9786887168884277)","('NON-ESG', 0.0019581278320401907)","('NON-ESG', 0.0019102676305919886)"
Line 969,"GRI disclosure: 305-3Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 219,899 219,899 219,899 219,899 270,744 302,468 381,073 332,693 316,465 413,807 620,237 311,Scope 1 normalized (GJ per $M  COPS), legacy Bard236 232 217 204 242 258 305 256 236 287 610 Scope 1 absolute (GJ), legacy BD 1,640,772 1,663,840 1,707,033 1,615,278 1,568,897 1,442,703 1,459,149 1,447,472 1,410,399 1,695,223 1,922,421 1,953,Scope 1 normalized (GJ per $M  COPS), legacy BD345 351 334 303 284 256 240 259 217 277 250 Scope 1 absolute (GJ), combined 1,860,671 1,883,740 1,926,933 1,835,178 1,839,641 1,745,171 1,840,221 1,780,165 1,726,864 2,109,030 2,542,658 2,265,Scope 1 normalized (GJ per $M  COPS), combined327 331 315 286 277 256 251 258 220 279 292 Scope 2 absolute (GJ), legacy Bard 449,174 450,250 450,346 450,346 463,907 475,639 495,386 560,506 575,758 623,298 612,855 587,Scope 2 normalized (GJ per $M  COPS), legacy Bard482 476 445 417 414 406 396 431 429 432 603 Scope 2 absolute (GJ), legacy BD 3,654,412 3,651,153 3,773,760 3,740,213 3,689,441 3,605,946 3,660,163 3,620,781 3,647,823 3,597,540 3,725,284 3,782,Scope 2 normalized (GJ per $M  COPS), legacy BD769 770 738 702 668 639 602 648 562 587 484 Scope 2 absolute (GJ), combined 4,103,586 4,101,402 4,224,106 4,190,559 4,153,349 4,081,585 4,155,548 4,181,287 4,223,582 4,220,837 4,338,138 4,370,Scope 2 normalized (GJ per $M  COPS), combined722 721 690 654 625 599 567 607 539 558 498 Total absolute (GJ), legacy Bard 669,073 670,149 670,245 670,245 734,651 778,107 876,458 893,199 892,223 1,037,105 1,233,092 899,Total normalized (GJ per $M COPS),  legacy Bard718 708 663 621 656 664 701 687 664 719 1,214 % reduction from baseline 9% Total absolute (GJ), legacy BD 5,295,183 5,314,993 5,480,794 5,355,491 5,258,338 5,048,649 5,119,311 5,068,253 5,058,223 5,292,763 5,647,705 5,736,Total normalized (GJ per $M COPS),  legacy BD1,114 1,121 1,072 1,005 952 895 842 907 779 864 734 % reduction from baseline 32% Total absolute (GJ), combined 5,964,257 5,985,142 6,151,039 6,025,737 5,992,990 5,826,756 5,995,770 5,961,452 5,950,446 6,329,868 6,880,797 6,635,Total normalized (GJ per $M COPS),  combined1,049 1,053 1,004 941 902 855 818 866 759 836 790 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Systemic_Risk_Management', 0.2997798025608063)","('Competitive_Behavior', 0.12819336354732513)","('Management_Of_Legal_And_Regulatory_Framework', 0.11962343007326126)","('NON-ESG', 0.2997798025608063)","('NON-ESG', 0.12819336354732513)","('NON-ESG', 0.11962343007326126)"
Line 970,"GRI disclosure: 305-3Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 219,899 219,899 219,899 219,899 270,744 302,468 381,073 332,693 316,465 413,807 620,237 311,Scope 1 normalized (GJ per $M  COPS), legacy Bard236 232 217 204 242 258 305 256 236 287 610 Scope 1 absolute (GJ), legacy BD 1,640,772 1,663,840 1,707,033 1,615,278 1,568,897 1,442,703 1,459,149 1,447,472 1,410,399 1,695,223 1,922,421 1,953,Scope 1 normalized (GJ per $M  COPS), legacy BD345 351 334 303 284 256 240 259 217 277 250 Scope 1 absolute (GJ), combined 1,860,671 1,883,740 1,926,933 1,835,178 1,839,641 1,745,171 1,840,221 1,780,165 1,726,864 2,109,030 2,542,658 2,265,Scope 1 normalized (GJ per $M  COPS), combined327 331 315 286 277 256 251 258 220 279 292 Scope 2 absolute (GJ), legacy Bard 449,174 450,250 450,346 450,346 463,907 475,639 495,386 560,506 575,758 623,298 612,855 587,Scope 2 normalized (GJ per $M  COPS), legacy Bard482 476 445 417 414 406 396 431 429 432 603 Scope 2 absolute (GJ), legacy BD 3,654,412 3,651,153 3,773,760 3,740,213 3,689,441 3,605,946 3,660,163 3,620,781 3,647,823 3,597,540 3,725,284 3,782,Scope 2 normalized (GJ per $M  COPS), legacy BD769 770 738 702 668 639 602 648 562 587 484 Scope 2 absolute (GJ), combined 4,103,586 4,101,402 4,224,106 4,190,559 4,153,349 4,081,585 4,155,548 4,181,287 4,223,582 4,220,837 4,338,138 4,370,Scope 2 normalized (GJ per $M  COPS), combined722 721 690 654 625 599 567 607 539 558 498 Total absolute (GJ), legacy Bard 669,073 670,149 670,245 670,245 734,651 778,107 876,458 893,199 892,223 1,037,105 1,233,092 899,Total normalized (GJ per $M COPS),  legacy Bard718 708 663 621 656 664 701 687 664 719 1,214 % reduction from baseline 9% Total absolute (GJ), legacy BD 5,295,183 5,314,993 5,480,794 5,355,491 5,258,338 5,048,649 5,119,311 5,068,253 5,058,223 5,292,763 5,647,705 5,736,Total normalized (GJ per $M COPS),  legacy BD1,114 1,121 1,072 1,005 952 895 842 907 779 864 734 % reduction from baseline 32% Total absolute (GJ), combined 5,964,257 5,985,142 6,151,039 6,025,737 5,992,990 5,826,756 5,995,770 5,961,452 5,950,446 6,329,868 6,880,797 6,635,Total normalized (GJ per $M COPS),  combined1,049 1,053 1,004 941 902 855 818 866 759 836 790 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Systemic_Risk_Management', 0.33259981870651245)","('Competitive_Behavior', 0.11629434674978256)","('Management_Of_Legal_And_Regulatory_Framework', 0.10484783351421356)","('NON-ESG', 0.33259981870651245)","('NON-ESG', 0.11629434674978256)","('NON-ESG', 0.10484783351421356)"
Line 971,"GRI disclosure: 305-3Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 219,899 219,899 219,899 219,899 270,744 302,468 381,073 332,693 316,465 413,807 620,237 311,Scope 1 normalized (GJ per $M  COPS), legacy Bard236 232 217 204 242 258 305 256 236 287 610 Scope 1 absolute (GJ), legacy BD 1,640,772 1,663,840 1,707,033 1,615,278 1,568,897 1,442,703 1,459,149 1,447,472 1,410,399 1,695,223 1,922,421 1,953,Scope 1 normalized (GJ per $M  COPS), legacy BD345 351 334 303 284 256 240 259 217 277 250 Scope 1 absolute (GJ), combined 1,860,671 1,883,740 1,926,933 1,835,178 1,839,641 1,745,171 1,840,221 1,780,165 1,726,864 2,109,030 2,542,658 2,265,Scope 1 normalized (GJ per $M  COPS), combined327 331 315 286 277 256 251 258 220 279 292 Scope 2 absolute (GJ), legacy Bard 449,174 450,250 450,346 450,346 463,907 475,639 495,386 560,506 575,758 623,298 612,855 587,Scope 2 normalized (GJ per $M  COPS), legacy Bard482 476 445 417 414 406 396 431 429 432 603 Scope 2 absolute (GJ), legacy BD 3,654,412 3,651,153 3,773,760 3,740,213 3,689,441 3,605,946 3,660,163 3,620,781 3,647,823 3,597,540 3,725,284 3,782,Scope 2 normalized (GJ per $M  COPS), legacy BD769 770 738 702 668 639 602 648 562 587 484 Scope 2 absolute (GJ), combined 4,103,586 4,101,402 4,224,106 4,190,559 4,153,349 4,081,585 4,155,548 4,181,287 4,223,582 4,220,837 4,338,138 4,370,Scope 2 normalized (GJ per $M  COPS), combined722 721 690 654 625 599 567 607 539 558 498 Total absolute (GJ), legacy Bard 669,073 670,149 670,245 670,245 734,651 778,107 876,458 893,199 892,223 1,037,105 1,233,092 899,Total normalized (GJ per $M COPS),  legacy Bard718 708 663 621 656 664 701 687 664 719 1,214 % reduction from baseline 9% Total absolute (GJ), legacy BD 5,295,183 5,314,993 5,480,794 5,355,491 5,258,338 5,048,649 5,119,311 5,068,253 5,058,223 5,292,763 5,647,705 5,736,Total normalized (GJ per $M COPS),  legacy BD1,114 1,121 1,072 1,005 952 895 842 907 779 864 734 % reduction from baseline 32% Total absolute (GJ), combined 5,964,257 5,985,142 6,151,039 6,025,737 5,992,990 5,826,756 5,995,770 5,961,452 5,950,446 6,329,868 6,880,797 6,635,Total normalized (GJ per $M COPS),  combined1,049 1,053 1,004 941 902 855 818 866 759 836 790 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Management_Of_Legal_And_Regulatory_Framework', 0.23215368390083313)","('Systemic_Risk_Management', 0.2249470204114914)","('Competitive_Behavior', 0.09372185915708542)","('NON-ESG', 0.23215368390083313)","('NON-ESG', 0.2249470204114914)","('NON-ESG', 0.09372185915708542)"
Line 972,"GRI disclosure: 305-3Innovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total energy consumption Scope 1 absolute (GJ), legacy Bard 219,899 219,899 219,899 219,899 270,744 302,468 381,073 332,693 316,465 413,807 620,237 311,Scope 1 normalized (GJ per $M  COPS), legacy Bard236 232 217 204 242 258 305 256 236 287 610 Scope 1 absolute (GJ), legacy BD 1,640,772 1,663,840 1,707,033 1,615,278 1,568,897 1,442,703 1,459,149 1,447,472 1,410,399 1,695,223 1,922,421 1,953,Scope 1 normalized (GJ per $M  COPS), legacy BD345 351 334 303 284 256 240 259 217 277 250 Scope 1 absolute (GJ), combined 1,860,671 1,883,740 1,926,933 1,835,178 1,839,641 1,745,171 1,840,221 1,780,165 1,726,864 2,109,030 2,542,658 2,265,Scope 1 normalized (GJ per $M  COPS), combined327 331 315 286 277 256 251 258 220 279 292 Scope 2 absolute (GJ), legacy Bard 449,174 450,250 450,346 450,346 463,907 475,639 495,386 560,506 575,758 623,298 612,855 587,Scope 2 normalized (GJ per $M  COPS), legacy Bard482 476 445 417 414 406 396 431 429 432 603 Scope 2 absolute (GJ), legacy BD 3,654,412 3,651,153 3,773,760 3,740,213 3,689,441 3,605,946 3,660,163 3,620,781 3,647,823 3,597,540 3,725,284 3,782,Scope 2 normalized (GJ per $M  COPS), legacy BD769 770 738 702 668 639 602 648 562 587 484 Scope 2 absolute (GJ), combined 4,103,586 4,101,402 4,224,106 4,190,559 4,153,349 4,081,585 4,155,548 4,181,287 4,223,582 4,220,837 4,338,138 4,370,Scope 2 normalized (GJ per $M  COPS), combined722 721 690 654 625 599 567 607 539 558 498 Total absolute (GJ), legacy Bard 669,073 670,149 670,245 670,245 734,651 778,107 876,458 893,199 892,223 1,037,105 1,233,092 899,Total normalized (GJ per $M COPS),  legacy Bard718 708 663 621 656 664 701 687 664 719 1,214 % reduction from baseline 9% Total absolute (GJ), legacy BD 5,295,183 5,314,993 5,480,794 5,355,491 5,258,338 5,048,649 5,119,311 5,068,253 5,058,223 5,292,763 5,647,705 5,736,Total normalized (GJ per $M COPS),  legacy BD1,114 1,121 1,072 1,005 952 895 842 907 779 864 734 % reduction from baseline 32% Total absolute (GJ), combined 5,964,257 5,985,142 6,151,039 6,025,737 5,992,990 5,826,756 5,995,770 5,961,452 5,950,446 6,329,868 6,880,797 6,635,Total normalized (GJ per $M COPS),  combined1,049 1,053 1,004 941 902 855 818 866 759 836 790 2020 goal: Reduce energy consumption by 40% (normalized by COPS).
","('Energy_Management', 0.9746689200401306)","('Management_Of_Legal_And_Regulatory_Framework', 0.002351365750655532)","('Air_Quality', 0.0020359489135444164)","(['Operational Eco-Efficiency'], 0.9746689200401306)","('NON-ESG', 0.002351365750655532)","('NON-ESG', 0.0020359489135444164)"
Line 973,"Current status: reduced by 30% Data represents Scope 1 (direct) and Scope 2 (indirect from electricity) energy sources.
","('Energy_Management', 0.9775353074073792)","('Management_Of_Legal_And_Regulatory_Framework', 0.0029941301327198744)","('Water_And_Wastewater_Management', 0.002291895914822817)","(['Operational Eco-Efficiency'], 0.9775353074073792)","('NON-ESG', 0.0029941301327198744)","('NON-ESG', 0.002291895914822817)"
Line 974,"GRI disclosures: 302-1, 302-3, 302-42020 goal Minimize  our environmental footprint and conserve natural resources  Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Renewable energy (RECs, Green Power)—combined Electric power 4,053,831 4,062,147 4,186,898 4,153,453 4,114,317 4,037,109 4,109,512 4,136,047 4,178,426 4,214,796 4,294,092 4,313,Green energy 104,745 161,475 181,361 264,315 203,857 172,132 100,695 98,970 249,444 449,119 347,022 577,Renewable Energy Credit (REC) 18,547 133,415 570,815 670,714 1,012,696 1,318,215 1,326,356 1,492,190 1,861,873 2,020,847 1,920,501 1,463,Total Greenpower 123,293 294,890 752,176 935,030 1,216,554 1,490,347 1,427,051 1,591,160 2,111,316 2,469,966 2,267,524 2,041,As part of electric power  consumption: % from RECs 0.5% 3% 14% 16% 25% 33% 32% 36% 45% 48% 45% 34% % from green energy 3% 4% 4% 6% 5% 4% 2% 2% 6% 11% 8% 13% % of all green power 3% 7% 18% 23% 30% 37% 35% 38% 51% 59% 53% 47% As part of total energy: % from RECs: 0.3% 2% 9% 11% 17% 23% 22% 25% 31% 32% 28% 22% % of all green energy 2% 5% 12% 16% 20% 26% 24% 27% 35% 39% 33% 31% 2020 goal:  Increase renewable energy consumption by 50% of total energy (absolute).
","('Energy_Management', 0.9755927324295044)","('Product_Design_And_Lifecycle_Management', 0.002311375690624118)","('Management_Of_Legal_And_Regulatory_Framework', 0.0022732496727257967)","(['Operational Eco-Efficiency'], 0.9755927324295044)","('NON-ESG', 0.002311375690624118)","('NON-ESG', 0.0022732496727257967)"
Line 975,"GRI disclosures: 302-1, 302-3, 302-42020 goal Minimize  our environmental footprint and conserve natural resources  Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Renewable energy (RECs, Green Power)—combined Electric power 4,053,831 4,062,147 4,186,898 4,153,453 4,114,317 4,037,109 4,109,512 4,136,047 4,178,426 4,214,796 4,294,092 4,313,Green energy 104,745 161,475 181,361 264,315 203,857 172,132 100,695 98,970 249,444 449,119 347,022 577,Renewable Energy Credit (REC) 18,547 133,415 570,815 670,714 1,012,696 1,318,215 1,326,356 1,492,190 1,861,873 2,020,847 1,920,501 1,463,Total Greenpower 123,293 294,890 752,176 935,030 1,216,554 1,490,347 1,427,051 1,591,160 2,111,316 2,469,966 2,267,524 2,041,As part of electric power  consumption: % from RECs 0.5% 3% 14% 16% 25% 33% 32% 36% 45% 48% 45% 34% % from green energy 3% 4% 4% 6% 5% 4% 2% 2% 6% 11% 8% 13% % of all green power 3% 7% 18% 23% 30% 37% 35% 38% 51% 59% 53% 47% As part of total energy: % from RECs: 0.3% 2% 9% 11% 17% 23% 22% 25% 31% 32% 28% 22% % of all green energy 2% 5% 12% 16% 20% 26% 24% 27% 35% 39% 33% 31% 2020 goal:  Increase renewable energy consumption by 50% of total energy (absolute).
","('Energy_Management', 0.9755955934524536)","('Management_Of_Legal_And_Regulatory_Framework', 0.0025677401572465897)","('Product_Design_And_Lifecycle_Management', 0.002073664218187332)","(['Operational Eco-Efficiency'], 0.9755955934524536)","('NON-ESG', 0.0025677401572465897)","('NON-ESG', 0.002073664218187332)"
Line 976,"GRI disclosures: 302-1, 302-3, 302-42020 goal Minimize  our environmental footprint and conserve natural resources  Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesEnergy Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Renewable energy (RECs, Green Power)—combined Electric power 4,053,831 4,062,147 4,186,898 4,153,453 4,114,317 4,037,109 4,109,512 4,136,047 4,178,426 4,214,796 4,294,092 4,313,Green energy 104,745 161,475 181,361 264,315 203,857 172,132 100,695 98,970 249,444 449,119 347,022 577,Renewable Energy Credit (REC) 18,547 133,415 570,815 670,714 1,012,696 1,318,215 1,326,356 1,492,190 1,861,873 2,020,847 1,920,501 1,463,Total Greenpower 123,293 294,890 752,176 935,030 1,216,554 1,490,347 1,427,051 1,591,160 2,111,316 2,469,966 2,267,524 2,041,As part of electric power  consumption: % from RECs 0.5% 3% 14% 16% 25% 33% 32% 36% 45% 48% 45% 34% % from green energy 3% 4% 4% 6% 5% 4% 2% 2% 6% 11% 8% 13% % of all green power 3% 7% 18% 23% 30% 37% 35% 38% 51% 59% 53% 47% As part of total energy: % from RECs: 0.3% 2% 9% 11% 17% 23% 22% 25% 31% 32% 28% 22% % of all green energy 2% 5% 12% 16% 20% 26% 24% 27% 35% 39% 33% 31% 2020 goal:  Increase renewable energy consumption by 50% of total energy (absolute).
","('Energy_Management', 0.9771007299423218)","('Management_Of_Legal_And_Regulatory_Framework', 0.002444891259074211)","('Critical_Incident_Risk_Management', 0.0017765533411875367)","(['Operational Eco-Efficiency'], 0.9771007299423218)","('NON-ESG', 0.002444891259074211)","('NON-ESG', 0.0017765533411875367)"
Line 977,"Current status:  increased to 31% GRI disclosure: 302-Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Water consumption Absolute (cubic meters), legacy Bard 704,997 939,996 939,996 939,996 948,089 915,978 917,275 924,565 933,623 910,725 1,262,707 1,122,Normalized (cubic meters per $M  COPS), legacy Bard756 993 929 871 847 782 734 711 695 631 1243 % discharge, legacy Bard -7% Absolute (cubic meters), legacy BD 5,525,385 5,032,947 4,539,546 4,536,329 4,524,766 4,590,243 4,869,887 5,043,004 4,967,181 4,433,752 4,696,157 4,696,Normalized (cubic meters per $M  COPS), legacy BD1,163 1,062 888 851 819 814 801 903 765 724 610 % reduction from baseline, legacy BD 47% Absolute (cubic meters), combined 6,230,381 5,972,943 5,479,542 5,476,325 5,472,855 5,506,221 5,787,162 5,967,569 5,900,804 5,344,477 5,958,863 5,819,Normalized (cubic meters per $M  COPS), combined1,096 1,050 895 855 824 808 790 866 753 706 684 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Energy_Management', 0.573871374130249)","('Water_And_Wastewater_Management', 0.33530062437057495)","('Air_Quality', 0.008056444115936756)","(['Operational Eco-Efficiency'], 0.573871374130249)","('NON-ESG', 0.33530062437057495)","('NON-ESG', 0.008056444115936756)"
Line 978,"Current status:  increased to 31% GRI disclosure: 302-Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Water consumption Absolute (cubic meters), legacy Bard 704,997 939,996 939,996 939,996 948,089 915,978 917,275 924,565 933,623 910,725 1,262,707 1,122,Normalized (cubic meters per $M  COPS), legacy Bard756 993 929 871 847 782 734 711 695 631 1243 % discharge, legacy Bard -7% Absolute (cubic meters), legacy BD 5,525,385 5,032,947 4,539,546 4,536,329 4,524,766 4,590,243 4,869,887 5,043,004 4,967,181 4,433,752 4,696,157 4,696,Normalized (cubic meters per $M  COPS), legacy BD1,163 1,062 888 851 819 814 801 903 765 724 610 % reduction from baseline, legacy BD 47% Absolute (cubic meters), combined 6,230,381 5,972,943 5,479,542 5,476,325 5,472,855 5,506,221 5,787,162 5,967,569 5,900,804 5,344,477 5,958,863 5,819,Normalized (cubic meters per $M  COPS), combined1,096 1,050 895 855 824 808 790 866 753 706 684 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Energy_Management', 0.22931352257728577)","('Water_And_Wastewater_Management', 0.10039994865655899)","('Customer_Welfare', 0.08398585021495819)","('NON-ESG', 0.22931352257728577)","('NON-ESG', 0.10039994865655899)","('NON-ESG', 0.08398585021495819)"
Line 979,"Current status:  increased to 31% GRI disclosure: 302-Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWater Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Water consumption Absolute (cubic meters), legacy Bard 704,997 939,996 939,996 939,996 948,089 915,978 917,275 924,565 933,623 910,725 1,262,707 1,122,Normalized (cubic meters per $M  COPS), legacy Bard756 993 929 871 847 782 734 711 695 631 1243 % discharge, legacy Bard -7% Absolute (cubic meters), legacy BD 5,525,385 5,032,947 4,539,546 4,536,329 4,524,766 4,590,243 4,869,887 5,043,004 4,967,181 4,433,752 4,696,157 4,696,Normalized (cubic meters per $M  COPS), legacy BD1,163 1,062 888 851 819 814 801 903 765 724 610 % reduction from baseline, legacy BD 47% Absolute (cubic meters), combined 6,230,381 5,972,943 5,479,542 5,476,325 5,472,855 5,506,221 5,787,162 5,967,569 5,900,804 5,344,477 5,958,863 5,819,Normalized (cubic meters per $M  COPS), combined1,096 1,050 895 855 824 808 790 866 753 706 684 2020 goal: Reduce water consumption by 40% (normalized by COPS).
","('Water_And_Wastewater_Management', 0.9368917942047119)","('Energy_Management', 0.020646370947360992)","('Waste_And_Hazardous_Materials_Management', 0.004401797894388437)","(['Operational Eco-Efficiency'], 0.9368917942047119)","('NON-ESG', 0.020646370947360992)","('NON-ESG', 0.004401797894388437)"
Line 980,"Current status:  reduced by 41%.
","('Management_Of_Legal_And_Regulatory_Framework', 0.18176010251045227)","('Director_Removal', 0.13699860870838165)","('Systemic_Risk_Management', 0.13448508083820343)","('NON-ESG', 0.18176010251045227)","('NON-ESG', 0.13699860870838165)","('NON-ESG', 0.13448508083820343)"
Line 981,"TARGET ACHIEVED Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Waste water discharge Absolute (cubic meters), legacy Bard 0 0 0 0 0 185,028 242,905 242,536 248,418 359,572 775,805 824,Normalized (cubic meters per $M  COPS), legacy Bard0 0 0 0 0 158 194 186 185 249 764 % discharge, legacy Bard 0% 0% 0% 0% 0% 20% 26% 26% 27% 39% 61% 73% Absolute (cubic meters), legacy BD 4,310,030 4,007,322 3,182,309 3,152,513 3,282,185 3,415,973 3,716,419 3,633,440 3,507,233 3,240,171 3,627,941 3,953,Normalized (cubic meters per $M  COPS), legacy BD907 845 623 592 594 605 611 650 540 529 471 % discharge, legacy BD 78% 80% 70% 69% 73% 74% 76% 72% 71% 73% 77% 84% Absolute (cubic meters), combined 4,310,030 4,007,322 3,182,309 3,152,513 3,282,185 3,601,001 3,959,324 3,875,976 3,755,650 3,599,743 4,403,746 4,778,Normalized (cubic meters per $M  COPS), combined*758 705 520 492 494 529 540 563 479 475 505 % discharge, combined 69% 67% 58% 58% 60% 65% 68% 65% 64% 67% 74% 82% *Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Water_And_Wastewater_Management', 0.6203344464302063)","('Waste_And_Hazardous_Materials_Management', 0.2673129141330719)","('Air_Quality', 0.015509122982621193)","(['Operational Eco-Efficiency'], 0.6203344464302063)","('NON-ESG', 0.2673129141330719)","('NON-ESG', 0.015509122982621193)"
Line 982,"TARGET ACHIEVED Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Waste water discharge Absolute (cubic meters), legacy Bard 0 0 0 0 0 185,028 242,905 242,536 248,418 359,572 775,805 824,Normalized (cubic meters per $M  COPS), legacy Bard0 0 0 0 0 158 194 186 185 249 764 % discharge, legacy Bard 0% 0% 0% 0% 0% 20% 26% 26% 27% 39% 61% 73% Absolute (cubic meters), legacy BD 4,310,030 4,007,322 3,182,309 3,152,513 3,282,185 3,415,973 3,716,419 3,633,440 3,507,233 3,240,171 3,627,941 3,953,Normalized (cubic meters per $M  COPS), legacy BD907 845 623 592 594 605 611 650 540 529 471 % discharge, legacy BD 78% 80% 70% 69% 73% 74% 76% 72% 71% 73% 77% 84% Absolute (cubic meters), combined 4,310,030 4,007,322 3,182,309 3,152,513 3,282,185 3,601,001 3,959,324 3,875,976 3,755,650 3,599,743 4,403,746 4,778,Normalized (cubic meters per $M  COPS), combined*758 705 520 492 494 529 540 563 479 475 505 % discharge, combined 69% 67% 58% 58% 60% 65% 68% 65% 64% 67% 74% 82% *Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Energy_Management', 0.2885717749595642)","('Water_And_Wastewater_Management', 0.13763679563999176)","('Customer_Welfare', 0.09116866439580917)","('NON-ESG', 0.2885717749595642)","('NON-ESG', 0.13763679563999176)","('NON-ESG', 0.09116866439580917)"
Line 983,"TARGET ACHIEVED Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Waste water discharge Absolute (cubic meters), legacy Bard 0 0 0 0 0 185,028 242,905 242,536 248,418 359,572 775,805 824,Normalized (cubic meters per $M  COPS), legacy Bard0 0 0 0 0 158 194 186 185 249 764 % discharge, legacy Bard 0% 0% 0% 0% 0% 20% 26% 26% 27% 39% 61% 73% Absolute (cubic meters), legacy BD 4,310,030 4,007,322 3,182,309 3,152,513 3,282,185 3,415,973 3,716,419 3,633,440 3,507,233 3,240,171 3,627,941 3,953,Normalized (cubic meters per $M  COPS), legacy BD907 845 623 592 594 605 611 650 540 529 471 % discharge, legacy BD 78% 80% 70% 69% 73% 74% 76% 72% 71% 73% 77% 84% Absolute (cubic meters), combined 4,310,030 4,007,322 3,182,309 3,152,513 3,282,185 3,601,001 3,959,324 3,875,976 3,755,650 3,599,743 4,403,746 4,778,Normalized (cubic meters per $M  COPS), combined*758 705 520 492 494 529 540 563 479 475 505 % discharge, combined 69% 67% 58% 58% 60% 65% 68% 65% 64% 67% 74% 82% *Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.29452502727508545)","('Business_Model_Resilience', 0.2595464885234833)","('Management_Of_Legal_And_Regulatory_Framework', 0.0732932910323143)","('NON-ESG', 0.29452502727508545)","('NON-ESG', 0.2595464885234833)","('NON-ESG', 0.0732932910323143)"
Line 984,"GRI disclosures: 303-4, 303- Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total nonhazardous waste generated Absolute (Metric tonnes), legacy Bard 3,799 5,066 5,066 5,066 5,066 5,582 6,201 7,589 8,002 9,113 12,829 8,Normalized (Metric tonnes per $M  COPS), incl.
","('Waste_And_Hazardous_Materials_Management', 0.9776588082313538)","('Water_And_Wastewater_Management', 0.003385523334145546)","('Air_Quality', 0.0018194103613495827)","(['Operational Eco-Efficiency'], 0.9776588082313538)","('NON-ESG', 0.003385523334145546)","('NON-ESG', 0.0018194103613495827)"
Line 985,"GRI disclosures: 303-4, 303- Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Total nonhazardous waste generated Absolute (Metric tonnes), legacy Bard 3,799 5,066 5,066 5,066 5,066 5,582 6,201 7,589 8,002 9,113 12,829 8,Normalized (Metric tonnes per $M  COPS), incl.
","('Critical_Incident_Risk_Management', 0.2747381925582886)","('Business_Ethics', 0.1853734254837036)","('Labor_Practices', 0.053447358310222626)","('NON-ESG', 0.2747381925582886)","('NON-ESG', 0.1853734254837036)","('NON-ESG', 0.053447358310222626)"
Line 986,"regulated waste, legacy  Bard4.08 5.35 5.01 4.70 4.52 4.77 4.96 5.83 5.96 6.32 12.63 6.% reduction from baseline, legacy Bard -57% Absolute (Metric tonnes), legacy BD 50,882 47,610 48,929 49,105 47,441 46,800 45,078 44,159 49,862 46,371 54,712 58,Normalized (Metric tonnes per $M  COPS), incl.
","('Waste_And_Hazardous_Materials_Management', 0.977989137172699)","('Water_And_Wastewater_Management', 0.0033781803213059902)","('Air_Quality', 0.0016253560315817595)","(['Operational Eco-Efficiency'], 0.977989137172699)","('NON-ESG', 0.0033781803213059902)","('NON-ESG', 0.0016253560315817595)"
Line 987,"regulated waste, legacy BD10.71 10.04 9.57 9.22 8.59 8.30 7.42 7.90 7.68 7.57 7.11 7.% reduction from baseline, legacy BD 29% Absolute (Metric tonnes), combined 54,681 52,676 53,994 54,171 52,506 52,383 51,280 51,748 57,864 55,484 67,541 66,Normalized (Metric tonnes per $M  COPS), incl.
","('Waste_And_Hazardous_Materials_Management', 0.9788817167282104)","('Water_And_Wastewater_Management', 0.0030292528681457043)","('Air_Quality', 0.0015960460295900702)","(['Operational Eco-Efficiency'], 0.9788817167282104)","('NON-ESG', 0.0030292528681457043)","('NON-ESG', 0.0015960460295900702)"
Line 988,"regulated waste, combined9.62 9.26 8.82 8.46 7.90 7.69 7.00 7.51 7.38 7.33 7.75 7.2020 goal:  Reduce total waste by 50% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9833480715751648)","('Water_And_Wastewater_Management', 0.0015752327162772417)","('Data_Security', 0.001281377044506371)","(['Operational Eco-Efficiency'], 0.9833480715751648)","('NON-ESG', 0.0015752327162772417)","('NON-ESG', 0.001281377044506371)"
Line 989,"Current status:  reduced by 23% Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste landfilled Absolute (Metric tonnes), legacy Bard 1,364 1,819 1,819 1,819 1,819 2,093 2,592 2,870 2,917 3,184 3,813 2,Normalized (Metric tonnes per $M  COPS), legacy Bard1.46 1.92 1.80 1.69 1.62 1.79 2.07 2.21 2.17 2.21 3.75 2.% landfilled, legacy Bard 36% 36% 36% 36% 36% 37% 42% 38% 36% 35% 30% 34% % diversion, legacy Bard 64% 64% 64% 64% 64% 63% 58% 62% 64% 65% 70% 66% Absolute (Metric tonnes), legacy BD 24,107 23,707 19,912 15,545 13,189 12,267 9,363 8,229 9,654 9,466 11,981 12,Normalized (Metric tonnes per $M  COPS), legacy BD5.07 5.00 3.90 2.92 2.39 2.17 1.54 1.47 1.49 1.54 1.56 1.% landfilled, legacy BD 47% 50% 41% 32% 28% 26% 21% 19% 19% 20% 22% 21% % diversion, legacy BD 53% 50% 59% 68% 72% 74% 79% 81% 81% 80% 78% 79% Absolute (Metric tonnes), combined 25,472 25,526 21,731 17,364 15,008 14,360 11,955 11,099 12,571 12,649 15,794 15,Normalized (Metric tonnes per $M  COPS), combined4.48 4.49 3.55 2.71 2.26 2.11 1.63 1.61 1.60 1.67 1.81 1.% landfilled, combined 47% 48% 40% 32% 29% 27% 23% 21% 22% 23% 23% 23% % diversion, combined 53% 52% 60% 68% 71% 73% 77% 79% 78% 77% 77% 77% 2020 goal:  Increase diversion rate by over 85% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.9810962080955505)","('Water_And_Wastewater_Management', 0.002230126643553376)","('Air_Quality', 0.0015409400220960379)","(['Operational Eco-Efficiency'], 0.9810962080955505)","('NON-ESG', 0.002230126643553376)","('NON-ESG', 0.0015409400220960379)"
Line 990,"Current status:  reduced by 23% Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste landfilled Absolute (Metric tonnes), legacy Bard 1,364 1,819 1,819 1,819 1,819 2,093 2,592 2,870 2,917 3,184 3,813 2,Normalized (Metric tonnes per $M  COPS), legacy Bard1.46 1.92 1.80 1.69 1.62 1.79 2.07 2.21 2.17 2.21 3.75 2.% landfilled, legacy Bard 36% 36% 36% 36% 36% 37% 42% 38% 36% 35% 30% 34% % diversion, legacy Bard 64% 64% 64% 64% 64% 63% 58% 62% 64% 65% 70% 66% Absolute (Metric tonnes), legacy BD 24,107 23,707 19,912 15,545 13,189 12,267 9,363 8,229 9,654 9,466 11,981 12,Normalized (Metric tonnes per $M  COPS), legacy BD5.07 5.00 3.90 2.92 2.39 2.17 1.54 1.47 1.49 1.54 1.56 1.% landfilled, legacy BD 47% 50% 41% 32% 28% 26% 21% 19% 19% 20% 22% 21% % diversion, legacy BD 53% 50% 59% 68% 72% 74% 79% 81% 81% 80% 78% 79% Absolute (Metric tonnes), combined 25,472 25,526 21,731 17,364 15,008 14,360 11,955 11,099 12,571 12,649 15,794 15,Normalized (Metric tonnes per $M  COPS), combined4.48 4.49 3.55 2.71 2.26 2.11 1.63 1.61 1.60 1.67 1.81 1.% landfilled, combined 47% 48% 40% 32% 29% 27% 23% 21% 22% 23% 23% 23% % diversion, combined 53% 52% 60% 68% 71% 73% 77% 79% 78% 77% 77% 77% 2020 goal:  Increase diversion rate by over 85% (absolute as % of total nonhazardous waste).
","('Energy_Management', 0.12389232963323593)","('Management_Of_Legal_And_Regulatory_Framework', 0.09455905854701996)","('Supply_Chain_Management', 0.08862020820379257)","('NON-ESG', 0.12389232963323593)","('NON-ESG', 0.09455905854701996)","('NON-ESG', 0.08862020820379257)"
Line 991,"Current status:  reduced by 23% Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste landfilled Absolute (Metric tonnes), legacy Bard 1,364 1,819 1,819 1,819 1,819 2,093 2,592 2,870 2,917 3,184 3,813 2,Normalized (Metric tonnes per $M  COPS), legacy Bard1.46 1.92 1.80 1.69 1.62 1.79 2.07 2.21 2.17 2.21 3.75 2.% landfilled, legacy Bard 36% 36% 36% 36% 36% 37% 42% 38% 36% 35% 30% 34% % diversion, legacy Bard 64% 64% 64% 64% 64% 63% 58% 62% 64% 65% 70% 66% Absolute (Metric tonnes), legacy BD 24,107 23,707 19,912 15,545 13,189 12,267 9,363 8,229 9,654 9,466 11,981 12,Normalized (Metric tonnes per $M  COPS), legacy BD5.07 5.00 3.90 2.92 2.39 2.17 1.54 1.47 1.49 1.54 1.56 1.% landfilled, legacy BD 47% 50% 41% 32% 28% 26% 21% 19% 19% 20% 22% 21% % diversion, legacy BD 53% 50% 59% 68% 72% 74% 79% 81% 81% 80% 78% 79% Absolute (Metric tonnes), combined 25,472 25,526 21,731 17,364 15,008 14,360 11,955 11,099 12,571 12,649 15,794 15,Normalized (Metric tonnes per $M  COPS), combined4.48 4.49 3.55 2.71 2.26 2.11 1.63 1.61 1.60 1.67 1.81 1.% landfilled, combined 47% 48% 40% 32% 29% 27% 23% 21% 22% 23% 23% 23% % diversion, combined 53% 52% 60% 68% 71% 73% 77% 79% 78% 77% 77% 77% 2020 goal:  Increase diversion rate by over 85% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.9804462790489197)","('Water_And_Wastewater_Management', 0.0029324654024094343)","('Air_Quality', 0.0014235373819246888)","(['Operational Eco-Efficiency'], 0.9804462790489197)","('NON-ESG', 0.0029324654024094343)","('NON-ESG', 0.0014235373819246888)"
Line 992,"Current status:  increased to 77% GRI disclosures: 306-3, 306- Legacy Bard  Legacy BD BD + Bard combined Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste incinerated Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 22 212 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0.02 0.21 0.% incinerated, legacy Bard 0 0 0 0 0 0 0 0 0 0% 2% 3% Absolute (Metric tonnes), legacy BD 5,096 3,226 3,228 3,198 2,998 4,156 4,231 3,550 5,980 6,237 8,158 9,Normalized (Metric tonnes per $M  COPS), legacy BD1.07 0.68 0.63 0.60 0.54 0.74 0.70 0.64 0.92 1.02 1.06 1.% incinerated, legacy BD 10% 7% 7% 7% 6% 9% 9% 8% 12% 13% 15% 16% Absolute (Metric tonnes), combined 5,096 3,226 3,228 3,198 2,998 4,156 4,231 3,550 5,980 6,259 8,371 9,Normalized (Metric tonnes per $M  COPS), combined*0.90 0.57 0.53 0.50 0.45 0.61 0.58 0.52 0.76 0.83 0.96 1.% reduction from baseline, combined 9% 6% 6% 6% 6% 8% 8% 7% 10% 11% 12% 15% *Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.9701168537139893)","('Water_And_Wastewater_Management', 0.004207194782793522)","('Air_Quality', 0.0029842043295502663)","(['Operational Eco-Efficiency'], 0.9701168537139893)","('NON-ESG', 0.004207194782793522)","('NON-ESG', 0.0029842043295502663)"
Line 993,"Current status:  increased to 77% GRI disclosures: 306-3, 306- Legacy Bard  Legacy BD BD + Bard combined Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste incinerated Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 22 212 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0.02 0.21 0.% incinerated, legacy Bard 0 0 0 0 0 0 0 0 0 0% 2% 3% Absolute (Metric tonnes), legacy BD 5,096 3,226 3,228 3,198 2,998 4,156 4,231 3,550 5,980 6,237 8,158 9,Normalized (Metric tonnes per $M  COPS), legacy BD1.07 0.68 0.63 0.60 0.54 0.74 0.70 0.64 0.92 1.02 1.06 1.% incinerated, legacy BD 10% 7% 7% 7% 6% 9% 9% 8% 12% 13% 15% 16% Absolute (Metric tonnes), combined 5,096 3,226 3,228 3,198 2,998 4,156 4,231 3,550 5,980 6,259 8,371 9,Normalized (Metric tonnes per $M  COPS), combined*0.90 0.57 0.53 0.50 0.45 0.61 0.58 0.52 0.76 0.83 0.96 1.% reduction from baseline, combined 9% 6% 6% 6% 6% 8% 8% 7% 10% 11% 12% 15% *Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.8249316811561584)","('Water_And_Wastewater_Management', 0.029064051806926727)","('Air_Quality', 0.024083465337753296)","(['Operational Eco-Efficiency'], 0.8249316811561584)","('NON-ESG', 0.029064051806926727)","('NON-ESG', 0.024083465337753296)"
Line 994,"Current status:  increased to 77% GRI disclosures: 306-3, 306- Legacy Bard  Legacy BD BD + Bard combined Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWaste—nonhazardous Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste incinerated Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 22 212 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0.02 0.21 0.% incinerated, legacy Bard 0 0 0 0 0 0 0 0 0 0% 2% 3% Absolute (Metric tonnes), legacy BD 5,096 3,226 3,228 3,198 2,998 4,156 4,231 3,550 5,980 6,237 8,158 9,Normalized (Metric tonnes per $M  COPS), legacy BD1.07 0.68 0.63 0.60 0.54 0.74 0.70 0.64 0.92 1.02 1.06 1.% incinerated, legacy BD 10% 7% 7% 7% 6% 9% 9% 8% 12% 13% 15% 16% Absolute (Metric tonnes), combined 5,096 3,226 3,228 3,198 2,998 4,156 4,231 3,550 5,980 6,259 8,371 9,Normalized (Metric tonnes per $M  COPS), combined*0.90 0.57 0.53 0.50 0.45 0.61 0.58 0.52 0.76 0.83 0.96 1.% reduction from baseline, combined 9% 6% 6% 6% 6% 8% 8% 7% 10% 11% 12% 15% *Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.1748170107603073)","('Energy_Management', 0.11944129317998886)","('Management_Of_Legal_And_Regulatory_Framework', 0.10345827788114548)","('NON-ESG', 0.1748170107603073)","('NON-ESG', 0.11944129317998886)","('NON-ESG', 0.10345827788114548)"
Line 995,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste recycled Absolute (Metric tonnes), legacy Bard 2,435 3,247 3,247 3,247 3,247 3,489 3,609 4,720 5,085 5,907 8,803 5,Normalized (Metric tonnes per $M  COPS), legacy Bard2.61 3.43 3.21 3.01 2.90 2.98 2.89 3.63 3.78 4.09 8.66 4.% recycled, legacy Bard 64% 64% 64% 64% 64% 63% 58% 62% 64% 65% 69% 64% Absolute (Metric tonnes), legacy BD 21,678 20,677 25,788 30,362 31,253 30,377 31,485 32,380 34,228 30,668 34,573 36,Normalized (Metric tonnes per $M  COPS), legacy BD4.56 4.36 5.04 5.70 5.66 5.38 5.18 5.80 5.27 5.00 4.49 4.% recycled, legacy BD 43% 43% 53% 62% 66% 65% 70% 73% 69% 66% 63% 63% Absolute (Metric tonnes), combined 24,113 23,924 29,035 33,609 34,500 33,866 35,094 37,099 39,313 36,576 43,376 42,Normalized (Metric tonnes per $M  COPS), combined4.24 4.21 4.74 5.25 5.19 4.97 4.79 5.39 5.02 4.83 4.98 4.% recycled, combined 44% 45% 54% 62% 66% 65% 68% 72% 68% 66% 64% 63% 2020 goal:  Increase recycling rate by over 70% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.9802261590957642)","('Water_And_Wastewater_Management', 0.0024511986412107944)","('Air_Quality', 0.001275850459933281)","(['Operational Eco-Efficiency'], 0.9802261590957642)","('NON-ESG', 0.0024511986412107944)","('NON-ESG', 0.001275850459933281)"
Line 996,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste recycled Absolute (Metric tonnes), legacy Bard 2,435 3,247 3,247 3,247 3,247 3,489 3,609 4,720 5,085 5,907 8,803 5,Normalized (Metric tonnes per $M  COPS), legacy Bard2.61 3.43 3.21 3.01 2.90 2.98 2.89 3.63 3.78 4.09 8.66 4.% recycled, legacy Bard 64% 64% 64% 64% 64% 63% 58% 62% 64% 65% 69% 64% Absolute (Metric tonnes), legacy BD 21,678 20,677 25,788 30,362 31,253 30,377 31,485 32,380 34,228 30,668 34,573 36,Normalized (Metric tonnes per $M  COPS), legacy BD4.56 4.36 5.04 5.70 5.66 5.38 5.18 5.80 5.27 5.00 4.49 4.% recycled, legacy BD 43% 43% 53% 62% 66% 65% 70% 73% 69% 66% 63% 63% Absolute (Metric tonnes), combined 24,113 23,924 29,035 33,609 34,500 33,866 35,094 37,099 39,313 36,576 43,376 42,Normalized (Metric tonnes per $M  COPS), combined4.24 4.21 4.74 5.25 5.19 4.97 4.79 5.39 5.02 4.83 4.98 4.% recycled, combined 44% 45% 54% 62% 66% 65% 68% 72% 68% 66% 64% 63% 2020 goal:  Increase recycling rate by over 70% (absolute as % of total nonhazardous waste).
","('Product_Design_And_Lifecycle_Management', 0.19819994270801544)","('Energy_Management', 0.16685429215431213)","('Supply_Chain_Management', 0.11761192977428436)","('NON-ESG', 0.19819994270801544)","('NON-ESG', 0.16685429215431213)","('NON-ESG', 0.11761192977428436)"
Line 997,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Nonhazardous waste recycled Absolute (Metric tonnes), legacy Bard 2,435 3,247 3,247 3,247 3,247 3,489 3,609 4,720 5,085 5,907 8,803 5,Normalized (Metric tonnes per $M  COPS), legacy Bard2.61 3.43 3.21 3.01 2.90 2.98 2.89 3.63 3.78 4.09 8.66 4.% recycled, legacy Bard 64% 64% 64% 64% 64% 63% 58% 62% 64% 65% 69% 64% Absolute (Metric tonnes), legacy BD 21,678 20,677 25,788 30,362 31,253 30,377 31,485 32,380 34,228 30,668 34,573 36,Normalized (Metric tonnes per $M  COPS), legacy BD4.56 4.36 5.04 5.70 5.66 5.38 5.18 5.80 5.27 5.00 4.49 4.% recycled, legacy BD 43% 43% 53% 62% 66% 65% 70% 73% 69% 66% 63% 63% Absolute (Metric tonnes), combined 24,113 23,924 29,035 33,609 34,500 33,866 35,094 37,099 39,313 36,576 43,376 42,Normalized (Metric tonnes per $M  COPS), combined4.24 4.21 4.74 5.25 5.19 4.97 4.79 5.39 5.02 4.83 4.98 4.% recycled, combined 44% 45% 54% 62% 66% 65% 68% 72% 68% 66% 64% 63% 2020 goal:  Increase recycling rate by over 70% (absolute as % of total nonhazardous waste).
","('Waste_And_Hazardous_Materials_Management', 0.9805011749267578)","('Water_And_Wastewater_Management', 0.0021185954101383686)","('Product_Design_And_Lifecycle_Management', 0.0016349977813661098)","(['Operational Eco-Efficiency'], 0.9805011749267578)","('NON-ESG', 0.0021185954101383686)","('NON-ESG', 0.0016349977813661098)"
Line 998,"Current status:  increased to 63% GRI disclosures: 306-4, 306- Legacy Bard  Legacy BD BD + Bard combined Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWaste—regulated Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Regulated waste (bio-hazardous and controlled waste) Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 5 187 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.Absolute (Metric tonnes), legacy BD 196 181 707 1,504 858 687 1,028 1,216 1,117 1,095 934 1,Normalized (Metric tonnes per $M  COPS), legacy BD0.04 0.04 0.14 0.28 0.16 0.12 0.17 0.22 0.17 0.18 0.12 0.Absolute (Metric tonnes), combined 196 181 707 1,504 858 687 1,028 1,216 1,117 1,101 1,121 1,Normalized (Metric tonnes per $M  COPS), combined*0.03 0.03 0.12 0.23 0.13 0.10 0.14 0.18 0.14 0.15 0.13 0.*Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.9719957113265991)","('Water_And_Wastewater_Management', 0.0032006995752453804)","('Air_Quality', 0.002554151462391019)","(['Operational Eco-Efficiency'], 0.9719957113265991)","('NON-ESG', 0.0032006995752453804)","('NON-ESG', 0.002554151462391019)"
Line 999,"Current status:  increased to 63% GRI disclosures: 306-4, 306- Legacy Bard  Legacy BD BD + Bard combined Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWaste—regulated Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Regulated waste (bio-hazardous and controlled waste) Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 5 187 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.Absolute (Metric tonnes), legacy BD 196 181 707 1,504 858 687 1,028 1,216 1,117 1,095 934 1,Normalized (Metric tonnes per $M  COPS), legacy BD0.04 0.04 0.14 0.28 0.16 0.12 0.17 0.22 0.17 0.18 0.12 0.Absolute (Metric tonnes), combined 196 181 707 1,504 858 687 1,028 1,216 1,117 1,101 1,121 1,Normalized (Metric tonnes per $M  COPS), combined*0.03 0.03 0.12 0.23 0.13 0.10 0.14 0.18 0.14 0.15 0.13 0.*Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.964883029460907)","('Water_And_Wastewater_Management', 0.004759485833346844)","('Supply_Chain_Management', 0.002251975005492568)","(['Operational Eco-Efficiency'], 0.964883029460907)","('NON-ESG', 0.004759485833346844)","('NON-ESG', 0.002251975005492568)"
Line 1000,"Current status:  increased to 63% GRI disclosures: 306-4, 306- Legacy Bard  Legacy BD BD + Bard combined Innovation               Innovation                Access                     Access                      Empowerment       Empowerment        Efficiency                Efficiency                Efficiency data tablesWaste—regulated Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Regulated waste (bio-hazardous and controlled waste) Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 5 187 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.18 0.Absolute (Metric tonnes), legacy BD 196 181 707 1,504 858 687 1,028 1,216 1,117 1,095 934 1,Normalized (Metric tonnes per $M  COPS), legacy BD0.04 0.04 0.14 0.28 0.16 0.12 0.17 0.22 0.17 0.18 0.12 0.Absolute (Metric tonnes), combined 196 181 707 1,504 858 687 1,028 1,216 1,117 1,101 1,121 1,Normalized (Metric tonnes per $M  COPS), combined*0.03 0.03 0.12 0.23 0.13 0.10 0.14 0.18 0.14 0.15 0.13 0.*Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Competitive_Behavior', 0.22578589618206024)","('Business_Model_Resilience', 0.14090119302272797)","('Systemic_Risk_Management', 0.1279161274433136)","('NON-ESG', 0.22578589618206024)","('NON-ESG', 0.14090119302272797)","('NON-ESG', 0.1279161274433136)"
Line 1001,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Hazardous waste generation Absolute (Metric tonnes), legacy Bard 253 338 338 338 347 449 1,066 1,178 1,098 1,227 1,199 Normalized (Metric tonnes per $M  COPS), legacy Bard0.27 0.36 0.33 0.31 0.31 0.38 0.85 0.91 0.82 0.85 1.18 0.% reduction, legacy Bard -143% Absolute (Metric tonnes), legacy BD 2,853 2,219 2,617 2,141 1,939 1,896 1,728 1,806 1,946 1,756 2,088 1,Normalized (Metric tonnes per $M  COPS), legacy BD0.60 0.47 0.51 0.40 0.35 0.34 0.28 0.32 0.30 0.29 0.27 0.% reduction, legacy BD 61% Absolute (Metric tonnes), combined 3,107 2,556 2,954 2,479 2,286 2,345 2,794 2,984 3,044 2,983 3,287 2,Normalized (Metric tonnes per $M  COPS), combined0.55 0.45 0.48 0.39 0.34 0.34 0.38 0.43 0.39 0.39 0.38 0.2020 goal:  Reduce hazardous waste by more than 60% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9816933274269104)","('Water_And_Wastewater_Management', 0.0017756936140358448)","('Air_Quality', 0.00148785172495991)","(['Operational Eco-Efficiency'], 0.9816933274269104)","('NON-ESG', 0.0017756936140358448)","('NON-ESG', 0.00148785172495991)"
Line 1002,"Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Hazardous waste generation Absolute (Metric tonnes), legacy Bard 253 338 338 338 347 449 1,066 1,178 1,098 1,227 1,199 Normalized (Metric tonnes per $M  COPS), legacy Bard0.27 0.36 0.33 0.31 0.31 0.38 0.85 0.91 0.82 0.85 1.18 0.% reduction, legacy Bard -143% Absolute (Metric tonnes), legacy BD 2,853 2,219 2,617 2,141 1,939 1,896 1,728 1,806 1,946 1,756 2,088 1,Normalized (Metric tonnes per $M  COPS), legacy BD0.60 0.47 0.51 0.40 0.35 0.34 0.28 0.32 0.30 0.29 0.27 0.% reduction, legacy BD 61% Absolute (Metric tonnes), combined 3,107 2,556 2,954 2,479 2,286 2,345 2,794 2,984 3,044 2,983 3,287 2,Normalized (Metric tonnes per $M  COPS), combined0.55 0.45 0.48 0.39 0.34 0.34 0.38 0.43 0.39 0.39 0.38 0.2020 goal:  Reduce hazardous waste by more than 60% (normalized by COPS).
","('Waste_And_Hazardous_Materials_Management', 0.9832049012184143)","('Water_And_Wastewater_Management', 0.0013103241799399257)","('Air_Quality', 0.0011885393178090453)","(['Operational Eco-Efficiency'], 0.9832049012184143)","('NON-ESG', 0.0013103241799399257)","('NON-ESG', 0.0011885393178090453)"
Line 1003,"Current status:  reduced by 45%Waste—hazardous GRI disclosure: 306- Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesVOC emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY VOC emissions Absolute (Metric tonnes), legacy Bard – – – – – – – – – – 182 Normalized (Metric tonnes per $M  COPS), legacy Bard– – – – – – – – – – 0.18 0.Absolute (Metric tonnes), legacy BD 339 139 116 113 134 123 139 138 151 191 225 Normalized (Metric tonnes per $M  COPS), legacy BD0.07 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.Absolute (Metric tonnes), combined 339 139 116 113 134 123 139 138 151 191 407 Normalized (Metric tonnes per $M  COPS), combined*0.06 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.05 0.*Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Waste_And_Hazardous_Materials_Management', 0.9582067728042603)","('Air_Quality', 0.010116906836628914)","('Water_And_Wastewater_Management', 0.0046165017411112785)","(['Operational Eco-Efficiency'], 0.9582067728042603)","('NON-ESG', 0.010116906836628914)","('NON-ESG', 0.0046165017411112785)"
Line 1004,"Current status:  reduced by 45%Waste—hazardous GRI disclosure: 306- Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesVOC emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY VOC emissions Absolute (Metric tonnes), legacy Bard – – – – – – – – – – 182 Normalized (Metric tonnes per $M  COPS), legacy Bard– – – – – – – – – – 0.18 0.Absolute (Metric tonnes), legacy BD 339 139 116 113 134 123 139 138 151 191 225 Normalized (Metric tonnes per $M  COPS), legacy BD0.07 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.Absolute (Metric tonnes), combined 339 139 116 113 134 123 139 138 151 191 407 Normalized (Metric tonnes per $M  COPS), combined*0.06 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.05 0.*Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Management_Of_Legal_And_Regulatory_Framework', 0.3307737708091736)","('Systemic_Risk_Management', 0.06998760253190994)","('Human_Rights_And_Community_Relations', 0.05452139675617218)","('NON-ESG', 0.3307737708091736)","('NON-ESG', 0.06998760253190994)","('NON-ESG', 0.05452139675617218)"
Line 1005,"HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY HAPs emissions Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 0 82 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.08 0.Absolute (Metric tonnes), legacy BD 15 13 23 23 18 17 14 12 16 23 26 Normalized (Metric tonnes per $M  COPS), legacy BD0.003 0.003 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.004 0.003 0.Absolute (Metric tonnes), combined 15 13 23 23 18 17 14 12 16 23 107 Normalized (Metric tonnes per $M  COPS), combined*0.003 0.002 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.003 0.012 0.*Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('GHG_Emissions', 0.5341832637786865)","('Air_Quality', 0.3152666687965393)","('Energy_Management', 0.02743718773126602)","(['Climate Change'], 0.5341832637786865)","('NON-ESG', 0.3152666687965393)","('NON-ESG', 0.02743718773126602)"
Line 1006,"HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY HAPs emissions Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 0 82 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.08 0.Absolute (Metric tonnes), legacy BD 15 13 23 23 18 17 14 12 16 23 26 Normalized (Metric tonnes per $M  COPS), legacy BD0.003 0.003 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.004 0.003 0.Absolute (Metric tonnes), combined 15 13 23 23 18 17 14 12 16 23 107 Normalized (Metric tonnes per $M  COPS), combined*0.003 0.002 0.004 0.004 0.003 0.003 0.002 0.002 0.002 0.003 0.012 0.*Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.20535701513290405)","('Management_Of_Legal_And_Regulatory_Framework', 0.2004653960466385)","('Competitive_Behavior', 0.10522093623876572)","('NON-ESG', 0.20535701513290405)","('NON-ESG', 0.2004653960466385)","('NON-ESG', 0.10522093623876572)"
Line 1007,"GRI disclosure: 305- Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesVOC + HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY HAPs emissions Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 0 264 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.26 0.Absolute (Metric tonnes), legacy BD 355 152 138 137 152 141 153 150 167 214 251 Normalized (Metric tonnes per $M  COPS), legacy BD0.07 0.03 0.03 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.% reduction, legacy BD 60% Absolute (Metric tonnes), combined 355 152 138 137 152 141 153 150 167 214 515 Normalized (Metric tonnes per $M  COPS), combined*0.06 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.06 0.2020 goal: Reduce VOC and HAPs emissions by 65% (normalized by COPS).
","('Air_Quality', 0.903915286064148)","('GHG_Emissions', 0.0349125899374485)","('Energy_Management', 0.01446839701384306)","(['Operational Eco-Efficiency'], 0.903915286064148)","('NON-ESG', 0.0349125899374485)","('NON-ESG', 0.01446839701384306)"
Line 1008,"GRI disclosure: 305- Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                Efficiency data tablesVOC + HAPs emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY HAPs emissions Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 0 264 Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0.26 0.Absolute (Metric tonnes), legacy BD 355 152 138 137 152 141 153 150 167 214 251 Normalized (Metric tonnes per $M  COPS), legacy BD0.07 0.03 0.03 0.03 0.03 0.02 0.03 0.03 0.03 0.03 0.03 0.% reduction, legacy BD 60% Absolute (Metric tonnes), combined 355 152 138 137 152 141 153 150 167 214 515 Normalized (Metric tonnes per $M  COPS), combined*0.06 0.03 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.03 0.06 0.2020 goal: Reduce VOC and HAPs emissions by 65% (normalized by COPS).
","('Air_Quality', 0.571718156337738)","('GHG_Emissions', 0.2655789256095886)","('Energy_Management', 0.0471225306391716)","(['Operational Eco-Efficiency'], 0.571718156337738)","('NON-ESG', 0.2655789256095886)","('NON-ESG', 0.0471225306391716)"
Line 1009,"Current status: reduced by 18% *Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.33818840980529785)","('Management_Of_Legal_And_Regulatory_Framework', 0.22079594433307648)","('Business_Model_Resilience', 0.10824154317378998)","('NON-ESG', 0.33818840980529785)","('NON-ESG', 0.22079594433307648)","('NON-ESG', 0.10824154317378998)"
Line 1010,"Ozone-depleting substances emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Ozone-depleting substances emissions Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 0 0 0.Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0 0.Absolute (Metric tonnes), legacy BD*339 274 249 254 235 236 228 218 192 185 172 Normalized (Metric tonnes per $M  COPS), legacy BD0.07 0.06 0.05 0.05 0.04 0.04 0.04 0.04 0.03 0.03 0.02 0.% reduction, legacy BD 81% *Legacy BD data has been restated in FY 2018, due to error detected in data calculation.
","('GHG_Emissions', 0.6583318710327148)","('Air_Quality', 0.16286751627922058)","('Waste_And_Hazardous_Materials_Management', 0.02568863146007061)","(['Climate Change'], 0.6583318710327148)","('NON-ESG', 0.16286751627922058)","('NON-ESG', 0.02568863146007061)"
Line 1011,"Ozone-depleting substances emissions Measurement and UOM FY 2008  baseline  FY 2009  FY 2010  FY 2011  FY 2012  FY 2013  FY 2014  FY 2015  FY 2016 FY 2017 FY 2018 FY Ozone-depleting substances emissions Absolute (Metric tonnes), legacy Bard 0 0 0 0 0 0 0 0 0 0 0 0.Normalized (Metric tonnes per $M  COPS), legacy Bard0 0 0 0 0 0 0 0 0 0 0 0.Absolute (Metric tonnes), legacy BD*339 274 249 254 235 236 228 218 192 185 172 Normalized (Metric tonnes per $M  COPS), legacy BD0.07 0.06 0.05 0.05 0.04 0.04 0.04 0.04 0.03 0.03 0.02 0.% reduction, legacy BD 81% *Legacy BD data has been restated in FY 2018, due to error detected in data calculation.
","('Data_Security', 0.629009485244751)","('Business_Ethics', 0.10929708927869797)","('Systemic_Risk_Management', 0.060203004628419876)","(['Information Security/Cybersecurity & System Availability'], 0.629009485244751)","('NON-ESG', 0.10929708927869797)","('NON-ESG', 0.060203004628419876)"
Line 1012,"Absolute (Metric tonnes), combined 339 274 249 254 235 236 228 218 192 185 172 Normalized (Metric tonnes per $M  COPS), combined†0.06 0.05 0.04 0.04 0.04 0.03 0.03 0.03 0.02 0.02 0.02 0.2020 goal:  Reduce ozone-depleting substance emissions by 95% (normalized by COPS).
","('GHG_Emissions', 0.7081450819969177)","('Air_Quality', 0.11506365984678268)","('Energy_Management', 0.03398039564490318)","(['Climate Change'], 0.7081450819969177)","('NON-ESG', 0.11506365984678268)","('NON-ESG', 0.03398039564490318)"
Line 1013,"Current status:  reduced by 81% 2020 goal:  100% elimination of use of HCFC141b in manufacturing.
","('Customer_Welfare', 0.16600298881530762)","('Management_Of_Legal_And_Regulatory_Framework', 0.11121392995119095)","('Product_Design_And_Lifecycle_Management', 0.11059682071208954)","('NON-ESG', 0.16600298881530762)","('NON-ESG', 0.11121392995119095)","('NON-ESG', 0.11059682071208954)"
Line 1014,"Current status:  While a number of our facilities have completed conversion plans and eliminated the use of hydrochlorofluorocarbon (HCFC), we continue to make  progress implementing conversion plans at remaining facilities and expect to complete all conversions as scheduled.
","('Energy_Management', 0.463260293006897)","('Customer_Welfare', 0.13600687682628632)","('GHG_Emissions', 0.09522730112075806)","('NON-ESG', 0.463260293006897)","('NON-ESG', 0.13600687682628632)","('NON-ESG', 0.09522730112075806)"
Line 1015,"†Combined COPS were used to calculate normalized performance back to FY 2008 baseline.
","('Systemic_Risk_Management', 0.30233991146087646)","('Business_Model_Resilience', 0.1715635508298874)","('Competitive_Behavior', 0.15053601562976837)","('NON-ESG', 0.30233991146087646)","('NON-ESG', 0.1715635508298874)","('NON-ESG', 0.15053601562976837)"
Line 1016,"GRI disclosures: 305-6, 305- Legacy Bard  Legacy BD BD + Bard combinedInnovation               Access                     Empowerment       Efficiency                68Introduction We profoundly respect that what we do is for the good of people.
","('Access_And_Affordability', 0.47567322850227356)","('Human_Rights_And_Community_Relations', 0.24836573004722595)","('Employee_Engagement_Inclusion_And_Diversity', 0.04161490872502327)","('NON-ESG', 0.47567322850227356)","('NON-ESG', 0.24836573004722595)","('NON-ESG', 0.04161490872502327)"
Line 1017,"That’s why BD associates work with  humanity and kindness across cultures, regions and relationships.
","('Human_Rights_And_Community_Relations', 0.7209609746932983)","('Employee_Engagement_Inclusion_And_Diversity', 0.09700347483158112)","('Employee_Health_And_Safety', 0.016185341402888298)","(['Community Relations'], 0.7209609746932983)","('NON-ESG', 0.09700347483158112)","('NON-ESG', 0.016185341402888298)"
Line 1018,"It is the behavior that is necessary to  be responsible global citizens.
","('Business_Ethics', 0.5378378033638)","('Competitive_Behavior', 0.12208263576030731)","('Management_Of_Legal_And_Regulatory_Framework', 0.07134158164262772)","(['Business Ethics'], 0.5378378033638)","('NON-ESG', 0.12208263576030731)","('NON-ESG', 0.07134158164262772)"
Line 1019,"It is what it means to care.Empowerment Positive workforce and   community impacts 2020 goal Increase the diversity of our workplace, particularly in leadership roles At BD, we are committed to driving inclusion and diversity across our global organization by building and engaging strong and  inclusive teams and individuals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9768547415733337)","('Employee_Health_And_Safety', 0.0020684923510998487)","('Human_Rights_And_Community_Relations', 0.0016648104647174478)","(['Human Capital Development'], 0.9768547415733337)","('NON-ESG', 0.0020684923510998487)","('NON-ESG', 0.0016648104647174478)"
Line 1020,"We leverage their unique ideas, backgrounds and experiences to deliver better outcomes for our  global marketplace.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9491241574287415)","('Business_Model_Resilience', 0.006101135164499283)","('Product_Design_And_Lifecycle_Management', 0.004003970418125391)","(['Human Capital Development'], 0.9491241574287415)","('NON-ESG', 0.006101135164499283)","('NON-ESG', 0.004003970418125391)"
Line 1021,"We’ve become a more inclusive organization, celebrating our diversity and embedding both in the BD Way:  “Inclusion and diversity make us a stronger team.” Our associates come from all backgrounds, races, ages, colors, creeds, religions,  genders, orientations, abilities, thoughts and experiences, reflecting the communities we live and work in, the customers and patients  we serve, and our broad range of thought and experience.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9754098653793335)","('Employee_Health_And_Safety', 0.0021817481610924006)","('Human_Rights_And_Community_Relations', 0.001838605385273695)","(['Human Capital Development'], 0.9754098653793335)","('NON-ESG', 0.0021817481610924006)","('NON-ESG', 0.001838605385273695)"
Line 1022,"Their diversity is an integral part of our success.
","('Employee_Engagement_Inclusion_And_Diversity', 0.967019259929657)","('Business_Model_Resilience', 0.0023596903774887323)","('Human_Rights_And_Community_Relations', 0.002170323161408305)","(['Human Capital Development'], 0.967019259929657)","('NON-ESG', 0.0023596903774887323)","('NON-ESG', 0.002170323161408305)"
Line 1023,"We are better because of  it and we all share the responsibility to drive our culture of inclusion, where all associates feel they belong at all times.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9456366896629333)","('Human_Rights_And_Community_Relations', 0.00961095467209816)","('Employee_Health_And_Safety', 0.004628218710422516)","(['Human Capital Development'], 0.9456366896629333)","('NON-ESG', 0.00961095467209816)","('NON-ESG', 0.004628218710422516)"
Line 1024,"We look to our Associate Resource Groups (ARGs) to provide  insights and counsel on how BD can best attract, develop and  retain diverse talent in ways that meet their unique needs, drive  business improvement and innovation, and help us to continually  commit to being a socially responsible community partner.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9269145131111145)","('Business_Model_Resilience', 0.011504539288580418)","('Human_Rights_And_Community_Relations', 0.006568409036844969)","(['Human Capital Development'], 0.9269145131111145)","('NON-ESG', 0.011504539288580418)","('NON-ESG', 0.006568409036844969)"
Line 1025,"Our ARGs raise awareness and celebrate the differences that make  us unique, while ensuring our associates feel a sense of belonging,  and contribute to our business goals.
","('Employee_Engagement_Inclusion_And_Diversity', 0.32547712326049805)","('Business_Model_Resilience', 0.1920652538537979)","('Human_Rights_And_Community_Relations', 0.15281999111175537)","('NON-ESG', 0.32547712326049805)","('NON-ESG', 0.1920652538537979)","('NON-ESG', 0.15281999111175537)"
Line 1026,"Our first ARG—the Women’s  Initiative Network (WIN)—launched in 2015 and we have  continuously added additional ARGs since that time.
","('Human_Rights_And_Community_Relations', 0.3586006462574005)","('Employee_Engagement_Inclusion_And_Diversity', 0.2001183182001114)","('Access_And_Affordability', 0.1322464495897293)","('NON-ESG', 0.3586006462574005)","('NON-ESG', 0.2001183182001114)","('NON-ESG', 0.1322464495897293)"
Line 1027,"This year, we  successfully launched two more ARGs: • LimitlessBD, whose mission is to raise awareness of people’s  unique abilities and ensures a supportive environment where  those impacted are continually advancing to their fullest  potential; and • Network for Employee-led Cross-Company Transformation  (NEXT), whose mission is to foster a community that empowers  associates looking to lead BD in the cross-company  transformation of culture, policy and capabilities.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6244298815727234)","('Human_Rights_And_Community_Relations', 0.09523377567529678)","('Business_Model_Resilience', 0.038701966404914856)","(['Human Capital Development'], 0.6244298815727234)","('NON-ESG', 0.09523377567529678)","('NON-ESG', 0.038701966404914856)"
Line 1028,"We now have eight ARGs, each with at least one member of our  Executive Leadership team as an executive sponsor.
","('Director_Removal', 0.6011598706245422)","('Employee_Engagement_Inclusion_And_Diversity', 0.07186170667409897)","('Business_Model_Resilience', 0.06436756998300552)","(['Anti-Crime Policy & Measures'], 0.6011598706245422)","('NON-ESG', 0.07186170667409897)","('NON-ESG', 0.06436756998300552)"
Line 1029,"The ARGs create professional development opportunities for associates  through peer mentoring, leadership and networking.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7870475649833679)","('Access_And_Affordability', 0.03958327695727348)","('Human_Rights_And_Community_Relations', 0.020828869193792343)","(['Human Capital Development'], 0.7870475649833679)","('NON-ESG', 0.03958327695727348)","('NON-ESG', 0.020828869193792343)"
Line 1030,"Each ARG  aligns its mission with the inclusion and diversity strategy and  establishes annual impact objectives that affect our culture,  business, community and associate professional development.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9733431339263916)","('Human_Rights_And_Community_Relations', 0.0029104859568178654)","('Employee_Health_And_Safety', 0.0018167298985645175)","(['Human Capital Development'], 0.9733431339263916)","('NON-ESG', 0.0029104859568178654)","('NON-ESG', 0.0018167298985645175)"
Line 1031,"This year, our ARGs focused efforts on diversity recruiting.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9715189933776855)","('Employee_Health_And_Safety', 0.0021752493921667337)","('Human_Rights_And_Community_Relations', 0.0018601956544443965)","(['Human Capital Development'], 0.9715189933776855)","('NON-ESG', 0.0021752493921667337)","('NON-ESG', 0.0018601956544443965)"
Line 1032,"BD supports organizations like the National Black MBA   Association, Society of Women Engineers, National Sales Network  and MVPvets.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7282329201698303)","('Director_Removal', 0.0463288277387619)","('Labor_Practices', 0.035808198153972626)","(['Human Capital Development'], 0.7282329201698303)","('NON-ESG', 0.0463288277387619)","('NON-ESG', 0.035808198153972626)"
Line 1033,"Our ARGs also identified areas to improve supplier  diversity, influence company policies, programs and technology  and continued building cultural competence and awareness.
","('Employee_Engagement_Inclusion_And_Diversity', 0.954138994216919)","('Human_Rights_And_Community_Relations', 0.0038855555467307568)","('Labor_Practices', 0.0036346560809761286)","(['Human Capital Development'], 0.954138994216919)","('NON-ESG', 0.0038855555467307568)","('NON-ESG', 0.0036346560809761286)"
Line 1034,"In partnership with our CEO, Tom Polen, ARGs provided quarterly  career development sessions, open to all associates globally,  engaging senior leaders to share stories of their personal career  pursuits, challenges encountered and the resulting lessons learned.
","('Employee_Engagement_Inclusion_And_Diversity', 0.7981486916542053)","('Business_Model_Resilience', 0.0312979631125927)","('Human_Rights_And_Community_Relations', 0.01636500656604767)","(['Human Capital Development'], 0.7981486916542053)","('NON-ESG', 0.0312979631125927)","('NON-ESG', 0.01636500656604767)"
Line 1035,"ARGs were also instrumental in addressing community-based  needs by supporting organizations like the Human Rights  Campaign, First Robotics and Special Olympics of New Jersey.
","('Human_Rights_And_Community_Relations', 0.9565524458885193)","('Access_And_Affordability', 0.006136964075267315)","('Labor_Practices', 0.0037000728771090508)","(['Community Relations'], 0.9565524458885193)","('NON-ESG', 0.006136964075267315)","('NON-ESG', 0.0037000728771090508)"
Line 1036,"They also partnered with organizations like Girl Scouts of the USA  for a day of mentoring, Rise Against Hunger for our MLK Day of  Service and Heart to Heart International, supporting asylum  seekers at the U.S. border.Associate Resource GroupsInnovation               Access                     Efficiency                Empowerment       69BD continued leadership engagement in inclusion and diversity in  2019 through our Global Inclusion Council, made up of senior  leaders representing each business, region and function across the  global enterprise.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9635430574417114)","('Human_Rights_And_Community_Relations', 0.004693970084190369)","('Access_And_Affordability', 0.003979452885687351)","(['Human Capital Development'], 0.9635430574417114)","('NON-ESG', 0.004693970084190369)","('NON-ESG', 0.003979452885687351)"
Line 1037,"They also partnered with organizations like Girl Scouts of the USA  for a day of mentoring, Rise Against Hunger for our MLK Day of  Service and Heart to Heart International, supporting asylum  seekers at the U.S. border.Associate Resource GroupsInnovation               Access                     Efficiency                Empowerment       69BD continued leadership engagement in inclusion and diversity in  2019 through our Global Inclusion Council, made up of senior  leaders representing each business, region and function across the  global enterprise.
","('Competitive_Behavior', 0.281546413898468)","('Business_Model_Resilience', 0.24134275317192078)","('Systemic_Risk_Management', 0.1055607944726944)","('NON-ESG', 0.281546413898468)","('NON-ESG', 0.24134275317192078)","('NON-ESG', 0.1055607944726944)"
Line 1038,"The council continues to advance inclusion and  diversity to drive innovation and growth, ensuring a better  understanding of our organizational needs and making BD the  best possible place for all people to work.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9754250049591064)","('Employee_Health_And_Safety', 0.001959397690370679)","('Human_Rights_And_Community_Relations', 0.001707105664536357)","(['Human Capital Development'], 0.9754250049591064)","('NON-ESG', 0.001959397690370679)","('NON-ESG', 0.001707105664536357)"
Line 1039,"Each year, council  members and their respective executive leaders identify inclusion  and diversity priorities and associated objectives and metrics to  work towards over the course of the year.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9729173183441162)","('Human_Rights_And_Community_Relations', 0.0020097061060369015)","('Employee_Health_And_Safety', 0.0018103007460013032)","(['Human Capital Development'], 0.9729173183441162)","('NON-ESG', 0.0020097061060369015)","('NON-ESG', 0.0018103007460013032)"
Line 1040,"This year, the council’s  top priority was to lay a foundation of education for all associates on conscious inclusion, opening our associates to greater  awareness of their personal biases and reaffirming the conscious  behaviors and decision-making that drive our culture of inclusion.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9576784372329712)","('Human_Rights_And_Community_Relations', 0.004878187086433172)","('Employee_Health_And_Safety', 0.003491408657282591)","(['Human Capital Development'], 0.9576784372329712)","('NON-ESG', 0.004878187086433172)","('NON-ESG', 0.003491408657282591)"
Line 1041,"Council members identified leaders to be trained to deliver the  learning content to associates within their respective organizations  and across the enterprise, resulting in approximately 250 leader  teachers.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6754986047744751)","('Human_Rights_And_Community_Relations', 0.04932057112455368)","('Access_And_Affordability', 0.032392945140600204)","(['Human Capital Development'], 0.6754986047744751)","('NON-ESG', 0.04932057112455368)","('NON-ESG', 0.032392945140600204)"
Line 1042,"The training continues as we enter 2020 and will remain  a priority for the council, along with designing future learning  curriculum to build upon the foundation established.Global Inclusion Council We are proud that our inclusion and diversity efforts have not only  been instrumental to shaping our culture and impactful to our  associates at BD but have also afforded us recognition by leading  external organizations in inclusion and diversity.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9720110297203064)","('Employee_Health_And_Safety', 0.0027969551738351583)","('Human_Rights_And_Community_Relations', 0.0023913164623081684)","(['Human Capital Development'], 0.9720110297203064)","('NON-ESG', 0.0027969551738351583)","('NON-ESG', 0.0023913164623081684)"
Line 1043,"In 2019, BD was  recognized for gender diversity by, among others, the Women’s  Forum of New York, Executive Women of New Jersey, Society of  Women Engineers and the Australian Government’s Workplace  Gender Equality Agency.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9590360522270203)","('Labor_Practices', 0.007093220017850399)","('Employee_Health_And_Safety', 0.004429830703884363)","(['Human Capital Development'], 0.9590360522270203)","('NON-ESG', 0.007093220017850399)","('NON-ESG', 0.004429830703884363)"
Line 1044,"For the first time, BD was named as a Best Place to Work for  Disability Inclusion with a score of 90 on Disability:IN’s 2019  Disability Equality Index® (DEI).
","('Employee_Engagement_Inclusion_And_Diversity', 0.9443138241767883)","('Employee_Health_And_Safety', 0.013911536894738674)","('Human_Rights_And_Community_Relations', 0.003896593116223812)","(['Human Capital Development'], 0.9443138241767883)","('NON-ESG', 0.013911536894738674)","('NON-ESG', 0.003896593116223812)"
Line 1045,"The DEI is a joint initiative by  Disability:IN and the American Association of People with  Disabilities (AAPD), and is considered the most comprehensive  benchmarking tool for corporate disability inclusion developed by  disability advocates and business leaders.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9075621962547302)","('Employee_Health_And_Safety', 0.03022986464202404)","('Human_Rights_And_Community_Relations', 0.006210001185536385)","(['Human Capital Development'], 0.9075621962547302)","('NON-ESG', 0.03022986464202404)","('NON-ESG', 0.006210001185536385)"
Line 1046,"For the third consecutive year, BD was named to the 2020 list of  Best Places to Work for LGBT Equality by the Human Rights  Campaign and received a 100% score on its Corporate Equality  Index (CEI).
","('Human_Rights_And_Community_Relations', 0.4923573434352875)","('Employee_Engagement_Inclusion_And_Diversity', 0.3016115427017212)","('Labor_Practices', 0.03745071217417717)","('NON-ESG', 0.4923573434352875)","('NON-ESG', 0.3016115427017212)","('NON-ESG', 0.03745071217417717)"
Line 1047,"The CEI recognizes companies who have taken  concrete steps to ensure greater equity for LGBTQ workers and  their families in the form of comprehensive policies, benefits and  practices.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8044247627258301)","('Labor_Practices', 0.07850494235754013)","('Employee_Health_And_Safety', 0.031253062188625336)","(['Human Capital Development'], 0.8044247627258301)","('NON-ESG', 0.07850494235754013)","('NON-ESG', 0.031253062188625336)"
Line 1048,"In addition to our internal work this year, BD actively  lobbied for the Equality Act, demonstrating our support for  consistent and explicit nondiscrimination protections for the LGBT  community in the United States.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9438784122467041)","('Human_Rights_And_Community_Relations', 0.009907379746437073)","('Employee_Health_And_Safety', 0.005049736239016056)","(['Human Capital Development'], 0.9438784122467041)","('NON-ESG', 0.009907379746437073)","('NON-ESG', 0.005049736239016056)"
Line 1049,"BD also became a signatory for  the United Nations’ LGBTI Business Standards and Open for  Business, further demonstrating our commitment to equality and  inclusion for the global LGBT+ community.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9627131819725037)","('Human_Rights_And_Community_Relations', 0.005269505549222231)","('Employee_Health_And_Safety', 0.0034468306694179773)","(['Human Capital Development'], 0.9627131819725037)","('NON-ESG', 0.005269505549222231)","('NON-ESG', 0.0034468306694179773)"
Line 1050,"Finally, in 2019, we also increased our leadership role in  industry-specific inclusion and diversity advocacy.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9735115766525269)","('Employee_Health_And_Safety', 0.0022226679138839245)","('Human_Rights_And_Community_Relations', 0.0020490416791290045)","(['Human Capital Development'], 0.9735115766525269)","('NON-ESG', 0.0022226679138839245)","('NON-ESG', 0.0020490416791290045)"
Line 1051,"BD is one   of several peer companies playing a leadership role in AdvaMed’s  efforts to leverage collective expertise to help other U.S. medical technology companies achieve meaningful progress in improving  the representation of diversity throughout the leadership pipeline.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9742133021354675)","('Employee_Health_And_Safety', 0.0020975633524358273)","('Competitive_Behavior', 0.0015778867527842522)","(['Human Capital Development'], 0.9742133021354675)","('NON-ESG', 0.0020975633524358273)","('NON-ESG', 0.0015778867527842522)"
Line 1052,"With our Chairman, Vince Forlenza, on the AdvaMed Board’s  Inclusion & Diversity (I&D) Committee and our VP of I&D,   Johnel Evans, a subcommittee member, BD is highly engaged   and actively working towards improving diversity in the medical  technology industry.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9712522029876709)","('Employee_Health_And_Safety', 0.002862853230908513)","('Human_Rights_And_Community_Relations', 0.0020104236900806427)","(['Human Capital Development'], 0.9712522029876709)","('NON-ESG', 0.002862853230908513)","('NON-ESG', 0.0020104236900806427)"
Line 1053,"In FY 2020 and beyond, we are challenging ourselves to further  mature our inclusion and diversity commitment, programs and  impact.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9750170707702637)","('Employee_Health_And_Safety', 0.002099048811942339)","('Human_Rights_And_Community_Relations', 0.001941837021149695)","(['Human Capital Development'], 0.9750170707702637)","('NON-ESG', 0.002099048811942339)","('NON-ESG', 0.001941837021149695)"
Line 1054,"Next year, through our ARGs, we will focus on encouraging  a culture of greater dialogue.
","('Human_Rights_And_Community_Relations', 0.5754263401031494)","('Management_Of_Legal_And_Regulatory_Framework', 0.10913798213005066)","('Employee_Engagement_Inclusion_And_Diversity', 0.03954031690955162)","(['Community Relations'], 0.5754263401031494)","('NON-ESG', 0.10913798213005066)","('NON-ESG', 0.03954031690955162)"
Line 1055,"And, through our I&D Center of  Excellence, we will develop a new 3-year inclusion and diversity  strategy to continue advancing our efforts and meeting the needs  of our culture and our talent.Recognition Innovation               Access                     Efficiency                Empowerment       End of FY 2016 End of FY 2017 End of FY 2018 End of FY Executive gender 22% 21% 23% 25% Management gender 37% 38% 39% 39% Executive ethnicity 14% 17% 17% 18% Management ethnicity 26% 27% 27% 26% FY 2019 data includes Bard associates.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9744985103607178)","('Employee_Health_And_Safety', 0.0019898174796253443)","('Business_Model_Resilience', 0.0016958380583673716)","(['Human Capital Development'], 0.9744985103607178)","('NON-ESG', 0.0019898174796253443)","('NON-ESG', 0.0016958380583673716)"
Line 1056,"And, through our I&D Center of  Excellence, we will develop a new 3-year inclusion and diversity  strategy to continue advancing our efforts and meeting the needs  of our culture and our talent.Recognition Innovation               Access                     Efficiency                Empowerment       End of FY 2016 End of FY 2017 End of FY 2018 End of FY Executive gender 22% 21% 23% 25% Management gender 37% 38% 39% 39% Executive ethnicity 14% 17% 17% 18% Management ethnicity 26% 27% 27% 26% FY 2019 data includes Bard associates.
","('Business_Ethics', 0.32743218541145325)","('Competitive_Behavior', 0.14115159213542938)","('Management_Of_Legal_And_Regulatory_Framework', 0.05904417112469673)","('NON-ESG', 0.32743218541145325)","('NON-ESG', 0.14115159213542938)","('NON-ESG', 0.05904417112469673)"
Line 1057,"2019 Board of Directors—ethnicity Asian/Indian Black or African American Hispanic/Latino Other White *Includes Vincent A.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9729209542274475)","('Labor_Practices', 0.001803392544388771)","('Human_Rights_And_Community_Relations', 0.0017618605634197593)","(['Human Capital Development'], 0.9729209542274475)","('NON-ESG', 0.001803392544388771)","('NON-ESG', 0.0017618605634197593)"
Line 1058,"Forlenza, Chairman of the Board and former CEO.Gender breakdown of the Board of Directors and executive officers Board of DirectorsWomen Executive officers Officers 4Men 8* 10* GRI disclosure: 405-1FY 2019 worldwide associates by gender 49% Women50% Men 70,Total associates Demographic data In this section of the report, the total number of associates  being reported is 70,193, which includes Bard associates.
","('Director_Removal', 0.6321333646774292)","('Employee_Engagement_Inclusion_And_Diversity', 0.10681897401809692)","('Labor_Practices', 0.033991049975156784)","(['Anti-Crime Policy & Measures'], 0.6321333646774292)","('NON-ESG', 0.10681897401809692)","('NON-ESG', 0.033991049975156784)"
Line 1059,"As part of the integration activities following the acquisition of  Bard, BD worked to incorporate Bard associates into our single  HR IT system.
","('Systemic_Risk_Management', 0.3387190103530884)","('Data_Security', 0.11730629205703735)","('Business_Model_Resilience', 0.11279450356960297)","('NON-ESG', 0.3387190103530884)","('NON-ESG', 0.11730629205703735)","('NON-ESG', 0.11279450356960297)"
Line 1060,"FY 2019 is the first reporting year to reflect this  change in data; FY 2019 forward will include Bard associates.
","('Business_Model_Resilience', 0.2940065264701843)","('Physical_Impacts_Of_Climate_Change', 0.2201267033815384)","('Systemic_Risk_Management', 0.09751015156507492)","('NON-ESG', 0.2940065264701843)","('NON-ESG', 0.2201267033815384)","('NON-ESG', 0.09751015156507492)"
Line 1061,"All reporting data for years previous to FY 2019 does not include  Bard associates.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2163875252008438)","('Systemic_Risk_Management', 0.13602490723133087)","('Physical_Impacts_Of_Climate_Change', 0.09244941920042038)","('NON-ESG', 0.2163875252008438)","('NON-ESG', 0.13602490723133087)","('NON-ESG', 0.09244941920042038)"
Line 1062,"In the charts below, “other” is defined as people who do not  identify as those ethnicities listed above, or who identify as  more than one ethnicity, and “not disclosed” indicates that the  associate chose not to answer.Leadership representation metrics In FY 2019, gender was not disclosed for 1% of the dataset.Innovation               Access                     Efficiency                Empowerment       71Executive and management positions For the following tables, the total number of associates for each disclosure in executive and management positions  is noted in the corresponding table.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9721863269805908)","('Customer_Privacy', 0.002584905130788684)","('Human_Rights_And_Community_Relations', 0.0018588514067232609)","(['Human Capital Development'], 0.9721863269805908)","('NON-ESG', 0.002584905130788684)","('NON-ESG', 0.0018588514067232609)"
Line 1063,"In the charts below, “other” is defined as people who do not  identify as those ethnicities listed above, or who identify as  more than one ethnicity, and “not disclosed” indicates that the  associate chose not to answer.Leadership representation metrics In FY 2019, gender was not disclosed for 1% of the dataset.Innovation               Access                     Efficiency                Empowerment       71Executive and management positions For the following tables, the total number of associates for each disclosure in executive and management positions  is noted in the corresponding table.
","('Director_Removal', 0.5354173183441162)","('Employee_Engagement_Inclusion_And_Diversity', 0.12265432626008987)","('Business_Model_Resilience', 0.04696788638830185)","(['Anti-Crime Policy & Measures'], 0.5354173183441162)","('NON-ESG', 0.12265432626008987)","('NON-ESG', 0.04696788638830185)"
Line 1064,"Bard associates are included in FY 2019 data.
","('Systemic_Risk_Management', 0.18936064839363098)","('Business_Model_Resilience', 0.14702875912189484)","('Management_Of_Legal_And_Regulatory_Framework', 0.11453365534543991)","('NON-ESG', 0.18936064839363098)","('NON-ESG', 0.14702875912189484)","('NON-ESG', 0.11453365534543991)"
Line 1065,"Executives and management positions by gender (worldwide) Executive Management FY 2016 FY 2017 FY 2018FY BD+ BardFY 2016 FY 2017 FY 2018FY BD+ Bard Female 22% 21% 23% 25% 38% 38% 39% 39% Male 78% 79% 77% 75% 62% 62% 61% 61% Total associates 295 280 283 354 6,923 7,340 7,722 10,BD defines executives as those in VP, SVP or EVP roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.6239169836044312)","('Director_Removal', 0.13862305879592896)","('Business_Model_Resilience', 0.03927435725927353)","(['Human Capital Development'], 0.6239169836044312)","('NON-ESG', 0.13862305879592896)","('NON-ESG', 0.03927435725927353)"
Line 1066,"Management positions are defined as those in manager, director or equivalent roles.
","('Director_Removal', 0.6405739784240723)","('Employee_Engagement_Inclusion_And_Diversity', 0.07774262875318527)","('Labor_Practices', 0.04481257498264313)","(['Anti-Crime Policy & Measures'], 0.6405739784240723)","('NON-ESG', 0.07774262875318527)","('NON-ESG', 0.04481257498264313)"
Line 1067,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1068,"All previous years excluded Bard associates.
","('Business_Ethics', 0.22909188270568848)","('Director_Removal', 0.14913439750671387)","('Competitive_Behavior', 0.10171574354171753)","('NON-ESG', 0.22909188270568848)","('NON-ESG', 0.14913439750671387)","('NON-ESG', 0.10171574354171753)"
Line 1069,"Executive and management positions by age (worldwide) Executive Management FY 2016 FY 2017 FY 2018FY BD+ BardFY 2016 FY 2017 FY 2018FY BD+ Bard Under 35 0% 1% 0% 0% 11% 11% 11% 11% 35–54 72% 70% 68% 72% 72% 72% 72% 72% 55 and older 27% 29% 32% 28% 17% 17% 17% 17% Total associates 295 280 283 354 6,923 7,340 7,722 10,BD defines executives as those in VP, SVP or EVP roles.
","('Director_Removal', 0.3733959197998047)","('Employee_Engagement_Inclusion_And_Diversity', 0.2670353055000305)","('Business_Model_Resilience', 0.06233878433704376)","('NON-ESG', 0.3733959197998047)","('NON-ESG', 0.2670353055000305)","('NON-ESG', 0.06233878433704376)"
Line 1070,"Management positions are defined as those in manager, director or equivalent roles.
","('Director_Removal', 0.6405739784240723)","('Employee_Engagement_Inclusion_And_Diversity', 0.07774262875318527)","('Labor_Practices', 0.04481257498264313)","(['Anti-Crime Policy & Measures'], 0.6405739784240723)","('NON-ESG', 0.07774262875318527)","('NON-ESG', 0.04481257498264313)"
Line 1071,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1072,"All previous years excluded Bard associates.
","('Business_Ethics', 0.22909188270568848)","('Director_Removal', 0.14913439750671387)","('Competitive_Behavior', 0.10171574354171753)","('NON-ESG', 0.22909188270568848)","('NON-ESG', 0.14913439750671387)","('NON-ESG', 0.10171574354171753)"
Line 1073,"Executive and management positions by ethnicity (U.S. only) Executive Management FY 2016 FY 2017 FY 2018FY BD+ BardFY 2016 FY 2017 FY 2018FY BD+ Bard Asian/Indian 9% 11% 10% 10% 14% 15% 14% 14% Black or African American 3% 3% 2% 3% 4% 4% 4% 3% Hispanic/Latino 2% 3% 4% 4% 5% 7% 7% 8% Not disclosed 5% 2% 3% 4% 4% 3% 5% 5% Other 0% 1% 1% 1% 3% 2% 2% 1% White 81% 81% 80% 78% 71% 71% 68% 69% Total associates 237 225 225 291 4,354 4,555 4,698 6,BD defines executives as those in VP, SVP or EVP roles.
","('Employee_Engagement_Inclusion_And_Diversity', 0.963901937007904)","('Business_Model_Resilience', 0.00284808361902833)","('Customer_Privacy', 0.0027611127588897943)","(['Human Capital Development'], 0.963901937007904)","('NON-ESG', 0.00284808361902833)","('NON-ESG', 0.0027611127588897943)"
Line 1074,"Management positions are defined as those in manager, director or equivalent roles.
","('Director_Removal', 0.6405739784240723)","('Employee_Engagement_Inclusion_And_Diversity', 0.07774262875318527)","('Labor_Practices', 0.04481257498264313)","(['Anti-Crime Policy & Measures'], 0.6405739784240723)","('NON-ESG', 0.07774262875318527)","('NON-ESG', 0.04481257498264313)"
Line 1075,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1076,"All previous years excluded Bard associates.
","('Business_Ethics', 0.22909188270568848)","('Director_Removal', 0.14913439750671387)","('Competitive_Behavior', 0.10171574354171753)","('NON-ESG', 0.22909188270568848)","('NON-ESG', 0.14913439750671387)","('NON-ESG', 0.10171574354171753)"
Line 1077,"GRI disclosure: 405-1Innovation               Access                     Efficiency                Empowerment       72Associates For the following tables, the total number of associates for each disclosure is noted in the corresponding table.
","('Energy_Management', 0.8486582040786743)","('Product_Design_And_Lifecycle_Management', 0.027227044105529785)","('Supply_Chain_Management', 0.013215549290180206)","(['Operational Eco-Efficiency'], 0.8486582040786743)","('NON-ESG', 0.027227044105529785)","('NON-ESG', 0.013215549290180206)"
Line 1078,"Bard associates are included in FY 2019 data.
","('Systemic_Risk_Management', 0.18936064839363098)","('Business_Model_Resilience', 0.14702875912189484)","('Management_Of_Legal_And_Regulatory_Framework', 0.11453365534543991)","('NON-ESG', 0.18936064839363098)","('NON-ESG', 0.14702875912189484)","('NON-ESG', 0.11453365534543991)"
Line 1079,"GRI disclosures: 401-1, 405-1Associates by age (worldwide) FY 2016 FY 2017 FY 2018 FY Under 35 35% 36% 32% 38% 35–54 52% 51% 54% 50% 55 and older 12% 12% 14% 12% Total associates 45,814 47,750 43,581 70,In 2016 and 2017, age was not disclosed for 1% of the dataset.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8712896108627319)","('Access_And_Affordability', 0.01510616485029459)","('Business_Model_Resilience', 0.010772814974188805)","(['Human Capital Development'], 0.8712896108627319)","('NON-ESG', 0.01510616485029459)","('NON-ESG', 0.010772814974188805)"
Line 1080,"Workforce includes  all associates, both management and nonmanagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.36550042033195496)","('Labor_Practices', 0.11059073358774185)","('Systemic_Risk_Management', 0.08379524201154709)","('NON-ESG', 0.36550042033195496)","('NON-ESG', 0.11059073358774185)","('NON-ESG', 0.08379524201154709)"
Line 1081,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1082,"All previous years excluded  Bard associates.
","('Business_Ethics', 0.22909188270568848)","('Director_Removal', 0.14913439750671387)","('Competitive_Behavior', 0.10171574354171753)","('NON-ESG', 0.22909188270568848)","('NON-ESG', 0.14913439750671387)","('NON-ESG', 0.10171574354171753)"
Line 1083,"Associates by ethnicity (U.S. only) FY 2016 FY 2017 FY 2018 FY Asian/Indian 13% 13% 13% 11% Black or African American 7% 8% 8% 9% Hispanic/Latino 13% 16% 15% 16% Not disclosed 5% 3% 2% 9% Other 3% 2% 7% 2% White 59% 59% 55% 54% Total associates 17,375 17,528 17,943 24,Ethnicity data reflects that of the U.S. workforce including Alaska and Hawaii, but  excluding Puerto Rico or any other U.S. territories.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9680726528167725)","('Customer_Privacy', 0.002776250010356307)","('Competitive_Behavior', 0.0021005424205213785)","(['Human Capital Development'], 0.9680726528167725)","('NON-ESG', 0.002776250010356307)","('NON-ESG', 0.0021005424205213785)"
Line 1084,"Workforce includes all associates,  both management and nonmanagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.36550042033195496)","('Labor_Practices', 0.11059073358774185)","('Systemic_Risk_Management', 0.08379524201154709)","('NON-ESG', 0.36550042033195496)","('NON-ESG', 0.11059073358774185)","('NON-ESG', 0.08379524201154709)"
Line 1085,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1086,"All previous years excluded  Bard associates.New hire rate by age (worldwide) FY 2016 FY 2017 FY 2018 FY Under 35 10% 13% 13% 20% 35–54 6% 5% 7% 7% 55 and older 1% 0% 1% 1% Workforce includes all associates, both management and nonmanagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8663793206214905)","('Labor_Practices', 0.030073456466197968)","('Director_Removal', 0.011222339235246181)","(['Human Capital Development'], 0.8663793206214905)","('NON-ESG', 0.030073456466197968)","('NON-ESG', 0.011222339235246181)"
Line 1087,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1088,"All previous years excluded  Bard associates.
","('Business_Ethics', 0.22909188270568848)","('Director_Removal', 0.14913439750671387)","('Competitive_Behavior', 0.10171574354171753)","('NON-ESG', 0.22909188270568848)","('NON-ESG', 0.14913439750671387)","('NON-ESG', 0.10171574354171753)"
Line 1089,"Turnover rate by age (worldwide) FY 2016 FY 2017 FY 2018 FY Under 35 13% 15% 8% 10% 35–54 7% 7% 6% 3% 55 and older 13% 2% 2% 3% By turnovers, we mean the associates in the workforce who were with the company  on the last day of the previous financial year (September 30, 2018) but no longer  with the company in the reporting time period.
","('Employee_Engagement_Inclusion_And_Diversity', 0.594576358795166)","('Labor_Practices', 0.10439736396074295)","('Director_Removal', 0.06513670086860657)","(['Human Capital Development'], 0.594576358795166)","('NON-ESG', 0.10439736396074295)","('NON-ESG', 0.06513670086860657)"
Line 1090,"Workforce includes all associates,  both management and nonmanagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.36550042033195496)","('Labor_Practices', 0.11059073358774185)","('Systemic_Risk_Management', 0.08379524201154709)","('NON-ESG', 0.36550042033195496)","('NON-ESG', 0.11059073358774185)","('NON-ESG', 0.08379524201154709)"
Line 1091,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1092,"All previous years excluded  Bard associates.New hire rate by gender (worldwide) FY 2016 FY 2017 FY 2018FY 2019  +Bard  Female 8% 10% 9% 15% Male 9% 9% 11% 14% Workforce includes all associates, both management and nonmanagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8006073236465454)","('Labor_Practices', 0.06253110617399216)","('Director_Removal', 0.020622557029128075)","(['Human Capital Development'], 0.8006073236465454)","('NON-ESG', 0.06253110617399216)","('NON-ESG', 0.020622557029128075)"
Line 1093,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1094,"All previous years excluded  Bard associates.
","('Business_Ethics', 0.22909188270568848)","('Director_Removal', 0.14913439750671387)","('Competitive_Behavior', 0.10171574354171753)","('NON-ESG', 0.22909188270568848)","('NON-ESG', 0.14913439750671387)","('NON-ESG', 0.10171574354171753)"
Line 1095,"Turnover rate by gender (worldwide) FY 2016 FY 2017 FY 2018 FY Female 12% 14% 8% 6% Male 9% 10% 9% 5% By turnovers, we mean the associates in the workforce who were with the company  on the last day of the previous financial year (September 30, 2018) but no longer  with the company in the reporting time period.
","('Labor_Practices', 0.3179762363433838)","('Employee_Engagement_Inclusion_And_Diversity', 0.3133060932159424)","('Director_Removal', 0.09137697517871857)","('NON-ESG', 0.3179762363433838)","('NON-ESG', 0.3133060932159424)","('NON-ESG', 0.09137697517871857)"
Line 1096,"Workforce includes all associates,  both management and nonmanagement.
","('Employee_Engagement_Inclusion_And_Diversity', 0.36550042033195496)","('Labor_Practices', 0.11059073358774185)","('Systemic_Risk_Management', 0.08379524201154709)","('NON-ESG', 0.36550042033195496)","('NON-ESG', 0.11059073358774185)","('NON-ESG', 0.08379524201154709)"
Line 1097,"FY 2019 reporting numbers include Bard associates.
","('Systemic_Risk_Management', 0.19721415638923645)","('Management_Of_Legal_And_Regulatory_Framework', 0.1965589076280594)","('Director_Removal', 0.07982182502746582)","('NON-ESG', 0.19721415638923645)","('NON-ESG', 0.1965589076280594)","('NON-ESG', 0.07982182502746582)"
Line 1098,"All previous years excluded  Bard associates.Innovation               Access                     Efficiency                Empowerment       732020 goal Achieve best-in-class associate safety performance FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY LTIFR* per 200,000  hours worked 0.29 0.32 0.26 0.OIFR† per 200,000  hours worked 0.004 0.03 0.00 0.Occupational IIR‡ rate per  200,000 hours worked1.4 1.2 1.1 1.0 1.0 0.9 1.1 0.9 0.7 0.7 0.6 0.Data provided reflects manufacturing sites only.
","('Employee_Health_And_Safety', 0.615053117275238)","('Product_Quality_And_Safety', 0.10470501333475113)","('Labor_Practices', 0.10160035640001297)","(['Operational Eco-Efficiency'], 0.615053117275238)","('NON-ESG', 0.10470501333475113)","('NON-ESG', 0.10160035640001297)"
Line 1099,"All previous years excluded  Bard associates.Innovation               Access                     Efficiency                Empowerment       732020 goal Achieve best-in-class associate safety performance FY 2008 FY 2009 FY 2010 FY 2011 FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2017 FY 2018 FY LTIFR* per 200,000  hours worked 0.29 0.32 0.26 0.OIFR† per 200,000  hours worked 0.004 0.03 0.00 0.Occupational IIR‡ rate per  200,000 hours worked1.4 1.2 1.1 1.0 1.0 0.9 1.1 0.9 0.7 0.7 0.6 0.Data provided reflects manufacturing sites only.
","('Waste_And_Hazardous_Materials_Management', 0.2407652735710144)","('Supply_Chain_Management', 0.20267745852470398)","('Product_Design_And_Lifecycle_Management', 0.12961949408054352)","('NON-ESG', 0.2407652735710144)","('NON-ESG', 0.20267745852470398)","('NON-ESG', 0.12961949408054352)"
Line 1100,"FY 2008–FY 2017, excludes Bard.
","('Business_Model_Resilience', 0.15073394775390625)","('Management_Of_Legal_And_Regulatory_Framework', 0.12816786766052246)","('Physical_Impacts_Of_Climate_Change', 0.10720972716808319)","('NON-ESG', 0.15073394775390625)","('NON-ESG', 0.12816786766052246)","('NON-ESG', 0.10720972716808319)"
Line 1101,"*Lost time injury frequency rate (LTIFR) †Occupational illness frequency rate (OIFR) ‡Occupational injury and illness rate (IIR) There have been no fatalities since 2014.
","('Employee_Health_And_Safety', 0.9841777086257935)","('Employee_Engagement_Inclusion_And_Diversity', 0.0015533661935478449)","('Critical_Incident_Risk_Management', 0.0011299120960757136)","(['Operational Eco-Efficiency'], 0.9841777086257935)","('NON-ESG', 0.0015533661935478449)","('NON-ESG', 0.0011299120960757136)"
Line 1102,"GRI disclosure: 403-9At BD, safety is our priority.
","('Product_Quality_And_Safety', 0.7704575657844543)","('Employee_Health_And_Safety', 0.1039678156375885)","('Product_Design_And_Lifecycle_Management', 0.015176056884229183)","(['Product Quality & Recall Management'], 0.7704575657844543)","('NON-ESG', 0.1039678156375885)","('NON-ESG', 0.015176056884229183)"
Line 1103,"Our EHS efforts are driven by the  goal of ensuring all associates are working safely and in an  environment designed to protect and maintain health.
","('Employee_Health_And_Safety', 0.9740384221076965)","('Critical_Incident_Risk_Management', 0.0057222493924200535)","('Employee_Engagement_Inclusion_And_Diversity', 0.0021396588999778032)","(['Operational Eco-Efficiency'], 0.9740384221076965)","('NON-ESG', 0.0057222493924200535)","('NON-ESG', 0.0021396588999778032)"
Line 1104,"Our work in FY 2019 sought to continue our EHS integration  work across BD and Bard.
","('Management_Of_Legal_And_Regulatory_Framework', 0.2926516532897949)","('Access_And_Affordability', 0.26032358407974243)","('Product_Quality_And_Safety', 0.0853571966290474)","('NON-ESG', 0.2926516532897949)","('NON-ESG', 0.26032358407974243)","('NON-ESG', 0.0853571966290474)"
Line 1105,"We completed BD corporate audits for  all legacy Bard facilities against the BD corporate standard, and  have laid the groundwork to transition to a new governance  model that enables us to standardize high-level EHS objectives  as one BD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6698827147483826)","('Systemic_Risk_Management', 0.07779604941606522)","('Business_Ethics', 0.07132650911808014)","(['Corporate Governance'], 0.6698827147483826)","('NON-ESG', 0.07779604941606522)","('NON-ESG', 0.07132650911808014)"
Line 1106,"This will allow us to drive objectives core to the  organization directly to our sites in a more systemic fashion and  will streamline EHS communications, ultimately facilitating an  effective integration of two EHS cultures.
","('Systemic_Risk_Management', 0.925705075263977)","('Business_Model_Resilience', 0.01346009410917759)","('Business_Ethics', 0.007824096828699112)","(['Risk & Crisis Management'], 0.925705075263977)","('NON-ESG', 0.01346009410917759)","('NON-ESG', 0.007824096828699112)"
Line 1107,"This project  culminated in the establishment of a global advisory council  consisting of business units, EHS and regional leaders—this  council began meeting in early FY 2020 to solidify the work  systems moving forward.
","('Management_Of_Legal_And_Regulatory_Framework', 0.4946342408657074)","('Business_Model_Resilience', 0.0979723185300827)","('Human_Rights_And_Community_Relations', 0.06684543937444687)","('NON-ESG', 0.4946342408657074)","('NON-ESG', 0.0979723185300827)","('NON-ESG', 0.06684543937444687)"
Line 1108,"In addition to our focus on designing a new governance model, we also worked to design a new audit  model that will be launched in FY 2020 taking into consideration  the depth and breadth of our new organization.
","('Management_Of_Legal_And_Regulatory_Framework', 0.8149343132972717)","('Systemic_Risk_Management', 0.02441823109984398)","('Business_Ethics', 0.022914256900548935)","(['Corporate Governance'], 0.8149343132972717)","('NON-ESG', 0.02441823109984398)","('NON-ESG', 0.022914256900548935)"
Line 1109,"BD continues to reinforce systems that strengthen our goal to  drive a culture in which the health and well-being of our  associates, visitors and contractors are an integral part of every  decision we make at BD.
","('Employee_Health_And_Safety', 0.8632395267486572)","('Access_And_Affordability', 0.038406141102313995)","('Human_Rights_And_Community_Relations', 0.01013394258916378)","(['Operational Eco-Efficiency'], 0.8632395267486572)","('NON-ESG', 0.038406141102313995)","('NON-ESG', 0.01013394258916378)"
Line 1110,"Instrumental in driving this vision is the  continuation of programs that drive management and  leadership engagement, peer-to-peer coaching, and education  and training.
","('Employee_Engagement_Inclusion_And_Diversity', 0.501065731048584)","('Access_And_Affordability', 0.17667879164218903)","('Human_Rights_And_Community_Relations', 0.08674690127372742)","(['Human Capital Development'], 0.501065731048584)","('NON-ESG', 0.17667879164218903)","('NON-ESG', 0.08674690127372742)"
Line 1111,"Further details about our EHS management programs, please  see EHS management in the Efficiency  section of this report.
","('Energy_Management', 0.93356853723526)","('Management_Of_Legal_And_Regulatory_Framework', 0.017978252843022346)","('Air_Quality', 0.005198264494538307)","(['Operational Eco-Efficiency'], 0.93356853723526)","('NON-ESG', 0.017978252843022346)","('NON-ESG', 0.005198264494538307)"
Line 1112,"Innovation               Access                     Efficiency                Empowerment       74Social Investing Total cash donations $10 million Total product donations $14 million Value of company match to associate donations $1.7 million Number of grants issued, worldwide Number of nonprofit beneficiaries Number of matching gifts distributed 13,$5,100,000   $680,000$2,100,000 $465,000  $304,000  $1,300,000  Higher education $9,949,000   Total contributionsOther†Disaster relief Health and human services§Civic and social welfare‡ Arts and cultureFY 2019 cash contributionsFY 2019 charitable giving summary $24,870,000   Total contributions (cash and product) $320,Volunteering—pro bono  hours donated$550,Volunteering—skills-based $14,000,Product donations$10,000,Cash donations * *Includes matching gifts and contributions from individual BD locations †Includes inclusion and diversity and   volunteer associate engagement ‡Includes basic needs/hometown giving  §Includes care for the uninsured/underinsured, diabetes and prevention, global health, infection prevention, maternal and newborn health, vaccine preventable    diseases, women’s health, cancer and other healthCharitable giving summary, by the numbersInnovation               Access                     Efficiency                Empowerment       752020 goal Partner with nonprofits to address unmet needs, locally and globally BD Helping Build Healthy Communities ™ Initiative, by the numbers Product donations have reached 400,000 patients .
","('Critical_Incident_Risk_Management', 0.9032111763954163)","('Access_And_Affordability', 0.01636555604636669)","('Employee_Health_And_Safety', 0.012780100107192993)","(['Risk & Crisis Management'], 0.9032111763954163)","('NON-ESG', 0.01636555604636669)","('NON-ESG', 0.012780100107192993)"
Line 1113,"Innovation               Access                     Efficiency                Empowerment       74Social Investing Total cash donations $10 million Total product donations $14 million Value of company match to associate donations $1.7 million Number of grants issued, worldwide Number of nonprofit beneficiaries Number of matching gifts distributed 13,$5,100,000   $680,000$2,100,000 $465,000  $304,000  $1,300,000  Higher education $9,949,000   Total contributionsOther†Disaster relief Health and human services§Civic and social welfare‡ Arts and cultureFY 2019 cash contributionsFY 2019 charitable giving summary $24,870,000   Total contributions (cash and product) $320,Volunteering—pro bono  hours donated$550,Volunteering—skills-based $14,000,Product donations$10,000,Cash donations * *Includes matching gifts and contributions from individual BD locations †Includes inclusion and diversity and   volunteer associate engagement ‡Includes basic needs/hometown giving  §Includes care for the uninsured/underinsured, diabetes and prevention, global health, infection prevention, maternal and newborn health, vaccine preventable    diseases, women’s health, cancer and other healthCharitable giving summary, by the numbersInnovation               Access                     Efficiency                Empowerment       752020 goal Partner with nonprofits to address unmet needs, locally and globally BD Helping Build Healthy Communities ™ Initiative, by the numbers Product donations have reached 400,000 patients .
","('Employee_Engagement_Inclusion_And_Diversity', 0.689647376537323)","('Access_And_Affordability', 0.11657644808292389)","('Human_Rights_And_Community_Relations', 0.05207538977265358)","(['Human Capital Development'], 0.689647376537323)","('NON-ESG', 0.11657644808292389)","('NON-ESG', 0.05207538977265358)"
Line 1114,"Innovation               Access                     Efficiency                Empowerment       74Social Investing Total cash donations $10 million Total product donations $14 million Value of company match to associate donations $1.7 million Number of grants issued, worldwide Number of nonprofit beneficiaries Number of matching gifts distributed 13,$5,100,000   $680,000$2,100,000 $465,000  $304,000  $1,300,000  Higher education $9,949,000   Total contributionsOther†Disaster relief Health and human services§Civic and social welfare‡ Arts and cultureFY 2019 cash contributionsFY 2019 charitable giving summary $24,870,000   Total contributions (cash and product) $320,Volunteering—pro bono  hours donated$550,Volunteering—skills-based $14,000,Product donations$10,000,Cash donations * *Includes matching gifts and contributions from individual BD locations †Includes inclusion and diversity and   volunteer associate engagement ‡Includes basic needs/hometown giving  §Includes care for the uninsured/underinsured, diabetes and prevention, global health, infection prevention, maternal and newborn health, vaccine preventable    diseases, women’s health, cancer and other healthCharitable giving summary, by the numbersInnovation               Access                     Efficiency                Empowerment       752020 goal Partner with nonprofits to address unmet needs, locally and globally BD Helping Build Healthy Communities ™ Initiative, by the numbers Product donations have reached 400,000 patients .
","('Access_And_Affordability', 0.5709757208824158)","('Employee_Health_And_Safety', 0.18980741500854492)","('Product_Quality_And_Safety', 0.03679239749908447)","(['Health Outcome Contribution'], 0.5709757208824158)","('NON-ESG', 0.18980741500854492)","('NON-ESG', 0.03679239749908447)"
Line 1115,"Health outcomes of 65,000 patients  have been  improved through our cash support.BD has provided Direct Relief with more than   34 million insulin syringes  and 720,000 pen  needles , valued at $9.9 million .
","('Access_And_Affordability', 0.5061800479888916)","('Employee_Health_And_Safety', 0.235131174325943)","('Product_Quality_And_Safety', 0.04903724044561386)","(['Health Outcome Contribution'], 0.5061800479888916)","('NON-ESG', 0.235131174325943)","('NON-ESG', 0.04903724044561386)"
Line 1116,"42 grants , totaling $5.8 million , have been issued  to community health centers in 20 states .These items have been distributed to 1,300  community health centers, free clinics and  community clinics in all 50 states and Puerto Rico .Community health centers are on the front lines, every   day, providing life-saving care to more than 29 million   people in vulnerable rural and urban communities across    the United States.
","('Access_And_Affordability', 0.805686891078949)","('Human_Rights_And_Community_Relations', 0.041681014001369476)","('Critical_Incident_Risk_Management', 0.028078129515051842)","(['Health Outcome Contribution'], 0.805686891078949)","('NON-ESG', 0.041681014001369476)","('NON-ESG', 0.028078129515051842)"
Line 1117,"Without these community-based “family doctors,” millions of  uninsured and underinsured patients would go without healthcare.
","('Employee_Engagement_Inclusion_And_Diversity', 0.1948786973953247)","('Access_And_Affordability', 0.18241232633590698)","('Labor_Practices', 0.1481604427099228)","('NON-ESG', 0.1948786973953247)","('NON-ESG', 0.18241232633590698)","('NON-ESG', 0.1481604427099228)"
Line 1118,"Implemented in partnership with Direct Relief and the National  Association of Community Health Centers , the BD Helping Build  Healthy Communities ™ Program awards grants to community  health centers to support the implementation of innovative  approaches to meeting the unique healthcare needs of local,  underserved and vulnerable populations.• In FY 2019, the program’s 7th year, BD invested $1.2 million,  with 6 health centers each receiving $200,000.
","('Access_And_Affordability', 0.9422135353088379)","('Human_Rights_And_Community_Relations', 0.006823194678872824)","('Critical_Incident_Risk_Management', 0.005690229590982199)","(['Health Outcome Contribution'], 0.9422135353088379)","('NON-ESG', 0.006823194678872824)","('NON-ESG', 0.005690229590982199)"
Line 1119,"• Clinical data indicates that this funding is having a  meaningful impact in the grant winners’ ability to expand  access to quality patient care, particularly among patients  with diabetes, hypertension, depression and difficulty with  medication compliance.
","('Access_And_Affordability', 0.750813901424408)","('Product_Quality_And_Safety', 0.035800378769636154)","('Employee_Health_And_Safety', 0.030920563265681267)","(['Health Outcome Contribution'], 0.750813901424408)","('NON-ESG', 0.035800378769636154)","('NON-ESG', 0.030920563265681267)"
Line 1120,"• In FY 2020, BD will continue to work with Direct Relief to  monitor the longer-term clinical impacts this funding is  having on patient care.BD Helping Build Healthy Communities™ Initiative   Innovation               Access                     Efficiency                Empowerment       76In response to the success of the BD Helping Build Healthy  Communities ™ Program, and to reach an even broader vulnerable  population, BD worked with the National Association of Free and  Charitable Clinics (NAFC)  to introduce three companion programs  in 2017, which support free and charitable clinics.
","('Access_And_Affordability', 0.5650485754013062)","('Human_Rights_And_Community_Relations', 0.2675628066062927)","('Employee_Engagement_Inclusion_And_Diversity', 0.02329307794570923)","(['Health Outcome Contribution'], 0.5650485754013062)","('NON-ESG', 0.2675628066062927)","('NON-ESG', 0.02329307794570923)"
Line 1121,"• In FY 2020, BD will continue to work with Direct Relief to  monitor the longer-term clinical impacts this funding is  having on patient care.BD Helping Build Healthy Communities™ Initiative   Innovation               Access                     Efficiency                Empowerment       76In response to the success of the BD Helping Build Healthy  Communities ™ Program, and to reach an even broader vulnerable  population, BD worked with the National Association of Free and  Charitable Clinics (NAFC)  to introduce three companion programs  in 2017, which support free and charitable clinics.
","('Access_And_Affordability', 0.5796982049942017)","('Management_Of_Legal_And_Regulatory_Framework', 0.1804826855659485)","('Product_Quality_And_Safety', 0.021443946287035942)","(['Health Outcome Contribution'], 0.5796982049942017)","('NON-ESG', 0.1804826855659485)","('NON-ESG', 0.021443946287035942)"
Line 1122,"One of these programs, the BD® Advancing Community Health:  Enhancing Clinical Effectiveness Program , was co-developed with  Heart to Heart International .
","('Access_And_Affordability', 0.5995432734489441)","('Customer_Welfare', 0.06996230781078339)","('Product_Quality_And_Safety', 0.04339595139026642)","(['Health Outcome Contribution'], 0.5995432734489441)","('NON-ESG', 0.06996230781078339)","('NON-ESG', 0.04339595139026642)"
Line 1123,"It aims to improve the diagnosis  and treatment of chronic disease among vulnerable populations  through the installation of point-of-care (POC) laboratories.Through this program in FY 2019: • BD awarded $360,000 in funding and $14,000 in product to  support lab installations at six community clinics located in  Indiana, Georgia, Maryland, Mississippi, Virginia and Louisiana.
","('Access_And_Affordability', 0.3507780134677887)","('Employee_Health_And_Safety', 0.2947925329208374)","('Product_Quality_And_Safety', 0.051473863422870636)","('NON-ESG', 0.3507780134677887)","('NON-ESG', 0.2947925329208374)","('NON-ESG', 0.051473863422870636)"
Line 1124,"• BD associate volunteers were deployed to six clinics, and spent  2–3 days each, providing mentorship, laboratory set up  guidance and diagnostic training.
","('Access_And_Affordability', 0.5647615790367126)","('Employee_Engagement_Inclusion_And_Diversity', 0.16665178537368774)","('Employee_Health_And_Safety', 0.03308272734284401)","(['Health Outcome Contribution'], 0.5647615790367126)","('NON-ESG', 0.16665178537368774)","('NON-ESG', 0.03308272734284401)"
Line 1125,"Expanding on program success For more than a decade, BD has partnered with international  relief agencies, such as Direct Relief, AmeriCares, MAP  International and Heart to Heart International, to ensure its  supplies and financial support are deployed as quickly and  efficiently as possible to the people and communities who need  them most.
","('Critical_Incident_Risk_Management', 0.3955073952674866)","('Human_Rights_And_Community_Relations', 0.20130817592144012)","('Access_And_Affordability', 0.16163349151611328)","('NON-ESG', 0.3955073952674866)","('NON-ESG', 0.20130817592144012)","('NON-ESG', 0.16163349151611328)"
Line 1126,"Notable FY 2019 product donations include: • $1 million in insulin syringes, pen needles, swabs and lancets   to 150+ summer camps for children with type 1 diabetes via  Direct Relief .
","('Access_And_Affordability', 0.4479053020477295)","('Product_Quality_And_Safety', 0.13195058703422546)","('Customer_Welfare', 0.10673918575048447)","('NON-ESG', 0.4479053020477295)","('NON-ESG', 0.13195058703422546)","('NON-ESG', 0.10673918575048447)"
Line 1127,"• 600,000 syringes, swabs and sharps containers  donated to  Direct Relief for distribution to U.S. community health centers  to accompany Pfizer’s Naloxone product donations for people  experiencing a drug overdose in  49 states and territories .
","('Product_Quality_And_Safety', 0.22446990013122559)","('Selling_Practices_And_Product_Labeling', 0.09486189484596252)","('Business_Ethics', 0.08563918620347977)","('NON-ESG', 0.22446990013122559)","('NON-ESG', 0.09486189484596252)","('NON-ESG', 0.08563918620347977)"
Line 1128,"The  impact of this donation has contributed to saving an  estimated 10,000 lives  that would have been lost to drug use.
","('Access_And_Affordability', 0.5395984053611755)","('Customer_Welfare', 0.06367294490337372)","('Employee_Health_And_Safety', 0.05382320657372475)","(['Health Outcome Contribution'], 0.5395984053611755)","('NON-ESG', 0.06367294490337372)","('NON-ESG', 0.05382320657372475)"
Line 1129,"•  $1.3 million in instrument donations  (BD FACSymphony ™  System, BD FACSMelody ™ Cell Sorter, BD FACSLyric ™ System)  to Johns Hopkins Bloomberg School of Public Health’s  Immune Function Lab  to support interdisciplinary,  translational research efforts.Strategic product donation Innovation               Access                     Efficiency                Empowerment       772020 goal Drive social impact and associate engagement through volunteer programs Having celebrated its 15th year in 2019, the company’s Volunteer  Service Trip (VST) Program sends teams of BD associates to  developing countries to help strengthen local health systems  through training, education, laboratory services and construction  projects.
","('Product_Design_And_Lifecycle_Management', 0.24090416729450226)","('Access_And_Affordability', 0.20917285978794098)","('Customer_Welfare', 0.146246075630188)","('NON-ESG', 0.24090416729450226)","('NON-ESG', 0.20917285978794098)","('NON-ESG', 0.146246075630188)"
Line 1130,"•  $1.3 million in instrument donations  (BD FACSymphony ™  System, BD FACSMelody ™ Cell Sorter, BD FACSLyric ™ System)  to Johns Hopkins Bloomberg School of Public Health’s  Immune Function Lab  to support interdisciplinary,  translational research efforts.Strategic product donation Innovation               Access                     Efficiency                Empowerment       772020 goal Drive social impact and associate engagement through volunteer programs Having celebrated its 15th year in 2019, the company’s Volunteer  Service Trip (VST) Program sends teams of BD associates to  developing countries to help strengthen local health systems  through training, education, laboratory services and construction  projects.
","('Access_And_Affordability', 0.6172578930854797)","('Human_Rights_And_Community_Relations', 0.12152859568595886)","('Employee_Health_And_Safety', 0.08792135119438171)","(['Health Outcome Contribution'], 0.6172578930854797)","('NON-ESG', 0.12152859568595886)","('NON-ESG', 0.08792135119438171)"
Line 1131,"In FY 2019: •  14 BD associates completed the company’s second VST to  Mexico , where they continued efforts to serve Casa de la  Amistad, a nongovernmental organization that provides  comprehensive services to pediatric cancer patients and their  caregivers.
","('Access_And_Affordability', 0.809231698513031)","('Employee_Health_And_Safety', 0.03067198395729065)","('Product_Quality_And_Safety', 0.018061919137835503)","(['Health Outcome Contribution'], 0.809231698513031)","('NON-ESG', 0.03067198395729065)","('NON-ESG', 0.018061919137835503)"
Line 1132,"The team continued work on projects ranging  from business development, marketing and program  management to space utilization, process efficiency and IT.
","('Energy_Management', 0.7621017694473267)","('Product_Design_And_Lifecycle_Management', 0.11970441043376923)","('Supply_Chain_Management', 0.01403854787349701)","(['Operational Eco-Efficiency'], 0.7621017694473267)","('NON-ESG', 0.11970441043376923)","('NON-ESG', 0.01403854787349701)"
Line 1133,"•  17 BD associates completed a VST to Haiti , where they  worked with Heart to Heart International to provide training to help local healthcare workers, nurses and lab technicians  improve the quality of care  they deliver to thousands of local  families living in poverty.
","('Access_And_Affordability', 0.7516663074493408)","('Human_Rights_And_Community_Relations', 0.07478935271501541)","('Critical_Incident_Risk_Management', 0.027725931257009506)","(['Health Outcome Contribution'], 0.7516663074493408)","('NON-ESG', 0.07478935271501541)","('NON-ESG', 0.027725931257009506)"
Line 1134,"The volunteers also completed  construction projects to strengthen the infrastructure of a  local healthcare clinic, which provides health services to   3,000 vulnerable women.
","('Access_And_Affordability', 0.8122312426567078)","('Human_Rights_And_Community_Relations', 0.05504449084401131)","('Employee_Engagement_Inclusion_And_Diversity', 0.018921103328466415)","(['Health Outcome Contribution'], 0.8122312426567078)","('NON-ESG', 0.05504449084401131)","('NON-ESG', 0.018921103328466415)"
Line 1135,"•  29 BD associates from our Humacao, Puerto Rico site took  part in a 2-day , local VST to transform a local school—which  had been closed since Hurricane Maria—into a thriving  community center that offers a health clinic, health fairs,  summer camps and serves as a disaster relief shelter.
","('Critical_Incident_Risk_Management', 0.942288339138031)","('Physical_Impacts_Of_Climate_Change', 0.01469939760863781)","('Air_Quality', 0.004684280138462782)","(['Risk & Crisis Management'], 0.942288339138031)","('NON-ESG', 0.01469939760863781)","('NON-ESG', 0.004684280138462782)"
Line 1136,"This  project was accepted as a Clinton Global Initiative (CGI)  Commitment to Action.BD Volunteer Service Trip Program Innovation               Access                     Efficiency                Empowerment       78in grants$80,000 14 nonprofit  organizationsBD associates recognized  for volunteerismHenry P .
","('Access_And_Affordability', 0.30778220295906067)","('Employee_Health_And_Safety', 0.2468966692686081)","('Human_Rights_And_Community_Relations', 0.11448779702186584)","('NON-ESG', 0.30778220295906067)","('NON-ESG', 0.2468966692686081)","('NON-ESG', 0.11448779702186584)"
Line 1137,"Becton Volunteer Impact AwardsBD Volunteer Service Trips, by the numbers These global awards celebrate the outstanding and creative volunteer service of BD associates.
","('Employee_Health_And_Safety', 0.47753989696502686)","('Human_Rights_And_Community_Relations', 0.1398593783378601)","('Access_And_Affordability', 0.09709682315587997)","('NON-ESG', 0.47753989696502686)","('NON-ESG', 0.1398593783378601)","('NON-ESG', 0.09709682315587997)"
Line 1138,"In FY 2019, BD awarded grants totaling  $80,000 to 14 nonprofit organizations around the world, recognizing the community service of 14 associates from 3 countries.BD sites, globally 262   BD volunteersyears of   VST programscountry locations Innovation               Access                     Efficiency                Empowerment       79BD Matching Gift Program BD matches charitable donations to eligible nonprofit organizations,  up to $5,000 per U.S. associate, per year.
","('Management_Of_Legal_And_Regulatory_Framework', 0.40876051783561707)","('Access_And_Affordability', 0.30655986070632935)","('Human_Rights_And_Community_Relations', 0.07576735317707062)","('NON-ESG', 0.40876051783561707)","('NON-ESG', 0.30655986070632935)","('NON-ESG', 0.07576735317707062)"
Line 1139,"In FY 2019, BD matched  30,000+ associate donations to 501(c)(3) organizations in the United  States, for a total investment of $1.7 million.
","('Management_Of_Legal_And_Regulatory_Framework', 0.7805219888687134)","('Director_Removal', 0.025875501334667206)","('Business_Ethics', 0.021018274128437042)","(['Corporate Governance'], 0.7805219888687134)","('NON-ESG', 0.025875501334667206)","('NON-ESG', 0.021018274128437042)"
Line 1140,"In FY 2018, BD harmonized its matching gift program with Bard’s to  ensure all associates receive the same match for their FY 2019  community giving.
","('Management_Of_Legal_And_Regulatory_Framework', 0.38717809319496155)","('Access_And_Affordability', 0.206228107213974)","('Human_Rights_And_Community_Relations', 0.03517083451151848)","('NON-ESG', 0.38717809319496155)","('NON-ESG', 0.206228107213974)","('NON-ESG', 0.03517083451151848)"
Line 1141,"In 2019, BD expanded its Annual Payroll  Deduction Campaign to include legacy Bard associates.
","('Management_Of_Legal_And_Regulatory_Framework', 0.6576279997825623)","('Labor_Practices', 0.1779261976480484)","('Director_Removal', 0.03226538002490997)","(['Corporate Governance'], 0.6576279997825623)","('NON-ESG', 0.1779261976480484)","('NON-ESG', 0.03226538002490997)"
Line 1142,"Dr. Martin Luther King Jr. Day of Service BD is committed to encouraging associates around the world to join  together to serve their local communities through volunteerism— with the goal of bringing our company’s values to life, while making  meaningful differences in the communities where they live and work.
","('Human_Rights_And_Community_Relations', 0.7006401419639587)","('Employee_Health_And_Safety', 0.0834994688630104)","('Employee_Engagement_Inclusion_And_Diversity', 0.04533069580793381)","(['Community Relations'], 0.7006401419639587)","('NON-ESG', 0.0834994688630104)","('NON-ESG', 0.04533069580793381)"
Line 1143,"As just a single example of this team-based volunteerism, in 2019,  1,000+ BD associates at 14 sites across the United States celebrated  the Dr. Martin Luther King Jr. Day of Service by packaging 260,000+  meals over 3 days for Rise Against Hunger programs.
","('Access_And_Affordability', 0.23650524020195007)","('Employee_Health_And_Safety', 0.19043384492397308)","('Labor_Practices', 0.11203502863645554)","('NON-ESG', 0.23650524020195007)","('NON-ESG', 0.19043384492397308)","('NON-ESG', 0.11203502863645554)"
Line 1144,"BD associate  resource groups, including the Women’s Initiative Network (WIN)  and African Americans at BD (AABD) helped coordinate the event at  several sites, as did local associate volunteer councils at each  location.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8737808465957642)","('Human_Rights_And_Community_Relations', 0.029798977077007294)","('Access_And_Affordability', 0.013454938307404518)","(['Human Capital Development'], 0.8737808465957642)","('NON-ESG', 0.029798977077007294)","('NON-ESG', 0.013454938307404518)"
Line 1145,"In FY 2020, BD associates are aiming to reach the  ambitious goal of packing their one-millionth meal for Rise Against  Hunger through this day of service initiative.
","('Access_And_Affordability', 0.38378408551216125)","('Labor_Practices', 0.1113152727484703)","('Customer_Welfare', 0.07463663071393967)","('NON-ESG', 0.38378408551216125)","('NON-ESG', 0.1113152727484703)","('NON-ESG', 0.07463663071393967)"
Line 1146,"World Water Day BD collaborated with the Planet Water Foundation to celebrate  World Water Day by deploying 22 BD associates to volunteer   132 hours to Project 24, a 1-day volunteer effort that brought clean  water to 18,000 people, and health and hygiene education and  lasting change to 18 communities in 4 countries.
","('Water_And_Wastewater_Management', 0.954005241394043)","('Human_Rights_And_Community_Relations', 0.003694603918120265)","('GHG_Emissions', 0.003333138069137931)","(['Operational Eco-Efficiency'], 0.954005241394043)","('NON-ESG', 0.003694603918120265)","('NON-ESG', 0.003333138069137931)"
Line 1147,"In a later  deployment, a second team of 10 BD volunteers from Mexico  participated in another 1-day service project to construct a water  tower serving 360 students and 2,500 residents of the community   of San Jacinto.
","('Water_And_Wastewater_Management', 0.7159454226493835)","('Energy_Management', 0.06683408468961716)","('Access_And_Affordability', 0.04394843429327011)","(['Operational Eco-Efficiency'], 0.7159454226493835)","('NON-ESG', 0.06683408468961716)","('NON-ESG', 0.04394843429327011)"
Line 1148,"Innovation               Access                     Efficiency                Empowerment       80Awards, recognitions and affiliations Corporate recognition Dow Jones Sustainability North America Index since Forbes  Just 100 list FORTUNE’s  2019 World’s Most Admired Companies list FORTUNE’s  2019 Change the World list FTSE4Good Index since CR Magazine’s  100 Best Corporate Citizens List 2019 CPA-Zicklin Index on Corporate Political Disclosure and Accountability—Center for  Political Accountability Newsweek’s  America’s Most Responsible Companies List Innovation 2020 Derwent Top 100 Global Innovators list—Clarivate Analytics Efficiency U.S. EPA Green Power Partner U.S. EPA SmartWay® Transport Partner Empowerment Best Places to Work for LGBTQ Equality—Human Rights Campaign Foundation Bloomberg—2020 Gender Equality Index Disability Equality Index - Best Places to Work—The American Association of People  with Disabilities and Disability Employer of Choice for Gender Equality—Australia Workplace Gender Equality  Agency (Australia) Forbes  Best Employers for Diversity Top Employers Africa 2019—Top Employers Institute (Africa) Top Employers China 2019—Top Employers Institute (China) BD and the BD Logo are trademarks of Becton, Dickinson and Company.
","('Business_Ethics', 0.8114402294158936)","('Management_Of_Legal_And_Regulatory_Framework', 0.09123050421476364)","('Competitive_Behavior', 0.02557535283267498)","(['Business Ethics'], 0.8114402294158936)","('NON-ESG', 0.09123050421476364)","('NON-ESG', 0.02557535283267498)"
Line 1149,"Innovation               Access                     Efficiency                Empowerment       80Awards, recognitions and affiliations Corporate recognition Dow Jones Sustainability North America Index since Forbes  Just 100 list FORTUNE’s  2019 World’s Most Admired Companies list FORTUNE’s  2019 Change the World list FTSE4Good Index since CR Magazine’s  100 Best Corporate Citizens List 2019 CPA-Zicklin Index on Corporate Political Disclosure and Accountability—Center for  Political Accountability Newsweek’s  America’s Most Responsible Companies List Innovation 2020 Derwent Top 100 Global Innovators list—Clarivate Analytics Efficiency U.S. EPA Green Power Partner U.S. EPA SmartWay® Transport Partner Empowerment Best Places to Work for LGBTQ Equality—Human Rights Campaign Foundation Bloomberg—2020 Gender Equality Index Disability Equality Index - Best Places to Work—The American Association of People  with Disabilities and Disability Employer of Choice for Gender Equality—Australia Workplace Gender Equality  Agency (Australia) Forbes  Best Employers for Diversity Top Employers Africa 2019—Top Employers Institute (Africa) Top Employers China 2019—Top Employers Institute (China) BD and the BD Logo are trademarks of Becton, Dickinson and Company.
","('Employee_Engagement_Inclusion_And_Diversity', 0.8459630012512207)","('Employee_Health_And_Safety', 0.04088969528675079)","('Human_Rights_And_Community_Relations', 0.02525341510772705)","(['Human Capital Development'], 0.8459630012512207)","('NON-ESG', 0.04088969528675079)","('NON-ESG', 0.02525341510772705)"
Line 1150,"Innovation               Access                     Efficiency                Empowerment       80Awards, recognitions and affiliations Corporate recognition Dow Jones Sustainability North America Index since Forbes  Just 100 list FORTUNE’s  2019 World’s Most Admired Companies list FORTUNE’s  2019 Change the World list FTSE4Good Index since CR Magazine’s  100 Best Corporate Citizens List 2019 CPA-Zicklin Index on Corporate Political Disclosure and Accountability—Center for  Political Accountability Newsweek’s  America’s Most Responsible Companies List Innovation 2020 Derwent Top 100 Global Innovators list—Clarivate Analytics Efficiency U.S. EPA Green Power Partner U.S. EPA SmartWay® Transport Partner Empowerment Best Places to Work for LGBTQ Equality—Human Rights Campaign Foundation Bloomberg—2020 Gender Equality Index Disability Equality Index - Best Places to Work—The American Association of People  with Disabilities and Disability Employer of Choice for Gender Equality—Australia Workplace Gender Equality  Agency (Australia) Forbes  Best Employers for Diversity Top Employers Africa 2019—Top Employers Institute (Africa) Top Employers China 2019—Top Employers Institute (China) BD and the BD Logo are trademarks of Becton, Dickinson and Company.
","('Employee_Engagement_Inclusion_And_Diversity', 0.9653300642967224)","('Employee_Health_And_Safety', 0.004669589456170797)","('Labor_Practices', 0.002943760482594371)","(['Human Capital Development'], 0.9653300642967224)","('NON-ESG', 0.004669589456170797)","('NON-ESG', 0.002943760482594371)"
Line 1151,"All other trademarks   are the property of their respective owners.
","('Customer_Privacy', 0.36981719732284546)","('Competitive_Behavior', 0.16144846379756927)","('Business_Ethics', 0.05697965994477272)","('NON-ESG', 0.36981719732284546)","('NON-ESG', 0.16144846379756927)","('NON-ESG', 0.05697965994477272)"
Line 1152,"© 2020 BD.
","('Management_Of_Legal_And_Regulatory_Framework', 0.5946881175041199)","('Access_And_Affordability', 0.05336204916238785)","('GHG_Emissions', 0.03396601602435112)","(['Corporate Governance'], 0.5946881175041199)","('NON-ESG', 0.05336204916238785)","('NON-ESG', 0.03396601602435112)"
Line 1153,"All rights reserved.
","('Customer_Privacy', 0.18397872149944305)","('Human_Rights_And_Community_Relations', 0.07860073447227478)","('Waste_And_Hazardous_Materials_Management', 0.07202215492725372)","('NON-ESG', 0.18397872149944305)","('NON-ESG', 0.07860073447227478)","('NON-ESG', 0.07202215492725372)"
Line 1154,"3910 (0720)bd.comBD, Franklin Lakes, NJ, 07417, U.S.To find out more about sustainability at BD or to provide feedback on our reporting,   please contact  BD_Sustainability_Office@bd.com","('Product_Design_And_Lifecycle_Management', 0.24798454344272614)","('Supply_Chain_Management', 0.18630310893058777)","('Product_Quality_And_Safety', 0.08821386843919754)","('NON-ESG', 0.24798454344272614)","('NON-ESG', 0.18630310893058777)","('NON-ESG', 0.08821386843919754)"
